Stock Market Today 15.10.2025

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals 88% Rating

October 16, 2025, 5:58 AM EDT. Validea's guru fundamental report for Bristol-Myers Squibb Co (BMY) rates the stock highly under Partha Mohanram's P/B Growth Investor model. The growth framework searches for low book-to-market stocks with signs of sustained future growth. BMY achieves an 88% rating-strong but not in the elite top tier-with a typical threshold of 80% for interest and 90% for strong interest. The summary table shows most tests PASS, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS, RETURN ON ASSETS VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, and RESEARCH AND DEVELOPMENT TO ASSETS (the latter FAILED). The report frames BMY as a large-cap growth stock in Biotechnology & Drugs with fundamental and valuation signals supporting its potential.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 16, 2025, 5:56 AM EDT. Validea's guru-based view assigns BMY a high score under the P/B Growth model developed by Partha Mohanram. The company is a large-cap growth stock in the Biotechnology & Drugs space, with an 88% rating indicating notable interest. The model targets low book-to-market stocks showing traits tied to sustained growth. In practice, BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics pass the criteria, underscoring solid fundamentals. The emphasis on ROA, cash flow efficiency, and R&D to assets dynamics aligns with the growth framework. Overall, the strategy signals favorable positioning for BMY within its sector, suggesting investors may view it as a stock with meaningful growth potential under this factor-based approach.

BMY Factor-Based Stock Analysis: 88% Mohanram Growth Score

October 16, 2025, 5:54 AM EDT. Validea's guru fundamental report ranks BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model devised by Partha Mohanram. The model targets low book-to-market stocks with indicators of sustained future growth. BMY carries a 88% score, signaling 'some interest' (scores above 90% indicate strong interest). The stock sits in the Biotechnology & Drugs space and is a large-cap growth name. In the model's table, the stock passes on BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics; a few components like RESEARCH AND DEVELOPMENT TO ASSETS demand attention. Overall, the analysis suggests favorable fundamentals, though not at the 'strong interest' tier, given the sub-90% rating.

BMY Factor-Based Stock Analysis Highlights Partha Mohanram Growth Model

October 16, 2025, 5:52 AM EDT. Validea's guru fundamental report rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model. The large-cap biotech stock earns an 88% rating from this growth framework, signaling potential interest from growth-oriented investors. The model targets low book-to-market names with durable growth traits; for BMY, the score reflects strengths across key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS. The accompanying table shows a mix of PASS results and caveats, illustrating where BMY aligns with Mohanram's criteria and where the model places less emphasis. Overall, Validea presents BMY as a stock with notable growth characteristics under this guru approach, consistent with investors seeking sustained expansion.

BMY Factor-Based Growth Analysis Highlights

October 16, 2025, 5:50 AM EDT. Validea's guru-based view on BRISTOL-MYERS SQUIBB CO (BMY) highlights a high score under Partha Mohanram's P/B Growth Investor model. The stock, a large-cap player in Biotechnology & Drugs, shows a favorable book-to-market dynamics and growth orientation, with the model rating at 88% and a threshold of 80% for interest. The analysis notes strong performance on Return on Assets, cash flow from operations to assets and the efficiency of R&D to assets, while some criteria like capital expenditures to assets and advertising to assets pass. Overall, the model suggests sustained growth potential with measurable risk reflected in variance metrics. Investors considering growth screens may see BMY as a candidate for further evaluation under Mohanram's framework.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals High Interest

October 16, 2025, 5:48 AM EDT. Bristol-Myers Squibb Co (BMY) earns a top score under Validea's Partha Mohanram-driven P/B Growth Investor model, targeting low book-to-market stocks with sustained growth. As a large-cap growth stock in Biotechnology & Drugs, BMY carries an 88% rating-well above the 80% threshold indicating interest and approaching the 90% mark for strong interest. The table shows multiple PASS readings across key tests-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, and RESEARCH AND DEVELOPMENT TO ASSETS-highlighting favorable fundamentals. The analysis reflects Mohanram's research and Validea's application of his framework to identify potential winners among low book-to-market stocks.

BMY tops Validea's guru screen under Partha Mohanram's P/B Growth model

October 16, 2025, 5:46 AM EDT. Validea's guru report for Bristol-Myers Squibb Co (BMY) shows it rates highest among Validea's 22 guru strategies under the P/B Growth Investor model, published by Partha Mohanram. The growth framework seeks low book-to-market stocks with signs of sustained future growth. The stock is categorized as a large-cap growth name in the Biotechnology & Drugs space, with an overall rating of 88%, indicating notable interest (80%+ is interest; 90%+ is strong interest). In the test table, most metrics pass, including Book/Market, ROA, CFO/Assets, and related measures, while R&D to Assets failed. The result suggests a constructive growth thesis for BMY within the guru framework.

BMY Factor-Based Analysis: Validea Growth Model Rates Bristol-Myers Squibb at 88% (Partha Mohanram)

October 16, 2025, 5:44 AM EDT. Validea's guru-fundamental report places BRISTOL-MYERS SQUIBB CO (BMY) at the top of its 22-strategy suite under the P/B Growth Investor approach. This growth model seeks low book-to-market stocks with signs of sustained expansion, and BMY-an large-cap name in the Biotechnology & Drugs space-scores 88%, signaling notable fundamental and valuation strength. Highlights: BOOK/MARKET RATIO, RETURN ON ASSETS, and operating cash flow pass; ROA variance and sales variance pass; most asset-related metrics pass, with the notable exception of RESEARCH AND DEVELOPMENT TO ASSETS, which FAILED. A rating this high (80%+ indicates interest; 90%+ strong interest) suggests incremental upside from this strategy's lens, though investors should note the R&D linkage as a potential caveat.

BMY Factor-Based Stock Analysis – Partha Mohanram Growth Model Scores 88%

October 16, 2025, 5:42 AM EDT. Bristol-Myers Squibb Co (BMY) earns top marks under Validea's Partha Mohanram P/B Growth Investor model, a growth screen focusing on low book-to-market stocks with proven growth traits. The stock rates 88%, signaling meaningful interest from this strategy (80% suggests some interest; >90% signals strong interest). BMY is classified as a large-cap growth stock in the Biotechnology & Drugs sector. The model flags most tests as PASS across metrics like BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and CFO/ROA, with a noted exception: RESEARCH AND DEVELOPMENT TO ASSETS fails. Overall, the score implies the stock aligns with Mohanram's growth criteria, though elevated R&D intensity is a characteristic to watch.

BMY Factor-Based Stock Analysis: Validea Mohanram Growth Model Rates Bristol-Myers at 88%

October 16, 2025, 5:40 AM EDT. Validea's guru-based analysis of Bristol-Myers Squibb (BMY) shows the stock ranks highest under Partha Mohanram's P/B Growth model. The growth-oriented framework searches for low book-to-market stocks with indicators of sustained future expansion. BMY earns an 88% rating from this strategy, indicating notable interest (80%+ signals potential; 90%+ signals strong interest). The study notes BMY as a large-cap growth name in Biotechnology & Drugs, with many tests passing (Book/Market, ROA, CFO/Assets, R&D to assets, etc.) and a few caveats dependent on weighting. Overall, for growth-focused portfolios tracking factor-based signals, BMY currently presents a compelling tilt toward growth, per Mohanram's framework.

BMY: Partha Mohanram Growth Model Scores 88% in Factor-Based Stock Analysis

October 16, 2025, 5:38 AM EDT. Bristol-Myers Squibb Co (BMY) earns top marks from Validea's Partha Mohanram P/B Growth Investor model, scoring 88% and signaling strong interest from this factor-based framework. The model seeks low book-to-market stocks with signs of sustained growth, and BMY is characterized as a large-cap growth stock in the Biotechnology & Drugs industry. The analysis shows several strong passes: Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, CFO to Assets vs. ROA, ROA Variance, Sales Variance, Advertising to Assets, and Capital Expenditures to Assets. The sole caveat is R&D to Assets, which fails, highlighting higher R&D intensity relative to assets. Overall, a compelling basis for investor consideration under Mohanram's growth framework.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 16, 2025, 5:36 AM EDT. Bristol-Myers Squibb Co. (BMY) earns the top rating among Validea's 22 guru strategies when applying Partha Mohanram's P/B Growth model. The model seeks low book-to-market stocks with indicators of sustained growth, and BMY scores 88% based on fundamentals and valuation. The table shows consistent results across tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS. Key strengths include favorable CASH FLOW FROM OPERATIONS TO ASSETS and R&D TO ASSETS balance, while not all criteria weigh equally. Overall, a score above 80% suggests meaningful interest, with BMY moving toward growth-oriented consideration for the biotech/Drugs space.

BMY Scores 88% on Partha Mohanram Growth Model, Signaling Growth Tilt

October 16, 2025, 5:34 AM EDT. Validea's guru-style view on Bristol-Myers Squibb (BMY) shows an 88% score under Partha Mohanram's P/B Growth Investor model, indicating some to strong interest from the strategy. The growth screen targets low book-to-market stocks with signs of sustained future growth, classifying BMY as a large-cap Biotechnology & Drugs name. The test table reports PASS on key metrics such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and RESEARCH AND DEVELOPMENT TO ASSETS, with one caveat: the RESEARCH AND DEVELOPMENT TO ASSETS test is listed as FAILED. Overall, an 88% rating suggests investors should monitor the growth signals while noting the weakness in R&D allocation relative to assets.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Score 88%

October 16, 2025, 5:32 AM EDT. Validea's guru fundamental report flags BMY as a top pick under the P/B Growth Investor model developed by Partha Mohanram. The model targets low book-to-market stocks with indicators of sustained future growth. For BRISTOL-MYERS SQUIBB CO (BMY), the rating is 88%, with scores above 80% suggesting interest and above 90% indicating strong interest. Key criteria show BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, ROA VARIANCE: PASS, SALES VARIANCE: PASS, ADVERTISING TO ASSETS: PASS, CAPITAL EXPENDITURES TO ASSETS: PASS, but RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. As a large-cap growth stock in the Biotech & Drugs sector, it appears attractive to growth investors exploring factor-based signals, albeit with a noted R&D-to-assets shortfall.

BMY 88% Mohanram P/B Growth Signal; R&D to Assets Concern

October 16, 2025, 5:30 AM EDT. Validea's guru fundamental report for Bristol-Myers Squibb (BMY) shows the stock scoring 88% on the published P/B Growth Investor model based on Partha Mohanram. The model searches for low book-to-market stocks with characteristics of sustained growth. Classified as a large-cap growth stock in Biotechnology & Drugs, BMY's rating implies meaningful interest (scores ≥80%), with strong interest typically at ≥90%. The analysis notes that BMY passes most tests (Book/Market, ROA, CFO to assets, CFO/ROA variance, Sales variance, Advertising to assets, Capex to assets, R&D to assets) but has a failure on R&D to assets. Overall, the factors suggest favorable, growth-oriented alignment under Mohanram's framework.

BMY Shines in Partha Mohanram P/B Growth Model with 88% Rating

October 16, 2025, 5:28 AM EDT. Validea's guru-based assessment ranks BMY highly under the Partha Mohanram P/B Growth Investor model, scoring 88% based on fundamentals and valuation. The model seeks low book-to-market stocks with signs of sustained growth, and BMY passes key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D/Assets, among others. As a large-cap growth stock in the Biotechnology & Drugs sector, BMY's strength centers on its growth characteristics and solid cash flow profile, although the score signals room for further upside beyond the threshold where interest is strongest. Overall, the model suggests notable upside potential but should be considered alongside other factors and market conditions.

Bristol-Myers Squibb (BMY) Gains with Partha Mohanram Growth Model (P/B Growth)

October 16, 2025, 5:26 AM EDT. Validea's guru-based analysis for BRISTOL-MYERS SQUIBB CO (BMY) shows a strong signal under the Partha Mohanram P/B Growth Investor model, which seeks low book-to-market stocks with sustained growth. BMY rates 88%, well above the 80% threshold and approaching the 90% mark that signals strong interest. Of the 22 guru strategies Validea tracks, this model ranks BMY near the top. The assessment notes passes on key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, with favorable readings on related metrics like R&D TO ASSETS and CAPITAL EXPENDITURES TO ASSETS. With BMY as a large-cap biotechnology/drugs stock, the growth-model view suggests solid fundamentals and valuation support, implying potential upside if the growth trajectory continues.

BMY Factor-Based Growth Analysis: Partha Mohanram P/B Growth Model Signals High Confidence

October 16, 2025, 5:24 AM EDT. Validea's guru analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under Partha Mohanram's P/B Growth Investor model. The growth framework seeks low book-to-market stocks with signs of sustained expansion. BMY scores 88%, with 80%+ indicating interest and 90%+ indicating strong interest. The assessment shows PASS on key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS (ROA), CASH FLOW FROM OPERATIONS TO ASSETS (CFO/Assets), and related asset-efficiency metrics; some items like variance metrics are mixed. As a large-cap biotech & drugs name, BMY's fundamentals-including ROA, CFO/Assets, R&D to Assets, and CAPEX to Assets-support the growth thesis. Investors should view this analysis as one pillar among guru strategies, incorporating broader market context when evaluating BRISTOL-MYERS SQUIBB.

BMY Factor-Based Stock Analysis: Validea's Partha Mohanram Growth Model Signals 88% Rating

October 16, 2025, 5:22 AM EDT. Validea's guru-based analysis rates Bristol-Myers Squibb (BMY) highest among 22 strategies under the Partha Mohanram P/B Growth Investor model. The approach targets low book-to-market, high-growth potential stocks; BMY posts an 88% score indicating considerable interest. Classified as a large-cap Biotechnology & Drugs stock, BMY shows strength across key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D-related measures, with many criteria passing. The rating suggests investors may view BMY as consistent with Mohanram's growth framework, though some metrics may warrant closer scrutiny given the model's focus on growth over value. Overall, Validea's analysis highlights favorable fundamentals for BMY within this strategy.

BMY Factor-Based Stock Analysis: Partha Mohanram P/B Growth Model Highlights

October 16, 2025, 5:20 AM EDT. BRISTOL-MYERS SQUIBB CO (BMY) earns an 88% rating from Validea's Partha Mohanram P/B Growth model, a growth-factor approach that seeks low book-to-market stocks with durable growth. The stock is identified as a large-cap growth name in the Biotechnology & Drugs industry. Key tests show frequent passes, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS. The model notes solid fundamentals and a valuation that underpins growth prospects. An 88% score signals notable interest, with a score above 90% typically indicating stronger conviction. As with all factor-based analyses, investors should view this alongside other guru strategies to form a balanced view on BMY and its growth potential.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 16, 2025, 5:18 AM EDT. Validea's guru-based assessment for BRISTOL-MYERS SQUIBB CO (BMY) shows a high rating under the Partha Mohanram P/B Growth Investor model, at 88%. The growth framework seeks low book-to-market stocks with sustained growth traits, and BMY passes key tests in ROA, cash flow from operations to assets, and R&D to assets. As a large-cap biotech, the stock demonstrates favorable cash flow efficiency and modest operating asset turnover variance, supporting a growth signal. An 88% score indicates strong interest, with scores above 90% signaling very strong interest. Investors should view this as a factor-based view anchored in fundamentals rather than short-term price moves, and consider BMY within a broader growth-oriented portfolio.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 16, 2025, 5:16 AM EDT. Validea rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model from Partha Mohanram, scoring 88% and signaling substantial interest. The approach seeks low book-to-market stocks with sustained growth traits. In the Guru Analysis, key tests mostly pass, including Book/Market Ratio: PASS, Return on Assets: PASS, Cash Flow From Operations to Assets: PASS, and CFO to Assets vs. ROA, though some metrics like ROA Variance and Sales Variance show strength. Other criteria such as Advertising to Assets, Capital Expenditures to Assets, and R&D to Assets also pass. BMY is a large-cap growth stock in the Biotechnology & Drugs sector. A score above 90% would indicate stronger interest, while 80%+ signals notable interest. Overall, the model suggests the stock could merit closer scrutiny for growth and valuation, with awareness of industry risk.

BMY Tops Partha Mohanram Growth Screen with 88% in Validea Factor-Based Analysis

October 16, 2025, 5:14 AM EDT. BMY (Bristol-Myers Squibb) posts an 88% score on the Partha Mohanram P/B Growth Investor model, indicating notable interest from Validea's guru framework. The growth screen targets low book-to-market names with signs of sustained expansion, placing BMY among large-cap Growth stocks in Biotechnology & Drugs. The analysis shows several PASSes, including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, plus passes for ROA variance, Sales variance, Advertising to assets, and Capex to assets. The lone exception is RESEARCH AND DEVELOPMENT TO ASSETS, which FAILS the criteria. A score near 90% signals strong interest; above 80% generally suggests follow-through. As always, factor signals should be weighed alongside fundamentals and industry context via Validea.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Scores Bristol-Myers Squibb at 88%

October 16, 2025, 5:12 AM EDT. BRISTOL-MYERS SQUIBB CO (BMY), a large-cap Biotechnology & Drugs stock, scores 88% on Validea's Partha Mohanram P/B Growth Investor model, indicating some to strong interest per the strategy's thresholds. The analysis shows PASS on most criteria, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS, RETURN ON ASSETS VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, and CAPITAL EXPENDITURES TO ASSETS, but RESEARCH AND DEVELOPMENT TO ASSETS fails. The Mohanram framework targets low book-to-market stocks with growth traits, and a high-80s score signals interest; a score above 90% would imply stronger interest. This review mirrors Validea's guru-based assessment and its use of fundamentals to position BMY.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Sees Bristol-Myers

October 16, 2025, 5:10 AM EDT. Validea's guru-based look at BRISTOL-MYERS SQUIBB CO (BMY) applies the P/B Growth Investor model from Partha Mohanram. The stock earns an 88% score, signaling notable interest from this growth framework. BMY, a large-cap name in Biotechnology & Drugs, shows strong fundamentals with most tests marked PASS. Highlights include solid BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS metrics, plus favorable comparisons such as CFO to ASSETS and ROA VARIANCE. The model aligns with low book-to-market traits and growth signals, underscoring potential upside. The lone caveat is R&D TO ASSETS, which FAILS this criterion. Overall, the analysis points to meaningful interest from Mohanram's growth lens, with one notable underperformance in R&D alignment.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Highlights 88% Rating

October 16, 2025, 5:08 AM EDT. Validea's guru-based assessment rates BRISTOL-MYERS SQUIBB CO (BMY) at 88% under the Partha Mohanram P/B Growth Investor model. The growth framework favors low book-to-market stocks with signs of sustained future growth, and BMY sits as a large-cap growth name in Biotechnology & Drugs. The model notes that several tests pass, including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, with the CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS passing; however, RESEARCH AND DEVELOPMENT TO ASSETS is marked as FAILED in the summary. The headline takeaway: an 88% rating signals notable interest from the growth-oriented model, with scores above 90% indicating stronger conviction. Investors should weigh the R&D asset allocation weakness against the growth profile.

Bristol-Myers Squibb (BMY) Earns 88% on Partha Mohanram P/B Growth Model (Validea)

October 16, 2025, 5:06 AM EDT. Bristol-Myers Squibb Co (BMY) earns an 88% rating from Validea's Partha Mohanram P/B Growth Investor model, signaling notable interest among growth-focused screens. The Mohanram framework targets low book-to-market stocks with characteristics linked to sustained growth, and BMY ranks highest across Validea's 22 guru strategies under this model. Classified as a large-cap growth stock in the Biotechnology & Drugs sector, the overall read shows several PASS criteria, though R&D to Assets: FAILED stands out as a caveat. With thresholds of 80%+ for interest and 90%+ for strong interest, BMY sits in the solid interest band but with a noted weakness to monitor. Investors should weigh the growth signals against the R&D to Assets weakness when evaluating exposure to the health sector.

BMY Tops Partha Mohanram P/B Growth Model in Validea Guru Analysis

October 16, 2025, 5:04 AM EDT. Validea's guru-based review of BRISTOL-MYERS SQUIBB CO (BMY) ranks the stock highly under the Partha Mohanram P/B Growth Investor model. The growth strategy targets low book-to-market names with signs of sustained expansion. BMY, a large-cap stock in the Biotechnology & Drugs group, earns an 88% rating, with 80%+ indicating interest and 90%+ signaling strong interest. The accompanying table shows many tests as PASS (e.g., BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, etc.), though RESEARCH AND DEVELOPMENT TO ASSETS: FAIL is noted. Overall, the analysis underscores BMY's fundamentals and valuation strength within this growth framework, per Validea's methodology.

BMY Rated Top by Partha Mohanram's P/B Growth Model: 88% Guru Score

October 16, 2025, 5:02 AM EDT. Validea's guru analysis for BRISTOL-MYERS SQUIBB CO (BMY) shows it rates highest among 22 guru strategies under the P/B Growth Investor model derived from Partha Mohanram. The growth-oriented framework seeks low book-to-market stocks with indicators of sustained future expansion. BMY carries a strong 88% score on this strategy, with a reading that a score above 80% signals interest and above 90% signals strong interest. The analysis notes multiple PASS outcomes across tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and others, indicating favorable fundamentals relative to growth criteria. As a large-cap Biotechnology & Drugs name, BMY's valuation remains a key variable, but the model highlights notable upside potential for investors focused on factor-based growth signals.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Highlights

October 16, 2025, 5:00 AM EDT. Bristol-Myers Squibb Co. (BMY) scores highly under Validea's guru framework using Partha Mohanram's P/B Growth Investor model. The growth-focused screen seeks low book-to-market stocks with strong fundamentals and cash flow signals. BMY's rating is 88%, with 80%+ signaling interest and 90%+ signaling strong interest. In the model's tests, BMY passes key areas: BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS, RETURN ON ASSETS VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, and RESEARCH AND DEVELOPMENT TO ASSETS. The analysis emphasizes BMY's large-cap biotech growth profile and suggests the stock could be of interest to Mohanram-followers, while noting that a single model is only one data point for investors.

Bristol-Myers Squibb (BMY) Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals 88%

October 16, 2025, 4:58 AM EDT. Validea's guru-based analysis places Bristol-Myers Squibb (BMY) among top picks under the P/B Growth Investor model, a strategy from Partha Mohanram that seeks low book-to-market, high-growth stocks. With an 88% rating, the stock shows solid fundamentals and valuation according to this model, where a score above 80% signals interest and above 90% signals strong interest. In the assessed framework, BMY passes key tests (e.g., BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS), reflecting favorable efficiency and growth dynamics within the Biotechnology & Drugs sector. Investors should note the model's focus on growth signals despite broader market factors.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Scores 88%

October 16, 2025, 4:56 AM EDT. Bristol-Myers Squibb Co. (BMY) earns an 88% score from Validea's guru-based assessment using the P/B Growth Investor model inspired by Partha Mohanram. The strategy favors low book-to-market stocks with signs of sustained growth. BMY sits in the Biotechnology & Drugs large-cap space and shows a number of strengths across tests, including Book/Market ratio, Return on Assets, and Cash Flow from Operations to Assets, with just one miss on R&D to Assets. A rating of 80%+ signals interest; 90%+ would indicate strong interest. Investors should weigh the robust fundamentals against the R&D funding signal, as the growth tilt appears solid but the model flags a potential issue with how R&D investment is captured in assets.

BMY Factor-Based Stock Analysis: Validea's Partha Mohanram P/B Growth Strategy Rates Bristol-Myers 88%

October 16, 2025, 4:54 AM EDT. Validea's guru fundamental report rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model, the published strategy of Partha Mohanram. The model seeks low book-to-market stocks with growth characteristics, and BMY scores 88% on fundamentals and valuation, indicating meaningful investor interest (80%+) and especially strong interest (90%+). The analysis shows BMY passes key tests such as Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, with the sole weakness noted as R&D to Assets failing in the table. The report positions BMY as a large-cap growth stock in the Biotechnology & Drugs space, highlighting the strategy's emphasis on sustained growth signals despite some variability in asset allocation. Overall, the stock earns attention from this growth framework.

Bristol-Myers Squibb (BMY) earns 88% rating from Partha Mohanram P/B Growth model; key pass/fail signals

October 16, 2025, 4:52 AM EDT. Bristol-Myers Squibb Co (BMY) earns an 88% rating under Validea's Partha Mohanram P/B Growth Investor model, which targets low book-to-market stocks with sustained growth potential. BMY is described as a large-cap Biotechnology & Drugs stock. The table shows multiple PASS signals across BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CFO to ROA, CFO/Assets vs ROA, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS. A notable FAIL occurs for RESEARCH AND DEVELOPMENT TO ASSETS. The overall impression is that the strategy has some interest in BMY, but investors should weigh the R&D-asset issue in context of the firm's pipeline.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Highlights

October 16, 2025, 4:50 AM EDT. BRISTOL-MYERS SQUIBB CO (BMY) earns an 88% score under Validea's Partha Mohanram P/B Growth Investor model, which targets low book-to-market stocks with sustained growth. The stock is a large-cap growth pick in Biotechnology & Drugs. An 88% rating signals some institutional interest (80%+ indicates interest; 90%+ would signal strong interest). The table shows PASS on key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, with R&D TO ASSETS: FAIL. Overall, BMY appears as a growth-oriented candidate under this guru's framework, with caveats around R&D asset alignment.

Bristol-Myers Squibb (BMY) Tops Partha Mohanram P/B Growth Screen at 88%

October 16, 2025, 4:48 AM EDT. Validea's guru fundamental report ranks BRISTOL-MYERS SQUIBB CO (BMY) highest among 22 guru strategies under the P/B Growth Investor model based on Partha Mohanram's framework. The growth model targets low book-to-market stocks with signs of sustained growth. BMY, a large-cap growth name in the Biotechnology & Drugs industry, carries an 88% rating-above the typical threshold of 80% for interest and approaching the 90% level for strong interest. The summary table shows most tests as PASS (Book/Market, ROA, CFO to assets, CFO vs ROA, ROA variance, Sales variance, Advertising to assets, Capital expenditures to assets) but flags R&D to assets: FAILED. Overall, the stock demonstrates the strategy's appeal with a notable exception in R&D accounting. The note also provides context on Mohanram's growth research and Validea's methodology.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates 88%

October 16, 2025, 4:46 AM EDT. Bristol-Myers Squibb Co. (BMY) earns strong momentum under Validea's guru framework from Partha Mohanram's P/B Growth Investor model. The model targets low book-to-market stocks with signs of sustained growth, and BMY scores 88%, well above the 80% threshold that signals interest and approaching the 90% level for strong interest. The stock is categorized as a large-cap growth play in Biotech & Drugs, with key tests like BOOK/MARKET, ROA, CFO to assets, CFO vs ROA, ROA variance, Sales variance, Advertising to assets, Capex to assets passing. The notable caveat is R&D to assets that failed, potentially tempering enthusiasm. Overall, BMY remains a notable factor-based idea for growth-focused portfolios.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates Bristol-Myers Squibb at 88%

October 16, 2025, 4:44 AM EDT. Bristol-Myers Squibb Co (BMY) scores highly under Validea's Partha Mohanram P/B Growth Investor model, rating 88% and signaling strong interest from this factor. The growth strategy targets low book-to-market stocks with evidence of sustained expansion, and BMY is described as a large-cap Biotechnology & Drugs stock. The rating summary shows pass outcomes on most tests-Book/Market, Return on Assets, Cash Flow from Operations to Assets, CF/Assets vs ROA variance, Sales variance, Advertising to Assets, Capital Expenditures to Assets-but flags a miss on R&D to Assets. An overall score above 80% suggests the strategy has some interest; above 90% would indicate strong interest. Investors may view BMY favorably from a growth-factor lens, though they should consider fundamentals and risk before acting.

BMY Factor-Based Stock Analysis: Partha Mohanram P/B Growth Model Highlights

October 16, 2025, 4:42 AM EDT. Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) flags BMY as a top pick under the P/B Growth Investor model attributed to Partha Mohanram. The growth model seeks low book-to-market stocks with indicators of sustained future growth. BMY, a large-cap company in the Biotechnology & Drugs industry, scores 88% under this strategy, with 80%+ typical for interest and 90%+ for strong interest. The analysis notes several PASS tests, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D to ASSETS, painting a favorable, growth-oriented profile within Validea's framework.

Bristol-Myers Squibb (BMY) Tops Partha Mohanram P/B Growth Screen with 88% Validea Rating

October 16, 2025, 4:40 AM EDT. Validea's guru-based analysis places Bristol-Myers Squibb Co (BMY) at the top of the P/B Growth framework from Partha Mohanram. The large-cap Biotechnology & Drugs stock earns an 88% rating, signaling strong interest from the model based on fundamentals and valuation. Across the screen, most tests are PASS, including Book/Market, Return on Assets, Cash Flow from Operations to Assets, and their variants. Notably, the chart shows robust CFO/Assets and ROA dynamics. One caveat: R&D to Assets shows a FAIL, highlighting ongoing investment intensity. Overall, a high growth-model read with favorable fundamentals, flagging continued attention from growth-focused investors, while more clarity on R&D efficiency would help.

Bristol-Myers Squibb (BMY) Leads Partha Mohanram's P/B Growth Model in Validea Guru Analysis

October 16, 2025, 4:38 AM EDT. Validea's guru fundamental report rates Bristol-Myers Squibb Co (BMY) highest under the Partha Mohanram P/B Growth Investor model. The strategy seeks low book-to-market stocks with indicators of sustained future growth. BMY, a large-cap biotech/drugs stock, earns an 88% rating-below the threshold for 'strong interest' but signaling notable interest. The summary table shows strong PASS across key tests: BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CFO/ROA, ROA VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, and RESEARCH AND DEVELOPMENT TO ASSETS. Overall, the model flags favorable fundamentals and reasonable valuation rather than pure risk. For Mohanram, BMY's profile highlights growth resilience within a large-cap biotech framework, per Validea's Partha Mohanram portfolio.

BMY Scores 88% on Partha Mohanram P/B Growth Model

October 16, 2025, 4:36 AM EDT. Bristol-Myers Squibb (BMY) posts an 88% rating on Validea's Partha Mohanram P/B Growth model, signaling strong growth-oriented fundamentals in the Biotechnology & Drugs sector. The large-cap stock passes multiple tests-Book/Market, ROA, CFO to Assets, and other growth metrics-though the table notes a failure on Research & Development to Assets. In Mohanram's framework, a score above 80% indicates interest, with 90%+ signaling strong interest. Overall, BMY appears attractive to growth-focused investors, but the R&D to assets signal warrants closer scrutiny amid balance-sheet considerations.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 16, 2025, 4:34 AM EDT. Validea's guru-based assessment places Bristol-Myers Squibb Co. (BMY) at the top end of the Partha Mohanram P/B Growth Investor model. The growth model flags a low book-to-market, yet with characteristics tied to sustained future growth. BMY scores 88% on this strategy, where a score above 80% signals interest and above 90% signals strong interest. In the test table, most criteria are PASS – including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related measures – though RESEARCH AND DEVELOPMENT TO ASSETS is listed as FAILD. The stock is described as a large-cap growth name in Biotechnology & Drugs. Overall, the report highlights the model's focus on growth potential and valuation alignment for BMY.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals for Bristol-Myers Squibb

October 16, 2025, 4:32 AM EDT. Validea's guru report flags BRISTOL-MYERS SQUIBB CO (BMY) as a top pick under the Partha Mohanram P/B Growth Investor model. With an 88% rating, BMY sits in the large-cap Growth/Biotech arena and shows traits linked to sustained future expansion. The model's tests largely pass, including BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, and CASH FLOW FROM OPERATIONS TO ASSETS: PASS; however, RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. An 80%+ score signals notable interest; >90% would signal strong interest. The note places BMY within Validea's framework of Partha Mohanram's growth strategy and highlights the stock's favorable fundamentals and valuation under this approach.

BMY Factor-Based Growth Signal Under Partha Mohanram's P/B Growth Model

October 16, 2025, 4:30 AM EDT. Validea's guru fundamental report for Bristol-Myers Squibb Co (BMY) rates highly under the P/B Growth Investor model based on Partha Mohanram's framework. As a large-cap growth stock in the Biotechnology & Drugs industry, BMY earns an 88% rating, with scores above 90% signaling strong interest and 80% indicating some interest. The analysis shows BMY passes key tests across the table, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D to Assets, among others, with several criteria marked as PASS. The model targets low book-to-market stocks with characteristics linked to sustained growth, suggesting BMY could benefit from a growth profile despite sector cyclicality. Overall, the report frames BMY as a notable factor-based pick within growth investing.

BMY Tops Validea's Partha Mohanram P/B Growth Model with 88% Score

October 16, 2025, 4:28 AM EDT. Validea's guru fundamental report ranks Bristol-Myers Squibb Co (BMY) highly under Partha Mohanram's P/B Growth Investor model. The growth-focused screen identifies low book-to-market stocks with signs of sustained future expansion, and BMY scores 88%, indicating the strategy has some to strong interest. The accompanying table shows key tests-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS-as PASS, with multiple criteria supportive of growth and valuation. Although weights differ across tests, the overall verdict is favorable: a score above 80% typically signals interest, and above 90% signals strong interest. In short, under Mohanram's framework, BMY presents as a high-conviction growth candidate among large-cap biotech names.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Hits 88%

October 16, 2025, 4:26 AM EDT. Bristol-Myers Squibb (BMY) registers a high score under Validea's Partha Mohanram P/B Growth Investor model, placing it among the top picks among the 22 guru strategies. The model targets low book-to-market stocks with sustained growth, and BMY scores 88%, signaling meaningful interest from the growth screen. The stock is categorized as a large-cap growth stock in the Biotechnology & Drugs space. Key tests show several Pass outcomes-Book/Market, Return on Assets, Cash Flow from Operations to Assets, and related metrics-though the R&D to Assets criterion is listed as Fail. With an 88% rating and favorable valuation, the strategy suggests continued attention, especially if other growth signals align.

BMY Factor-Based Analysis: Partha Mohanram P/B Growth Model Yields 88% Rating

October 16, 2025, 4:24 AM EDT. Validea's guru-based review of BRISTOL-MYERS SQUIBB CO (BMY) applies Partha Mohanram's P/B Growth Investor model. The stock earns an 88% rating, signaling meaningful interest from this growth framework. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs space, with strong fundamentals and a valuation that supports elevated exposure. The model's test results are broadly favorable: Book/Market, Return on Assets, Cash Flow from Operations to Assets, and related metrics pass; R&D to Assets is flagged as a miss, and the overall strength rests on multiple cash-flow and efficiency criteria. In Validea's framework, ratings of 80%+ imply some interest, while 90%+ would indicate strong interest. Readers should note that the analysis emphasizes growth characteristics and may differ from other value-focused views.

BMY Factor-Based Stock Analysis: Partha Mohanram P/B Growth Model Signals Strong Interest

October 16, 2025, 4:22 AM EDT. Validea's guru-focused assessment rates Bristol-Myers Squibb Co (BMY) highly under the P/B Growth Investor framework developed from Partha Mohanram's research. Among 22 guru strategies followed, BMY yields the highest signal from this model, reflecting a low book-to-market profile paired with characteristics linked to sustained future growth. The stock's rating from this strategy sits at 88%, with scores above 80% signaling interest and above 90% indicating strong interest. The overview shows the stock passes key tests on BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and other asset-related metrics, while areas like R&D to assets contribute to the overall positive view. This analysis positions BMY for potential continued growth in the Biotechnology & Drugs space.

Bristol-Myers Squibb (BMY) Factor-Based Stock Analysis: Mohanram P/B Growth Model 88% Rating

October 16, 2025, 4:20 AM EDT. Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) shows BMY rates highest under Partha Mohanram's P/B Growth Investor model, a low book-to-market growth framework. The large-cap biotech stock earns an 88% rating, signaling substantial interest per the guru strategy (80% is meaningful; 90% would be strong). The summary table notes PASS on criteria like BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics; components such as R&D TO ASSETS are also favorable. This reflects Mohanram's research on separating winners from losers among low book-to-market stocks and positions BMY as a potential growth play within Healthcare/Biotechnology.

BMY Factor-Based Stock Analysis: Validea Highlights Mohanram Growth Model

October 16, 2025, 4:16 AM EDT. Validea's guru report for BRISTOL-MYERS SQUIBB CO (BMY) shows strong alignment with the P/B Growth Investor model of Partha Mohanram. The stock rates 88% under this growth framework, which favors low book-to-market names with durable growth characteristics. BMY passes key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, with the model signaling strong consistency in R&D to assets and CAPEX to assets. The analysis notes that Validea's growth model seeks firms with growth persistence, and a high score can indicate potential for continued expansion, per this Guru framework. Investors seeking growth exposure in a large-cap biotechnology name may consider BMY under this approach.

Validea Guru Analysis: BMY Tops Partha Mohanram P/B Growth Model

October 16, 2025, 4:14 AM EDT. Bristol-Myers Squibb Co. (BMY) ranks highly under Validea's guru framework, posting the top score among 22 strategies on the P/B Growth Investor model tied to Partha Mohanram. The growth-focused screen favors low book-to-market names with signs of sustained future expansion. BMY earns an 88% rating, signaling meaningful interest (scores above 80% suggest possible attention; above 90% signals strong interest). The summary table shows multiple tests as PASS, including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, though RESEARCH AND DEVELOPMENT TO ASSETS is listed as FAIL. Overall, the stock sits in large-cap biotech with notable growth characteristics per this model.

Bristol-Myers Squibb (BMY) Strong P/B Growth Signal Under Mohanram Growth Model (Validea)

October 16, 2025, 4:12 AM EDT. Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) shows strong alignment with the P/B Growth Investor model from Partha Mohanram. This growth framework seeks low book-to-market stocks with traits tied to durable growth. BMY scores 88% under the Mohanram strategy; scores above 80% signal interest, above 90% signal strong interest. The table indicates most tests are PASS (e.g., Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, CFO to ROA, Sales Variance, Advertising to Assets, CapEx to Assets), with R&D to Assets: FAILED as a noted weak point. As a large-cap growth stock in the Biotechnology & Drugs industry, BMY presents a notable standout under this model.

BMY Signals Strong Growth-Model Appeal Despite R&D Asset Concern

October 16, 2025, 4:10 AM EDT. Validea's guru analysis rates BRISTOL-MYERS SQUIBB CO (BMY) at 88% under the Partha Mohanram P/B Growth Investor model, among 22 guru strategies. This growth model targets low book-to-market stocks with characteristics linked to sustained future growth. BMY is categorized as a large-cap growth stock in Biotechnology & Drugs, and the rating suggests notable interest. The table shows PASS on BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS, RETURN ON ASSETS VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, and a FAIL on RESEARCH AND DEVELOPMENT TO ASSETS. Overall, the strategy signals interest, but the R&D TO ASSETS weakness warrants caution and further due diligence.

Bristol-Myers Squibb (BMY) Factor-Based Analysis: Partha Mohanram Growth Model Yields 88%

October 16, 2025, 4:08 AM EDT. Validea's guru fundamental report applies the P/B Growth Investor model by Partha Mohanram to Bristol-Myers Squibb Co. (BMY). As a large-cap Biotechnology & Drugs stock, BMY earns an 88% score under this growth framework, where 80%+ signals interest and 90%+ signals strong interest. The test results show most criteria as PASS, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, ROA VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS. The notable exception is RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. The model targets low book-to-market stocks with potential for sustained growth, and Mohanram's research is highlighted along with Validea's analysis approach.

Bristol-Myers Squibb Tops Validea's P/B Growth Guru Model with 88% Rating

October 16, 2025, 4:06 AM EDT. Validea's guru fundamental report flags BRISTOL-MYERS SQUIBB CO (BMY) as a top pick under the P/B Growth Investor model inspired by Partha Mohanram. The large-cap biotechnology stock earns an 88% rating, signaling meaningful interest from this growth framework. The model seeks low book-to-market names with characteristics linked to sustained future growth. BMY shows strong fundamentals and favorable valuation, with the majority of tests passing, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and others. Note: RESEARCH AND DEVELOPMENT TO ASSETS testing FAILED. A score above 80% suggests interest; above 90% signals strong interest.

BMY Factor-Based Stock Analysis: Validea's Partha Mohanram Growth Model Signals Strong Interest

October 16, 2025, 4:04 AM EDT. Validea's guru-based analysis of BMY scores highly under Partha Mohanram's P/B Growth Investor model. This growth framework targets low book-to-market stocks with characteristics tied to sustained future growth. BMY scores 88%, with thresholds of 80%+ indicating interest and 90%+ signaling strong interest. The evaluation shows passes on key criteria such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS. Classified as a large-cap name in Biotechnology & Drugs, the analysis highlights solid fundamentals and attractive valuation as tailwinds for continued earnings progress. Investors should weigh the model's growth signals, asset efficiency, and cash-flow dynamics when considering exposure to BMY.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 16, 2025, 4:02 AM EDT. Bristol-Myers Squibb Co. (BMY) receives a high score under Validea's Partha Mohanram Growth model, with an 88% rating indicating strong interest from this low book-to-market growth framework. The model seeks stocks with low book-to-market ratios that show characteristics associated with sustained future growth. In this analysis, BMY is a large-cap name in the Biotechnology & Drugs sector and passes many tests, earning favorable marks across metrics like return on assets and cash flow from operations to assets. The summary table shows PASS for key tests (ROA, CFO/Assets, comparisons of CFO/Assets vs ROA), with some areas such as R&D to assets and capital expenditures to assets highlighted. Overall, the stock aligns with the strategy's criteria, suggesting potential upside if fundamentals support continued growth.

BMY earns 88% score under Partha Mohanram P/B Growth Investor model

October 16, 2025, 4:00 AM EDT. Validea ranks BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model from Partha Mohanram, scoring 88%-well above the 80% threshold that signals interest and nearing the 90% mark for strong interest. The growth model targets low book-to-market stocks with indicators of sustained future growth. For BMY, the model flags strengths in core fundamentals and valuation, with the stock passing key checks like BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, and other asset-related tests. As a large-cap Biotechnology & Drugs stock, BMY's favorable score reflects a disciplined growth-oriented framework long associated with Mohanram's research. Analysts should note that higher scores imply stronger interest from this strategy.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Growth Potential

October 16, 2025, 3:58 AM EDT. Bristol-Myers Squibb Co. (BMY), a large-cap growth stock in the Biotechnology & Drugs sector, scores high under Validea's guru framework, led by the P/B Growth Investor model from Partha Mohanram. The stock earns 88% on this strategy, with a focus on low book-to-market characteristics linked to expected growth. In the table, metrics like BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D to assets show PASS or favorable signals, underscoring the model's confidence in continued growth. While a single strategy score isn't definitive, a score above 80% indicates interest and above 90% signals strong interest. Overall, BMY appears attractive to growth-oriented investors, supported by broader guru signals for confirmatory research.

Bristol-Myers Squibb (BMY) Scores 88% on Partha Mohanram Growth Model (Validea)

October 16, 2025, 3:56 AM EDT. Bristol-Myers Squibb (BMY) earns the top spot under Validea's guru fundamental analysis using Partha Mohanram's P/B Growth Investor model. The growth framework seeks low book-to-market stocks with sustained growth. BMY, a large-cap player in the Biotechnology & Drugs space, carries an 88% rating, indicating notable interest (scores above 80% show interest; above 90% would signal strong interest). In the test summary, key metrics are PASS for BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and other items; only RESEARCH AND DEVELOPMENT TO ASSETS fails. Overall, the model highlights solid fundamentals and favorable valuation despite the R&D edge case.

BMY Leads Validea's Partha Mohanram P/B Growth Model with 88% Score

October 16, 2025, 3:54 AM EDT. Bristol-Myers Squibb Co (BMY) ranks highest among Validea's guru models on the (Partha Mohanram) P/B Growth Investor strategy, scoring 88% based on fundamentals and valuation. The model targets low book-to-market stocks with signs of sustained growth and views BMY as a large-cap growth stock in the Biotechnology & Drugs sector. The summary table shows broad strengths across many tests: Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, Cash Flow from Operations to Assets vs. Return on Assets, ROA variance, Sales variance, Advertising to Assets, Capital Expenditures to Assets, and R&D to Assets (the latter marked as FAILED). A score at or above 80% signals interest, while above 90% signals strong interest. Overall, Validea flags BMY as a notable fit for this growth screen, with some development need in R&D efficiency.

BMY Factor-Based Stock Analysis: Validea's Partha Mohanram Growth Model Rates BMY 88%

October 16, 2025, 3:52 AM EDT. Validea's guru analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram Growth model. The stock earns an 88% score, indicating considerable interest from this growth framework. The strategy seeks low book-to-market stocks with sustainable growth traits, and BMY clears most tests, including BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, ROA VARIANCE: PASS, SALES VARIANCE: PASS, R&D TO ASSETS: PASS. It's categorized as a large-cap growth name in the Biotechnology & Drugs space, with a valuation implied by the high score. In Validea's system, a score of 80%+ suggests some interest, and 90%+ indicates strong interest. Investors should still compare with other models and monitor fundamental and industry trends.

BMY earns strong Partha Mohanram P/B Growth signals

October 16, 2025, 3:50 AM EDT. Bristol-Myers Squibb Co. (BMY) scores highly under Validea's Partha Mohanram P/B Growth Investor model, earning an 88% rating. The growth framework targets low book-to-market stocks with signs of sustained growth, and BMY sits as a large-cap player in the Biotechnology & Drugs space. An 88% score signals meaningful interest from this guru strategy, with 80%+ indicating notable potential (90%+ would signal strong interest). The analysis shows broad strength across tests, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics, all PASS except for RESEARCH AND DEVELOPMENT TO ASSETS, which is FAILED. Overall, BMY appears as a credible growth stock within this factor framework, deserving attention among other guru models Validea tracks.

BMY Factor-Based Stock Analysis: 88% P/B Growth Rating Under Partha Mohanram Model

October 16, 2025, 3:48 AM EDT. Validea's guru report places Bristol-Myers Squibb (BMY) at the top among 22 strategies using the Partha Mohanram P/B Growth model. The growth-oriented screen targets low book-to-market names with signs of sustained future expansion. BMY earns an 88% rating on fundamentals and valuation, signaling meaningful interest (80%+ is interest; 90% would be strong interest). The summary table shows most criteria pass, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and more. Notably, R&D to Assets is marked as FAILED, a potential headwind for growth trajectory. As a large-cap Biotechnology & Drugs stock, BMY's profile aligns with growth signals, but investors should monitor R&D efficiency alongside the valuation.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 16, 2025, 3:46 AM EDT. Validea's guru-fundamental view rates Bristol-Myers Squibb (BMY) highest among 22 guru strategies using the P/B Growth Investor model from Partha Mohanram. The model targets low book-to-market stocks with growth traits and assigns BMY an 88% rating, signaling potential interest; 80%+ flags interest and 90%+ signals strong interest. The table shows broad PASS across tests such as Book/Market, ROA, CFO to assets, CFO to ROA, ROA variance, Sales variance, Advertising to assets, and Capex to assets, with R&D to assets noted as FAILED. As a large-cap in the Biotechnology & Drugs space, this factor-based view highlights BMY as a candidate for continued growth scrutiny within Mohanram's framework and Validea's model portfolios.

Bristol-Myers Squibb (BMY) Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 16, 2025, 3:44 AM EDT. Validea's guru fundamental report on Bristol-Myers Squibb Co (BMY) shows the P/B Growth Investor model, based on Partha Mohanram, ranking BMY at 88%. The Mohanram growth framework seeks low book-to-market stocks with signs of sustained future growth. BMY is a large-cap growth stock in the Biotechnology & Drugs industry, with a score in the high 80s. The summary rubric indicates most tests pass, including Book/Market, Return on Assets (ROA), and Cash Flow from Operations to Assets, while R&D to Assets fails. This suggests the stock has favorable fundamentals under this growth screen, notwithstanding the R&D caveat. Overall, the model signals strong interest in BMY from a factor-based growth perspective, though investors should weigh the R&D metric alongside valuation and other fundamentals.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Moderate Interest

October 16, 2025, 3:42 AM EDT. Bristol-Myers Squibb Co (BMY) is analyzed with Validea's Partha Mohanram P/B Growth Investor model, a factor-based approach seeking low book-to-market stocks with sustained growth. The stock rates 88%, signaling meaningful but not strong interest under this model. BMY is a large-cap growth name in the Biotechnology & Drugs space. The table shows multiple PASS signals across metrics such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, and RESEARCH AND DEVELOPMENT TO ASSETS. The only caveat is the RESEARCH AND DEVELOPMENT TO ASSETS criterion, marked as FAILED. Since scores above 90% indicate strong interest, BMY's 88% sits in the range of some interest.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals High Interest

October 16, 2025, 3:40 AM EDT. Bristol-Myers Squibb Co (BMY) scores highest under Validea's P/B Growth Investor model, a Partha Mohanram framework that seeks low book-to-market stocks with signs of sustained growth. BMY is positioned as a large-cap growth stock in the Biotechnology & Drugs space. The strategy rating sits at 88%, with 80%+ commonly signaling interest and 90%+ signaling strong interest. In the criteria table, BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and ROA VARIANCE all PASS, as do SALES VARIANCE, ADVERTISING TO ASSETS, and CAPITAL EXPENDITURES TO ASSETS. The one noted shortcoming is RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. The analysis underscores Partha Mohanram's contributions to growth investing and Validea's guru-based research framework.

BMY: Partha Mohanram P/B Growth Model Flags Bristol-Myers Squibb as Top Growth Pick

October 16, 2025, 3:38 AM EDT. Bristol-Myers Squibb Co (BMY) earns a strong signal from Validea's Partha Mohanram P/B Growth Investor model, scoring 88% and placing it among top growth ideas. The model targets low book-to-market stocks with sustained growth traits. On the main tests, BMY passed on Book/Market ratio, Return on Assets, Cash Flow from Operations to Assets, CFO/ROA, Sales Variance, Advertising to Assets, Capital Expenditures to Assets, and R&D to Assets; the table notes one criterion labelled as FAILED (R&D to Assets). The company sits in the large-cap Biotechnology & Drugs space, suggesting potential for continued growth, though investors should weigh the single weaker criterion against the overall 88% rating.

BMY Factor-Based Stock Analysis: Validea Mohanram Growth Model Rates Bristol-Myers Squibb at 88%

October 16, 2025, 3:36 AM EDT. Validea's guru analysis for BRISTOL-MYERS SQUIBB CO (BMY) places it at the top of the P/B Growth Investor model, rooted in Partha Mohanram's framework. This growth model targets low book-to-market stocks with signs of enduring expansion, and BMY posts an 88% rating, above the 80% threshold and approaching the 90% level of strong interest. Identified as a large-cap Biotechnology & Drugs stock, BMY shows solid fundamentals and valuation. The table of tests shows major metrics like BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS passing, underscoring favorable growth-oriented characteristics within the strategy.

BMY Factor-Based Stock Analysis: Partha Mohanram P/B Growth Model Signals Strength (88%)

October 16, 2025, 3:34 AM EDT. Validea's guru-based assessment rates Bristol-Myers Squibb (BMY) highly on the Partha Mohanram P/B Growth model, with an 88% score. The growth framework seeks low book-to-market stocks with evidence of sustained expansion. BMY passes several tests-BOOK/MARKET, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS-indicating healthy asset efficiency and cash generation. The report notes that not all tests carry equal weight, but the overall read is favorable. As a large-cap in Biotechnology & Drugs, BMY appears to have potential upside under this growth lens, though investors should weigh pipeline risk, industry dynamics, and macro factors. In short, this model flags strong interest in BMY from a growth perspective, underscored by a high 88% score and favorable fundamentals.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Score 88%

October 16, 2025, 3:32 AM EDT. Validea's guru fundamental analysis ranks BRISTOL-MYERS SQUIBB CO (BMY) highly among 22 guru strategies. Using Partha Mohanram's P/B Growth Investor model, BMY scores 88%-well above the 80% threshold signaling interest and nearing the 90% mark for strong interest. The Mohanram growth model seeks low book-to-market stocks with sustained growth traits, and BMY qualifies as a large-cap growth name in the Biotech & Drugs space. The score reflects strong performance across many tests-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and ROA VARIANCE pass, among others-with R&D-TO-ASSETS listed as not meeting the criterion. Overall, the model suggests meaningful interest in BMY based on fundamentals and valuation.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals High Interest

October 16, 2025, 3:30 AM EDT. Bristol-Myers Squibb Co. (BMY) earns top marks under Validea's Partha Mohanram P/B Growth Investor model, which targets low book-to-market stocks with signs of sustained growth. Among 22 guru strategies, BMY ranks highest on this growth factor, delivering an 88% rating and implying meaningful upside, though a score above 90% would indicate stronger interest. The model flags a growth engine rather than pure value, with a PASS on key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, R&D TO ASSETS, and other related metrics; only a few criteria like variance show less emphasis. BMY is described as a large-cap growth stock in the Biotechnology & Drugs space, suggesting investors should weigh growth prospects against risk factors in this sector.

BMY Factor-Based Stock Analysis – Validea Partha Mohanram Growth Model Scores Bristol-Myers Squibb at 88%

October 16, 2025, 3:28 AM EDT. Validea's guru report rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model, at 88%. The model targets low book-to-market stocks with signs of sustained growth, framing BMY as a large-cap growth stock in Biotechnology & Drugs. A score above 80% typically signals interest, with near 90% implying strong interest. The accompanying test table shows many PASS metrics, including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS; however, RESEARCH AND DEVELOPMENT TO ASSETS is flagged as a weakness. Overall, the stock aligns with this growth framework, though R&D-to-assets should be monitored within broader fundamentals.

BMY Factor-Based Stock Analysis under Partha Mohanram's P/B Growth Investor model

October 16, 2025, 3:26 AM EDT. Validea's guru report ranks BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model from Partha Mohanram, labeling it a large-cap growth stock in the Biotechnology & Drugs space. The model scores 88%, with 80%+ signaling notable interest and 90%+ signaling strong interest. The summary table shows most tests passing, including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS; however, RESEARCH AND DEVELOPMENT TO ASSETS is marked as failed. The analysis reflects Mohanram's growth-focus approach, which seeks low book-to-market stocks with sustained growth characteristics. Investors should consider how this profile aligns with BMY's fundamentals, valuation, and the weight of the R&D metric within the strategy.

BMY Factor-Based Stock Analysis: Validea's Partha Mohanram Growth Model Rates Bristol-Myers Squibb at 88%

October 16, 2025, 3:24 AM EDT. Validea applies Partha Mohanram's growth-screen to Bristol-Myers Squibb (BMY), rating the stock 88% under the P/B Growth Investor model. The approach seeks low book-to-market names with signs of sustained growth. BMY is categorized as a large-cap Biotechnology & Drugs stock, with a strengthful fundamentals read but not a top-tier signal (80%+ suggests interest; >90% would signal strong interest). The summary table shows PASS on key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, among others, with a few tests highlighted as areas to watch (e.g., variance measures). The piece also references Mohanram's research and Validea's broader Factor-Based Stock Portfolios framework.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals 88% Rating

October 16, 2025, 3:22 AM EDT. Validea's guru-based review places Bristol-Myers Squibb (BMY) atop the market among growth-focused screens. Using the Partha Mohanram P/B Growth model, BMY earns an 88% rating, indicating strong interest from this growth framework. The model targets low book-to-market stocks with indicators of durable expansion. In this report, BMY passes key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, while the framework notes a PASS on R&D TO ASSETS and other asset-related measures. The overall takeaway: for investors tracking factor-based growth signals in the Biotechnology & Drugs space, BMY shows favorable fundamentals and valuation under this strategy.

BMY Factor-Based Stock Analysis: Mohanram Growth Score 88%

October 16, 2025, 3:20 AM EDT. Validea's guru report ranks BRISTOL-MYERS SQUIBB CO (BMY) highly under Partha Mohanram's P/B Growth Investor model, yielding an 88% score and signaling strong interest. The growth-focused framework looks for low book-to-market stocks with characteristics linked to sustained expansion. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs industry. Key tests show PASS across BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics; the report notes multiple PASS results across criteria. The summary table highlights the stock's favorable fundamentals under Mohanram's approach. The overall takeaway: this stock carries notable growth-oriented signals within Validea's guru framework.

BMY Factor-Based Stock Analysis: Partha Mohanram P/B Growth Model Signals 88% Rating

October 16, 2025, 3:18 AM EDT. Bristol-Myers Squibb Co. (BMY) earns an 88% rating from Validea's Partha Mohanram P/B Growth Investor model, a growth screen that favors low book-to-market stocks with sustained growth. Classified as a large-cap growth stock in Biotechnology & Drugs, the score indicates notable interest from this strategy (80%+; >90% = strong interest). The stock passes key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, among others, with several metrics tracking in line with growth characteristics. While some criteria may be weighted differently and are not all independent, the overall read is positive for pharma/biotech exposure under this model.

BMY Factor-Based Stock Analysis: High Mohanram P/B Growth Signal

October 16, 2025, 3:16 AM EDT. Validea rates Bristol-Myers Squibb (BMY) highly on the P/B Growth Investor model by Partha Mohanram, a growth framework favoring low book-to-market stocks with signs of sustained expansion. The stock earns an 88% score, indicating notable interest from this strategy. The analysis highlights criteria such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS as PASS, among others, though weights vary and not all tests are independent. A score above 90% would imply stronger enthusiasm. In sum, the factor-based view supports BMY as a growth stock within this model, while acknowledging the model's growth bias and the fundamentals that underlie the rating.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Highlights 88% Rating

October 16, 2025, 3:14 AM EDT. BRISTOL-MYERS SQUIBB CO (BMY) earns top marks under Validea's guru framework via the P/B Growth Investor model from Partha Mohanram, which targets low book-to-market stocks with signs of sustained future growth. BMY's rating is 88%, signaling meaningful interest under this framework (80%+ indicates interest; 90%+ would indicate strong conviction). The stock is a large-cap growth name in Biotechnology & Drugs. In the table, key metrics such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS all PASS, while R&D TO ASSETS appears FAILED. Overall, the model portrays BMY as a favorable fit within this growth framework, with a noted caveat on the R&D-to-assets criterion.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 16, 2025, 3:12 AM EDT. Validea's guru report on BRISTOL-MYERS SQUIBB CO (BMY) shows the stock ranking highest under the P/B Growth Investor model based on the published approach of Partha Mohanram. The growth model flags BMY as a large-cap growth name in Biotechnology & Drugs, with an 88% rating, implying meaningful investor interest (scores above 80% signal interest; above 90% strong interest). Across the test table, most criteria pass (Book/Market Ratio, Return on Assets, Cash Flow from Ops to Assets, ROA variance, Sales variance, Advertising to Assets, CapEx to Assets, etc.), but R&D to Assets is marked as Fail. The analysis highlights BMY's fundamentals and valuation strengths within Mohanram's framework, while noting the one notable weakness in R&D capitalization.

Bristol-Myers Squibb (BMY) Tops Partha Mohanram Growth Model with 88% Validea Score

October 16, 2025, 3:10 AM EDT. Bristol-Myers Squibb Co. (BMY) earns top marks from Validea's guru-based framework under Partha Mohanram's P/B Growth Investor model. With an 88% score, the growth-focused screen flags BMY as a stock with potential for sustained expansion. The analysis positions BMY as a large-cap growth stock in the Biotechnology & Drugs sector and shows favorable readings across key tests, including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS. The model emphasizes low book-to-market paired with growth signals, and highlights metrics like R&D to assets as supportive. An overall score above 80% suggests notable interest, while scores above 90% indicate strong interest according to Validea's framework.

BMY Scores 88% on Partha Mohanram's P/B Growth Model (Validea)

October 16, 2025, 3:08 AM EDT. Validea's guru fundamental analysis places Bristol-Myers Squibb Co (BMY) at the top of its 22-guru roster under the P/B Growth Investor model authored by Partha Mohanram. The model targets low book-to-market stocks with indicators of sustained growth; BMY delivers an 88% rating, signaling notable interest (80%+ implies some interest; 90%+ would signal strong interest). The summary table shows PASS on key tests including Book/Market Ratio, Return on Assets (ROA), Cash Flow from Operations to Assets, CFO to ROA, and Sales Variance, with a noted FAIL on R&D to Assets. Overall, BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs space with favorable fundamentals and valuation per Validea's framework.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals High Interest

October 16, 2025, 3:06 AM EDT. Bristol-Myers Squibb Co (BMY) is highlighted in Validea's Guru-based analysis, scoring 88% on Partha Mohanram's P/B Growth Investor model. The model seeks low book-to-market stocks with signs of sustained future growth. BMY sits in the large-cap Biotechnology & Drugs space and earns a high rating based on strong fundamentals and favorable valuation. A score of 80% or higher indicates interest, with 90%+ signaling strong interest. The summary table shows most tests as PASS (Book/Market, ROA, CFO-to-Assets, CFO-to-ROA, etc.), underscoring a favorable balance sheet and growth profile per Mohanram's criteria. Partha Mohanram's research underpins Validea's growth framework.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals 88% Rating

October 16, 2025, 3:04 AM EDT. Validea's guru-based assessment places Bristol-Myers Squibb (BMY) high under the P/B Growth Investor model developed by Partha Mohanram. Among 22 guru strategies, BMY rates highest, with a current score of 88%, signaling strong interest from this growth framework. The model targets low book-to-market stocks showing traits linked with sustained future growth, and BMY sits as a large-cap Biotechnology & Drugs stock. The accompanying criteria show BMY meeting many tests (BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, R&D TO ASSETS: PASS), supporting a favorable fundamental/valuation narrative. Note that a score above 90% indicates stronger interest, while 80%+ already suggests attention from the strategy.

BMY Factor-Based Stock Analysis: Partha Mohanram P/B Growth Model

October 16, 2025, 3:02 AM EDT. Validea's guru fundamental report flags Bristol-Myers Squibb Co (BMY) as a top pick under the P/B Growth Investor model developed by Partha Mohanram. This growth framework seeks low book-to-market stocks with characteristics of sustained future expansion. BMY earns an 88% rating, with the note that an 80%+ score signals interest and 90%+ indicates strong interest. The summary table shows many criteria as PASS-including Book/Market Ratio, Return on Assets, and Cash Flow from Operations to Assets-but lists R&D to Assets as a FAIL. Positioned as a large-cap in the Biotechnology & Drugs space, BMY is portrayed as a growth stock with solid fundamentals, according to Mohanram's framework. The report underscores Validea's emphasis on factor-based strategies and the potential for healthcare names to fit these models.

BMY Factor-Based Stock Analysis: Validea Guru Score Highlights Growth Model

October 16, 2025, 3:00 AM EDT. Validea sets Bristol-Myers Squibb (BMY) apart with a top score from the Partha Mohanram Growth/Book-to-Market model. BRISTOL-MYERS SQUIBB CO ranks 88% on the P/B Growth Investor approach, suggesting continued momentum from a low book-to-market profile paired with growth signals. The report notes PASS results for many metrics including Book/Market, Return on Assets, CFO/Assets, and R&D to Assets, while some criteria like ROA variance and Sales variance show stricter readings. With a large-cap biotech focus, the stock remains of interest to growth-oriented investors, typically signaling strength above 80% and stronger above 90%. Investors should weigh fundamentals against valuation and consider how the model's historical tilt toward growth names fits current market conditions.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 16, 2025, 2:58 AM EDT. BMY scores highest under Validea's P/B Growth Investor model, based on the published strategy of Partha Mohanram. The model seeks low book-to-market stocks with sustained growth traits, and here the stock rates 88%, suggesting notable strategic interest. Bristol-Myers Squibb is a large-cap growth name in the Biotechnology & Drugs space. A score of 80%+ implies interest, while 90%+ would imply strong interest. The accompanying tests show multiple PASS signals including Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, and R&D to Assets among others, painting a favorable fundamentals backdrop. The analysis underscores the potential for continued growth signals, though investors should consider broader risk factors and sector dynamics.

BMY Leads Validea's Partha Mohanram P/B Growth Model with 88% Rating

October 16, 2025, 2:56 AM EDT. Validea's guru fundamental report for Bristol-Myers Squibb Co (BMY) shows BMY ranking highest among 22 guru strategies under Partha Mohanram's P/B Growth Investor model. The growth model targets low book-to-market stocks with signs of durable growth. BMY, a large-cap growth stock in Biotechnology & Drugs, carries an 88% rating, signaling above-average interest (80% threshold) and near the strong-interest zone (90% threshold). The stock passes many tests across BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics; the table notes RESEARCH AND DEVELOPMENT TO ASSETS: FAILED. Overall, the model highlights BMY's fundamentals and valuation favorably within this framework and implies continued attention from growth-focused investors.

BMY: Validea Guru Analysis Highlights Partha Mohanram Growth Model

October 16, 2025, 2:54 AM EDT. Validea's guru fundamental report rates BMY (BRISTOL-MYERS SQUIBB CO) highly under Partha Mohanram's P/B Growth Investor model. The growth screen looks for low book-to-market stocks with signs of sustained future growth, and BMY scores 88%, signaling strong interest. The overview shows the stock passes key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS, with many metrics also passing for efficiency and investment intensity. Described as a large-cap growth stock in Biotechnology & Drugs, the analysis reflects Mohanram's view that selecting winners from low B/M stocks can outperform. The takeaway: this guru framework flags BMY as a favorable growth candidate with a high-strength signal, though not a guaranteed winner.

BMY Factor-Based Stock Analysis: Validea's Partha Mohanram Growth Model Highlights

October 16, 2025, 2:52 AM EDT. Validea's guru report places BMY at the top of Partha Mohanram's P/B Growth Investor model, which seeks low book-to-market stocks with durable growth. BMY scores 88%, signaling some interest rather than strong conviction (80%+ is interesting; 90%+ is strong). The stock is categorized as a large-cap growth name in the Biotechnology & Drugs space. In the table, most tests show PASS (BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, ROA VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS). The notable WEAKNESS is RESEARCH AND DEVELOPMENT TO ASSETS: FAILED. Overall, the outlook suggests potential interest for growth-focused investors, with caveats on how R&D is valued.

BMY Factor-Based Stock Analysis: Partha Mohanram P/B Growth Model Signals

October 16, 2025, 2:50 AM EDT. Validea's guru-based analysis ranks BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model from Partha Mohanram, scoring 88%. The growth screen favors low book-to-market stocks with signs of sustained future expansion. BMY is described as a large-cap growth stock in the Biotechnology & Drugs industry. The score suggests the strategy has at least some interest (scores ≥80%), with higher thresholds (≥90%) signaling stronger interest. Within the model's tests, Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, ROA variance, Sales variance, Advertising/Assets, CapEx/Assets, and R&D/Assets are evaluated; most pass, though R&D to Assets reportedly fails in this instance. Overall, the report highlights favorable fundamentals from this factor-based lens, with caveats noted on R&D capitalization.

Bristol-Myers Squibb (BMY) Factor-Based Growth Score Highlights Partha Mohanram Model

October 16, 2025, 2:48 AM EDT. BMY shows a strong tilt under Validea's Partha Mohanram P/B Growth Investor model, earning an 88% score and signaling meaningful interest from the growth framework. The model targets low book-to-market stocks with sustained growth traits. BMY passes key tests across the board, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS, RESEARCH AND DEVELOPMENT TO ASSETS, and other asset-related metrics. While weights vary by criterion, the stock's profile indicates solid efficiency and development investment, with a strong overall score suggesting notable interest for growth-oriented investors. The framework notes that scores above 80% imply interest, and above 90% imply strong interest, positioning BMY as a candidate for further review within a biotech growth context.

BMY Tops Partha Mohanram P/B Growth Model with 88% Rating

October 16, 2025, 2:46 AM EDT. Validea's guru analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model, delivering an 88% score. The growth framework seeks stocks with a low book-to-market and signs of sustained future expansion. BMY is positioned as a large-cap growth stock in the Biotechnology & Drugs sector. In this report, key tests such as book/market ratio, return on assets (ROA), cash flow from operations to assets, and R&D to assets pass, aligning with the model's emphasis on fundamentals and valuation. An 88% rating indicates strong interest, with higher signals (above 90%) reserved for especially compelling cases. The analysis underscores Mohanram's focus on growth persistence among low B/M stocks and points to BMY's fundamentals supporting the strategy's thesis within this framework.

BMY Factor-Based Stock Analysis: 88% Mohanram Growth Rating from Validea

October 16, 2025, 2:44 AM EDT. Validea's guru report on BMY shows the stock scoring 88% under Partha Mohanram's P/B Growth Investor model, a framework that seeks low book-to-market stocks with signs of sustained growth. Classified as a large-cap growth stock in the Biotechnology & Drugs group, BMY ranks near the top among Validea's 22 guru strategies. The rating suggests potential investor interest: scores of 80%+ indicate interest, and 90%+ signal strong interest. The model's test table mostly shows PASS across criteria like Book/Market, ROA, cash flow from operations to assets, and related metrics; one weakness noted is R&D to assets: FAIL. Overall, the signal reflects growth-oriented momentum tempered by biotech development risk.

Bristol-Myers Squibb (BMY) Factor-Based Growth Analysis Under Partha Mohanram Model

October 16, 2025, 2:42 AM EDT. Validea's guru fundamental report rates BMY highly under the P/B Growth Investor model from Partha Mohanram, a growth model focused on low book-to-market stocks with potential for sustained growth. The stock's rating is 88%, with scores above 90% signaling strong interest. The summary table shows most tests PASS, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS vs. RETURN ON ASSETS, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS; however, RESEARCH AND DEVELOPMENT TO ASSETS is marked FAILED. Overall, this frames BMY as a noteworthy candidate within this factor-based framework, balancing fundamentals and valuation per Mohanram's research.

BMY: Validea's 88% Partha Mohanram Growth Score Signals Strength for Bristol-Myers Squibb

October 16, 2025, 2:40 AM EDT. Bristol-Myers Squibb Co (BMY) earns an 88% score on Validea's Partha Mohanram P/B Growth Investor model, suggesting a favorable stance within growth stocks in the Biotechnology & Drugs space. The model targets low book-to-market stocks with characteristics linked to sustained future growth. BMY is classified as a large-cap growth name, with the rating driven by solid fundamentals and valuation signals. Most tests pass under the strategy, though R&D to assets: FAILED stands out as a caveat. The analysis highlights strong cash flow and asset efficiency alongside development investments. Investors should balance this factor-based signal with broader market factors and company fundamentals before trading.

BMY Factor-Based Stock Analysis: Validea Growth Model Highlights

October 16, 2025, 2:38 AM EDT. Validea's guru framework rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model. This growth model seeks low book-to-market stocks with signs of sustained future growth. BMY earns an 88% rating, indicating notable interest based on fundamentals and valuation (80% = some interest; 90% = strong interest). The accompanying test table shows many PASS results across criteria like BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, and RESEARCH AND DEVELOPMENT TO ASSETS. The analysis also highlights Partha Mohanram's growth framework and Validea's guru-based research. In short, BMY appears as a high-interest candidate under this growth-and-value approach, reflecting solid fundamentals and valuation signals.

BMY Factor-Based Stock Analysis – Partha Mohanram Growth Model

October 16, 2025, 2:36 AM EDT. Bristol-Myers Squibb Co (BMY) earns an 88% score on Validea's Partha Mohanram Growth Model, a growth framework focused on assessing stocks with a low book-to-market profile that still shows sustained potential. Classified as a large-cap growth stock in the Biotechnology & Drugs industry, BMY's fundamentals align with the model's criteria, yielding high interest (scores ≥80% indicate notable interest, and ≥90% signal strong interest). The firm shows PASS on key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, R&D to assets, among others. The analysis underscores the ongoing relevance of Mohanram's approach-separating winners from losers among low B/M stocks-while highlighting BMY's growth orientation and valuation as a driver of merit within Validea's guru framework.

GLW Factor-Based Stock Analysis: Pim van Vliet's Low-Volatility Momentum Model Yields Mixed Signals for Corning

October 16, 2025, 2:34 AM EDT. Validea's guru-based analysis for CORNING INCORPORATED (GLW) applies the Pim van Vliet-inspired Multi-Factor Investor model, which emphasizes low volatility, momentum, and high net payout yield. GLW rates highest among 22 guru strategies in this framework, yet the overall 62% rating reflects a middling stance based on fundamentals and valuation. The accompanying test table shows Market Cap: PASS and Standard Deviation: PASS, but Twelve Minus One Momentum: NEUTRAL and Net Payout Yield: NEUTRAL, yielding a Final Rank: FAILED. With a score below the typical 80% threshold for interest, the model signals cautious interest rather than conviction. The Pim van Vliet framework is from Robeco's Conservative Equities research, which argues for lower-risk exposures, though the final verdict here remains mixed for GLW.

GLW Factor-Based Stock Analysis: Pim van Vliet Multi-Factor View on Corning

October 16, 2025, 2:32 AM EDT. Validea flags CORNING INCORPORATED (GLW) as a top pick under the Pim van Vliet multi-factor framework. The model emphasizes low volatility, momentum, and high net payout yield, assigning GLW a 62% score, with thresholds of 80%/90% for stronger interest. The analysis shows the stock passes on Market Cap and Standard Deviation, is Neutral on Momentum and Net Payout Yield, and ends with a Final Rank: Failed. As a large-cap growth name in the Personal & Household Prods., GLW's strategy highlights cautious risk characteristics within a conservative factor landscape.

GLW Factor-Based Stock Analysis: Pim van Vliet Multi-Factor View on Corning (GLW)

October 16, 2025, 2:30 AM EDT. Validea's Pim van Vliet multi-factor score pegs CORNING INCORPORATED (GLW) at 62%, signaling some interest but not peak conviction. The strategy emphasizes low volatility with momentum and net payout yield considerations. In this analysis, GLW shows: MARKET CAP: PASS, STANDARD DEVIATION: PASS, TWELVE MINUS ONE MOMENTUM: NEUTRAL, NET PAYOUT YIELD: NEUTRAL, and a FINAL RANK: FAILD. The stock is a large-cap growth name in the Personal & Household Prods. industry. While the 62% rating suggests potential, the threshold of 80% for interest and 90% for strong interest is not met. The report frames Pim van Vliet's conservative, low-risk approach as favoring stocks that balance volatility with growth signals, and positions GLW as a moderate idea within this framework.

GLW Factor-Based Stock Analysis: Pim van Vliet Strategy Signals Mixed

October 16, 2025, 2:28 AM EDT. CORNING INCORPORATED (GLW) is evaluated by Validea's Pim van Vliet multi-factor model, which targets low volatility stocks with strong momentum and healthy net payout yield. The overall score sits at 62%, signaling some interest but not a top-tier signal. In the model's table, key tests show: MARKET CAP: PASS, STANDARD DEVIATION: PASS, TWELVE MINUS ONE MOMENTUM: NEUTRAL, NET PAYOUT YIELD: NEUTRAL, FINAL RANK: FAILED. GLW is a large-cap growth stock in the Personal & Household Prods. industry. While the strategy emphasizes lower risk and steady performance, the mixed readings and a failed final rank suggest caution for investors relying solely on this factor mix. Investors should consider corroborating signals beyond this single framework.

GLW Factor-Based Stock Analysis: Pim van Vliet Multi-Factor View on Corning

October 16, 2025, 2:26 AM EDT. Validea's Pim van Vliet-based framework casts CORNING INCORPORATED (GLW) as the top pick among 22 guru strategies, applying a multi-factor model that targets low-volatility stocks with momentum and high net payout yields. GLW is categorized as a large-cap growth stock in the Personal & Household Prods. industry, with a 62% rating based on fundamentals and valuation. The score signals some interest but is not a slam dunk. Key readings show Market Cap: PASS, Standard Deviation: PASS, Twelve Minus One Momentum: NEUTRAL, Net Payout Yield: NEUTRAL, and Final Rank: FAIL. In short, the factor mix indicates potential, but the overall screen yields a Fail and a moderate score-mixed signals rather than a clear buy.

GLW Factor-Based Stock Analysis: Pim van Vliet Multi-Factor View on Corning

October 16, 2025, 2:22 AM EDT. Validea's guru report rates CORNING INCORPORATED (GLW) highest among 22 strategies under Pim van Vliet's multi-factor framework, which targets low volatility, momentum, and net payout yield. The GLW score is 62% (below the typical interest thresholds of 80% or 90%), and the official rating final rank is FAILED. The overview table shows: Market Cap: PASS, Standard Deviation: PASS, Twelve Minus One Momentum: NEUTRAL, Net Payout Yield: NEUTRAL. GLW is a large-cap growth stock in the Personal & Household Prods. industry. The Pim van Vliet approach emphasizes conservative factor investing, but this stock does not pass this strategy's tests.

GLW Factor-Based Stock Analysis: Pim van Vliet Strategy Rates CORNING at 62%

October 16, 2025, 2:20 AM EDT. CORNING INCORPORATED (GLW) surfaces as the top pick within Validea's Pim van Vliet-based, multi-factor framework, which prioritizes low volatility, momentum, and high net payout yield. The GLW score sits at 62% for this strategy, suggesting some fundamental interest but not across the board. Key signals: MARKET CAP: PASS and STANDARD DEVIATION: PASS indicate favorable size and stability, while TWELVE MINUS ONE MOMENTUM: NEUTRAL and NET PAYOUT YIELD: NEUTRAL reduce conviction. The overall FINAL RANK: FAILED meaning the stock doesn't meet enough weightings to attract the strategy's strongest interest. In short, GLW shows mixed signals under this conservative-factor lens, offering a cautious read for risk-conscious investors.

GLW Factor-Based Stock Analysis: Pim van Vliet Multi-Factor Signal Mixed

October 16, 2025, 2:18 AM EDT. Validea's guru fundamental report for CORNING INCORPORATED (GLW) highlights the Pim van Vliet multi-factor model, which seeks low volatility stocks with momentum and strong net payout yields. GLW, a large-cap growth stock in Personal & Household Prods., scores 62% under the strategy, suggesting some interest but not a strong signal. Key checks: MARKET CAP: PASS; STANDARD DEVIATION: PASS; TWELVE MINUS ONE MOMENTUM: NEUTRAL; NET PAYOUT YIELD: NEUTRAL; FINAL RANK: FAILD. The result implies a mixed-to-moderate fit with this approach, despite meeting several low-vol criteria. Investors should weigh these factor signals against broader fundamentals and strategy context from Validea and Pim van Vliet.

GLW Factor-Based Stock Analysis: Pim van Vliet Multi-Factor View on Corning

October 16, 2025, 2:16 AM EDT. Validea's Pim van Vliet factor model flags CORNING INCORPORATED (GLW) as the top pick among its 22 guru strategies, emphasizing low volatility stocks with momentum and net payout yield advantages. The rating sits at 62%, below the typical 80% threshold for interest and far from the 90% level that signals strong interest. The table reads: Market Cap: PASS, Standard Deviation: PASS, Twelve Minus One Momentum: NEUTRAL, Net Payout Yield: NEUTRAL, Final Rank: FAIL. GLW is a large-cap growth name in Personal & Household Prods. While the strategy notes some favorable fundamentals, the overall signal is not compelling enough for endorsement. Investors should weigh the neutral momentum and payout signals against the cap and volatility positives.

GLW Factor-Based Stock Analysis: Pim van Vliet Model Rates Corning at 62%

October 16, 2025, 2:14 AM EDT. Corning Incorporated (GLW) registers as the top pick among Validea's Pim van Vliet multi-factor framework, which targets low volatility, momentum, and net payout yield. The stock earns a 62% fundamental/valuation score but receives a FINAL RANK: FAILED under this strategy. It passes MARKET CAP and STANDARD DEVIATION tests, while TWELVE MINUS ONE MOMENTUM is neutral and NET PAYOUT YIELD is neutral. GLW sits as a large-cap growth name in the Personal & Household Prods. group. The takeaway: the model favors risk-aware exposure with limited momentum signals, indicating modest interest despite the strong underlying fundamentals.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 16, 2025, 2:10 AM EDT. Validea's guru-based review rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram Growth (P/B Growth) framework. The model seeks low book-to-market names with evidence of sustained future growth. BMY earns an 88% rating from this strategy, with a threshold of 80% signaling interest and 90% signaling strong interest. The analysis flags a string of supportive signals, including PASS on BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, as well as multiple ROA-related metrics. While every criterion carries weight, the overall read is favorable for growth-focused exposure in the Biotechnology & Drugs space. Investors may view this as a potential driver for further research, noting the stock's large-cap profile and growth orientation within the Validea framework.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals High Interest

October 16, 2025, 2:08 AM EDT. Bristol-Myers Squibb Co. (BMY) scores highly under Validea's P/B Growth Investor model, a Partha Mohanram growth framework that favors low book-to-market stocks with sustained growth. The stock earns 88% in this guru strategy, signaling notable interest (80%+ indicates interest; 90%+ strong interest). In the summary table, BMY passes criteria such as Book/Market, Return on Assets, and CFO to Assets, and R&D to Assets is marked as FAILED. The analysis highlights BMY as a large-cap Biotechnology & Drugs name with growth characteristics, but the model flags some weaknesses in R&D to Assets allocation despite other strengths. Overall, the rating suggests the strategy finds potential in BMY's fundamentals and valuation within the context of this guru approach.

BMY earns 88% on Validea's Partha Mohanram Growth model

October 16, 2025, 2:06 AM EDT. Bristol-Myers Squibb Co. (BMY) earns top marks on Validea's Partha Mohanram Growth model, scoring 88% for combining a low book-to-market profile with indicators of sustained growth. The guru analysis notes the stock passes key tests-Book/Market Ratio, Return on Assets, and Cash Flow from Operations to Assets-and highlights related metrics like R&D to Assets. With a rating above 80%, the strategy signals meaningful interest, and a score near 90% suggests stronger appeal. Classified as a large-cap growth stock in Biotechnology & Drugs, BMY is positioned as a growth-oriented selection within the sector, though investors should consider industry dynamics and potential variability in growth signals.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model – 88% Rating

October 16, 2025, 2:04 AM EDT. Validea applies Partha Mohanram's Growth model to BRISTOL-MYERS SQUIBB CO (BMY), rating it 88% under the P/B Growth Investor approach. The model seeks low book-to-market stocks with signs of sustained future growth. BMY is a large-cap growth stock in the Biotechnology & Drugs industry. The Guru score suggests strong interest, typically 80% or higher, with readings often above 90%. The accompanying table shows tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS, generally PASS, with results aligned to the strategy. Overall, the analysis highlights solid fundamentals and valuation alignment with Mohanram's criteria within Validea's factor-based framework.

BMY Leads Validea's P/B Growth Investor Screen (Partha Mohanram)

October 16, 2025, 2:02 AM EDT. Bristol-Myers Squibb Co (BMY) earns the highest score among Validea's guru strategies on the P/B Growth Investor model, the growth framework popularized by Partha Mohanram. The model targets low book-to-market names with evidence of sustained future growth, and BMY posts an 88% rating-above the 80% threshold and approaching the level that signals strong interest near 90%. The analysis shows favorable readings on key tests, including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, with the overall signal supporting exposure to the Biotechnology & Drugs space. While not all criteria are equal, the composite score under Mohanram's growth approach highlights BMY as a noteworthy growth stock, grounded in fundamental strength and strategy-specific criteria.

Bristol-Myers Squibb (BMY) Tops Partha Mohanram P/B Growth Model in Validea Guru Analysis

October 16, 2025, 2:00 AM EDT. Validea's guru report for Bristol-Myers Squibb (BMY) shows the stock at the top of Partha Mohanram's P/B Growth model. This growth model screens for low book-to-market names with durable earnings potential. BMY garners an 88% rating, with thresholds of 80% for interest and 90% for strong interest. The scorecard indicates a mix of PASS signals across key metrics (BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CFO/ROA, ROA variance, SALES VARIANCE, ADVERTISING TO ASSETS, CAPEX TO ASSETS), with RESEARCH AND DEVELOPMENT TO ASSETS noted as a FAILED criterion. As a large-cap growth stock in the Biotechnology & Drugs sector, BMY's fundamentals align with growth exposure, suggesting continued monitoring for earnings growth and valuation support.

Bristol-Myers Squibb shines under Partha Mohanram's P/B Growth model (Validea Guru Analysis)

October 16, 2025, 1:58 AM EDT. Validea's guru analysis shows BRISTOL-MYERS SQUIBB CO (BMY) rates highest under the P/B Growth Investor model, a Partha Mohanram strategy focused on low book-to-market stocks with strong growth traits. The stock scores 88% overall, with a rating in the range that signals interest (80%+) and near-strong interest (90%+). In this framework, key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS pass, while the overall narrative emphasizes robust fundamentals in a large-cap Biotechnology & Drugs profile. The analysis also highlights Mohanram's contribution to growth investing and notes the firm's methodology and how Validea compiles his signals into stock ideas.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates Bristol-Myers Squibb at 88%

October 16, 2025, 1:56 AM EDT. Validea's guru fundamental report places Bristol-Myers Squibb (BMY) at the top of 22 guru strategies under the P/B Growth Investor model, based on Partha Mohanram's framework. The model seeks low book-to-market stocks with signs of sustained growth. BMY, a large-cap growth stock in the Biotechnology & Drugs space, earns an 88% rating from this strategy-well above threshold for interest. The accompanying criteria table shows broad strength across metrics like Book/Market, Return on Assets, and Cash Flow, but flags a FAIL on R&D to assets. The score implies interest from the strategy, with a few concerns before broader conviction.

BMY Factor-Based Stock Analysis: Validea's Partha Mohanram Growth Model Signals Strong Interest

October 16, 2025, 1:54 AM EDT. Bristol-Myers Squibb (BMY) earns an 88% score under Validea's Partha Mohanram P/B Growth Investor model, a growth-screen that favors low book-to-market stocks with sustained growth. As a large-cap Biotechnology & Drugs stock, BMY shows PASS on key tests (Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, and R&D to Assets). The model's emphasis on growth and valuation yields notable strong interest at 88% (scores above 90% indicate stronger conviction). This analysis reflects Validea's use of Mohanram's research to separate growth leaders from laggards, highlighting BMY as a potential factor-based candidate for growth-oriented portfolios.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Scores Bristol-Myers Squibb 88%

October 16, 2025, 1:52 AM EDT. Bristol-Myers Squibb (BMY) earns top marks under Validea's guru framework, driven by Partha Mohanram's P/B Growth Investor model. The strategy seeks low book-to-market stocks with sustained growth traits, and BMY posts an 88% score-above the threshold signaling investor interest, with scores above 90% indicating strong interest. In Validea's table, the stock passes key screens such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, while RESEARCH AND DEVELOPMENT TO ASSETS is flagged as a weakness. As a large-cap Biotechnology & Drugs name, BMY may appeal to growth-oriented investors, though the model warns that R&D intensity can affect asset-based metrics. Validea contextualizes how Mohanram's growth philosophy applies to BMY and its portfolio implications.

BMY Factor-Based Growth Rating Highlights Partha Mohanram Model

October 16, 2025, 1:50 AM EDT. Validea's guru-based analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highest in the P/B Growth Investor model by Partha Mohanram, with an 88% rating. The growth model seeks low book-to-market stocks with signs of durable growth, and BMY ranks strongly among the 22 guru strategies. The summary table shows strengths on several tests, including Book/Market, Return on Assets, and Cash Flow from Operations to Assets, while noting a FAIL on R&D to Assets. Overall, BMY presents a favorable mix of fundamentals and valuation signals under Mohanram's framework, with scores in the 80%+ range indicating some interest and the potential for strong interest (90%+) in select cases. Investors should monitor R&D efficiency and industry dynamics.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 16, 2025, 1:48 AM EDT. Validea's guru framework places BRISTOL-MYERS SQUIBB CO (BMY) near the top among 22 strategies with the P/B Growth Investor model (Partha Mohanram). The stock earns an 88% score, signaling meaningful interest, with a high-growth tilt through low book-to-market metrics and sustained growth indicators. Across the criteria, key tests such as BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, and CASH FLOW FROM OPERATIONS TO ASSETS: PASS support, though RESEARCH AND DEVELOPMENT TO ASSETS is marked as a potential weakness (FAIL). In Validea's framework, scores above 80% spark interest and above 90% denote strong interest.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Yields 88%

October 16, 2025, 1:46 AM EDT. Validea's guru report places Bristol-Myers Squibb Co (BMY) at the top among 22 guru strategies using the P/B Growth Investor model tied to Partha Mohanram. The growth framework seeks low book-to-market stocks with characteristics associated with durable expansion. As a large-cap growth stock in the Biotechnology & Drugs sector, BMY earns an 88% rating under this strategy, with higher scores suggesting stronger interest. The table shows tests like BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, while RESEARCH AND DEVELOPMENT TO ASSETS: FAIL highlights a potential weakness. The report walks through Mohanram's research and Validea's interpretation. Investors should weigh this growth signal against other fundamentals and risk factors.

BMY Shines in Partha Mohanram P/B Growth Model: Validea Guru Analysis

October 16, 2025, 1:44 AM EDT. Validea's guru fundamental report rates Bristol-Myers Squibb Co (BMY) highly under the P/B Growth Investor model based on Partha Mohanram's research. The growth model targets low book-to-market stocks with indicators of sustained future growth, and BMY earns an 88% rating-an indication of interest but not the strongest conviction (90%+). The analysis notes several credits: the stock passes the metrics for BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, among others, while RESEARCH AND DEVELOPMENT TO ASSETS is listed as FAILED. As a large-cap Biotechnology & Drugs stock, BMY combines solid fundamentals with a growth tilt that aligns with Mohanram's framework.

BMY Factor-Based Growth Analysis: Partha Mohanram Model Highlights

October 16, 2025, 1:42 AM EDT. Validea's guru-based analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model, a Partha Mohanram framework that favors low book-to-market stocks with growth signals. BMY earns an 88% rating, indicating notable interest from the strategy. The report flags positives: the stock passes the BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS tests, among others. While valuation and growth drive the signal, the model also underscores solid cash flow and asset efficiency in a large-cap biotechnology group. For investors seeking exposure to a credible growth stock in pharma, this analysis emphasizes fundamentals over hype and supports a constructive view on BMY.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Signals Strong Interest

October 16, 2025, 1:40 AM EDT. Validea's guru fundamental report on BRISTOL-MYERS SQUIBB CO (BMY) shows the stock ranking highest among 22 guru strategies under Partha Mohanram's P/B Growth Investor model. The growth framework targets low book-to-market names with sustainable future expansion. BMY's rating stands at 88% – indicating solid fundamentals and valuation; in Validea's scale, 80%+ signals some interest, 90%+ signals strong interest. In the factor table, several key tests pass: BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related efficiency gauges. Notably, R&D to assets is marked as FAIL, while other areas like SALES VARIANCE and CAPEX TO ASSETS pass. BMY is categorized as a large-cap growth stock in Biotechnology & Drugs, suggesting growth-oriented investors may find the stock appealing based on this framework.

Bristol-Myers Squibb (BMY) Scores 88% on Partha Mohanram P/B Growth Model (Validea Guru Analysis)

October 16, 2025, 1:38 AM EDT. Validea's guru analysis assigns Bristol-Myers Squibb (BMY) an 88% rating under the P/B Growth Investor model from Partha Mohanram, highlighting its growth characteristics in the Biotechnology & Drugs space. The model seeks low book-to-market stocks with proven growth traits, and an 88% score suggests meaningful interest from this strategy (scores above 90% indicate stronger interest). The accompanying table shows most criteria as PASS across measures such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS, though RESEARCH AND DEVELOPMENT TO ASSETS is flagged as a weakness (marked FAIL). Overall, the report portrays BMY as a growth-oriented name within Validea's framework, reflecting its appeal to this guru approach.

BMY Factor-Based Growth Analysis Signals Mohanram Strategy Interest

October 16, 2025, 1:36 AM EDT. Validea's guru fundamental report ranks BRISTOL-MYERS SQUIBB CO (BMY) highly among 22 guru strategies. The P/B Growth Investor model, based on Partha Mohanram, rates BMY at 88%-indicating meaningful interest from the strategy. The model searches for low book-to-market names with sustained growth traits, and BMY is categorized as a large-cap Biotechnology & Drugs stock. A score above 80% suggests interest, with 90% signaling strong interest. Of the tests, most criteria are PASS, including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW measures. Notable exception: RESEARCH AND DEVELOPMENT TO ASSETS is FAIL. Overall, the stock shows notable appeal under this factor-based approach, with a potential caveat around R&D intensity alignment.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strength

October 16, 2025, 1:34 AM EDT. Validea's guru fundamental report flags BRISTOL-MYERS SQUIBB CO (BMY) as a standout under the P/B Growth Investor model (published by Partha Mohanram), rating it 88% based on solid fundamentals and valuation. BMY is a large-cap growth stock in the Biotechnology & Drugs industry, with the growth screen targeting low book-to-market stocks showing signs of sustained future expansion. The model reports PASS on core tests-from BOOK/MARKET RATIO and RETURN ON ASSETS to CASH FLOW FROM OPERATIONS TO ASSETS and beyond-supporting growth momentum. With a score above 80%, the strategy indicates interest, and a score above 90% would imply strong interest. Investors should consider how these factors align with growth potential and risk in biotech.

BMY Factor-Based Stock Analysis Highlights Mohanram Growth Model

October 16, 2025, 1:32 AM EDT. BMY earns a high score under Validea's Partha Mohanram P/B Growth Investor model, signaling a potential continued rise for this large-cap biotechnology & drugs stock. The analysis shows low book-to-market characteristics paired with growth indicators, with a current rating of 88% (scores above 90% suggest strong interest). The model's tests show passes on Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, and other key metrics, with detailed weaknesses limited in the table. As the Guru framework prioritizes growth factors, BMY stands out among its peers, though investors should weigh the model's emphasis on fundamentals and valuation before trading.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Scores 88%

October 16, 2025, 1:30 AM EDT. Validea's guru fundamental report places Bristol-Myers Squibb Co. (BMY) at the top of its factor-based screen using the P/B Growth Investor model from Partha Mohanram. The stock earns an 88% rating, signaling strong interest from this growth framework, which targets low book-to-market stocks with growth characteristics. In the assessment, BMY passes key tests across criteria such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, with supportive signals in CFO to Assets and ROA dynamics. The report notes that a score of 80% or above implies some interest, with above 90% indicating strong interest. Investors should view this as one piece of the puzzle, combining it with broader fundamentals and biotech industry context.

BMY Factor-Based Stock Analysis – Validea Mohanram Growth Model Scores 88%

October 16, 2025, 1:28 AM EDT. Validea's guru report ranks BRISTOL-MYERS SQUIBB CO (BMY) highly on the Partha Mohanram P/B Growth Investor model, a growth framework focused on low book-to-market stocks with signs of sustained expansion. BMY earns an 88% rating under this strategy, signaling interest from the model (scores 80%+ indicate interest; 90%+ suggest strong interest). The stock is described as a large-cap growth name in the Biotechnology & Drugs sector. The table shows the stock PASSing most tests-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, and RESEARCH AND DEVELOPMENT TO ASSETS is marked as FAILED. Overall, the analysis highlights foundational strength but a potential weakness in R&D TO ASSETS alignment.

BMY Factor-Based Growth Score: 88% Under Mohanram P/B Growth Model

October 16, 2025, 1:26 AM EDT. Validea's guru fundamental report for Bristol-Myers Squibb Co (BMY) shows the stock topping the 22-guru framework under Partha Mohanram's P/B Growth model. The growth-oriented screen looks for low book-to-market stocks with signs of sustained future expansion. BMY, a large-cap in Biotechnology & Drugs, earns an 88% rating on fundamentals and valuation-well above the 80% threshold, with 90%+ signaling strong interest. The score summary flags a mix of largely favorable tests: Book/Market, Return on Assets, Cash Flow from Operations to Assets, Cash Flow to ROA, Sales Variance, Advertising to Assets, Capital Expenditures to Assets, and R&D to Assets (the latter appears to fail). Note: This model emphasizes growth persistence over simple value, and a high Mohanram score suggests potential upside if growth drivers persist.

BMY Factor-Based Stock Analysis: Validea's Mohanram Growth Model Yields 88%

October 16, 2025, 1:24 AM EDT. Validea's guru report rates BRISTOL-MYERS SQUIBB CO (BMY) highly on the P/B Growth Investor model, which targets low book-to-market stocks with durable growth. BMY earns an 88% score, signaling strong interest from this strategy and a favorable valuation read. The analysis shows Pass marks on key tests – including Book/Market, ROA, CFO/Assets, CFO/ROA variance, Sales variance, R&D to assets – with a focus on capital deployment. Overall, BMY appears as a growth-oriented large-cap in Biotechnology & Drugs under Mohanram's framework, reflecting Validea's test framework and the strategy's emphasis on quality growth signals.

Bristol-Myers Squibb (BMY) High Mohanram P/B Growth Rating from Validea

October 16, 2025, 1:22 AM EDT. Validea's guru analysis ranks Bristol-Myers Squibb (BMY) highest among its 22 growth-focused strategies using the P/B Growth Investor model anchored to Partha Mohanram's framework. The model seeks low book-to-market stocks with growth characteristics, and BMY posts an 88% rating, well above the typical thresholds (80% indicates interest; 90% signals strong interest). The summary table shows passes across core tests like Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, and related metrics, with several sections emphasizing solid asset efficiency, R&D intensity, and capex alignment to assets. Overall, the stock presents a favorable signal under this factor-based approach, though investors should consider industry dynamics and broader market risk before trading.

BMY Factor-Based Stock Analysis: Mohanram P/B Growth Signals Strong Interest

October 16, 2025, 1:20 AM EDT. Validea's guru-analysis ranks BRISTOL-MYERS SQUIBB CO (BMY) highest among 22 strategies under Partha Mohanram's P/B Growth Investor model. The growth model targets low book-to-market stocks with sustained growth traits, and BMY scores 88%, indicating strong interest. The stock is categorized as a large-cap growth play in Biotechnology & Drugs. The model reports PASS on measures such as Book/Market, Return on Assets, Cash Flow from Operations to Assets, and Cash Flow to ROA, with favorable ROA variance and cash-flow dynamics. While not all criteria bear equal weight, the takeaway is that BMY benefits from growth-oriented signals under this strategy. Investors may view BMY as a candidate for growth-tilted portfolios, given the Mohanram framework and the 88% rating.

BMY Factor-Based Stock Analysis: Partha Mohanram's P/B Growth Model Signals for Bristol-Myers Squibb

October 16, 2025, 1:18 AM EDT. Validea's guru fundamental report rates BRISTOL-MYERS SQUIBB CO (BMY) highly under Partha Mohanram's P/B Growth Investor model. The growth framework seeks low book-to-market stocks with indicators of sustained future expansion, and BMY earns a sharp 88% score-above the 80% threshold and below the 90% mark that signals strong interest. The table shows PASS on key criteria, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and ROA-related measures, with R&D to assets: FAIL. As a large-cap Biotechnology & Drugs stock, BMY remains of interest to growth investors under this factor-based approach, despite some weaknesses in R&D asset accounting.

Bristol-Myers Squibb (BMY) Factor-Based Stock Analysis: 88% Score Under Partha Mohanram Growth Model

October 16, 2025, 1:16 AM EDT. Bristol-Myers Squibb Co. (BMY) earns an 88% score under Validea's P/B Growth Investor model, a Partha Mohanram framework that highlights growth potential in low book-to-market stocks. The stock is a large-cap growth name in the Biotechnology & Drugs sector. The model flags strengths across tests such as Book/Market Ratio, Return on Assets (ROA), CFO to Assets, and Sales Variance, while noting a weakness on R&D to Assets. Overall, the reading signals meaningful interest from the strategy, with the caveat that a detailed review of R&D allocation and other growth drivers is prudent. In short, BMY shows compelling fundamentals under this growth lens, but investors should weigh R&D efficiency against potential long-term growth.

Bristol-Myers Squibb (BMY) Factor-Based Stock Analysis: 88% on Mohanram Growth Model

October 16, 2025, 1:14 AM EDT. Validea's guru-based assessment ranks BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model derived from Partha Mohanram. The stock scores 88%, with a score above 80% signaling notable interest and above 90% signaling strong interest. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs industry. The model favors low book-to-market stocks that exhibit sustained growth, and the accompanying table shows many tests as PASS (e.g., BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, R&D TO ASSETS), highlighting strengths across valuation and fundamentals. The analysis also provides background on Partha Mohanram and Validea's approach to factor-based portfolios, underscoring how his growth framework seeks winners among growth stocks.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model

October 16, 2025, 1:12 AM EDT. Bristol-Myers Squibb Co (BMY) earns the top rating in Validea's Partha Mohanram P/B Growth model with an 88% score. The model seeks low book-to-market stocks with growth characteristics, and BMY's fundamentals align with sustained growth. The strategy shows PASS on key tests, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS (though the last is listed as FAIL in the report). The overall score above 80% signals notable interest; 90%+ would indicate strong interest. Investors should view this as a growth-oriented signal from a respected academic-based framework, while noting the single R&D TO ASSETS FAIL caveat and the absence of a flawless pass across all criteria.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Highlights 88% Rating

October 16, 2025, 1:10 AM EDT. Validea's guru fundamentals rate BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model. The growth screen seeks low book-to-market stocks with signs of sustained growth. BMY, a large-cap company in the Biotechnology & Drugs industry, earns 88% on this strategy-indicating at least some investor interest (scores above 90% imply strong interest). The summary table shows PASS across key tests: BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, ROA VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, R&D TO ASSETS. Overall, BMY meets the model's criteria with a favorable fundamental/valuation read.

BMY: Validea Growth Score 88% Under Partha Mohanram P/B Growth Model

October 16, 2025, 1:08 AM EDT. Validea's guru-based analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under Partha Mohanram's P/B Growth model, scoring 88%. The model seeks low book-to-market stocks with sustained growth, placing BMY in the large-cap Biotechnology & Drugs arena. Key takeaways: BOOK/MARKET RATIO, RETURN ON ASSETS, and operations metrics all show PASS; R&D, CAPEX, and cash-flow dynamics support ongoing growth. The table indicates a favorable profile with multiple PASS signals, though weights are not uniform across tests. A score above 90% signals strong interest; at 88%, BMY shows notable interest but may require corroboration before a top-weighted position. Overall, the stock is a growth-oriented, high-quality biotech with strong fundamentals per this strategy.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates Bristol-Myers Squibb 88%

October 16, 2025, 1:06 AM EDT. Bristol-Myers Squibb (BMY) ranks highest on Validea's Partha Mohanram P/B Growth Investor model, a growth screen that seeks low book-to-market stocks with signs of sustained expansion. The stock earns an 88% rating, indicating strong interest from the strategy (thresholds: 80% to 90%+, with >90% showing stronger conviction). In tests, BMY passes key metrics such as Book/Market Ratio, ROA, CFO/Assets, ROA Variance, Sales Variance, Advertising to Assets, and Capital Expenditures to Assets; only R&D to Assets fails. The analysis notes that weights vary and that growth signals can be nuanced. The framework draws on Mohanram's research, 'Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis,' and positions BMY as a large-cap growth stock in Biotechnology & Drugs.

BMY Ranked 88% by Partha Mohanram's P/B Growth Investor Model (Validea)

October 16, 2025, 1:04 AM EDT. Validea's guru analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under Partha Mohanram's P/B Growth Investor model. The growth framework seeks low book-to-market stocks with signs of sustained future growth. BMY scores 88%, signaling strong interest from this strategy (80% threshold; 90% signals "strong interest"). The stock is categorized as a large-cap Growth name in Biotechnology & Drugs. In the model's test table, key metrics such as Book/Market, Return on Assets, Cash Flow from Operations to Assets, and R&D to Assets are noted as PASS, with R&D to Assets the sole failure. Overall, the model highlights BMY's fundamentals and valuation as a potential contributor to upside under this framework, though other guru lenses should be considered.

Bristol-Myers Squibb (BMY) Rated by Partha Mohanram P/B Growth Model on Validea

October 16, 2025, 1:02 AM EDT. Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) ranks highly under the Partha Mohanram P/B Growth Investor model, a growth-focused approach that seeks low book-to-market names with durable expansion. BMY scores 88% across 22 guru strategies, indicating some but not top-tier interest (scores above 90% signal strong interest). The detailed tests show several PASS outcomes, including BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, CAPITAL EXPENDITURES TO ASSETS: PASS, with a notable exception: RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. As a large-cap biotechnology stock, BMY blends growth signals with the need to reconcile R&D investment against asset bases. Overall, the stock is worth watching for growth-oriented portfolios under this framework.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Signals Strong Interest

October 16, 2025, 1:00 AM EDT. Bristol-Myers Squibb (BMY) scores highly under Validea's Partha Mohanram Growth model, landing an 88% rating and signaling investor interest. The model targets low book-to-market names that show signs of sustained earnings growth, and BMY fits as a large-cap growth stock in Biotechnology & Drugs with a favorable balance among key tests. Highlights include passing the BOOK/MARKET, RETURN ON ASSETS, and OPERATIONS cashflow metrics, plus strong ROA stability and positive operating cash flow to assets. While all criteria are weighted differently, the overall reading suggests the stock may offer growth durability and valuation alignment under this guru framework. Investors should consider how BMY's fundamentals align with their growth-oriented thesis and risk tolerance.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Highlights

October 16, 2025, 12:58 AM EDT. Validea's guru-based review rates Bristol-Myers Squibb (BMY) highest under the P/B Growth Investor model developed by Partha Mohanram. This growth screen targets low book-to-market stocks with signs of sustained expansion. BMY scores 88%, suggesting strong interest from this strategy and potential upside. The accompanying table shows PASS on several tests, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS, and R&D to assets. While not a guarantee, the high rating highlights a growth tilt for investors tracking large-cap biotech names like BMY.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Highlights

October 16, 2025, 12:56 AM EDT. Validea's guru-based take on Bristol-Myers Squibb Co. (BMY) centers on the P/B Growth Investor model from Partha Mohanram. The large-cap biotech/drug stock earns an 88% rating under this growth framework, suggesting meaningful interest from the strategy. The analysis flags a favorable skew toward low book-to-market, high-growth candidates, with the table noting passes for BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and other asset-to-growth metrics, and a notable PASS for R&D TO ASSETS. While not all criteria are equal, the overall read is supportive of continued growth momentum. Investors should weigh this against broader market factors and the stock's valuation, as a score above 90% would indicate strong interest, while the 80%+ range signals continued attention.

BMY Scores High Under Partha Mohanram P/B Growth Model

October 16, 2025, 12:54 AM EDT. Validea's guru-based analysis places Bristol-Myers Squibb (BMY) at the top of its P/B Growth Investor model developed by Partha Mohanram. The stock is categorized as a large-cap growth name in the Biotechnology & Drugs space, earning an 88% rating-above the 80% threshold and near the 90% line that signals strong interest. The model's tests show PASS for key measures such as BOOK/MARKET RATIO, RETURN ON ASSETS, and cash-flow metrics, with R&D TO ASSETS marked as a FAIL. The write-up also covers Mohanram's background and Validea's framework for factor-based portfolios. In short, the Growth model flags meaningful interest in BMY among growth-focused investors, though the R&D intensity caveat remains a consideration.

BMY Factor-Based Growth Signal: Validea Rates Bristol-Myers Squibb at 88% Under Mohanram P/B Growth

October 16, 2025, 12:52 AM EDT. Validea's guru-based report ranks BRISTOL-MYERS SQUIBB CO (BMY) highest on Partha Mohanram's P/B Growth Investor model. The growth framework targets low book-to-market names with signs of sustained expansion. BMY, a large-cap player in the Biotechnology & Drugs sector, earns an 88% rating under this strategy, with the threshold for interest at 80% and strong interest above 90%. The accompanying table shows most tests passing-such as BOOK/MARKET RATIO and various ROA and cash-flow metrics-while notably RESEARCH AND DEVELOPMENT TO ASSETS failed. Overall, Mohanram's model flags BMY as a meaningful growth candidate within Validea's factor-based portfolios, pending broader context and other factors.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals High Interest

October 16, 2025, 12:50 AM EDT. BMY's guru score under Validea's Partha Mohanram P/B Growth Investor model clocks in at 88%, the highest among 22 guru strategies for Bristol-Myers Squibb (BMY). The model seeks low book-to-market stocks with growth traits. With an 88% rating, the stock shows notable growth indicators, and a score above 90% would indicate strong interest. The analysis notes most tests are PASS for criteria like BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, ROA VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, and CAPITAL EXPENDITURES TO ASSETS, but RESEARCH AND DEVELOPMENT TO ASSETS fails. Investors should weigh this mix in the context of Bristol-Myers Squibb's large-cap biotechnology profile.

BMY Factor-Based Stock Analysis: Partha Mohanram P/B Growth Model Signals Growth Potential

October 16, 2025, 12:48 AM EDT. Validea's guru analysis on BMY shows it scoring highly under Partha Mohanram's P/B Growth Investor model, a framework that screens for low book-to-market stocks with growth signals. BRISTOL-MYERS SQUIBB CO earns an 88% rating from this strategy, suggesting strong interest. Classified as a large-cap in the Biotechnology & Drugs space, the stock passes several tests-BOOK/MARKET RATIO, RETURN ON ASSETS, and related cash-flow criteria-though weights vary across criteria. The takeaway: BMY's growth signals look compelling, but investors should balance these signals with other value and volatility factors in this sector.

Bristol-Myers Squibb (BMY) Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals High Interest

October 16, 2025, 12:46 AM EDT. Validea's guru-based analysis rates Bristol-Myers Squibb (BMY) 88% on the P/B Growth Investor model, the strategy associated with Partha Mohanram. The model targets low book-to-market stocks with earnings acceleration, and the BMY score signals meaningful interest from this growth framework. BMY is a large-cap growth stock in the Biotechnology & Drugs group. Among the criteria, most tests pass (e.g., Book/Market, Return on Assets, Cash Flow from Operations to Assets), while R&D to Assets did not meet the threshold. The takeaway is that the stock has attractive fundamentals per this growth-factor approach, though investors should weigh the R&D to Assets weakness against broader growth drivers. This report sits within Validea's factor-based signals and highlights potential upside from sustained earnings growth.

Bristol-Myers Squibb (BMY) Earns 88% on Partha Mohanram P/B Growth Model

October 16, 2025, 12:44 AM EDT. Validea's guru-based analysis ranks Bristol-Myers Squibb (BMY) highly under the P/B Growth Investor model from Partha Mohanram. As a large-cap growth stock in Biotech/Drugs, BMY earns an 88% score, with 80%+ signaling interest and 90%+ signaling strong interest. The model targets low book-to-market stocks with growth traits; BMY passes key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and other asset-related metrics, while some tests cover R&D to Assets and CAPEX to ASSETS. The write-up also highlights Mohanram's research on separating winners among low B/M stocks. Overall, BMY appears timely within this framework, illustrating how growth signals can persist for large-cap pharma.

BMY Factor-Based Analysis: Partha Mohanram P/B Growth Score Hits 88%

October 16, 2025, 12:42 AM EDT. Validea's guru-based analysis ranks BRISTOL-MYERS SQUIBB CO (BMY) highly on the Partha Mohanram P/B Growth Investor model. The model targets low book-to-market stocks with signs of sustained future growth. BMY scores 88%, with strong fundamentals and valuation; a score above 80% signals interest, above 90% signals strong interest. The table shows BMY passes key tests across BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, ROA VARIANCE, SALES VARIANCE, and asset-related metrics such as ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, and RESEARCH AND DEVELOPMENT TO ASSETS. This reflects Partha Mohanram's growth framework applied to a large-cap Biotechnology & Drugs stock, with Validea highlighting BMY as a name with potential based on growth persistence in low book-to-market stocks.

BMY Tops Validea with Partha Mohanram Growth Model Rating

October 16, 2025, 12:40 AM EDT. Validea's guru analysis places BRISTOL-MYERS SQUIBB CO (BMY) highest among 22 guru strategies using the P/B Growth Investor model from Partha Mohanram. The growth framework seeks low book-to-market stocks with signs of sustained future growth. BMY earns an 88% rating, with a score above 80% signaling interest and above 90% signaling strong interest. In this model, key checks like BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, and several other criteria also PASS, though RESEARCH AND DEVELOPMENT TO ASSETS: FAIL is noted. BMY sits in the large-cap Biotechnology & Drugs space; the table summarizes strong points and a few weaknesses in the context of Mohanram's criteria.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Moderate to High Interest

October 16, 2025, 12:38 AM EDT. Validea rates BRISTOL-MYERS SQUIBB CO (BMY) at 88% under the Partha Mohanram P/B Growth model, signaling notable interest from this growth-focused framework. The model screens for low book-to-market stocks with signs of sustained growth. BMY is a large-cap Biotechnology & Drugs stock with favorable fundamentals and valuation. Key signals: BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, CFO/ROA: PASS, ROA VARIANCE: PASS, SALES VARIANCE: PASS, ADVERTISING TO ASSETS: PASS, CAPITAL EXPENDITURES TO ASSETS: PASS; but RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. An overall score at or above 80% suggests the strategy has some interest; above 90% would imply strong interest. Investors should weigh the growth signals against the single R&D intensity concern and consider BMY's long-term trajectory in the biotech space.

Bristol-Myers Squibb (BMY) earns 88% on Partha Mohanram Growth Model per Validea guru analysis

October 16, 2025, 12:36 AM EDT. BRISTOL-MYERS SQUIBB CO (BMY) is analyzed by Validea under the Partha Mohanram P/B Growth model. The growth-focused framework flags a 88% rating, with the guideline that 80% or higher indicates some interest and 90% signals strong interest. BMY is a large-cap Biotechnology & Drugs stock, and the table shows most tests PASS, including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS. It also passes CFO/ROA VARIANCE and several asset-related measures, while RESEARCH AND DEVELOPMENT TO ASSETS is listed as FAIL. Overall, the model supports favorable growth-oriented fundamentals for BMY, though the failed R&D TO ASSETS criterion warrants closer scrutiny before any buy decision.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals for Bristol-Myers Squibb

October 16, 2025, 12:34 AM EDT. Validea's guru-based analysis rates Bristol-Myers Squibb (BMY) highly on the P/B Growth Investor model, founded on Partha Mohanram's growth framework. At 88%, the score signals strong interest from this approach, which seeks low book-to-market stocks with durable growth. The overview shows strengths in BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, with RESEARCH AND DEVELOPMENT TO ASSETS passing. As a large-cap in Biotechnology & Drugs, BMY aligns with the growth profile despite sector risks. This factor-based signal should be weighed alongside overall fundamentals, valuation, and portfolio risk tolerance.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 16, 2025, 12:32 AM EDT. Validea's guru-based analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highest on the P/B Growth Investor model from Partha Mohanram. The growth model screens for low book-to-market stocks with signals of sustained future growth. BMY earns an 88% score under this framework, indicating meaningful interest from this strategy. The summary table shows many tests are PASS (e.g., BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS), with the overall emphasis on growth characteristics rather than traditional value. As one of 22 guru strategies Validea tracks, this analysis highlights BMY as a potential growth stock in the Biotechnology & Drugs sector, driven by fundamentals and valuation signals aligned with Partha Mohanram's research.

BMY Tops Partha Mohanram P/B Growth Model with 88% Rating

October 16, 2025, 12:30 AM EDT. Validea's guru analysis ranks BRISTOL-MYERS SQUIBB CO (BMY) highly on the Partha Mohanram P/B Growth Investor model, scoring 88% based on fundamentals and valuation. The model seeks low book-to-market stocks with evidence of sustained future growth. BMY is a large-cap Biotechnology & Drugs stock, and the score signals some to strong interest under this strategy (80%+). The accompanying table shows strong performance on several tests, including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW TO ASSETS, with multiple criteria passing. Overall, the analysis suggests BMY could fit a growth-oriented portfolio tilt per Mohanram's framework, though investors should consider broader fundamentals and healthcare sector dynamics.

BMY Factor-Based Analysis: Partha Mohanram Growth Model Rates BMY at 88%

October 16, 2025, 12:28 AM EDT. Validea's guru fundamental report flags BRISTOL-MYERS SQUIBB CO (BMY) as a top pickup under Partha Mohanram's P/B Growth Investor model. The growth framework seeks low book-to-market stocks with signs of sustained future expansion. BMY, a large-cap in Biotechnology & Drugs, earns 88% from this strategy-well above 80% and signaling some interest, with near-90% rating approaching strong interest. The criteria table shows most tests passing, including Book/Market, Return on Assets, CFO to Assets, and ROA Variance; note R&D to Assets is listed as failing. Additional context covers Mohanram's methodology and Validea's approach. The bottom line: this model flags BMY as a potentially favorable growth-positioned holding.

Validea Guru Analysis: BMY Rates High Under Mohanram's P/B Growth Model

October 16, 2025, 12:26 AM EDT. Validea's guru-based analysis ranks BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model by Partha Mohanram. The methodology seeks low book-to-market stocks with growth characteristics, and BMY scores 88%, suggesting notable interest (versus the 80% threshold) and near-strong conviction beyond 90%. The model reports many positive signals across its tests, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS. While some criteria are weighted, the table highlights strengths in operating efficiency and asset use, with multiple tests marked PASS. Overall, the stock sits in a large-cap Biotechnology & Drugs space with a growth orientation, indicating the model's favorable view on sustained future expansion.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Signals Strong Growth

October 16, 2025, 12:24 AM EDT. BRISTOL-MYERS SQUIBB CO (BMY) earns an 88% rating under Validea's Partha Mohanram P/B Growth Investor model, signaling notable interest from this growth framework. The model seeks low book-to-market stocks with sustained growth, and BMY sits as a large-cap Biotechnology & Drugs name with growth characteristics. The accompanying table shows most tests PASS (Book/Market Ratio, ROA, Cash Flow from Operations to Assets, CFO to Assets vs. ROA, ROA variance, Sales variance, Advertising to Assets, CapEx to Assets) with R&D to Assets: FAIL. The 80%+ threshold typically flags interest, while 90%+ suggests stronger interest. Overall, the stock carries growth signals under Mohanram's approach, though the single R&D-to-Assets weakness tempers the view. Investors should weigh robust operating metrics against R&D intensity.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Signals Growth Potential

October 16, 2025, 12:22 AM EDT. Validea's guru fundamental review rates Bristol-Myers Squibb Co (BMY) at 88% under Partha Mohanram's P/B Growth Investor model, signaling meaningful interest from growth-focused investors. The growth framework targets low book-to-market stocks with signs of sustained expansion, placing BMY in the large-cap Biotechnology & Drugs space. Key takeaways: BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS VS. ROA: PASS, ROA VARIANCE: PASS, SALES VARIANCE: PASS, ADVERTISING TO ASSETS: PASS, CAPITAL EXPENDITURES TO ASSETS: PASS, RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. The rating indicates the strategy has noteworthy interest, though it falls short of the strongest tier (≥90%).

Bristol-Myers Squibb (BMY) Shines in Partha Mohanram's P/B Growth Guru Model – 88%

October 16, 2025, 12:20 AM EDT. Validea's guru analysis rates Bristol-Myers Squibb (BMY) highly under the P/B Growth Investor model developed by Partha Mohanram, placing the stock in strong interest territory with a current score of 88%. The model seeks low book-to-market names with signs of sustained growth, and BMY is classified as a large-cap Biotechnology & Drugs stock. The breakdown shows broad PASS signals for key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and CAPITAL EXPENDITURES TO ASSETS, but the table notes a FAIL on RESEARCH AND DEVELOPMENT TO ASSETS. With an 80%+ threshold for interest and 90%+ for strong interest, BMY sits in the favorable range according to this strategy.

Bristol-Myers Squibb (BMY) Factor-Based Stock Analysis: Mohanram Growth Model Yields 88% Rating

October 16, 2025, 12:16 AM EDT. Validea's guru fundamental report on Bristol-Myers Squibb (BMY) shows the stock ranking highest among 22 guru strategies under the P/B Growth Investor model developed by Partha Mohanram. The model seeks low book-to-market stocks with sustained growth traits, and for BMY the strategy yields an 88% rating, indicating strong interest (80%+; >90% is strong interest). The accompanying criteria table reports PASS for key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics, with RESEARCH AND DEVELOPMENT TO ASSETS as the notable FAIL. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs industry. The write-up also provides background on Mohanram and Validea's framework.

BMY Factor-Based Growth Signal Under Mohanram Model – Validea Analysis

October 16, 2025, 12:14 AM EDT. Validea's guru framework grades BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram 'P/B Growth' model. Among 22 guru strategies, BMY earns the top score on this growth screen, reflecting a favorable mix of a low book-to-market profile and indicators of durable future expansion. The firm's 88% rating under the growth model suggests meaningful interest, though not yet at the "strongest" threshold (≥90%). The analysis notes broad strength on key tests-Book/Market, ROA, CFO to assets, and related profitability metrics-while R&D to assets flags an area of weakness. As a large-cap Biotechnology & Drugs name, BMY's growth orientation must still reconcile capital allocations, cash flow drivers, and development spend with valuation. Overall, a growth-attractor with caveats centered on R&D intensity and cyclicality.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 16, 2025, 12:12 AM EDT. Validea's guru analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model, which seeks low book-to-market stocks with growth characteristics. BMY scores 88% for this strategy, with the guideline that 80%+ indicates interest and 90%+ strong interest. The model's overview shows PASS on key criteria such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics like R&D to Assets and CAPEX to Assets. As a large-cap biotechnology stock, BMY's fundamentals and valuation align with the growth-focused, low-book-to-market cohort. Investors can consider how these signals integrate with their risk tolerance and diversification goals within the sector.

Bristol-Myers Squibb (BMY) Factor-Based Growth Analysis: Validea Guru Report Highlights Partha Mohanram Model

October 16, 2025, 12:10 AM EDT. Bristol-Myers Squibb (BMY) earns a high score on Validea's guru-based analysis using the P/B Growth model derived from Partha Mohanram's work. The report flags BMY as a large-cap growth stock in the Biotechnology & Drugs industry, with an 88% rating under this strategy, suggesting meaningful interest from the model and valuation. The summary table shows strengths in Book/Market, Return on Assets, Cash Flow from Operations to Assets, and other asset-related metrics, with the table noting several criteria pass. The analysis highlights the model's focus on low book-to-market stocks with indicators of sustained growth, and places BMY among stocks that may warrant further consideration for growth-oriented portfolios.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Signals High Interest

October 16, 2025, 12:08 AM EDT. Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) shows the stock ranking highly under the Partha Mohanram P/B Growth Investor model. BMY is described as a large-cap growth stock in the Biotechnology & Drugs industry, with an 88% rating, signaling strong interest from the model. The analysis notes that most tests pass, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS, RETURN ON ASSETS VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, and CAPITAL EXPENDITURES TO ASSETS; the R&D TO ASSETS: FAIL. While weights vary, the overall read is favorable for growth potential, aligning with Mohanram's approach to identifying low book-to-market stocks with sustained growth.

BMY: Partha Mohanram P/B Growth Signal – 88% Rating (Validea)

October 16, 2025, 12:06 AM EDT. Validea's guru-based analysis flags Bristol-Myers Squibb (BMY) as a top pick under Partha Mohanram's P/B Growth Investor model. The growth framework seeks low book-to-market stocks with indicators of sustained expansion, and BMY earns an 88% rating, signaling notable interest. BMY is described as a large-cap growth stock in Biotechnology & Drugs, with the model noting several positive checks. The table shows multiple criteria such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS as PASS, while others are supportive. An 80%+ score suggests investor interest; a 90%+ would indicate stronger conviction. The report also references Guru Analysis, Partha Mohanram's portfolio approach, and related factor-based portfolios.

Bristol-Myers Squibb (BMY) Scores 88% on Partha Mohanram Growth Model, Validea Reports

October 16, 2025, 12:04 AM EDT. Validea's guru-based analysis rates Bristol-Myers Squibb (BMY) at 88% under the Partha Mohanram Growth model, indicating notable interest. The model searches for low book-to-market stocks with signs of sustained growth. For BMY, the table shows BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, R&D TO ASSETS: PASS, and other tests also PASS or strong. As a large-cap biotech, BMY is positioned as a growth stock within the Biotechnology & Drugs space. A score above 80% signals interest; above 90% signals strong interest according to Validea. Overall, the analysis highlights BMY as a candidate to watch for growth-oriented portfolios.

Bristol-Myers Squibb (BMY) Indicator Strength Under Partha Mohanram Growth Model | Validea Guru Analysis

October 16, 2025, 12:02 AM EDT. Validea's guru analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram Growth Model. This low book-to-market, growth-oriented approach ranks BMY at 88%, with a threshold of 80% indicating interest and 90% signaling strong interest. The stock is categorized as a large-cap growth name in the Biotechnology & Drugs sector. The model shows PASS on key tests, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CFO to ROA, ROA VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, and RESEARCH AND DEVELOPMENT TO ASSETS. Overall, the result suggests solid growth-oriented fundamentals for BMY with notable interest from the strategy and a backdrop of healthcare exposure.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Interest

October 16, 2025, 12:00 AM EDT. Validea's guru-based assessment ranks Bristol-Myers Squibb (BMY) highly on the P/B Growth Investor model tied to Partha Mohanram. With an 88% score, the stock shows strong interest from this growth framework. The firm is a large-cap player in the Biotechnology & Drugs space and exhibits favorable readings on key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS. The analysis also notes solid ROA vs. cash flow dynamics and encouraging R&D-to-assets signals, while metrics like CAPITAL EXPENDITURES TO ASSETS receive attention. Overall, the 88% rating suggests potential upside under this factor-based approach, though investors should consider diversification and broader risk alongside fundamentals.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates Bristol-Myers at 88%

October 15, 2025, 11:58 PM EDT. Bristol-Myers Squibb Co. (BMY) scores highly under Validea's Partha Mohanram P/B Growth Investor model, a growth framework that targets low book-to-market stocks with sustained expansion. BMY, a large-cap player in Biotechnology & Drugs, carries an 88% rating based on fundamentals and valuation, signaling notable interest. The model flags strengths across multiple tests-e.g., Book/Market, Return on Assets, and Cash Flow from Operations signals-with most criteria passing. One exception: Research and Development to Assets was marked as FAILED. A sub-90% score suggests room for upside but also volatility typical of biotech names, so investors should weigh the growth thesis against risk and confirm alignment with their own portfolio goals.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Rates Bristol-Myers Squibb at 88%

October 15, 2025, 11:56 PM EDT. Validea's guru-based analysis of BRISTOL-MYERS SQUIBB CO (BMY) shows it ranks highest under the P/B Growth Investor model attributed to Partha Mohanram. The model seeks low book-to-market stocks with characteristics of sustained growth. BMY earns an 88% rating under this strategy, with many tests passing (e.g., BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS). The analysis notes a large-cap growth profile in Biotechnology & Drugs and states that a score at or above 80% indicates interest, with 90%+ signaling strong interest. Overall, the report frames BMY as a potential candidate under factor-based growth strategies, supported by fundamentals, valuation, and growth alignments.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Scores 88%

October 15, 2025, 11:54 PM EDT. Validea's guru-focused report rates BRISTOL-MYERS SQUIBB CO (BMY) highest under Partha Mohanram's P/B Growth Investor model. The growth screen seeks low book-to-market stocks with sustained growth and assigns BMY an 88% rating, signaling notable interest from this strategy. BMY, a large-cap in Biotechnology & Drugs, shows a string of PASS marks across key tests-BOOK/MARKET RATIO, ROA, CFO/Assets, CFO/ROA variance, and R&D-to-Assets, among others-even as some criteria carry different weights. The result underscores a potential growth catalyst in BMY's fundamentals, though investors should weigh this within broader value vs growth dynamics and the stock's longer-term fundamentals.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Interest

October 15, 2025, 11:52 PM EDT. Bristol-Myers Squibb Co (BMY) rates highest on Validea's P/B Growth Investor model, derived from Partha Mohanram's growth framework that targets low book-to-market stocks with durable growth. The stock earns an 88% score, with scores above 80% signaling interest and above 90% signaling strong interest. The guru-table shows several PASS signals, such as BOOK/MARKET RATIO and RETURN ON ASSETS, plus favorable cash-flow metrics, consistent with Mohanram growth criteria. As a large-cap within Biotechnology & Drugs, BMY remains a relevant candidate for factor-based growth strategies, and Validea aggregates this view with other guru methodologies. Overall takeaway: BMY aligns with the growth-oriented, factor-based approach under the Partha Mohanram framework, yielding notable investor interest.

BMY Tops Validea's Partha Mohanram Growth-Model Analysis (88% Score)

October 15, 2025, 11:50 PM EDT. Validea's guru report ranks BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model by Partha Mohanram, placing BMY among growth prospects with a score of 88%. The model targets low book-to-market stocks with indicators of sustained growth. In this large-cap Biotechnology & Drugs stock, BMY earns PASS on key tests including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, among others. The analysis highlights a favorable alignment of fundamentals and valuation, suggesting this stock may be of interest to growth-oriented portfolios. The report provides background on Partha Mohanram and his work on distinguishing winners among low book-to-market stocks. Investors should consider the model's growth emphasis when evaluating BMY.

BMY Factor-Based Stock Analysis: 88% Mohanram Growth Rating for Bristol-Myers Squibb

October 15, 2025, 11:48 PM EDT. Validea rates Bristol-Myers Squibb (BMY) highly under Partha Mohanram's P/B Growth Investor model, which targets low book-to-market stocks with signs of sustained growth. BMY earns an 88% score-well above the 80% threshold signaling interest and approaching the 90% mark for strong interest. The model's table shows passes on key metrics such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS, with a noted failure on RESEARCH AND DEVELOPMENT TO ASSETS. As a large-cap in the Biotechnology & Drugs space, the stock is evaluated on growth, profitability, and balance-sheet signals within the growth framework. Investors should assess how BMY's fundamentals align with the Mohanram criteria and biotech dynamics.

BMY Factor-Based Stock Analysis – Validea Growth Model Signals Strong Interest

October 15, 2025, 11:46 PM EDT. Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) shows the stock ranking highest on the P/B Growth Investor model, a growth framework by Partha Mohanram. The stock is categorized as a large-cap growth name in the Biotechnology & Drugs space. The model returns an 88% rating, signaling notable interest (a score above 90% indicates strong interest; above 80% suggests some interest). The analysis summarizes key tests: BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS VS. ROA: PASS, RETURN ON ASSETS VARIANCE: PASS, SALES VARIANCE: PASS, ADVERTISING TO ASSETS: PASS, CAPITAL EXPENDITURES TO ASSETS: PASS, and RESEARCH AND DEVELOPMENT TO ASSETS: FAILED. The report links to more on Mohanram and the guru methodology.

BMY Factor-Based Analysis: Partha Mohanram Growth Model Signals Interest

October 15, 2025, 11:44 PM EDT. Validea rates BRISTOL-MYERS SQUIBB CO (BMY) highly on the Partha Mohanram P/B Growth Investor model, giving an 88% score. The growth framework seeks low book-to-market stocks with characteristics linked to sustained future growth. In Validea's report, BMY is a large-cap growth stock in the Biotechnology & Drugs industry. A score of 80%+ indicates interest, while above 90% signals strong interest. The table shows multiple tests as PASS (e.g., BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, ROA VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, RESEARCH AND DEVELOPMENT TO ASSETS) with one criterion not meeting the target for R&D to assets. Overall, the model suggests potential interest for growth-focused investors following Mohanram's framework.

BMY Factor-Based Stock Analysis: 88% Mohanram Growth Score

October 15, 2025, 11:42 PM EDT. Validea's guru report flags Bristol-Myers Squibb Co (BMY) as a top pick under the Partha Mohanram P/B Growth Investor model, which favors low book-to-market stocks with growth traits. BMY carries a score of 88%, well above the 80% threshold and signaling strong interest. The detailed checks show most criteria pass, including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS (and related ROA variance and sales variance). The sole weakness is RESEARCH AND DEVELOPMENT TO ASSETS: FAILED. As a large-cap biotech, the model highlights growth potential despite the R&D caveat. Overall, the rating suggests meaningful exposure to continued growth for BMY within its sector.

Bristol-Myers Squibb (BMY) Scores 88% on Partha Mohanram Growth Model (Validea)

October 15, 2025, 11:40 PM EDT. Validea's guru report on Bristol-Myers Squibb (BMY) shows the stock scoring highly on the P/B Growth Investor model, Partha Mohanram's framework for identifying low book-to-market stocks with signs of sustained future growth. BMY, a large-cap in the Biotechnology & Drugs group, earns an 88% rating under this strategy, suggesting notable growth-oriented interest (scores above 90% reflect stronger conviction). The analysis highlights passing signals across key tests-BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS-with several criteria affirming strength and elements like R&D to assets and CAPEX to assets favorable. In short, Validea portrays BMY as a growth-friendly pick with solid fundamentals under Mohanram's model, though investors should weigh the usual biotechnology risks.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Growth Potential

October 15, 2025, 11:38 PM EDT. Bristol-Myers Squibb Co. (BMY) earns a high mark under Validea's Partha Mohanram Growth model, one of 22 guru strategies tracked. The growth framework seeks low book-to-market stocks with durable earnings growth, and BMY scores 88%-a level signaling meaningful investor interest (80%+ indicates potential; 90%+ strong interest). The firm is described as a large-cap growth stock in Biotechnology & Drugs, with most tests passing across metrics such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, though RESEARCH AND DEVELOPMENT TO ASSETS fails in this model. Overall, the report portrays BMY as a solid candidate under this growth criterion, suggesting potential for growth-focused investors following Mohanram's framework.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strength

October 15, 2025, 11:36 PM EDT. Validea's guru analysis rates Bristol-Myers Squibb Co (BMY) highest under the P/B Growth Investor model, the Partha Mohanram framework focused on low book-to-market stocks with growth characteristics. BMY earns an 88% score, indicating notable interest from the strategy (scores above 90% signal strong interest). The accompanying table shows multiple tests labeled PASS across criteria such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW TO ASSETS, among others, suggesting a favorable fundamentals/valuation mix. As a large-cap growth stock in Biotechnology & Drugs, BMY's placement aligns with Mohanram's growth signal and supports ongoing attention from factor-based portfolios.

BMY scores 88% on Partha Mohanram's P/B Growth model (Validea analysis)

October 15, 2025, 11:34 PM EDT. Bristol-Myers Squibb Co. (BMY) is rated a large-cap growth stock in the Biotechnology & Drugs space by Validea's Partha Mohanram P/B Growth model. The stock scores 88% based on fundamentals and valuation, signaling 'some to strong' interest for this growth-screen. The Mohanram growth model targets low book-to-market stocks with potential for sustained growth. In the summary table, most tests clear: Book/Market Ratio PASS, Return on Assets PASS, Cash Flow from Operations to Assets PASS, CFO to Assets vs ROA PASS, ROA variance PASS, Sales Variance PASS, Advertising to Assets PASS, Capital Expenditures to Assets PASS. The lone weakness is R&D to Assets: FAIL. Overall, BMY appears favorable on this factor-based screen, with the caveat that the R&D to Assets treatment drags the score slightly.

BMY Factor-Based Stock Analysis: Partha Mohanram P/B Growth Model at 88%

October 15, 2025, 11:32 PM EDT. Bristol-Myers Squibb Co. (BMY) earns a strong rating from Validea's Partha Mohanram P/B Growth Investor model, scoring 88% and signaling some interest from the growth-oriented screen. The model targets low book-to-market stocks with indicators of sustained future growth, placing BMY in the large-cap Biotechnology & Drugs space. The score suggests investors may find merit, though not yet at the strongest level (>90%). The accompanying test table shows many criteria as PASS-including Book/Market Ratio, Return on Assets, and CFO to Assets-but notes a R&D to Assets: FAIL in the current framework. Overall, BMY is highlighted as a notable holder within Partha Mohanram's factor-based stock portfolios.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Scores 88%

October 15, 2025, 11:30 PM EDT. Validea's guru-based analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth model, giving the stock an 88% score. This growth approach seeks low book-to-market names with sustained growth traits. BMY is classified as a large-cap growth stock in Biotech & Drugs, with the model highlighting favorable PASS results across key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS. The report notes the importance of R&D to assets and related investment dynamics. In Validea's framework, a score of 80%+ signals interest, while 90%+ signals strong conviction. At 88%, BMY sits in the high-intermediate range, suggesting meaningful interest for growth-minded portfolios and observers of Partha Mohanram's growth signals in healthcare.

Bristol-Myers Squibb (BMY) Tops Partha Mohanram Growth Model in Validea Rating

October 15, 2025, 11:28 PM EDT. Validea's guru-based view rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model derived from Partha Mohanram. The growth-focused screen seeks low book-to-market names with signs of sustained expansion. BMY clocks an 88% score, signaling meaningful interest from the strategy. The report notes multiple PASS outcomes across criteria such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, with favorable comparisons like CFO/Assets vs. ROA and solid R&D to Assets. While the note emphasizes growth tilt, it sits within Validea's broader framework where scores of 80%+ indicate potential interest and 90%+ strong conviction. Overall, BMY is highlighted as a large-cap growth stock in the Biotechnology & Drugs space with favorable fundamentals according to this model.

BMY Factor-Based Stock Analysis Under Partha Mohanram Growth Model

October 15, 2025, 11:26 PM EDT. Bristol-Myers Squibb (BMY) posts a high score under Validea's Partha Mohanram P/B Growth Investor model, signaling potential as a growth stock. The firm earns an 88% rating, with a score above 90% typically implying stronger interest. The model favors low book-to-market stocks exhibiting sustainable growth. Key tests are Book/Market, Return on Assets, CFO to assets, CFO to ROA, and related variance and asset-to-expense metrics, all passing, while R&D to assets fails. BMY is classified as a Large-Cap stock in the Biotechnology & Drugs space. Overall, the report underscores the model's emphasis on growth signals and notes the R&D allocation weakness as a potential point of concern.

BMY Factor-Based Growth Analysis: Partha Mohanram P/B Growth Score at 88%

October 15, 2025, 11:24 PM EDT. Bristol-Myers Squibb Co (BMY) earns a high 88% rating under Validea's Partha Mohanram P/B Growth Investor model, a growth framework that favors low book-to-market stocks with signs of sustained future expansion. BMY is a large-cap Biotechnology & Drugs stock scoring strongly on several criteria. The model's table shows most tests as PASS for BOOK/MARKET RATIO, ROA, cash flow metrics, and asset returns, with one notable exception: RESEARCH AND DEVELOPMENT TO ASSETS comes up as FAIL. The overall takeaway: the stock shows meaningful growth signals per this guru's approach, though investors should weigh the R&D-related concern against the strong fundamentals. A score above 90% would indicate stronger consensus; at 88%, BMY shows strong interest from this strategy without a full consensus.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals 88%

October 15, 2025, 11:22 PM EDT. Bristol-Myers Squibb Co. (BMY) earns top marks on Validea's Partha Mohanram P/B Growth Investor model, which seeks low book-to-market stocks with sustained growth. The large-cap biotech giant rates 88%, signaling strong interest from this growth-focused strategy. In the model's framework, key metrics such as Book/Market, Return on Assets, and Cash Flow from Operations to Assets appear favorable, while R&D to Assets is noted as a weaker point in the table. The result positions BMY as a potential growth play within the Biotechnology & Drugs space. Investors should note that factor-based signals are one input among many and do not guarantee future performance.

BMY Factor-Based Stock Analysis: Mohanram P/B Growth Model Signals Growth Interest

October 15, 2025, 11:20 PM EDT. Bristol-Myers Squibb (BMY) lands a high rating under Validea's guru framework, led by the P/B Growth Investor approach of Partha Mohanram. The model favors low book-to-market stocks with characteristics of sustained growth, and rates BMY at 88% – signaling strong interest from this strategy. The accompanying score suggests the stock is of interest when the rating is above 80%, with above 90% denoting strong interest. In the table of tests, BMY passes on BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics such as R&D to Assets and CAPEX to ASSETS, with a few caveats. Overall, the analysis frames BMY as a substantial growth candidate within the biotechnology/drugs sector, per the Mohanram model.

BMY shines under Partha Mohanram's P/B Growth model with an 88% rating

October 15, 2025, 11:18 PM EDT. Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) shows the stock scoring highest under Partha Mohanram's P/B Growth Investor model, a framework targeting low book-to-market names with signs of sustained growth. BMY, a large-cap growth stock in the Biotechnology & Drugs industry, earns an 88% rating, signaling notable interest from this strategy (scores above 90% show strong interest; around 80% signals some interest). Most tests come back PASS across the framework-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, ROA VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS-though RESEARCH AND DEVELOPMENT TO ASSETS is listed as FAIL, representing a key weakness. The model reflects Mohanram's approach to separating growth winners from losers among low book-to-market stocks.

Bristol-Myers Squibb (BMY) Shines in Partha Mohanram Growth Model – Validea Guru Analysis

October 15, 2025, 11:16 PM EDT. Validea's guru fundamental report ranks BRISTOL-MYERS SQUIBB CO (BMY) highest under the P/B Growth Investor model linked to Partha Mohanram. The growth-focused screen seeks low book-to-market stocks with signs of sustained future expansion. BMY is a large-cap growth stock in the Biotechnology & Drugs space. The overall rating is 88%, and Validea notes that a score of 80%+ signals interest, while a score above 90% signals strong interest. In the test table, key checks such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and others PASS, with R&D TO ASSETS noted as FAIL. The analysis ties to Mohanram's work and Validea's methodology, offering context for growth investors considering BMY.

BMY Factor-Based Stock Analysis: Partha Mohanram's P/B Growth Model Tops Validea

October 15, 2025, 11:14 PM EDT. Validea's guru-style assessment ranks BRISTOL-MYERS SQUIBB CO (BMY) highest under the P/B Growth Investor model authored by Partha Mohanram. The model targets low book-to-market stocks with signs of sustained future growth. BMY earns an 88% rating, well above the 80% threshold that signals interest and approaching the 90% mark for strong interest. The report pools 22 guru strategies, with this one placing BMY among the top picks in the Biotechnology & Drugs sector. In the detailed table, key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS largely pass, while endpoints like R&D TO ASSETS also contribute to the overall score. As a large-cap growth stock, BMY combines solid fundamentals with favorable valuation signals per Validea's framework.

BMY Rated Strongly by Partha Mohanram Growth Model (Validea Guru Analysis)

October 15, 2025, 11:12 PM EDT. Validea's guru fundamental report places BRISTOL-MYERS SQUIBB CO (BMY) at the top among 22 guru strategies under the P/B Growth Investor model authored by Partha Mohanram. This growth model screens for low book-to-market stocks with signs of sustained future growth. BMY earns an 88% rating from this strategy, with scores below 80% indicating little interest and above 90% signaling strong interest. In the model's test table, most criteria pass-Book/Market Ratio: PASS, Return on Assets: PASS, Cash Flow from Operations to Assets: PASS, and so on-except R&D to Assets: FAIL. The overall message: BMY is viewed as a high-interest candidate under this growth framework, reflecting its fundamentals and valuation despite the R&D caveat.

BMY Factor-Based Stock Analysis: Validea Growth Model Highlights 88% Score

October 15, 2025, 11:10 PM EDT. Validea rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram Growth model, delivering an 88% score and signaling interest in a low book-to-market stock with sustained growth prospects. As a large-cap player in the Biotechnology & Drugs industry, BMY shows a favorable balance of fundamentals and valuation per this strategy. The model's table notes core strengths across the framework, including BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, and related efficiency metrics, with other criteria such as ADVERTISING TO ASSETS: PASS and R&D TO ASSETS: PASS. While weights vary, the overall reading suggests the stock aligns with Mohanram's growth approach and may warrant further investor examination.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Yields 88% Rating (Validea)

October 15, 2025, 11:08 PM EDT. Bristol-Myers Squibb Co (BMY) garners the top rating among Validea's 22 guru strategies under Partha Mohanram's Growth Investor model, scoring 88% based on fundamentals and valuation. The model seeks low book-to-market stocks with indicators of sustained future growth. BMY is categorized as a large-cap Biotechnology & Drugs stock. A score of 80%+ signals interest; 90%+ would imply strong interest. The report notes BMY passes key tests such as Book/Market, Return on Assets, Cash Flow from Operations to Assets, and related metrics, with areas flagged for attention like advertising to assets, capital expenditures to assets, and R&D to assets. The analysis reflects Mohanram's work on separating winners from losers among low book-to-market stocks and positions BMY within Validea's factor-based portfolios.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Scores Bristol-Myers Squibb at 88%

October 15, 2025, 11:06 PM EDT. Bristol-Myers Squibb Co (BMY) scores highly under Validea's P/B Growth Investor model, a Partha Mohanram strategy that seeks low book-to-market stocks with growth potential. BMY earns an 88% rating-well within the range indicating interest and approaching strong interest above 90%. The stock is characterized as a large-cap growth name in the Biotechnology & Drugs space. In the factor table, most tests show PASS (Book/Market, ROA, cash flow metrics, etc.), with RESEARCH AND DEVELOPMENT TO ASSETS listed as a FAIL. Overall, the model highlights BMY as a candidate with solid fundamentals and valuation from this guru framework, though R&D efficiency to assets remains a caveat. Additional context on Partha Mohanram and related portfolios is provided.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Scores 88%

October 15, 2025, 11:04 PM EDT. Bristol-Myers Squibb Co. (BMY) scores highly under Validea's Partha Mohanram Growth Investor model, ranking 88% on the low book-to-market, growth-oriented approach. The large-cap biotech/drugs stock shows a favorable mix of fundamentals and valuation, with PASS marks on book/market ratio, return on assets, cash flow metrics, and asset efficiency metrics such as CFO/Assets, CFO/ROA, ROA variance, sales variance, advertising to assets, and capital expenditures to assets. The model flags one weakness: R&D to assets: FAIL, which can temper the optimism given biotechnology's heavy R&D intensity. Overall, the strategy indicates strong interest (score ≥80%) in BMY, suggesting potential for continued growth if R&D leverage translates into sustained profitability. Partha Mohanram's framework emphasizes growth traits in low B/M stocks, guiding this assessment.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Signals Interest

October 15, 2025, 11:02 PM EDT. Validea's guru fundamental report ranks Bristol-Myers Squibb Co (BMY) highly under Partha Mohanram's P/B Growth Investor model. BMY is a large-cap growth stock in the Biotechnology & Drugs space. The model shows an 88% rating, signaling notable interest (scores of 80%+ suggest interest; 90%+ would indicate strong interest). The summary table shows PASS results across key tests, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS, R&D TO ASSETS, and others, highlighting favorable fundamentals under this growth framework. This analysis reflects Mohanram's approach that targets low book-to-market firms with sustained growth. Overall, BMY rates highest among Validea's 22 guru strategies for this stock, suggesting potential upside per this factor-based method.

Bristol-Myers Squibb (BMY) Factor-Based Analysis Under Mohanram Growth Model – 88% Rating

October 15, 2025, 11:00 PM EDT. Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) shows BMY scoring highest under the Partha Mohanram P/B Growth Investor model, which targets low book-to-market stocks with enduring growth. The stock, a large-cap Biotechnology & Drugs name, earns an 88% rating, with 80% indicating interest and 90% indicating strong interest. The overview table shows many tests as PASS: BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CFO TO ROA, ROA VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS. The one FAIL is RESEARCH AND DEVELOPMENT TO ASSETS. Overall, the model highlights potential appeal within a growth framework, noting the single weakness in R&D asset allocation.

BMY Factor-Based Growth Analysis: High Mohanram Model Score

October 15, 2025, 10:58 PM EDT. Validea's guru-based assessment rates BRISTOL-MYERS SQUIBB CO (BMY) highly on the Partha Mohanram Growth model, with an 88% score indicating strong interest. The model searches for low book-to-market stocks with growth traits, and BMY passes key tests such as Book/Market, Return on Assets, Cash Flow from Operations to Assets, and R&D to Assets. The report highlights robust fundamentals in a large-cap Biotechnology & Drugs framework, noting strengths in cash flow efficiency and asset utilization while flagging areas where weights apply. Overall, a score above 80% suggests meaningful interest, with the mid-to-high 80s often signaling potential for continued outperformance under this strategy.

BMY Leads Validea's Partha Mohanram P/B Growth Model with 88% Rating

October 15, 2025, 10:56 PM EDT. Validea's guru report on Bristol-Myers Squibb (BMY) shows an 88% rating under Partha Mohanram's P/B Growth model, signaling strong interest in growth-oriented stocks. The model targets low book-to-market names with sustained growth, and BMY is categorized as a large-cap Biotechnology & Drugs stock. The table indicates PASS on key tests like BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics. The overall read suggests the strategy sees solid fundamentals and favorable valuation for continued growth, though investors should consider the broader market context and Validea's composite framework for a balanced view.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals High Interest

October 15, 2025, 10:54 PM EDT. Validea's guru report places BRISTOL-MYERS SQUIBB CO (BMY) at the top of 22 guru strategies when assessed with the Partha Mohanram P/B Growth Investor model. The growth framework seeks low book-to-market stocks with characteristics tied to sustained future growth. BMY scores 88% overall, reflecting strong fundamentals and valuation, with 80%+ signaling interest and 90%+ signaling strong interest. The model's tests show PASS on BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS, RETURN ON ASSETS VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS; the only weakness is RESEARCH AND DEVELOPMENT TO ASSETS, which FAILS. This suggests growth potential per Mohanram's framework, tempered by the R&D-to-assets caveat.

BMY Tops Validea's Partha Mohanram P/B Growth Model with 88% Rating

October 15, 2025, 10:52 PM EDT. Validea flags BRISTOL-MYERS SQUIBB CO (BMY) as a top pick under the P/B Growth Investor model from Partha Mohanram. The growth-oriented framework seeks low book-to-market stocks with signs of sustained growth, rating BMY at 88% based on fundamentals and valuation. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs industry. The accompanying summary shows multiple tests are PASS (including Book/Market Ratio, ROA, CF/OA, and R&D to assets), with the model highlighting notable strengths relative to the strategy's criteria. The report also provides context on Mohanram's research and Validea's Portfolio/Research links that underpin these scores. Investors should consider how the model's thresholds line up with BMY's current growth profile.

BRISTOL-MYERS SQUIBB (BMY) Validea Guru Analysis: 88% on Partha Mohanram Growth Model

October 15, 2025, 10:50 PM EDT. Validea's guru fundamental report places Bristol-Myers Squibb (BMY) at the top of the survey using the P/B Growth Investor model from Partha Mohanram. The growth-focused framework flags the stock as a large-cap Biotechnology & Drugs name with an 88% rating, indicating strong interest from this strategy. The analysis shows BMY passes key tests across the table, including Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, and related efficiency metrics, while noting some interdependencies. The results emphasize a low book-to-market profile paired with growth signals, hinting at potential sustained upside under this approach, subject to execution and broader market factors.

Bristol-Myers Squibb (BMY) Factor-Based Stock Analysis: Mohanram P/B Growth Model Signals Interest

October 15, 2025, 10:48 PM EDT. Validea's guru fundamental report for Bristol-Myers Squibb Co (BMY) shows the stock rating highest under the Partha Mohanram P/B Growth Investor model, a growth screen favoring low book-to-market names with signs of sustained expansion. The stock earns 88% on this strategy, with 80%-90% indicating growing interest and 90%+ signaling strong interest. Key tests pass include Book/Market, Return on Assets, and Cash Flow from Operations to Assets, with the CFO/Assets and asset-quality signals noted. Areas like Sales Variance and R&D to Assets are highlighted as meaningful inputs. Overall, BMY is characterized as a large-cap growth stock in the Biotechnology & Drugs space with favorable fundamentals from this model.

BMY Factor-Based Stock Analysis: Validea Signals 88% on Mohanram Growth Model

October 15, 2025, 10:46 PM EDT. Validea's guru-based analysis ranks Bristol-Myers Squibb (BMY) highly under Partha Mohanram's P/B Growth Investor model, rating 88% based on fundamental signals and growth-focused valuation. The model screens for low book-to-market with characteristics linked to sustained growth, and BMY scores well on key metrics such as book/market ratio, return on assets, cash flow from operations to assets, and R&D to assets. The report notes BMY is a large-cap growth stock in the Biotechnology & Drugs space, with a strong growth orientation and a bullish stance from this strategy; scores above 90% typically indicate strong interest. By contrast, the full analysis includes various tests and Mohanram's academic pedigree. Validea aggregates guru strategies to produce a composite view on stocks like BMY.

BMY Factor-Based Stock Analysis Under Mohanram P/B Growth Model

October 15, 2025, 10:44 PM EDT. Bristol-Myers Squibb (BMY) earns a high signal under Validea's guru framework. Using the Partha Mohanram P/B Growth Investor model, BMY ranks 88%, indicating a strong growth orientation. The model targets low book-to-market stocks that exhibit characteristics tied to sustained future growth. As a large-cap growth stock in Biotechnology & Drugs, BMY passes key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, among others, with several criteria meeting the model's criteria. The report notes that a score of 80% or higher suggests meaningful interest, while above 90% signals strong interest. Overall, the analysis presents a growth-driven case for BMY under Mohanram's framework, though investors should consider broader fundamentals.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Signals Strength

October 15, 2025, 10:42 PM EDT. Validea's guru fundamental report rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model. The strategy seeks low book-to-market names with sustained growth, and BMY scores an 88% valuation/fundamental rating, suggesting notable interest. In the summary tests, items such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS pass, with additional metrics like CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS and R&D TO ASSETS near or clear. BRISTOL-MYERS SQUIBB is a large-cap growth stock in the Biotechnology & Drugs industry. A score of 80% or above indicates some interest, and above 90% signals strong interest. The report underscores Mohanram's research on separating winners from losers among low book-to-market stocks and highlights BMY's solid fundamentals.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals

October 15, 2025, 10:40 PM EDT. Bristol-Myers Squibb (BMY) earns a favorable reading from Validea's Partha Mohanram P/B Growth Investor model, with a score of 88% and a characterization as a growth stock in the Biotechnology & Drugs space. The model targets low book-to-market names with indicators of sustained growth, and BMY screens as a strong growth candidate based on criteria like book/market, ROA, CFO/Assets, and R&D/Assets. The table shows many tests pass (e.g., CFO to Assets, ROA, R&D to Assets), with an overall signal that a score of 80% suggests interest and 90% strong interest. As a large-cap, the stock combines growth traits with established fundamentals, though investors should weigh industry risk and valuation.

BMY Factor-Based Stock Analysis – Partha Mohanram P/B Growth Model Rates BMY at 88%

October 15, 2025, 10:38 PM EDT. Validea's guru fundamental report on Bristol-Myers Squibb (BMY) applies Partha Mohanram's P/B Growth model, targeting low book-to-market stocks with growth traits. The stock rates 88% under this strategy, indicating interest (80%+ = some interest; 90%+ = strong interest). BMY is a large-cap growth name in Biotechnology & Drugs. Key tests show PASS for BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, with CASH FLOW FROM OPERATIONS TO ASSETS VS. ROA also PASS; RESEARCH AND DEVELOPMENT TO ASSETS is marked as FAILED. Overall, the growth-oriented signal is favorable, though R&D asset allocation remains a caveat.

BMY Factor-Based Growth Analysis: Partha Mohanram Model Highlights Strength

October 15, 2025, 10:36 PM EDT. Validea's guru fundamental report places BRISTOL-MYERS SQUIBB CO (BMY) at the top among 22 guru strategies with the P/B Growth Investor model named after Partha Mohanram. The growth-focused screen flags BMY as a large-cap growth stock in the Biotechnology & Drugs space, earning an 88% suitability score-well above the threshold for interest in the stock. The summary of tests shows broad strength: BOOK/MARKET RATIO pass, RETURN ON ASSETS pass, CASH FLOW FROM OPERATIONS TO ASSETS pass, and other metrics like R&D TO ASSETS pass, with a few tests not all equally weighted. Overall, the report underscores that the growth model views BMY as a stock with sustained growth characteristics and favorable fundamentals.

BMY Factor-Based Stock Analysis Highlights Growth Signals from Partha Mohanram Model

October 15, 2025, 10:34 PM EDT. Validea's guru analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model. The growth framework targets low book-to-market stocks with signs of sustained growth. BMY, a large-cap Biotechnology & Drugs name, earns an 88% overall rating, with 80%+ denoting interest and 90%+ signaling strong interest. The summary table shows most tests PASS across metrics like Book/Market, ROA, CFO/Assets, CFO/ROA variance, Sales variance, Advertising to assets, Capex to assets, and R&D to assets. Note: R&D to assets is listed as FAIL. The report links to Partha Mohanram and broader factor-based portfolios, underscoring a growth tilt in healthcare.

Bristol-Myers Squibb (BMY) earns 88% on Partha Mohanram P/B Growth model; solid growth signal

October 15, 2025, 10:32 PM EDT. Validea's guru-based review of BRISTOL-MYERS SQUIBB CO (BMY) shows it tops the list under Partha Mohanram's P/B Growth Investor model, signaling favorable growth fundamentals for a low book-to-market stock. With an 88% rating, the stock shows strong fundamentals and valuation alignment, though it remains just shy of the model's strongest interest tier (scores above 90%). The score is built on a suite of tests-Book/Market Ratio, Return on Assets, Cash Flow From Operations to Assets, and others-most of which pass, including R&D to assets and CapEx to assets. In sum, BMY's profile suggests continued growth potential within the large-cap Biotechnology & Drugs space, supported by steady cash flow and asset efficiency, albeit with room to push beyond the 90% threshold.

BMY Factor-Based Stock Analysis: Partha Mohanram P/B Growth Model Scores 88%

October 15, 2025, 10:30 PM EDT. Bristol-Myers Squibb Co (BMY) earns a high score under Validea's Partha Mohanram P/B Growth Investor model, ranking among the top signals across 22 guru strategies. The model targets low book-to-market stocks with growth characteristics, and BMY translates into an 88% rating, signaling substantial interest from the strategy. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs industry. The summary table shows numerous tests passing, including Book/Market Ratio, Return on Assets, and Cash Flow from Operations to Assets, with multiple checks on cash flow and R&D efficiency. An 88% rating is strong but below the firm's threshold of 90% for strong interest. The write-up also provides background on Partha Mohanram and the philosophy behind his growth model.

BMY: Partha Mohanram Growth Model Signals High Interest

October 15, 2025, 10:28 PM EDT. Bristol-Myers Squibb Co. (BMY) scores highly on Validea's guru framework, led by the Partha Mohanram P/B Growth model. The model seeks low book-to-market stocks with characteristics of sustained future growth. BMY's rating is 88%, signaling strong interest from the model. In Validea's table, key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, and R&D to Assets show favorable results (PASS on many criteria). As a large-cap growth stock in the Biotechnology & Drugs space, BMY's fundamentals and valuation align with a growth tilt, though the analysis summarizes published strategy signals rather than a guaranteed outcome. Investors should consider this as one data point among many in a diversified approach.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals 88% Rating

October 15, 2025, 10:26 PM EDT. Validea's guru report ranks Bristol-Myers Squibb (BMY) highly under the Partha Mohanram P/B Growth Investor model, a growth screen for low book-to-market stocks with durable growth characteristics. BMY, a large-cap in the Biotechnology & Drugs group, earns an 88% rating from this strategy, with 80% indicating interest and 90% strong interest. The table shows broad passes across tests, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and more. Notably, RESEARCH AND DEVELOPMENT TO ASSETS fails, suggesting R&D intensity may weigh on the model. Overall, the stock is viewed as attractive within this factor framework, though the R&D TO ASSETS signal may temper enthusiasm.

BMY Factor-Based Stock Analysis: 88% Mohanram Growth Score Highlights Growth Potential

October 15, 2025, 10:24 PM EDT. Validea's guru-based analysis rates Bristol-Myers Squibb Co. (BMY) at 88% under the P/B Growth Investor model derived from Partha Mohanram. The growth framework targets low book-to-market names with signs of sustained future growth. In this large-cap Biotechnology & Drugs stock, the model flags a strong overall fit: the table shows many criteria as PASS (e.g., BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and CFO/ROA), with a notable note that RESEARCH AND DEVELOPMENT TO ASSETS comes up FAIL. The takeaway: the stock carries notable interest from this strategy (score

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates Bristol-Myers Squibb at 88%

October 15, 2025, 10:22 PM EDT. Validea's Partha Mohanram P/B Growth Investor model flags BRISTOL-MYERS SQUIBB CO (BMY) as a high-conviction growth idea. Among 22 guru strategies, BMY ranks highest with an 88% rating, indicating favorable fundamentals and valuation for low book-to-market stocks with sustained growth. The summary table shows multiple PASS signals across key metrics: BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and CASH FLOW TO ASSETS vs. ROA. The stock also shows positive signals for R&D to Assets as part of the analysis, though the detailed table marks RESEARCH AND DEVELOPMENT TO ASSETS as FAILED in this instance, tempering the call. As a large-cap biotech/pharma stock, BMY could offer upside if these fundamentals persist.

BMY Factor-Based Stock Analysis: Validea Growth Signals Under Partha Mohanram's P/B Growth Model

October 15, 2025, 10:20 PM EDT. Bristol-Myers Squibb Co. (BMY) earns the top rating on Validea's Partha Mohanram-based growth model (P/B Growth Investor). The model seeks low book-to-market stocks with signs of sustained growth. BMY scores 88% under this strategy, with the note that scores of 80%+ indicate interest and 90%+ signal strong interest. BMY is described as a large-cap growth stock in the Biotechnology & Drugs space. The report highlights tests such as return on assets, cash flow from operations to assets, R&D to assets, and other capital- and asset-related metrics, many passing. The analysis also links Mohanram's background and portfolio approach, and positions Validea as a source of model-based stock ideas for disciplined growth investing.

Bristol-Myers Squibb (BMY) Tops Partha Mohanram's P/B Growth Strategy in Validea Guru Analysis

October 15, 2025, 10:18 PM EDT. Validea's guru-based analysis flags BRISTOL-MYERS SQUIBB CO (BMY) as a standout among 22 strategies. The stock earns the highest marks from the P/B Growth Investor model developed by Partha Mohanram for its low book-to-market profile and indicators of sustained growth. BMY scores 88%, with most tests shown as PASS, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS. The report positions BMY as a large-cap Biotechnology & Drugs stock with solid fundamentals and notes that scores above 80% indicate interest (stronger near 90%). The summary underscores the value of guru strategies in Validea's framework and the appeal of Mohanram's growth approach.

Bristol-Myers Squibb (BMY) Tops Partha Mohanram Growth Model with 88% Validea Rating

October 15, 2025, 10:16 PM EDT. Validea's guru analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highest on the P/B Growth Investor model created by Partha Mohanram. This growth screen seeks low book-to-market stocks with signs of sustained future expansion. BMY, a large-cap growth stock in the Biotechnology & Drugs group, earns an 88% rating; Validea notes that a score of 80% indicates some interest, while 90% implies strong interest. The summary table shows multiple tests as PASS (BOOK/MARKET, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, etc.), though R&D TO ASSETS is listed as FAIL. Overall, this factor-based signal suggests meaningful potential, but investors should corroborate with other strategies given some weak criteria.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Signals Strength for Bristol-Myers Squibb

October 15, 2025, 10:14 PM EDT. Validea's guru fundamental report for Bristol-Myers Squibb Co (BMY) places the stock at the top of the P/B Growth Investor model from Partha Mohanram. With a rating of 88%, the growth model flags a low book-to-market setup paired with sustained growth signals. BMY is treated as a large-cap growth stock in the Biotechnology & Drugs industry. The analysis highlights strong readings across key tests-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, R&D TO ASSETS-consistent with Mohanram's growth framework. An 88% score suggests meaningful interest (scores above 80% imply interest; above 90% imply strong interest). Validea frames this within the Partha Mohanram portfolio approach, emphasizing growth over value.

Bristol-Myers Squibb (BMY) Tops Validea P/B Growth Model Among Guru Strategies

October 15, 2025, 10:12 PM EDT. Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) shows BMY scoring highest on Partha Mohanram's P/B Growth Investor model, a growth screen that seeks low book-to-market stocks with sustained growth traits. The stock is categorized as a large-cap growth stock in Biotechnology & Drugs, with an 88% rating based on fundamentals and valuation. In Validea's framework, an 80%+ score signals interest, while 90%+ indicates strong interest. Across the strategy's tests, key metrics like BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS all PASS; however, R&D TO ASSETS appeared to fail in the detailed table. Overall, BMY's strength on this model underscores its growth characteristics even within a diversified pharma landscape.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals High Interest

October 15, 2025, 10:10 PM EDT. Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) shows the stock ranking highest on Partha Mohanram's P/B Growth Investor model. The growth style seeks low book-to-market names with signs of sustained future growth. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs space. The strategy assigns an 88% rating, signaling meaningful interest (80%+ typically indicates interest; >90% would signal strong interest). The table summarizes that BMY passes many tests: BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics, with a notable PASS on most items, though RESEARCH AND DEVELOPMENT TO ASSETS is listed as FAIL. Overall, the report reinforces a positive growth-oriented view of BMY within this factor model.

BMY Shines in Partha Mohanram Growth Model: Validea Rates BMY at 88% under P/B Growth Investor

October 15, 2025, 10:08 PM EDT. Bristol-Myers Squibb Co (BMY) earns an 88% score under Validea's P/B Growth Investor model, which targets low book-to-market stocks with signs of sustained growth. As a large-cap growth stock in Biotechnology & Drugs, BMY demonstrates many favorable tests-BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, and CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS, along with other positive metrics. Notably, R&D TO ASSETS: FAIL is called out as a caveat. The 88% rating signals "some interest," while scores above 90% would imply stronger conviction. This snapshot reflects Mohanram's framework rather than a universal buy recommendation.

Validea's Partha Mohanram Growth Model Rates Bristol-Myers Squibb (BMY) at 88%

October 15, 2025, 10:06 PM EDT. Bristol-Myers Squibb Co (BMY) is rated highest among Validea's 22 guru strategies by the Partha Mohanram Growth model, which seeks low book-to-market stocks with signs of sustained future growth. The large-cap biotech name earns an 88% score, signaling notable interest, with scores above 80% indicating some interest and above 90% signaling strong interest. The scorecard shows several PASS indicators (Book/Market, ROA, CFO/Assets, CFO vs ROA, Sales variance, Advertising to assets, Capex to assets) but lists a FAIL on Research & Development to assets. In short, this growth-factor signal suggests a favorable profile under this framework, even as certain criteria temper enthusiasm.

BMY Factor-Based Growth Analysis Signals 88% Rating Under Partha Mohanram's P/B Growth Model

October 15, 2025, 10:04 PM EDT. Validea's guru analysis for BMY shows Bristol-Myers Squibb Co scoring 88% on the P/B Growth Investor model by Partha Mohanram, indicating strong growth-oriented characteristics in biotech. The table of tests highlights robust passes across key metrics and warns that a score above 80% signals notable interest, with above 90% implying especially strong interest. Highlights include contributions from BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS; the model also notes relationships like CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS. As a large-cap growth stock in Biotechnology & Drugs, BMY is positioned as a growth candidate when low book-to-market aligns with sustained growth, though investors should weigh R&D and asset-intensity factors.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates Bristol-Myers Squibb at 88%

October 15, 2025, 10:02 PM EDT. Bristol-Myers Squibb Co (BMY) earns a high score under Validea's Partha Mohanram P/B Growth strategy. The model seeks low book-to-market stocks with signs of sustained future growth, and BMY posts an 88% rating, signaling strong interest. The stock is categorized as a large-cap growth play in Biotechnology & Drugs. In the test table, key factors like BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS pass, with several efficiency metrics meeting or exceeding thresholds. The report notes substantial emphasis on assets-to-operations metrics, R&D intensity, and capital allocation. Overall, this metric suggests investors may view BMY as a growth-oriented healthcare name with favorable fundamentals under this model.

BMY Factor-Based Stock Analysis: 88% Mohanram P/B Growth Rating

October 15, 2025, 10:00 PM EDT. Validea's guru fundamental report for Bristol-Myers Squibb Co (BMY) flags a high score under Partha Mohanram's P/B Growth Investor model. The growth framework searches for low book-to-market stocks with durability of future earnings. BMY, a large-cap stock in Biotechnology & Drugs, earns 88% from this strategy, signaling notable interest (80%+ indicates interest; >90% would be strong). Key tests largely pass, including Book/Market, ROA, CFO to assets, CFO to ROA, and advertising to assets. Notably, R&D to assets comes up short (FAILED), a common tension in growth screens for pharma. Overall, the rating suggests potential upside under this factor-based framework, but investors should weigh the strategy's assumptions against fundamentals and risk.

BMY Tops Validea's Partha Mohanram Growth Model with 88% Guru Score

October 15, 2025, 9:58 PM EDT. Bristol-Myers Squibb Co. (BMY) leads Validea's guru-based analysis under Partha Mohanram's Growth model, posting an 88% score and signaling strong interest from this framework. The model seeks low book-to-market stocks with signs of sustained future growth; BMY is a large-cap Growth stock in the Biotechnology & Drugs space. Across the test table, several pillars pass, including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS (plus related ROA VARIANCE and cash-flow stability). The caveat: RESEARCH AND DEVELOPMENT TO ASSETS fails, reflecting higher R&D intensity relative to assets. Overall, this is a high-score signal among Validea's guru strategies, with a nuanced caveat about R&D investment.

BMY Factor-Based Stock Analysis: Validea's Partha Mohanram Growth Signal

October 15, 2025, 9:56 PM EDT. Bristol-Myers Squibb Co (BMY) earns a high mark under Validea's Partha Mohanram P/B Growth Investor model, scoring 88% and signaling a potential growth tilt. The model seeks low book-to-market stocks with traits linked to durable growth, and BMY is categorized as a large-cap Biotechnology & Drugs stock with strong fundamentals. The detailed checks show key pass signals for BOOK/MARKET RATIO, RETURN ON ASSETS, CFO/Assets, CFO/ROA, and Sales Variance, but the model flags a failure on R&D to Assets. With a score above 80% often indicating potential interest, BMY's 88% rating suggests notable compatibility with the growth framework, though investors should review the R&D allocation in context.

BMY: 88% Partha Mohanram Growth Model Rating Highlights

October 15, 2025, 9:54 PM EDT. Bristol-Myers Squibb Co. (BMY) earns top marks from Validea's P/B Growth Investor model, a Partha Mohanram framework that targets low book-to-market stocks with growth characteristics. BMY rates 88% under this strategy, signaling strong fundamentals and favorable valuation. The model emphasizes cash flow efficiency and asset utilization, with PASS results across key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS. Classified as a large-cap growth stock in the Biotechnology & Drugs industry, the report notes that 80%+ indicates interest and 90%+ would signal strong interest. Validea positions BMY as aligned with Mohanram's research on separating winners from losers among growth stocks.

Bristol-Myers Squibb (BMY) Factor-Based Stock Analysis: Partha Mohanram Growth Model

October 15, 2025, 9:52 PM EDT. Validea's guru-based analysis rates Bristol-Myers Squibb (BMY) highly on the P/B Growth Investor framework from Partha Mohanram. The model targets low book-to-market stocks with signs of sustained growth, and assigns a high 88% rating to BMY, with many tests in the green such as Return on Assets, Cash Flow from Operations to Assets, and R&D to Assets. The table notes multiple PASS ratings (e.g., Sales Variance, Cash Flow to Assets, R&D to Assets). The report provides background on Mohanram and his growth thesis, contrasting with traditional value metrics. Investors may view BMY as a growth stock with favorable fundamentals and valuation, though it's one of many guru signals to weigh in a broader portfolio process.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates BMY at 88%

October 15, 2025, 9:50 PM EDT. Validea's guru-based Partha Mohanram Growth model rates BRISTOL-MYERS SQUIBB CO (BMY) at 88%, signaling strong interest from this strategy. The growth screen targets low book-to-market stocks with signs of sustained future expansion, and BMY sits as a large-cap growth stock in the Biotechnology & Drugs sector. The table shows multiple criteria passing-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS-and others, though RESEARCH AND DEVELOPMENT TO ASSETS is listed as FAIL. Overall, the 22-guru suite flags BMY as a meaningful candidate under the Mohanram Growth framework, with a score near 88% indicating the strategy's favorable view, while noting the single drawback on R&D TO ASSETS not meeting the criterion.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates Bristol-Myers Squibb at 88%

October 15, 2025, 9:48 PM EDT. Validea's guru framework assigns Bristol-Myers Squibb Co (BMY) a high mark from the Partha Mohanram Growth model, rating 88% on fundamentals and valuation. The growth approach seeks low book-to-market stocks with characteristics linked to sustained future expansion. In this report, BMY's profile shows favorable BOOK/MARKET RATIO and solid RETURN ON ASSETS, with CASH FLOW FROM OPERATIONS TO ASSETS strength and favorable comparisons of CFO/ROA. The analysis notes several tests as PASS (e.g., ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, RESEARCH AND DEVELOPMENT TO ASSETS), contributing to the overall score. A reading of 88% signals strong interest from this strategy, while scores above 90% would indicate very strong interest. Investors should consider this in the context of broader fundamentals and risk factors.

Bristol-Myers Squibb (BMY) Tops Validea's P/B Growth Model under Partha Mohanram

October 15, 2025, 9:46 PM EDT. Validea's guru fundamental report rates BRISTOL-MYERS SQUIBB CO (BMY) highest under the P/B Growth Investor model of Partha Mohanram. The growth framework targets low book-to-market stocks with traits tied to sustained expansion. BMY, a large-cap growth stock in the Biotechnology & Drugs sector, posts an 88% rating – above the 80% threshold (indicating interest) but below the 90% level for strong enthusiasm. The table shows multiple PASS signals, including Book/Market Ratio, Return on Assets, and Cash Flow from Operations to Assets; however, R&D to Assets is listed as FAIL. Overall, the model flags upside potential under this factor-based approach while pointing to a weakness in R&D to Assets efficiency relative to assets. This signals a selective, growth-oriented stance on BMY from Validea.

BMY Factor-Based Analysis: Growth Model Scores Bristol-Myers Squibb at 88%

October 15, 2025, 9:44 PM EDT. Bristol-Myers Squibb Co (BMY) earns top marks from Validea's guru-based analysis under the Partha Mohanram P/B Growth Investor model, which targets low book-to-market stocks with potential for sustained growth. BMY, a large-cap player in the Biotechnology & Drugs space, scores 88%, signaling strong interest from this strategy. The summary table shows key tests as PASS across BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and other growth-friendly metrics like R&D to assets. While some tests may not be independent, the reading highlights favorable fundamentals and a growth tilt. Investors should weigh this growth signal against valuation and sector risk, recognizing that the model reflects a specific, academic approach to identifying winners among low book-to-market stocks.

BMY Tops Partha Mohanram P/B Growth Model with 88% Validea Rating

October 15, 2025, 9:42 PM EDT. Validea's guru fundamental report on Bristol-Myers Squibb Co (BMY) shows it ranks highest on the Partha Mohanram P/B Growth Investor model, posting an 88% score. The growth framework targets low book-to-market stocks with signs of sustained expansion and places BMY among Large-Cap Growth in Biotechnology & Drugs. Key readings: the stock passes the Book/Market, Return on Assets, Cash Flow from Operations to Assets, CFO to ROA, Sales Variance, Advertising to Assets, Capital Expenditures to Assets criteria. It fails on R&D to Assets. The write-up also provides background on Partha Mohanram and Validea's methodology. An 88% rating signals notable interest from this model, with a caveat around the R&D-to-assets criterion.

BMY Factor-Based Growth Signal (Partha Mohanram's P/B Growth Model) – 88% Rating

October 15, 2025, 9:40 PM EDT. Validea's guru fundamental report rates BRISTOL-MYERS SQUIBB CO (BMY) highest under Partha Mohanram's P/B Growth model. The growth model seeks low book-to-market stocks with signs of sustained future growth. BMY, a large-cap biotechnology & drugs stock, earns an 88% score based on fundamentals and valuation, with scores above 90% signaling stronger interest. The summary of tests shows most criteria pass (e.g., BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS), though RESEARCH AND DEVELOPMENT TO ASSETS failed in this run. Note that weights vary and the table highlights relative strengths and weaknesses in the strategy's criteria.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Highlights Bristol-Myers Squibb

October 15, 2025, 9:38 PM EDT. Validea's guru analysis places Bristol-Myers Squibb (BMY) at the top among 22 strategies under the P/B Growth Investor model developed by Partha Mohanram. The model targets low book-to-market stocks with growth traits, and assigns BMY an 88% rating-indicating some interest (scores above 90% signal stronger interest). BMY is categorized as a large-cap growth stock in Biotechnology & Drugs. The overview shows broad strength: BOOK/MARKET RATIO PASS, RETURN ON ASSETS PASS, CASH FLOW FROM OPERATIONS TO ASSETS PASS, and CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS PASS; however, the table notes a weakness in RESEARCH AND DEVELOPMENT TO ASSETS listed as FAILED. Overall, the stock reflects growth-friendly fundamentals per Mohanram, with caveats on R&D capitalization.

BMY: 88% on Partha Mohanram P/B Growth Model (Validea)

October 15, 2025, 9:36 PM EDT. Bristol-Myers Squibb (BMY) earns a high score from Validea's guru-based analysis, led by the Partha Mohanram P/B Growth model. The strategy seeks low book-to-market stocks with signs of durable growth. On this framework, BMY delivers an 88% rating, signaling notable interest (scores above 80% indicate potential, with above 90% signaling strong interest). The model's table shows a broad set of PASS outcomes across criteria such as BOOK/MARKET RATIO, RETURN ON ASSETS (ROA), CASH FLOW FROM OPERATIONS TO ASSETS, and more, with the lone weakness being RESEARCH AND DEVELOPMENT TO ASSETS, which FAILED. As a large-cap in the Biotechnology & Drugs sector, BMY's fundamentals and valuation align with the growth-style criteria highlighted by Mohanram's approach as presented by Validea.

BMY Tops Mohanram P/B Growth Signals with 88% Rating

October 15, 2025, 9:34 PM EDT. Validea's guru fundamental report places BRISTOL-MYERS SQUIBB CO (BMY) among the top signals under the P/B Growth Investor model from Partha Mohanram. The stock rates 88%, with scores of 80%+ signaling some interest and 90%+ signaling strong interest. BMY is described as a large-cap growth stock in the Biotechnology & Drugs industry. The summary table shows passes on BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics, while the RESEARCH AND DEVELOPMENT TO ASSETS criterion is marked as FAILED. The analysis reflects Mohanram's growth tilt and the pharma sector's growth potential, alongside common R&D efficiency caveats. For context, Mohanram's framework and related portfolio details are highlighted by Validea.

BMY Factor-Based Stock Analysis: Validea Mohanram Growth Model Signals Strong Interest (88%)

October 15, 2025, 9:32 PM EDT. Validea rates Bristol-Myers Squibb Co (BMY) highly under the Partha Mohanram P/B Growth Investor model, with an 88% score implying strong interest. BMY is a large-cap Growth stock in the Biotechnology & Drugs sector. The model searches for low book-to-market stocks with indicators of sustained growth. Key tests mostly pass: BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics show strength. Notable detail: the R&D TO ASSETS test fails, suggesting R&D TO ASSETS intensity may not align with the model's efficiency criteria, even as other metrics confirm profitability and cash flow strength. Overall, with a score above 80%, the stock attracts interest from this strategy, though investors should note the R&D TO ASSETS discrepancy in evaluating growth prospects.

BMY Factor-Based Growth Analysis: Partha Mohanram P/B Growth Signals 88% Rating

October 15, 2025, 9:30 PM EDT. Validea's guru fundamental report ranks Bristol-Myers Squibb (BMY) on Partha Mohanram's P/B Growth Investor model, placing it among top-rated growth names. The model seeks low book-to-market stocks with durable growth, and BMY earns an 88% rating based on fundamentals and valuation. The test table shows BOOK/MARKET RATIO PASS, RETURN ON ASSETS PASS, CASH FLOW FROM OPERATIONS TO ASSETS PASS, and several other metrics, with RESEARCH AND DEVELOPMENT TO ASSETS: FAILED. A score at or above 80% signals notable interest, and above 90% indicates strong interest. The analysis situates Mohanram's growth framework in context, highlighting BMY as a potential Large-Cap Biotechnology & Drugs stock with growth characteristics and some caveats.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Returns 88% Rating

October 15, 2025, 9:28 PM EDT. Validea applies Partha Mohanram's P/B Growth Investor model to BRISTOL-MYERS SQUIBB CO (BMY). The model seeks low book-to-market stocks with indicators of sustained growth. BMY is a large-cap growth stock in the Biotechnology & Drugs industry and earns an 88% rating from this strategy, with scores above 80% signaling interest and above 90% signaling strong interest. The stock passes key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS (and their related comparisons), but shows a weakness in RESEARCH AND DEVELOPMENT TO ASSETS. Overall, the rating suggests favorable fundamentals and valuation alignment under Mohanram's growth framework.

BMY Scores 88% on Partha Mohanram Growth Model (Validea Guru Analysis)

October 15, 2025, 9:26 PM EDT. Validea's guru report ranks Bristol-Myers Squibb (BMY) at the top among 22 strategies under the Partha Mohanram P/B Growth Investor model. The growth-focused screen looks for low book-to-market stocks with signs of sustained expansion, and BMY earns an 88% score-above the typical 80% threshold and near the 90% level for strong interest. The analysis highlights passes across key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and others, suggesting favorable fundamentals and valuation. The write-up also notes Mohanram's academic lineage and his work on distinguishing growth winners from losers. Overall, BMY appears to be a compelling candidate within this factor-based framework offered by Validea.

BMY Factor-Based Stock Analysis: Partha Mohanram P/B Growth Model Signals Growth Potential

October 15, 2025, 9:24 PM EDT. Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) shows the stock scoring highest under Partha Mohanram's P/B Growth Investor model. The growth framework favors low book-to-market stocks with signs of sustained future growth. BMY, a large-cap biotech/drugs stock, earns an 88% rating-well above the threshold that signals analyst interest. Across the model's tests, BMY passes on key metrics such as Book/Market, Return on Assets, CFO to Assets, and related variance checks, with one noted exception: R&D to Assets fails. The result positions BMY as a candidate for growth-focused portfolios under this guru strategy, illustrating how Mohanram's framework seeks to identify firms with improving fundamentals and valuation dynamics despite the typical biotech risk. Validea notes this strategy's potential for long-run outperformance.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals 88% Rating

October 15, 2025, 9:22 PM EDT. Validea applies the P/B Growth Investor model from Partha Mohanram to BRISTOL-MYERS SQUIBB CO (BMY), rating it 88% based on fundamentals and valuation. The growth model searches for low book-to-market stocks with sustained growth traits, placing BMY as a large-cap growth stock in Biotechnology & Drugs. A rating of 80%+ signals interest; 90%+ signals strong interest. Under this framework, BMY PASSes for BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CFO TO ASSETS, ROA VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, but R&D TO ASSETS FAILS. Overall, the score reflects several validating signals with one notable weakness.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates 88%

October 15, 2025, 9:20 PM EDT. Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) shows the stock ranking highest among 22 guru strategies using the P/B Growth Investor model from Partha Mohanram. The model seeks low book-to-market stocks with signs of sustained future growth. BMY is a large-cap growth name in the Biotechnology & Drugs group. The overall rating is 88%, indicating interest, with 80%+ typically meaningful and 90%+ suggesting strong interest. In the table, most criteria are PASS (Book/Market, ROA, CFO to assets, CFO vs ROA, ROA variance, Sales variance, Advertising to assets, Capex to assets), while R&D to assets fails. Additional context covers Mohanram's portfolio and Validea's framework.

Bristol-Myers Squibb (BMY) Earns 88% Under Partha Mohanram P/B Growth Model

October 15, 2025, 9:18 PM EDT. Validea's guru analysis rates Bristol-Myers Squibb (BMY) highest under the P/B Growth Investor model from Partha Mohanram. The strategy targets low book-to-market stocks with traits of sustained growth. As a large-cap in Biotechnology & Drugs, BMY scores 88%, signaling notable interest (above the 80% threshold; >90% suggests strong interest). The table notes many PASS signals, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and RESEARCH AND DEVELOPMENT TO ASSETS. In short, the analysis highlights the model's emphasis on solid fundamentals and valuation to spot growth potential in BMY within the pharma sector.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 15, 2025, 9:16 PM EDT. Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) shows the stock rates highest on Partha Mohanram's P/B Growth Investor model. The growth strategy targets low book-to-market stocks with sustained growth, yielding an 88% score for BMY – above the 80% threshold and indicating strong interest (90%+ would be stronger). In the table, BMY passes key tests such as Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, Cash Flow from Operations to Assets vs. Return on Assets, ROA Variance, Sales Variance, Advertising to Assets, and Capital Expenditures to Assets; the lone miss is R&D to Assets (FAIL). The note also covers Partha Mohanram's background and Validea's methodology.

BMY Factor-Based Stock Analysis: 88% Mohanram Growth Model Signals Interest

October 15, 2025, 9:14 PM EDT. Validea's guru-based analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highest under the P/B Growth Investor model by Partha Mohanram. The growth screen targets low book-to-market stocks with sustained growth traits. BMY attains an 88% rating, and Validea notes that scores of 80%+ signal interest, while 90%+ signals strong interest. The accompanying table shows multiple PASS checks-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and more-alongside a FAILED assessment for RESEARCH AND DEVELOPMENT TO ASSETS. As a large-cap growth stock in Biotechnology & Drugs, BMY's fundamental profile through this model suggests notable, though not unanimous, strength for growth-oriented investors.

BMY Factor-Based Stock Analysis: Partha Mohanram P/B Growth Signal for Bristol-Myers Squibb

October 15, 2025, 9:12 PM EDT. Validea's guru-style analysis ranks BRISTOL-MYERS SQUIBB CO (BMY) highly on the P/B Growth Investor model from Partha Mohanram, giving an 88% rating. The model targets low book-to-market stocks with signs of sustained growth; in BMY's case the stock is categorized as a large-cap Biotechnology & Drugs stock with a growth tilt. The table flags a majority of criteria as PASS (e.g., Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, ROA Variance, Sales Variance, Advertising to Assets, Capital Expenditures to Assets), with R&D to Assets noted as a weakness. An 88% score suggests the strategy has notable interest but not the top-tier threshold (80%+ indicates interest; 90%+ indicates strong interest). The piece also provides background on Partha Mohanram and Validea's guru-based framework.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals High Interest

October 15, 2025, 9:10 PM EDT. Bristol-Myers Squibb Co. (BMY) earns top marks under Validea's Partha Mohanram P/B Growth Investor model, scoring 88% and signaling notable investor interest. The model targets low book-to-market stocks with signs of sustained growth, and BMY sits as a large-cap growth stock in the Biotechnology & Drugs space. Key positives include PASS results for Book/Market, Return on Assets, Cash Flow from Operations to Assets, and the CFO/ROA relationship, plus favorable ROA variance, Sales Variance, Advertising to Assets, and Capex to Assets. R&D to Assets is noted as a weakness. A score above 80% suggests strategy interest, with >90% signaling strong interest. Investors may weigh these signals with fundamentals and other guru scores before trading.

BMY Factor-Based Stock Analysis: Validea's Partha Mohanram Growth Model Report

October 15, 2025, 9:08 PM EDT. Validea's guru-based view rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model derived from Partha Mohanram. The strategy seeks low book-to-market stocks with implied long-term growth, and BMY receives an 88% score (above 80% indicates interest; above 90% signals strong interest). BMY is described as a large-cap growth stock in the Biotechnology & Drugs space. The model's test results show BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, CFO to Assets vs. ROA: PASS, ROA Variance: PASS, SALES Variance: PASS, ADVERTISING TO ASSETS: PASS, CAPITAL EXPENDITURES TO ASSETS: PASS, and RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. Context and links to Mohanram's work are provided by Validea.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 15, 2025, 9:06 PM EDT. Validea's guru-based analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model, which targets low book-to-market stocks with sustainable growth. BMY scores 88% on the strategy, signaling meaningful interest (scores above 80% are noteworthy; above 90% indicate strong interest). In the table, key tests show: Book/Market Ratio: PASS, ROA: PASS, Cash Flow from Operations to Assets: PASS, CFO to assets vs ROA: PASS, and ROA variance: PASS, along with Sales Variance: PASS, Advertising to Assets: PASS, CapEx to Assets: PASS. The lone weakness is R&D to Assets: FAIL. Overall, BMY is characterized as a large-cap growth stock in the Biotechnology & Drugs space with favorable fundamentals and valuation per this model.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strength

October 15, 2025, 9:04 PM EDT. Validea's guru report ranks Bristol-Myers Squibb (BMY) highly on the P/B Growth Investor model developed by Partha Mohanram, favoring low book-to-market stocks with potential for sustained growth. BMY, a large-cap Biotechnology & Drugs stock, earns an 88% rating on this strategy, suggesting notable interest, with scores above 90% signaling strong interest. The table shows strong pass rates on key tests including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics like R&D TO ASSETS and CAPITAL EXPENDITURES TO ASSETS; some criteria are weighted differently. Overall, the model indicates resilience of BMY's fundamentals and growth trajectory per Mohanram's framework.

BMY Factor-Based Growth Analysis: Partha Mohanram Growth Model Rates Bristol-Myers Squibb at 88%

October 15, 2025, 9:02 PM EDT. Validea's guru fundamental report rates BRISTOL-MYERS SQUIBB CO (BMY) highest under Partha Mohanram's P/B Growth Investor model among 22 guru strategies. The growth model looks for low book-to-market stocks with signs of sustained future growth. BMY earns 88%, where a score of 80%+ signals interest and 90%+ signals strong interest. Highlights show passes for BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics, with several criteria tied to asset usage and growth signals. The table notes PASS statuses for CFO TO ASSETS, CFO TO ROA, ROA VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, CAPEX TO ASSETS, and R&D TO ASSETS. Context on Mohanram and Validea's methodology is included.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates Bristol-Myers Squibb at 88%

October 15, 2025, 9:00 PM EDT. Bristol-Myers Squibb (BMY) scores 88% under Validea's Partha Mohanram P/B Growth Investor model, signaling a growth tilt among low book-to-market stocks. The large-cap drugmaker is labeled a Biotechnology & Drugs growth stock. Most tests pass, including BOOK/MARKET RATIO, RETURN ON ASSETS, CFO TO ASSETS, and CFO/ROA; R&D TO ASSETS is the lone failure. A score above 80% indicates interest; above 90% indicates strong interest. The report highlights Mohanram's research on separating winners from losers among low book-to-market stocks and explains how Validea compiles guru strategies. Investors can use this as a reference point within factor-based strategies and broader analyst coverage.

BMY Factor-Based Stock Analysis: 88% on Partha Mohanram P/B Growth Model

October 15, 2025, 8:58 PM EDT. Bristol-Myers Squibb Co (BMY) earns an 88% rating on Validea's P/B Growth Investor model by Partha Mohanram, signaling notable growth potential for a large-cap Biotechnology & Drugs stock. The analysis emphasizes a low book-to-market profile paired with growth traits; key tests are PASS across metrics such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, ROA variance, ADVERTISING TO ASSETS, and R&D TO ASSETS. A score above 80% denotes interest, with above 90% suggesting strong interest. Overall, BMY presents as a growth-oriented idea within the biotechnology space, supported by fundamentals like cash flow efficiency and R&D investment.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Highlights

October 15, 2025, 8:56 PM EDT. Validea's guru report rates Bristol-Myers Squibb (BMY) highly on the P/B Growth Investor model, which targets low book-to-market stocks with sustained growth. The stock earns an 88% score, suggesting strong interest from the model. The accompanying table shows most tests as PASS, including key metrics like BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, among others, while the criterion for RESEARCH AND DEVELOPMENT TO ASSETS is marked as FAIL. Overall, the analysis positions BMY as a large-cap growth stock in the Biotechnology & Drugs space, emphasizing growth characteristics and valuation signals. Investors should weigh these model-driven signals alongside other fundamentals and broader market context.

BMY Factor-Based Stock Analysis: Validea's Partha Mohanram Growth Model Signals 88%

October 15, 2025, 8:54 PM EDT. Validea's guru-based assessment places Bristol-Myers Squibb Co (BMY) at the top of the Partha Mohanram P/B Growth Investor model. The large-cap biotechnology stock scores 88%, signaling notable interest from the growth-focused framework. The model seeks low book-to-market stocks with traits linked to sustained growth. Across the key tests, BMY passes on BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS; it also passes CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS – while RESEARCH AND DEVELOPMENT TO ASSETS: FAIL in the summary table. The score indicates some interest, not strong consensus. Investors should weigh growth signals against sector risk and pipeline developments for a biotech giant like BMY.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates BMY at 88%

October 15, 2025, 8:52 PM EDT. Br istol-Myers Squibb Co (BMY) ranks highest among Validea's guru models under the P/B Growth Investor approach by Partha Mohanram. This growth framework seeks low book-to-market stocks with signs of sustained future growth. BMY scores 88%, where a score of 80%+ indicates some interest and 90%+ indicates strong interest. The test table shows most criteria are PASS, including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, among others. One criterion listed as failed is RESEARCH AND DEVELOPMENT TO ASSETS. The report also highlights Mohanram's academic background and Validea's broader focus on factor-based stock portfolios in the biotechnology and drugs sector.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strength

October 15, 2025, 8:50 PM EDT. Validea's guru fundamental report for Bristol-Myers Squibb Co (BMY) shows the stock ranking highest under the P/B Growth Investor model based on Partha Mohanram's framework. This growth model screens for low book-to-market stocks with traits linked to sustained future growth. BMY carries an 88% rating in this strategy, with 80%+ suggesting interest and 90%+ indicating strong interest. The summary table shows most tests passing-BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS, etc.-highlighting strengths like ROA and operating cash flow. Described as a large-cap growth stock in Biotechnology & Drugs, BMY benefits from diverse fundamentals, though growth-stock dynamics imply ongoing evaluation of valuation and fundamentals.

Bristol-Myers Squibb (BMY) Tops Partha Mohanram Growth Model in Validea Factor-Based Analysis

October 15, 2025, 8:48 PM EDT. Bristol-Myers Squibb (BMY) tops Validea's Partha Mohanram P/B Growth Investor model with an 88% score, signaling notable interest from this growth model. The model seeks low book-to-market stocks with sustained future growth, and BMY sits as a large-cap name in the Biotechnology & Drugs space. In the strategy's test table, most criteria show PASS: BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS, RETURN ON ASSETS VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS. The criterion R&D TO ASSETS is FAILED. A score of 80%+ typically signals interest, with 90%+ signaling strong interest. Overall, the model flags BMY as a compelling growth stock within its framework, though investors may note the R&D signal.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals for Bristol-Myers Squibb

October 15, 2025, 8:46 PM EDT. Validea's guru fundamental report for Bristol-Myers Squibb Co. (BMY) rates the stock highly under the P/B Growth Investor model from Partha Mohanram, a growth screen favoring low book-to-market names with potential for sustained growth. The stock earns 88% on fundamentals and valuation, indicating notable interest (with >90% signaling strong interest). The model's tests show BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS, RETURN ON ASSETS VARIANCE: PASS, SALES VARIANCE: PASS, ADVERTISING TO ASSETS: PASS, CAPITAL EXPENDITURES TO ASSETS: PASS; however, RESEARCH AND DEVELOPMENT TO ASSETS: FAILED. Overall, BMY is viewed as a high-conviction name within this factor-based framework.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates Bristol-Myers Squibb 88% (Validea)

October 15, 2025, 8:44 PM EDT. Validea's guru-factor report for Bristol-Myers Squibb (BMY) shows the stock scoring highly under Partha Mohanram's P/B Growth Investor model. The growth framework seeks low book-to-market names with sustained growth traits, and BMY is classified as a large-cap growth stock in the Biotechnology & Drugs space. The model assigns an 88% rating, well above the 80% threshold that signals interest and near the 90% level that suggests strong interest. The accompanying table indicates that key tests are PASS across metrics such as Book/Market Ratio, Return on Assets, Cash Flow from Ops to Assets, R&D to Assets, and others. Overall, the report positions BMY as a favorable candidate within this guru strategy framework, reflecting Partha Mohanram's growth-factor research.

BMY Factor-Based Stock Analysis: 88% Mohanram Growth Rating for Bristol-Myers Squibb

October 15, 2025, 8:42 PM EDT. BMY scores 88% under Validea's Partha Mohanram P/B Growth Investor model, signaling favorable growth-oriented fundamentals for a large-cap biotechnology stock. The model seeks low book-to-market names with sustained growth, and a rating above 80% indicates some interest, with 90% signaling strong interest. In this analysis, most tests pass: BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, ROA VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, and R&D TO ASSETS is the notable exception marked as FAIL. BRISTOL-MYERS SQUIBB CO (BMY) is highlighted as a growth stock in the Biotechnology & Drugs industry, suggesting cautious optimism from the model and potential for further upside depending on fundamentals and valuation.

Bristol-Myers Squibb (BMY) Scores 88% on Validea's Partha Mohanram Growth Model

October 15, 2025, 8:40 PM EDT. Validea's guru fundamental report ranks BRISTOL-MYERS SQUIBB CO (BMY) highly on the P/B Growth Investor model, based on Partha Mohanram's criteria. The stock earns an 88% rating under this growth framework, suggesting solid fundamentals and favorable valuation. The analysis emphasizes a low Book/Market Ratio with characteristics linked to sustained growth. The detailed results show PASS for key metrics such as Return on Assets, Cash Flow from Operations to Assets, and R&D to Assets, with supportive readings on other asset-based tests. BMY is categorized as a large-cap Biotechnology & Drugs stock, aligning with growth-oriented characteristics. While a score above 90% would indicate stronger interest, an 80%+ rating still signals noteworthy attention from factor-based investors examining growth trajectories.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Highlights

October 15, 2025, 8:38 PM EDT. Bristol-Myers Squibb Co (BMY) scores highly under Validea's Partha Mohanram P/B Growth Investor model, signaling potential interest for growth investors. The model targets low book-to-market stocks with signs of sustained future growth, and BMY earns an 88% rating based on fundamentals and valuation. The accompanying table shows PASS signals across key tests, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, and RESEARCH AND DEVELOPMENT TO ASSETS. Classified as a large-cap Biotechnology & Drugs stock, the Mohanram framework suggests potential for continued outperformance when criteria align. Validea notes Mohanram's research and its role within guru-based stock analysis.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals 88% Rating

October 15, 2025, 8:36 PM EDT. Validea's guru fundamental report rates Bristol-Myers Squibb (BMY) highly under the Partha Mohanram Growth Model. Among 22 guru strategies, BMY attains the highest score on the model focused on low book-to-market stocks with growth traits. The stock's rating stands at 88%, with thresholds: 80% indicates interest, 90% strong interest. The analysis shows several tests pass, including Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, and the CFO-to-ROA comparison. Most tests are favorable, but R&D to Assets fails, signaling potential concerns about R&D capitalization efficiency. BMY is characterized as a large-cap growth stock in the Biotechnology & Drugs space. Overall, the model suggests notable interest, with caveats from the R&D metric.

BMY Tops Partha Mohanram P/B Growth Investor Model with 88% Rating

October 15, 2025, 8:34 PM EDT. Validea's guru-based analysis ranks BRISTOL-MYERS SQUIBB CO (BMY) highly on Partha Mohanram's P/B Growth Investor model, scoring 88% and signaling potential interest. The Mohanram growth approach seeks low book-to-market stocks with evidence of sustained future growth. BMY is framed as a large-cap grower in the Biotechnology & Drugs space, with PASS on most tests like BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and others; the notable miss is RESEARCH AND DEVELOPMENT TO ASSETS, which FAILED. An 80%+ readout suggests some investment interest; 90%+ implies strong interest. Overall, the report highlights BMY as a candidate for growth-oriented portfolios under this model, while noting the incomplete R&D efficiency signal.

BMY Factor-Based Stock Analysis: Validea Growth Model Scores Bristol-Myers Squibb at 88%

October 15, 2025, 8:32 PM EDT. Validea's guru-based review rates BRISTOL-MYERS SQUIBB CO (BMY) highly under Partha Mohanram's Growth Model. The screen hunts for low book-to-market stocks with signs of sustained future growth. On this model, BMY scores 88%, indicating notable interest (scores above 90% imply strong interest; 80%+ signals some interest). The summary table shows BMY passes key tests across the BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics, while highlighting variables like R&D TO ASSETS and CAPEX TO ASSETS. In the Biotechnology & Drugs large-cap group, BMY's fundamentals align with a continued growth trajectory per Validea's guru aggregation. Investors should weigh this growth tilt against market risks and other factors before acting.

BMY Factor-Based Stock Analysis: Validea Rates Bristol-Myers Squibb 88% on Mohanram Growth Model

October 15, 2025, 8:30 PM EDT. Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) shows a strong signal from the Partha Mohanram Growth (P/B Growth) model. With a rating of 88%, the stock sits in the growth zone for this low book-to-market framework, implying potential for sustained future growth. BMY is a large-cap growth stock in the Biotechnology & Drugs sector. The test table shows many positives: Book/Market Ratio: PASS, Return on Assets: PASS, Cash Flow from Operations to Assets: PASS, and Cash Flow from Operations to Assets vs. ROA: PASS; however, R&D to Assets: FAIL. Validea emphasizes that a score of 80% indicates some interest, while 90%+ would signal strong interest. Overall, the high score supports cautious optimism, though investors should consider other factors beyond this single model.

BMY Factor-Based Stock Analysis: 88% Mohanram Growth Model Rating

October 15, 2025, 8:28 PM EDT. Bristol-Myers Squibb Co. (BMY) scores highly under Validea's Partha Mohanram P/B Growth Investor model, earning 88% and signaling strong interest from this growth framework. The analysis places BMY as a large-cap growth stock in the Biotechnology & Drugs space, with a low book-to-market orientation and growth characteristics. In the table of tests, key metrics such as BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, and CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS are favorable. Notably, RESEARCH AND DEVELOPMENT TO ASSETS is listed as FAIL, which may warrant caution regarding growth drivers. Overall, a score above 80% typically signals interest, with 90%+ indicating stronger conviction. This reflects Validea's guru-style framework (Partha Mohanram).

Bristol-Myers Squibb (BMY) Tops Partha Mohanram P/B Growth Model, Validea Guru Analysis

October 15, 2025, 8:26 PM EDT. Validea's guru fundamental report on Bristol-Myers Squibb (BMY) shows it ranks highest among 22 guru strategies using the P/B Growth Investor model crafted by Partha Mohanram. The growth framework targets low book-to-market stocks with traits linked to sustained future growth. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs industry, with a strategy rating of 88%; typically a score at or above 80% signals interest, and above 90% signals strong interest. The summary table indicates most tests pass (e.g., BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, etc.), though R&D to assets failed. Overall, the model implies notable upside under this growth-like framework, though note is given to test weights and non-independence of criteria.

BMY Gets High Marks under Partha Mohanram's P/B Growth Model (88% Score) | Validea Guru Analysis

October 15, 2025, 8:24 PM EDT. Validea's guru-based analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model tied to Partha Mohanram. BMY scores 88%, signaling strong interest from this growth framework. The model favors low book-to-market stocks demonstrating sustained growth, and BMY clears key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and ROA variance, with PASS on many criteria including advertising to assets, R&D to assets, and CAPEX to assets. While not all criteria are independent or weighted equally, the overall takeaway is that BMY aligns with Mohanram's growth screen, suggesting potential upside but investors should consider broader biotech dynamics and fundamentals beyond the score.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Signals Strong Interest

October 15, 2025, 8:22 PM EDT. Validea rates Bristol-Myers Squibb (BMY) highly under Partha Mohanram's P/B Growth Investor model. This growth framework searches for low book-to-market stocks with signs of sustained future growth. BMY's rating is 88%, with ratings at or above 80% suggesting interest and at or above 90% signaling strong interest. The analysis shows most tests pass within this framework, including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS. The sole weakness is RESEARCH AND DEVELOPMENT TO ASSETS, which fails. As a large-cap growth stock in the Biotechnology & Drugs group, BMY appears favorable on fundamentals and valuation under this model, though investors should note the R&D caveat as a potential growth risk point.

BMY favored by Partha Mohanram Growth Model with 88% score

October 15, 2025, 8:20 PM EDT. Bristol-Myers Squibb Co (BMY) rates strongest under Validea's Partha Mohanram Growth Investor model, posting an 88% score. The Mohanram growth framework seeks low book-to-market stocks with sustained growth, with a threshold of 80% for interest and 90% for strong interest. In the report, BMY shows BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, ROA VARIANCE: PASS, SALES VARIANCE: PASS, ADVERTISING TO ASSETS: PASS, CAPITAL EXPENDITURES TO ASSETS: PASS, but RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. Despite the R&D miss, the overall 88% rating indicates the strategy finds the stock worthwhile within its growth framework.

BMY Leads Validea's Partha Mohanram P/B Growth Coverage (88% Score)

October 15, 2025, 8:18 PM EDT. Bristol-Myers Squibb Co. (BMY) posts an 88% rating under Validea's Partha Mohanram P/B Growth model, signaling potential interest from growth-oriented investors. Classified as a large-cap growth stock in Biotechnology & Drugs, BMY shows low book-to-market characteristics coupled with indicators of sustained future growth. The model's tests largely pass: BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and CFO/ASSETS vs ROA are PASS, with other asset-related metrics also favorable. The analysis reflects Mohanram's approach that low book-to-market stocks can yield outsized growth, though the report notes that an 80%+ score indicates some interest and above 90% would imply stronger conviction. Overall, BMY's score suggests meaningful attention from this factor-based framework.

BMY: Validea P/B Growth Guru Rating at 88% (Partha Mohanram)

October 15, 2025, 8:16 PM EDT. Validea's guru fundamental report rates BRISTOL-MYERS SQUIBB CO (BMY) highest among 22 strategies using the P/B Growth Investor model, built on the work of Partha Mohanram. This growth framework targets low book-to-market stocks with signs of sustained growth, placing BMY in the large-cap Biotechnology & Drugs universe as a growth stock. The strategy assigns an 88% rating, with 80%+ typically signaling interest and 90%+ indicating strong interest. The included criteria table shows BMY passes several tests-such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS-though not all factors are independent. Overall, the stock's fundamentals and valuation align with the growth-focused, factor-based approach of this guru.

BMY Factor-Based Stock Analysis: Partha Mohanram's P/B Growth Model Signals Growth Potential

October 15, 2025, 8:14 PM EDT. Validea's guru fundamental report ranks Bristol-Myers Squibb Co (BMY) highly under the Partha Mohanram-based P/B Growth Investor model. The growth-oriented screen seeks low book-to-market names with signs of sustained future expansion. As a large-cap growth stock in the Biotechnology & Drugs sector, BMY earns an 88% score on this strategy, suggesting meaningful interest (scores north of 80% indicate at least some interest; above 90% signals strong interest). The accompanying table shows key tests all passing, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, R&D TO ASSETS, and others. Overall, the model flags BMY as attractive within its framework, reflecting favorable fundamentals per this guru approach available from Validea.

BMY Tops Partha Mohanram P/B Growth Model in Validea Guru Analysis

October 15, 2025, 8:12 PM EDT. Validea's guru fundamental report ranks BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model developed by Partha Mohanram. As a large-cap growth stock in the Biotechnology & Drugs space, BMY earns an 88% rating on the model, signaling strong interest from this strategy based on a low book-to-market profile paired with growth traits. The score reflects PASS readings for factors like Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, and others, with the notable exception of R&D to Assets which fails. The analysis highlights that the firm's fundamentals align with the model's emphasis on valuation and growth, contributing to the high score despite some variance areas.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Endorses Bristol-Myers Squibb

October 15, 2025, 8:10 PM EDT. Bristol-Myers Squibb (BMY) ranks highest among Validea's 22 guru strategies under the P/B Growth Investor model by Partha Mohanram. The growth model targets low book-to-market stocks with characteristics linked to sustained future growth. BMY scores 88%, suggesting notable interest from the strategy, with scores above 90% signaling strong interest. The test table shows BMY passing key criteria, including Book/Market Ratio PASS, Return on Assets PASS, Cash Flow from Operations to Assets PASS, CF Ops to Assets vs ROA PASS, ROA Variance PASS, Sales Variance PASS, Advertising to Assets PASS, Capital Expenditures to Assets PASS, and R&D to Assets PASS. Framed as a large-cap growth stock in Biotechnology & Drugs, the report highlights favorable fundamentals and valuation under Mohanram's model, per Validea's methodology.

BMY Factor-Based Analysis Shows High Growth Signal Under Mohanram Model

October 15, 2025, 8:08 PM EDT. Validea's guru analysis for BRISTOL-MYERS SQUIBB CO (BMY) shows the Partha Mohanram P/B Growth Investor model rates BMY at 88%, indicating notable interest from this growth framework. The model targets low book-to-market stocks with traits linked to sustained growth. BMY is described as a large-cap growth stock in the Biotechnology & Drugs industry. Under this strategy, a score of 80%+ signals interest, with 90%+ signaling strong interest. In the summary table, most tests are PASS: BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS, ROA VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS. The only cited shortcoming is RESEARCH AND DEVELOPMENT TO ASSETS: FAILED. Background on Partha Mohanram and Validea's approach is included.

BMY: Partha Mohanram Growth Model Signals Strength in Validea's Guru Analysis

October 15, 2025, 8:06 PM EDT. Validea's guru-based assessment rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model. The stock is highlighted as a large-cap growth name in Biotechnology & Drugs, with an 88% strategy score and a history of strong fundamentals. The model targets low book-to-market, growth-oriented stocks, and flags BMY as meeting key tests across metrics such as Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, and R&D to Assets. While some criteria are weighted differently, the overall takeaway is that BMY displays positive fundamental signals with favorable growth-oriented metrics. Investors should note the model's emphasis on sustained growth indicators rather than short-term momentum, and consider BMY within a diversified growth-focused portfolio.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model (Validea)

October 15, 2025, 8:04 PM EDT. Validea's guru analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model, with an 88% score signaling potential in a low book-to-market, growth-focused framework. The model seeks stocks with low book-to-market ratios and sustained growth characteristics. BMY, a large-cap in the Biotechnology & Drugs space, earns PASS on tests like BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS. The report emphasizes that scores at or above 80% indicate interest, with above 90% signaling strong interest. Readers get context on Mohanram and Validea's framework, which aggregates insights from published guru strategies. Investors can weigh BMY's fundamentals against this factor-based growth approach and the stock's valuation signals.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals

October 15, 2025, 8:02 PM EDT. Validea rates BRISTOL-MYERS SQUIBB CO (BMY) highly on the P/B Growth Investor model, one of 22 guru strategies followed. The model seeks low book-to-market stocks with sustained growth, and BMY scores 88%, signaling meaningful interest. The report notes multiple favorable tests, including: BOOK/MARKET RATIO pass, RETURN ON ASSETS pass, CASH FLOW FROM OPERATIONS TO ASSETS pass, and R&D/ASSETS pass, among others. Weak points are not explicit, but the table shows the stock aligns with several criteria that historically correlate with growth trajectories. Overall, the result positions BMY as a candidate favored by Mohanram's growth framework, while investors should consider broader fundamentals and market context.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates BMY at 88%

October 15, 2025, 8:00 PM EDT. Bristol-Myers Squibb Co (BMY) earns an 88% score under Validea's Partha Mohanram-based P/B Growth Investor model, a framework that favors low book-to-market stocks with sustained growth traits. Classified as a large-cap growth stock in the Biotechnology & Drugs industry, BMY shows strengths across core metrics: strong performance on the Book/Market ratio, Return on Assets, and Cash flow from operations to assets. The model also notes supporting signals in Cash flow from operations to assets vs. ROA, and wide passes on ROA variance, Sales variance, Advertising to assets, and Capital expenditures to assets. One criterion shows weakness: R&D to assets did not meet the threshold. Overall, the stock is rated by this strategy as a compelling growth pick, keeping an eye on fundamental persistence and valuation.

BMY Factor-Based Analysis: Partha Mohanram P/B Growth Model Rates Bristol-Myers Squibb at 88%

October 15, 2025, 7:58 PM EDT. Validea's guru-based review ranks BRISTOL-MYERS SQUIBB CO (BMY) highly under Partha Mohanram's P/B Growth Investor model. The model scans for low book-to-market stocks with signs of sustained future growth, and BMY earns an 88% rating, signalling strong interest from this growth framework. The analysis notes the stock is a large-cap in Biotechnology & Drugs and highlights key tests that pass, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS, among others. While not all criteria are weighted equally, the overall result suggests the stock aligns with Mohanram's growth criteria. The report summarizes Mohanram's academic work, and positions Validea as offering strategy-driven insights across guru-based portfolios.

BMY Factor-Based Stock Analysis: Validea's Partha Mohanram Growth Model Signals 88% Rating

October 15, 2025, 7:56 PM EDT. Validea's guru report for BRISTOL-MYERS SQUIBB CO (BMY) rates highest on the P/B Growth Investor model by Partha Mohanram. This growth screen favors low book-to-market stocks with sustained growth. BMY is a large-cap growth stock in the Biotechnology & Drugs group, with a model rating of 88%. An 80%+ score signals interest; 90%+ would indicate strong interest, so BMY sits in the camp of notable attention. The summary table shows many criteria pass (e.g., BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS), with RESEARCH AND DEVELOPMENT TO ASSETS listed as FAIL. Overall, the model suggests potential growth, but investors should evaluate the R&D asset linkage more closely.

BMY Factor-Based Growth Signal Under Partha Mohanram Model

October 15, 2025, 7:54 PM EDT. Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) ranks the stock highly under the P/B Growth Investor model, derived from Partha Mohanram's growth framework. The model targets low BOOK/MARKET stocks with sustained growth, and BMY scores 88%, indicating notable interest (scores above 80% signal interest; above 90% signal strong interest). In the detailed test table, key metrics show BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS VS. ROA: PASS, ROA VARIANCE: PASS, SALES VARIANCE: PASS, ADVERTISING TO ASSETS: PASS, CAPITAL EXPENDITURES TO ASSETS: PASS, while RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. Overall, BMY is characterized as a large-cap growth stock in the Biotechnology & Drugs industry, with the Mohanram framework signaling meaningful growth characteristics despite a R&D-to-assets weakness.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals High Interest

October 15, 2025, 7:52 PM EDT. Validea's guru fundamental report flags Bristol-Myers Squibb (BMY) as a standout on the Partha Mohanram P/B Growth Investor model. Among 22 guru strategies, BMY rates highest under this growth screen, which seeks low book-to-market names with sustained future growth. The stock is classified as a large-cap growth name in the Biotechnology & Drugs sector, with an 88% strategy rating-well above the threshold for interest favors (80%+) but shy of the strongest signals (>90%). The underlying table shows most tests as PASS (Book/Market, ROA, CFO/Assets, CFO/ROA, Cash Flow Variance, Sales Variance, Advertising to Assets, Capex to Assets). The only noted weakness is R&D to Assets: FAIL. Additional context covers Partha Mohanram's background and Validea's framework.

BMY Factor-Based Stock Analysis: Validea's Partha Mohanram Growth Model Signals Strong Interest

October 15, 2025, 7:50 PM EDT. Validea's guru-based analysis ranks BMY highly under the P/B Growth Investor model from Partha Mohanram. The model targets low book-to-market stocks with signs of sustained growth, yielding an 88% rating for Bristol-Myers Squibb, indicating notable interest (above 80%), with particularly strong interest above 90%. Among Validea's 22 guru strategies, this score emphasizes robust fundamentals and favorable valuation. The accompanying test table shows a majority of criteria as PASS (e.g., BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS), with some items such as R&D to assets flagged as not meeting the criterion. Overall, BMY is characterized as a large-cap growth stock in Biotechnology & Drugs with a favorable factor-based view under Mohanram's framework.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Flags Strong Interest

October 15, 2025, 7:48 PM EDT. Bristol-Myers Squibb Co (BMY) scores highly under Validea's Partha Mohanram P/B Growth Investor model, which targets low book-to-market stocks with growth characteristics. The stock is categorized as a large-cap growth name in the Biotechnology & Drugs sector. The model rates BMY at 88%, with 80%+ indicating some interest and 90%+ indicating strong interest. In this analysis, key tests were mostly PASS across BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics, though R&D TO ASSETS is marked FAILED. The profile highlights that Partha Mohanram's approach seeks to separate winners from losers among low B/M stocks, suggesting potential for continued growth if fundamentals hold. Overall, this setup points to positive positioning under this specific factor-based framework, albeit with caveats around R&D intensity.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Interest

October 15, 2025, 7:46 PM EDT. Validea assesses BRISTOL-MYERS SQUIBB CO (BMY) through the Partha Mohanram P/B Growth Investor model. The stock earns an 88% rating, signaling notable interest from this guru strategy. BMY is a large-cap growth stock in the Biotechnology & Drugs space, with a score above 80% indicating at least some portfolio interest and above 90% signaling strong interest. The model's table shows passes on multiple tests-book/market ratio, ROA, cash flow from operations to assets, cash flow vs. ROA, ROA variance, sales variance, advertising to assets, and capex to assets-while R&D to assets fails. Not all tests are equally weighted. Partha Mohanram's approach blends value-style screens with growth signals, and Validea frames these findings within his research.

Bristol-Myers Squibb (BMY) Signals Strong Interest from Partha Mohanram P/B Growth Model

October 15, 2025, 7:44 PM EDT. Bristol-Myers Squibb Co (BMY) registers a strong signal from Validea's guru-based assessment using the Partha Mohanram P/B Growth Investor model. The large-cap Biotechnology & Drugs name earns an 88% score, indicating substantial interest from the growth framework. It passes key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, with favorable notes on R&D TO ASSETS and asset efficiency. The Mohanram growth model seeks low book-to-market stocks with durable growth, and BMY's high score suggests potential for continued outperformance if fundamentals stay intact. As always, this Validea signal should be considered alongside broader risk factors and market context.

BMY Factor-Based Stock Analysis: Partha Mohanram P/B Growth Signals Interest

October 15, 2025, 7:42 PM EDT. Bristol-Myers Squibb Co (BMY) scores highest among Validea's guru models under the P/B Growth Investor framework developed by Partha Mohanram. The large-cap biotech/drugs stock earns an 88% rating, with 80% typically signaling interest and 90% signaling strong interest. The model targets low book-to-market stocks with growth traits. In the detailed checks, BMY passes the Book/Market, Return on Assets (ROA), Cash Flow from Operations to Assets, CFO to ROA, and ROA Variance tests, as well as Sales Variance, Advertising to Assets, Capital Expenditures to Assets, and R&D to Assets. Notably, R&D to Assets is marked as FAIL. Overall, the fundamental setup suggests modest-to-strong interest from this growth framework, with caveats on how R&D investments are weighted in asset allocation.

BMY Factor-Based Analysis: Partha Mohanram's P/B Growth Model Tops Validea's Guru Scores

October 15, 2025, 7:40 PM EDT. Bristol-Myers Squibb (BMY) leads Validea's factor-based review under the P/B Growth Investor model from Partha Mohanram, earning an 88% rating. The approach targets low book-to-market stocks with sustained growth traits. In the table of tests, key metrics PASS for Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, and related checks, while R&D to Assets is flagged as FAIL. A score above 80% signals interest; above 90% signals strong interest. The result positions BMY as a notable candidate within the Biotechnology & Drugs space according to this growth framework, though readers should weigh the R&D to Assets miss against the overall fundamentals and valuation.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals High Interest

October 15, 2025, 7:38 PM EDT. Bristol-Myers Squibb Co. (BMY) is highlighted by Validea's guru-based analysis under the P/B Growth Investor model from Partha Mohanram. The stock scores 88% on this growth framework, with a threshold of 80% signaling interest and 90% signaling strong interest. The model favors low book-to-market stocks with growth characteristics, and for BMY the model's tests largely pass: BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS (and related metrics) show favorable signals. As a large-cap Biotechnology & Drugs name, BMY sits in the spectrum of growth-oriented healthcare equities based on fundamentals and valuation. Investors may view this as notable exposure to a growth-driven segment, though wider research and risk considerations apply.

BMY: Partha Mohanram P/B Growth Model Signals Strong Growth Potential

October 15, 2025, 7:36 PM EDT. BMY (Bristol-Myers Squibb) ranks highly on Validea's Partha Mohanram P/B Growth model, scoring 88% based on fundamentals and valuation. The model targets low book-to-market stocks with potential for sustained growth, and a score above 80% signals notable interest. In this analysis, tests such as Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, and Cash Flow from Operations to Assets vs. ROA pass, while R&D to Assets fails within this framework. As a large-cap Biotechnology & Drugs stock, BMY is highlighted for growth characteristics under this guru strategy, reflecting the model's focus on earnings trajectory and balance-sheet signals. Note that weights and test independence vary, but a threshold near 90% indicates strong interest.

Bristol-Myers Squibb Co. (BMY) Factor-Based Growth Analysis – 88% Mohanram P/B Growth Score

October 15, 2025, 7:34 PM EDT. Validea's guru analysis rates BMY highly on Partha Mohanram's P/B Growth Investor model, which targets low book-to-market stocks with sustained future growth. BRISTOL-MYERS SQUIBB CO is a large-cap Biotechnology & Drugs stock, earning an 88% score under this strategy-well above the 80% threshold and close to a strong signal. The report shows PASS across key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, as well as R&D TO ASSETS and CAPITAL EXPENDITURES TO ASSETS. This paints a growth-oriented profile for BMY, though investors should review all criteria and the current market context.

Bristol-Myers Squibb Rated 88% by Partha Mohanram P/B Growth Model (Validea)

October 15, 2025, 7:32 PM EDT. Validea's guru-factor analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highest among the 22 strategies using the Partha Mohanram P/B Growth model. The model seeks low book-to-market stocks with characteristics linked to sustained growth. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs sector, earning an 88% score, with 80%+ signaling investor interest and 90%+ indicating strong interest. The rating reflects PASS results on key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and other asset-related measures. Detailed guru analysis emphasizes Mohanram's premise that growth stocks with solid fundamentals can outperform, and positions BMY within Validea's framework of factor-based portfolios and academic research. Investors should weigh fundamentals, growth prospects, and valuation in context of the broader market.

Bristol-Myers Squibb (BMY) Receives 88% Mohanram Growth Signal From Validea Guru Analysis

October 15, 2025, 7:30 PM EDT. Bristol-Myers Squibb Co (BMY) earns a high reading from Validea's Partha Mohanram Growth Investor model, posting an 88% score based on fundamentals and valuation. The growth framework seeks low book-to-market stocks with traits of sustained growth, and BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs industry. A score in the high 80s indicates some interest, with scores above 90% signaling strong interest. The Guru Analysis shows most tests pass, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and several asset-related metrics; the only noted weakness is RESEARCH AND DEVELOPMENT TO ASSETS, marked as FAILED. Overall, BMY appears on Validea's radar as a growth-oriented idea driven by Mohanram's research, with a caveat around R&D asset attribution.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Highlights

October 15, 2025, 7:28 PM EDT. Validea's guru fundamental report rates Bristol-Myers Squibb Co (BMY) highly under the Partha Mohanram P/B Growth Investor model. The growth model seeks low book-to-market stocks with signs of sustained future growth. BMY scores 88% under this strategy, with >80% indicating interest and >90% signaling strong interest. The stock is categorized as a large-cap growth name in Biotechnology & Drugs. Test results show: Book/Market PASS, ROA PASS, CFO to Assets PASS, CFO to Assets vs ROA PASS, ROA Variance PASS, Sales Variance PASS, Advertising to Assets PASS, Capex to Assets PASS, R&D to Assets FAIL. The report notes Mohanram's research on separating winners from losers among low book-to-market stocks and positions BMY as a growth-oriented pick within the healthcare space.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 15, 2025, 7:26 PM EDT. Validea's guru analysis flags BRISTOL-MYERS SQUIBB CO (BMY) as a top pick under the P/B Growth Investor model, based on the strategy published by Partha Mohanram. The model seeks low book-to-market stocks with indicators of sustained future growth. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs industry, earning an 88% rating-well above the 80% threshold and near the 90% mark that signals strong interest. The accompanying test table shows key positives: BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, and other measures like R&D to Assets and CAPEX to Assets also indicating favorable alignment. While not all criteria carry equal weight, the overall signal is that this growth-focused framework views BMY as a compelling growth candidate within its sector, per Validea's methodology.

Bristol-Myers Squibb (BMY) Factor-Based Analysis: Partha Mohanram Growth Model Signals Strength

October 15, 2025, 7:24 PM EDT. BMY scores highest under Validea's P/B Growth Investor model (Partha Mohanram) for low book-to-market, growth-oriented stocks with indicators of sustained future growth. The large-cap biotech/drug name carries an 88% rating, signaling strong fundamentals and valuation. Key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS pass, with favorable reads on R&D TO ASSETS and related metrics. This mirrors Mohanram's framework-separating winners from losers among growth stocks. Overall, BMY's fundamentals align with the strategy's criteria, though investors should compare this signal across Validea's guru strategies and other risk/reward factors before trading.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates Bristol-Myers Squibb at 88%

October 15, 2025, 7:22 PM EDT. Validea's guru-based assessment places Bristol-Myers Squibb Co (BMY) at the top among 22 strategies under the P/B Growth Investor model, a Partha Mohanram framework that favors low book-to-market stocks with sustained growth. The stock earns an 88% rating, signaling strong interest (scores above 80% attract attention; above 90% indicate strong interest). In the overview table, key tests like BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS all PASS, with R&D TO ASSETS noted as a failure. Described as a large-cap Biotechnology & Drugs stock, BMY combines growth signals with some efficiency caveats. The analysis reflects Mohanram's criteria and Validea's methodology, highlighting both solid fundamentals and areas needing closer scrutiny.

Validea Guru Analysis: Bristol-Myers Squibb (BMY) P/B Growth Model Signals Strong Interest

October 15, 2025, 7:20 PM EDT. Validea's guru fundamental review for BRISTOL-MYERS SQUIBB CO (BMY) shows BMY ranking highest on the Partha Mohanram P/B Growth model. This growth framework seeks low book-to-market names with enduring growth characteristics. BMY, a large-cap player in Biotechnology & Drugs, earns an 88% rating, with 80%+ indicating interest and 90%+ signaling strong interest. The accompanying criteria table shows most tests as PASS, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related measures; however, RESEARCH AND DEVELOPMENT TO ASSETS is marked as FAILED. Overall, Validea portrays BMY as a stock with meaningful fundamental strength under this factor-based lens, tied to growth expectations.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Returns 88%

October 15, 2025, 7:18 PM EDT. Bristol-Myers Squibb (BMY) earns a high score under Validea's Partha Mohanram P/B Growth Investor model, delivering an 88% rating and signaling strong interest from a growth-focused screen. The model targets low book-to-market stocks with signs of sustained growth. BMY is a large-cap Biotechnology & Drugs stock, and the report notes several passing tests-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS-with RESEARCH AND DEVELOPMENT TO ASSETS flagged as a failure. The analysis reflects Mohanram's thesis that growth can emerge from low B/M stocks and summarizes BMY's standing across 22 guru strategies. Investors should weigh the strong fundamentals against the single weakness and broader sector risks.

BMY Factor-Based Stock Analysis: Validea Highlights Partha Mohanram Growth Model for Bristol-Myers Squibb

October 15, 2025, 7:16 PM EDT. Validea's guru-based assessment ranks Bristol-Myers Squibb (BMY) highly under Partha Mohanram's Growth Investor model, which favors low book-to-market stocks with signs of durable growth. BMY scores 88% under this growth framework, with an 80%+ indicating interest and 90%+ signaling strong interest. In the detailed checks, key metrics pass such as Book/Market ratio, Return on Assets, Cash Flow from Operations to Assets, CFO vs ROA, ROA variance, Sales variance, Advertising to assets, and Capex to assets. The only notable miss is R&D to assets, which does not meet the model's criteria. Overall, BMY is positioned as a potential growth stock within large-cap Biotechnology & Drugs, supported by strong fundamentals and valuation signals from the Partha Mohanram framework.

BMY Lights Up Validea's Partha Mohanram Growth Screen (88%)

October 15, 2025, 7:14 PM EDT. Bristol-Myers Squibb Co (BMY) rates highly under Validea's P/B Growth Investor model, a strategy from Partha Mohanram that seeks low book-to-market stocks with signs of sustained growth. The stock earns an 88% rating, indicating interest but not the top tier (>=90%). The table shows most tests pass, including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, with favorable variances in several metrics. The notable exception is RESEARCH AND DEVELOPMENT TO ASSETS, which fails the screen. BMY is described as a large-cap Biotechnology & Drugs stock. Investors should note the model's growth bias and overall strength, while the R&D-to-assets signal warrants closer inspection.

Bristol-Myers Squibb (BMY) Shines on Partha Mohanram P/B Growth Model

October 15, 2025, 7:12 PM EDT. Bristol-Myers Squibb (BMY) scores highly on Validea's guru-based analysis, topping the Partha Mohanram P/B Growth Investor model. The strategy seeks low book-to-market stocks with signs of sustained growth. BMY's rating reaches 88%, with scores above 80% signaling interest and above 90% signaling strong interest. Among the tests, BMY passes on Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, and other metrics, with the report noting strength in profitability and asset efficiency. As a large-cap player in Biotechnology & Drugs, the stock shows favorable fundamentals versus peers according to this model, though readers should consider broader market factors and stock-specific risks.

BMY Factor-Based Stock Analysis: Partha Mohanram P/B Growth Model – 88% Rating

October 15, 2025, 7:10 PM EDT. Validea's guru analysis applies the P/B Growth Investor model of Partha Mohanram to Bristol-Myers Squibb (BMY). The stock scores 88%, indicating strong potential within this growth framework that favors low book-to-market stocks with durable growth traits. Under the criteria summary, key factors such as Book/Market Ratio, Return on Assets, and Cash Flow from Operations to Assets pass, supporting solid profitability and cash-flow dynamics. The comparison of Cash Flow from Operations to Assets vs. ROA also passes, as do Sales Variance and CAPEX to Assets. A noted weakness is R&D to Assets, marked FAILED, which may temper growth acceleration. Overall, the stock shows high interest under this strategy, with several metrics meeting expectations and the 88% rating signaling potential for further upside.

BMY Factor-Based Stock Analysis: Validea's Partha Mohanram Growth Score at 88%

October 15, 2025, 7:08 PM EDT. Validea's guru-based analysis places BRISTOL-MYERS SQUIBB CO (BMY) at the top of 22 guru strategies under the P/B Growth Investor model, based on Partha Mohanram's framework. The model seeks low book-to-market stocks with characteristics linked to sustained growth. BMY, a large-cap Biotechnology & Drugs stock, earns an 88% rating-typically signaling interest from the strategy (scores >80% show some interest; >90% strong interest). Key tests show Book/Market ratio, Return on Assets, and CFO to assets metrics passing, with R&D to assets flagged as a weakness. Overall, the analysis highlights BMY's fundamentals and valuation strength under this growth lens, while signaling a potential caveat on R&D capitalization compared to peers.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Interest

October 15, 2025, 7:06 PM EDT. Bristol-Myers Squibb (BMY) scores highly under Validea's Partha Mohanram P/B Growth Investor model, landing 88% and signaling market interest. The model seeks low book-to-market stocks with sustained growth, and rates BMY as a large-cap growth stock in Biotech & Drugs. A score in the 80s suggests some interest; above 90% would indicate strong interest. In the detailed rubric, BMY passes most tests-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, ROA VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, R&D TO ASSETS: FAIL. The framework notes R&D TO ASSETS as a weak point, while other metrics align with growth characteristics. The analysis reflects Partha Mohanram's research and Validea's guru-based approach.

BMY Factor-Based Growth Analysis with Mohanram Model Signals

October 15, 2025, 7:04 PM EDT. Validea's guru-style assessment places Bristol-Myers Squibb Co (BMY) among the top picks under the P/B Growth Investor model developed by Partha Mohanram. The stock earns an 88% score, with the note that a score of 80%+ signals some interest and 90%+ signals strong interest. The summary table shows the stock PASS on multiple criteria (BOOK/MARKET RATIO, RETURN ON ASSETS, CFO/Assets, etc.), highlighting a favorable growth-oriented profile for a large-cap in Biotechnology & Drugs. The analysis emphasizes Mohanram's tradition of separating growth winners among low book-to-market stocks, and positions BMY as a notable factor-based idea for growth-focused portfolios.

BMY Factor-Based Growth Signal: Validea's Mohanram Model Flags Some Interest

October 15, 2025, 7:02 PM EDT. Validea's guru analysis for BRISTOL-MYERS SQUIBB CO (BMY) shows the stock scoring 88% under the P/B Growth Investor model from Partha Mohanram. As a large-cap growth issue in Biotechnology & Drugs, BMY is evaluated on a low book-to-market paired with growth traits. The model's tests yield a mix: BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS VS. ROA: PASS, but RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. Overall, an 88% rating signals some investor interest (below the 90% threshold for strong interest). The framework emphasizes value/growth balance and Mohanram's growth model origin, offering a nuanced view of BMY's fundamentals and valuation in the healthcare space.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates Bristol-Myers Squibb at 88%

October 15, 2025, 7:00 PM EDT. Validea's guru-factor analysis rates Bristol-Myers Squibb Co (BMY) highest under the P/B Growth Investor model, a Mohanram-based framework that targets low book-to-market stocks with signs of sustained growth. BMY, a large-cap Biotechnology & Drugs stock, earns an 88% rating, indicating some interest from this strategy (scores above 90% signal strong interest). The criteria snapshot shows PASS for most tests, including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, with RESEARCH AND DEVELOPMENT TO ASSETS listed as a FAIL. Overall, the stock aligns with Mohanram's growth filter, illustrating how growth-oriented metrics can favor a biotech name, even when development spending weighs on certain ratios.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals 88% Rating

October 15, 2025, 6:58 PM EDT. Validea's guru fundamental report rates BRISTOL-MYERS SQUIBB CO (BMY) highly under Partha Mohanram's P/B Growth Investor model. The large-cap biotech is flagged as a stock with low book-to-market but indicators of sustained growth. BMY scores 88% under this strategy, above the 80% threshold that signals interest and approaching the 90% level for strong interest. The analysis shows key passings across many criteria, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, R&D TO ASSETS, and more. The report explains Mohanram's growth framework and the historical context of separating growth winners from losers in low B/M stocks.

BMY Signals Strong Interest Under Partha Mohanram Growth Model (Validea)

October 15, 2025, 6:56 PM EDT. Validea's guru fundamental report for Bristol-Myers Squibb Co (BMY) shows it rates highest under the P/B Growth Investor model, the strategy of Partha Mohanram. The growth model targets low book-to-market stocks with signs of sustained future expansion. The stock earns an 88% rating, with 80%+ signaling interest and 90%+ signaling strong interest. In tests, BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS, ROA VARIANCE: PASS, SALES VARIANCE: PASS, ADVERTISING TO ASSETS: PASS, CAPITAL EXPENDITURES TO ASSETS: PASS, while RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. BMY is a large-cap growth stock in the Biotechnology & Drugs sector.

Bristol-Myers Squibb (BMY) Factor-Based Stock Analysis: Partha Mohanram Growth Model

October 15, 2025, 6:54 PM EDT. Validea's guru fundamental report places Bristol-Myers Squibb (BMY) at the top of the P/B Growth Investor model by Partha Mohanram. The model seeks low book-to-market stocks with signs of sustained future growth. BMY is a large-cap growth stock in the Biotechnology & Drugs sector, rated 88% based on fundamentals and valuation, with 80%+ indicating some interest and 90%+ signaling strong interest. The summary table shows: BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, CFO to ROA: PASS, ROA VARIANCE: PASS, SALES VARIANCE: PASS, ADVERTISING TO ASSETS: PASS, CAPITAL EXPENDITURES TO ASSETS: PASS, RESEARCH AND DEVELOPMENT TO ASSETS: FAILD. Guru analysis and Partha Mohanram background are highlighted by Validea as context.

Bristol-Myers Squibb (BMY) Factor-Based Stock Analysis: Mohanram Growth Model Signals 88% Rating

October 15, 2025, 6:52 PM EDT. Bristol-Myers Squibb Co (BMY) earns the top spot in Validea's Partha Mohanram P/B Growth Investor model, scoring 88% based on fundamentals and valuation. The model targets low book-to-market stocks with indicators of sustained future growth. BMY is a large-cap growth stock in the Biotechnology & Drugs industry. A score of 80%+ suggests interest, while 90%+ indicates strong interest. The analysis shows many tests pass – notably BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CFO to assets vs. ROA, ROA VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, and CAPITAL EXPENDITURES TO ASSETS – but RESEARCH AND DEVELOPMENT TO ASSETS fails. Investors should weigh this growth signal against pharma-specific risks and R&D dynamics.

Bristol-Myers Squibb (BMY) Tops Partha Mohanram P/B Growth Screen per Validea Guru Analysis

October 15, 2025, 6:50 PM EDT. Bristol-Myers Squibb (BMY) scores highly on Validea's Partha Mohanram P/B Growth Investor model, landing 88% based on fundamentals and valuation. The model seeks low book-to-market stocks with strong future growth traits. In BMY's case, key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS all pass, with some weighting differences across criteria. The report highlights growth-oriented strengths in ROA, cash flow, R&D, and capital investments, while noting that not all criteria are independent. Overall, a 80%+ rating signals notable interest; above 90% would indicate strong enthusiasm. The piece frames BMY as a large-cap growth stock in Biotechnology & Drugs with favorable fundamentals per Mohanram's framework.

BMY Factor-Based Stock Analysis – Partha Mohanram Growth Score 88%

October 15, 2025, 6:48 PM EDT. Validea's guru fundamental report on BMY applies the Partha Mohanram P/B Growth Investor model to identify low book-to-market stocks with sustainable growth. Described as a large-cap growth stock in Biotechnology & Drugs, BMY shows an 88% rating-above the 80% threshold and near the 90% level that signals strong interest. The quick rubric shows PASS on most criteria (BOOK/MARKET RATIO, ROA, CFO to assets, CFO vs ROA, ROA variance, Sales variance, Advertising to assets, Capex to assets); however, R&D to assets is indicated as a FAIL. The write-up highlights Mohanram's research background and Validea's factor-based stock approach. Investors should weigh the growth signals against the model's R&D allocation signal.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals High Interest

October 15, 2025, 6:46 PM EDT. Validea's guru-based view on BRISTOL-MYERS SQUIBB CO (BMY) shows the stock scoring 88% under the Partha Mohanram Growth Investor model, indicating strong interest. The model seeks low book-to-market stocks with growth traits and flags BMY as a growth-oriented large-cap in biotechnology. Key tests largely pass: Book/Market, Return on Assets, Cash Flow from Operations to Assets, and related variance checks, plus favorable Sales Variance, Advertising to Assets, Capital Expenditures to Assets. The only noted weak point is R&D to Assets, which failed. Overall, the analysis portrays BMY as a stock with sustained growth characteristics per Validea's Partha Mohanram framework. Investors should weigh this growth tilt against their risk tolerance and other factors.

BMY Guru Factor Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 15, 2025, 6:44 PM EDT. Validea's guru analysis places BRISTOL-MYERS SQUIBB CO (BMY) at the top of the P/B Growth Investor signal from Partha Mohanram. The model targets low book-to-market stocks with sustainable growth, and BMY earns an 88% rating-well above the 80% threshold and near the level of strong interest. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs space. The score breakdown shows key tests as PASS for BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics, though R&D to Assets is flagged as FAIL. Overall, the report highlights the stock's growth orientation within a disciplined, factor-based framework.

BMY: Partha Mohanram Growth Model Rates Bristol-Myers Squibb at 88%

October 15, 2025, 6:42 PM EDT. Bristol-Myers Squibb Co (BMY) earns an 88% rating under Validea's Partha Mohanram P/B Growth Investor model, placing it in the high-interest range for growth stocks. The model favors low book-to-market, growth-oriented equities, and BMY is categorized as a large-cap Growth stock in Biotechnology & Drugs. A score of 80%+ signals interest; above 90% signals strong interest. In the detailed criteria, most tests pass-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related efficiency metrics-though it shows a failure in RESEARCH AND DEVELOPMENT TO ASSETS. Overall, the framework suggests positive fundamentals with a notable caveat on R&D intensity. Investors should weigh the growth signals against the R&D-related risk when evaluating BMY through this guru lens.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 15, 2025, 6:40 PM EDT. Validea's guru-based analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highest among 22 guru strategies under the Partha Mohanram Growth Investor model. The model seeks low book-to-market growth stocks with durable earnings trajectories. BMY earns an 88% rating, signaling meaningful interest from this strategy (scores above 90% indicate stronger conviction). The accompanying table shows key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS all PASS, with related metrics like ROA and CFO/Assets meeting thresholds. As a large-cap Biotechnology & Drugs stock, BMY is portrayed as a growth name with favorable fundamentals within this factor-based framework, though weights vary across criteria.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Highlights for Bristol-Myers Squibb

October 15, 2025, 6:38 PM EDT. Bristol-Myers Squibb Co. (BMY) ranks highest among Validea's Guru strategies under the P/B Growth Investor model, based on Partha Mohanram's growth framework. The model seeks low book-to-market stocks with sustained growth traits. BMY scores 88% for fundamentals and valuation, with 80%+ signaling interest and 90%+ signaling strong interest. The analysis shows PASS on BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CFO/ROA, ROA VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS; R&D TO ASSETS fails. Additional context covers Mohanram's background and the model's emphasis on identifying growth winners among low book-to-market stocks. Overall, BMY is viewed as a noteworthy name within the large-cap biotech/drug sector under this factor-based lens.

BMY Scores 88% under Partha Mohanram P/B Growth Model (Validea)

October 15, 2025, 6:36 PM EDT. Bristol-Myers Squibb Co (BMY) scores 88% under Validea's Partha Mohanram P/B Growth Investor model, signaling meaningful interest from this factor-based approach. The growth framework targets low book-to-market stocks with sustained growth traits. BMY, a large-cap Biotechnology & Drugs stock, shows PASS on most tests (e.g., BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS), with the lone exception of RESEARCH AND DEVELOPMENT TO ASSETS which FAIL. The overall rating suggests the strategy views BMY's fundamentals and valuation as favorable. As with any factor-based method, investors should couple this signal with broader fundamentals and current market conditions before trading.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates BRISTOL-MYERS SQUIBB CO at 88%

October 15, 2025, 6:34 PM EDT. Validea's guru framework places BRISTOL-MYERS SQUIBB CO (BMY) at the top among 22 strategies using the Partha Mohanram P/B Growth model. The growth-style screen seeks low book-to-market stocks with signs of sustained future expansion. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs group, receiving an 88% rating-above the 80% threshold that signals interest and below the 90% mark for strong interest. The model shows a majority of tests passing (Book/Market, ROA, CFO/Assets, CFO/Assets vs ROA, Asset efficiency in several areas), with one notable exception: RESEARCH AND DEVELOPMENT TO ASSETS FAILED. This indicates solid fundamentals and favorable valuation, but potential investors should weigh R&D efficiency. Overall, BMY shows meaningful growth-oriented exposure within healthcare with caveats on R&D metrics.

BMY Factor-Based Growth Analysis: 88% Mohanram Growth Score

October 15, 2025, 6:32 PM EDT. Validea's guru fundamental report for Bristol-Myers Squibb Co (BMY) applies Partha Mohanram's P/B Growth Investor model, seeking low book-to-market stocks with indicators of sustained growth. BMY is a large-cap growth stock in the Biotechnology & Drugs industry, earning an 88% rating under this strategy. An 80%+ score signals interest; 90%+ signals strong interest. The table shows PASS on BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics, with R&D TO ASSETS: FAIL. Overall, the stock presents favorable growth-oriented signals under this model, though the lone weak point in R&D to assets may temper conviction.

Validea Partha Mohanram Growth Model Signals Interest in BMY

October 15, 2025, 6:30 PM EDT. Validea's guru-based analysis rates BRISTOL-MYERS SQUIBB CO (BMY) at 88% under the P/B Growth Investor model, Partha Mohanram's framework that targets low book-to-market stocks with growth traits. The large-cap Biotechnology & Drugs stock appears as a growth candidate within Validea's methodology. The report shows PASS on key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, with related metrics like CASH FLOW FROM OPERATIONS TO ASSETS vs. RETURN ON ASSETS cited. Because the score is below 90%, the stock embodies some interest from this strategy rather than strong interest (90%+ would indicate stronger conviction).

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals 88% Rating

October 15, 2025, 6:28 PM EDT. Validea's guru analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model by Partha Mohanram, scoring 88%. This low book-to-market, high-growth framework favors firms with sustained expansion. BMY is categorized as a large-cap growth stock in Biotechnology & Drugs, and the model flags a majority of tests as PASS, including BOOK/MARKET, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS, while noting potential gaps in some criteria. Overall, a score above 80% indicates interest, with BMY at 88% suggesting strong interest from this growth-oriented discipline. Investors should consider factors like ROA variance, CFO/Assets dynamics, and the role of R&D intensity as part of a diversified portfolio.

BMY Factor-Based Stock Analysis: Partha Mohanram P/B Growth Signal Strong

October 15, 2025, 6:26 PM EDT. Bristol-Myers Squibb Co. (BMY) earns a high signal from Validea's Partha Mohanram P/B Growth Investor model, ranking among the top signals across the 22 guru strategies. This growth framework seeks low book-to-market stocks with attributes linked to sustained future growth. BMY delivers an 88% rating, with the note that a score of 80%+ suggests interest and 90%+ signals strong interest. The accompanying analysis shows favorable readings on several tests, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS (all pass). As a large-cap biotechnology/drugs stock, BMY appears to be a compelling growth-oriented pick under Mohanram's framework, per Validea's report.

BMY Factor-Based Stock Analysis: 88% P/B Growth Rating Under Partha Mohanram

October 15, 2025, 6:24 PM EDT. Validea's guru fundamental report flags Bristol-Myers Squibb Co (BMY) as a top pick under the P/B Growth Investor model developed by Partha Mohanram. The model looks for low book-to-market stocks with growth traits; BMY's score is 88%, above the 80% threshold that signals interest (90% would indicate strong interest). The scorecard shows PASS on inputs like Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, CFO to ROA, ROA Variance, Sales Variance, Advertising to Assets, and Capex to Assets; the only blemish is R&D to Assets: FAIL. As a large-cap Biotechnology & Drugs stock, BMY remains a growth-oriented name under this framework.

BMY Factor-Based Stock Analysis: Partha Mohanram P/B Growth Model Signals Growth Potential

October 15, 2025, 6:22 PM EDT. Validea's guru framework rates BRISTOL-MYERS SQUIBB CO (BMY) highly under Partha Mohanram's P/B Growth Investor model, giving BMY an 88% score. The growth screen seeks low book-to-market stocks with sustained future growth, and BMY-a large-cap Biotechnology & Drugs name-shows strong fundamentals. The analysis highlights passes on key tests such as Book/Market, Return on Assets, Cash Flow from Operations to Assets, and related metrics, with additional emphasis on R&D to Assets. An 88% rating signals notable interest from this strategy, while scores above 90% would imply stronger conviction. Overall, BMY's mix of profitability, cash flow, and pipeline investment aligns with a growth-oriented, value-conscious approach, though biotech risks remain a consideration for investors.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 15, 2025, 6:20 PM EDT. BMY, a large-cap growth stock in the Biotechnology & Drugs sector, earns an 88% rating under Validea's P/B Growth Investor model, based on Partha Mohanram's framework. The model seeks low book-to-market stocks with sustained growth, and Bristol-Myers Squibb shows favorable fundamentals and valuation. The score, generally indicating interest when above 80%, reflects a number of passing tests such as BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, and CASH FLOW FROM OPERATIONS TO ASSETS: PASS. A notable caveat is RESEARCH AND DEVELOPMENT TO ASSETS: FAIL, which could temper the growth thesis. Overall, Validea portrays upside potential under growth-oriented criteria but recommends monitoring R&D capitalization dynamics.

BMY Factor-Based Stock Analysis: Validea Growth Model Signals Strong Interest

October 15, 2025, 6:18 PM EDT. Bristol-Myers Squibb Co (BMY) earns the top rating among Validea's 22 guru strategies under Partha Mohanram's P/B Growth model. The growth-oriented approach favors low book-to-market names with sustained growth, and BMY scores 88% based on fundamentals and valuation. The stock passes tests for BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics; RESEARCH AND DEVELOPMENT TO ASSETS and CAPITAL EXPENDITURES TO ASSETS also pass, while some measures such as ROA variance and advertising-to-assets show weaker signals. Overall, this framework indicates strong interest in BMY from this strategy. Investors should weigh valuation, growth signals, and fundamental strength as they consider exposure to Bristol-Myers Squibb.

BMY Factor-Based Stock Analysis: Validea's Partha Mohanram Growth Model Signals 88%

October 15, 2025, 6:16 PM EDT. Bristol-Myers Squibb Co (BMY) earns a strong 88% rating under Validea's Partha Mohanram P/B Growth Investor model, which targets low book-to-market stocks with traits linked to sustained growth. Classified as a large-cap growth stock in the Biotechnology & Drugs sector, BMY sits in the realm where the model typically shows interest (80%+; strong conviction around 90%+). Core tests are largely favorable: BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, and related metrics such as ROA VARIANCE and SALES VARIANCE also PASS. The notable caveat is RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. Overall, the fundamentals and growth profile appear favorable, with the caveat that heavy R&D intensity may influence asset utilization and future outcomes.

BMY gains 88% on Partha Mohanram P/B Growth model

October 15, 2025, 6:14 PM EDT. BMY earns an 88% score on Validea's Partha Mohanram P/B Growth Investor model, which seeks low book-to-market stocks with sustained future growth. The stock is a large-cap Biotechnology & Drugs name with solid fundamentals and valuation. Key tests such as Book/Market ratio, Return on Assets, Cash Flow from Operations to Assets, R&D to Assets, Capital Expenditures to Assets pass, while the model notes ROA variance as a point of focus. Overall, the strategy signals strong interest (scores above 80% typically indicate interest). Investors should weigh BMY's growth signals against ongoing pipeline progress and broader market conditions.

Bristol-Myers Squibb (BMY) tops Partha Mohanram's P/B Growth model at 88%

October 15, 2025, 6:12 PM EDT. Bristol-Myers Squibb (BMY) posts a standout reading under Validea's Partha Mohanram P/B Growth Investor model, scoring 88% and topping 22 guru strategies. The growth model seeks low book-to-market stocks with sustained future growth, placing BMY in the large-cap Biotechnology & Drugs space with a growth tilt. An 88% rating signals notable interest (with >90% signaling stronger conviction). The analysis shows mostly PASS across tests-Book/Market, ROA, CFO to Assets, CFO/ROA, ROA variance, Sales variance, Advertising to Assets, Capex to Assets-while R&D to Assets failed. Validea frames this as a meaningful signal from the growth framework and from Mohanram's research.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Signals High Interest

October 15, 2025, 6:10 PM EDT. Validea's guru analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth model, giving an 88% score. This large-cap growth stock in Biotechnology & Drugs benefits from a low book-to-market profile and fundamentals that support sustained growth. In Validea's framework, a score above 80% signals interest, with above 90% indicating strong interest-BMY sits at 88%. The model reports PASS on key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, among others, with RESEARCH AND DEVELOPMENT TO ASSETS and ADVERTISING TO ASSETS highlighted. Overall, the Mohanram-based view portrays BMY as a growth-oriented, fundamentally solid pick within its sector, though investors should consider the broader biotech landscape.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Signals 88% Rating

October 15, 2025, 6:08 PM EDT. Validea's guru-based view on Bristol-Myers Squibb (BMY) shows strong alignment with Partha Mohanram's P/B Growth Investor model. The strategy seeks low book-to-market stocks with sustained growth, and BMY earns an 88% rating, suggesting meaningful interest (scores above 80% indicate some interest; above 90% indicate strong interest). BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs industry. The table of tests indicates several criteria are PASS (e.g., Book/Market, Return on Assets, Cash Flow from Operations to Assets) with other metrics also favorable. Overall, the rating implies a constructive signal from this growth-based framework, though investors should consider broader fundamentals and market conditions alongside this model's outputs.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Signal Dominates Validea

October 15, 2025, 6:06 PM EDT. Validea's guru fundamental report highlights Bristol-Myers Squibb Co (BMY) as a top pick under the P/B Growth Investor model from Partha Mohanram. Among 22 guru strategies, BMY earns the highest reads from this growth approach, reflecting a preference for low book-to-market stocks with signs of sustained future growth. The stock weighs in at 88% under this model, with a typical threshold of 80% to show interest and 90% for strong interest. The accompanying test table shows many positives-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS-while RESEARCH AND DEVELOPMENT TO ASSETS is listed as FAILED. BMY is a large-cap player in the Biotechnology & Drugs sector, reinforcing its growth tilt despite mixed indicators.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Highlights

October 15, 2025, 6:04 PM EDT. Bristol-Myers Squibb Co. (BMY) earns top marks under Validea's Partha Mohanram P/B Growth Investor model, signaling potential near-term strength in a large-cap Biotechnology & Drugs role. The growth-oriented screen flags BMY with an 88% rating, suggesting strong fundamentals and favorable valuation. Core tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and RESEARCH AND DEVELOPMENT TO ASSETS pass, while factors like ADVERTISING TO ASSETS and CAPITAL EXPENDITURES TO ASSETS are also favorable. The model aims to identify low book-to-market stocks with sustained growth, and BMY appears consistent with that thesis. As always, consider other factors and risk in any decision.

Bristol-Myers Squibb (BMY) Lands 88% in Partha Mohanram Growth Model (Validea Report)

October 15, 2025, 6:02 PM EDT. Bristol-Myers Squibb Co (BMY) receives a strong score under Validea's Partha Mohanram Growth Model, rating 88% and signaling meaningful interest from this guru strategy. The model targets low book-to-market stocks with characteristics associated with sustained future growth, and BMY sits as a large-cap growth stock in the Biotechnology & Drugs sector. Key points: the stock passes several tests, including Book/Market ratio, Return on Assets (ROA), Cash Flow from Operations to Assets (CFO/Assets), CFO to ROA, ROA variance, Sales variance, Advertising to Assets, Capital Expenditures to Assets, and R&D to Assets is noted as a FAIL. The overall 88% rating indicates 'some interest' by the strategy, with potential for stronger interest above 90%. This underscores Validea's emphasis on growth signals in the healthcare space.

BMY Factor-Based Stock Analysis Signals Growth Potential Under Mohanram Model

October 15, 2025, 6:00 PM EDT. Validea's guru analysis for Bristol-Myers Squibb Co (BMY) shows it rates highly under Partha Mohanram's P/B Growth Investor model, which seeks low book-to-market stocks with growth characteristics. BMY is labeled a large-cap growth stock in Biotechnology & Drugs, with an overall score of 88%, indicating notable interest (80%+ signals interest; 90%+ signals strong interest). The model's pass/fail snapshot includes: BOOK/MARKET RATIO: PASS; RETURN ON ASSETS: PASS; CASH FLOW FROM OPERATIONS TO ASSETS: PASS; CASH FLOW FROM OPERATIONS TO ASSETS VS. ROA: PASS; ROA VARIANCE: PASS; SALES VARIANCE: PASS; ADVERTISING TO ASSETS: PASS; CAPITAL EXPENDITURES TO ASSETS: PASS; RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. The report also provides background on Mohanram's research and Validea's framework, suggesting this growth-oriented screen fits despite the R&D asset setback.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals 88%

October 15, 2025, 5:58 PM EDT. Bristol-Myers Squibb Co. (BMY) scores highly under Validea's Partha Mohanram P/B Growth Investor model, a growth screen that seeks low book-to-market stocks with sustainable growth traits. The model rates BMY at 88%, signaling strong interest from this guru framework. Key tests pass, including Book/Market ratio, Return on assets (ROA), and Cash Flow from Operations to Assets, with favorable comparisons like CFO to assets vs. ROA and ROA variance. Other metrics in the table include Sales variance, Advertising to assets, Capital expenditures to assets, and R&D to assets. Overall, as a large-cap growth stock in Biotechnology & Drugs, BMY's fundamentals and valuation align with continued growth, yielding notable potential per this strategy.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 15, 2025, 5:56 PM EDT. Bristol-Myers Squibb Co. (BMY) earns the top score among Validea's 22 guru strategies when evaluated with Partha Mohanram's P/B Growth Investor model. The growth framework screens for low book-to-market stocks with indicators of sustained future expansion. On this model, BMY is characterized as a large-cap growth stock in the Biotechnology & Drugs space, receiving an 88% rating based on fundamentals and valuation – a level that signals notable interest from the strategy. The summary table shows most tests as PASS across metrics like BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D to Assets is the lone FAIL among the assets-based checks. Overall, a score above 80% suggests meaningful interest, with BMY close to strong interest (above 90% would indicate stronger conviction).

BMY Factor-Based Stock Analysis: Validea's Partha Mohanram Growth Model

October 15, 2025, 5:54 PM EDT. Validea's guru analysis ranks Bristol-Myers Squibb (BMY) highly under the P/B Growth Investor model, a Partha Mohanram framework that favors low book-to-market stocks with growth traits. BMY earns 88% from this strategy, signaling strong interest for investors seeking growth exposure. The model screens BMY across tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS, many of which PASS. As a large-cap biotechnology company, BMY appears to meet the criteria for sustained growth according to this strategy, though investors should weigh broader market factors and company-specific risks beyond this single score.

BMY Strong in Partha Mohanram's P/B Growth Model: 88% Score

October 15, 2025, 5:52 PM EDT. Validea's guru fundamental report places Bristol-Myers Squibb Co (BMY) high under the P/B Growth Investor model, a growth framework targeting low book-to-market stocks with signs of sustained future growth. The stock earns an 88% rating, signaling strong interest within the strategy. The test table shows passes for Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, CFO to ROA, ROA variance, Sales variance, Advertising to Assets, and Capital Expenditures to Assets, but a failure on Research and Development to Assets. As a large-cap growth name in Biotechnology & Drugs, the setup suggests a favorable fundamental and valuation fit under Mohanram's framework, with caveats around R&D linkage.

Bristol-Myers Squibb (BMY) Scores 88% on Partha Mohanram P/B Growth Model

October 15, 2025, 5:50 PM EDT. Validea's guru report places BMY at the top among 22 guru strategies using the P/B Growth Investor model based on Partha Mohanram's framework. The large-cap biotech stock earns 88%, signaling some investor interest (below the strong-interest threshold of 90% but above the 80% cut-off). The analysis shows many tests as PASS (e.g., BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS), with R&D TO ASSETS: FAIL. The stock operates in the Biotechnology & Drugs space, and the report notes that Mohanram's growth lens seeks low book-to-market stocks with sustained growth. Overall, BMY attracts attention but may require further validation before a strong conviction.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals for Bristol-Myers Squibb

October 15, 2025, 5:48 PM EDT. Bristol-Myers Squibb Co (BMY) receives a high score from Validea's Partha Mohanram Growth Investor model, ranking among the top for the 22 guru strategies tracked. The model targets low book-to-market stocks with sustained growth traits, and BMY posts a strong 88% rating, with a threshold of 80% to show interest and 90% for strong interest. The accompanying table indicates factors like BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and RESEARCH AND DEVELOPMENT TO ASSETS all pass, suggesting a favorable growth-oriented profile. While not all tests carry equal weight, the overall analysis highlights BRISTOL-MYERS SQUIBB as a candidate driven by growth fundamentals and solid operating cash flow, albeit within the biotechnology/drugs sector.

BMY Factor-Based Stock Analysis: Partha Mohanram P/B Growth Indicates High Interest

October 15, 2025, 5:46 PM EDT. Validea's guru framework rates BRISTOL-MYERS SQUIBB CO (BMY) highly under Partha Mohanram's P/B Growth/Growth Investor model. The strategy looks for low book-to-market stocks with signs of sustained growth. BMY scores 88% on this model, with a score above 80% indicating interest and above 90% signaling strong interest. In the detailed checks, key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and RESEARCH AND DEVELOPMENT TO ASSETS all show PASS; other criteria like RETURN ON ASSETS VARIANCE and SALES VARIANCE also PASS. Overall, BMY is positioned as a growth stock within the Biotechnology & Drugs space, with notable model interest.

BMY Outperforms Under Partha Mohanram P/B Growth Model: Validea Rating 88%

October 15, 2025, 5:44 PM EDT. Validea's guru report scores BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model. The model seeks low book-to-market stocks with traits linked to durable growth, and BMY earns an 88% rating, signaling meaningful interest from this growth framework. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs industry. The accompanying table shows broad pass rates across key tests-Book/Market, Return on Assets, cash-flow metrics-and notes that several criteria are pass with a few variances. The results illustrate how the stock meets many growth-oriented criteria while highlighting areas worth watching as fundamentals and valuation evolve.

BMY Highlighted by Validea Guru: Partha Mohanram Growth Model Signals

October 15, 2025, 5:42 PM EDT. Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) shows strong alignment with the P/B Growth Investor model from Partha Mohanram. The model targets low book-to-market stocks with signs of sustained growth, and BMY earns an 88% score, indicating notable guru interest. The accompanying table shows multiple tests passing, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS. The analysis notes pass status on CAPEX TO ASSETS and CASH FLOW FROM OPERATIONS TO ASSETS VS. ROA VARIANCE, underscoring solid fundamentals and valuation under this growth framework. Overall, the score implies potential interest for growth-focused investors, while the note clarifies the results reflect strategy weightings and are not a guarantee of future performance.

Bristol-Myers Squibb (BMY) Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Interest

October 15, 2025, 5:40 PM EDT. Validea's guru fundamentals rate BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model. The growth strategy targets low book-to-market stocks with sustained growth, and BMY scores 88%, signaling strong interest (80%+ usually merits attention; 90%+ indicates stronger conviction). BMY is a large-cap Biotechnology & Drugs stock. The analysis shows PASS on key tests across BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, with other measures like R&D to assets and CAPEX to assets also meeting criteria. The summary highlights the model's focus on growth and the stock's favorable fundamentals, noting weights vary by criterion. Overall, BMY appears to be a candidate with notable momentum under this growth framework.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Growth Potential

October 15, 2025, 5:38 PM EDT. Validea's guru fundamental report for Bristol-Myers Squibb Co (BMY) shows it rates highest under the Partha Mohanram P/B Growth model, a growth strategy focused on low book-to-market stocks with signs of sustained expansion. The stock is categorized as a large-cap growth name in Biotechnology & Drugs. The model assigns 88% overall, suggesting notable interest (80%+ signals potential traction; 90%+ signals strong interest). The summary table indicates the stock passes key tests like BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, among others, with some criteria variably weighted. Overall, the analysis implies a favorable factor-based view on BMY under this growth framework.

BMY Tops Partha Mohanram Growth Model with 88% Validea Rating

October 15, 2025, 5:36 PM EDT. Bristol-Myers Squibb Co. (BMY) earns a high score from Validea's guru analysis under Partha Mohanram's P/B Growth Investor model, rating 88% based on fundamentals and valuation. The model seeks low book-to-market stocks with signs of sustained growth, and BMY is classified as a large-cap growth stock in the Biotechnology & Drugs industry. A score of 80%+ suggests some interest, and 90%+ would indicate strong interest; BMY sits just below the top tier but still signals notable interest. The model shows multiple PASS readings across the key tests (Book/Market, ROA, CFO to assets, ROA variance, etc.), with a notable exception: R&D to assets FAIL. This provides context for investors considering growth-oriented strategies.

BMY Factor-Based Stock Analysis: Validea's Partha Mohanram P/B Growth Signal

October 15, 2025, 5:34 PM EDT. Validea rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model. The stock scores 88% on the growth-based screen, indicating strong interest from this guru strategy. BMY is a large-cap growth stock in the Biotechnology & Drugs sector. The accompanying table shows most criteria as PASS, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics, underscoring growth signals. The report also provides background on the Mohanram methodology and Validea's framework for evaluating factor-based portfolios. Overall, the analysis flags BMY as a candidate of interest for investors tracking growth-with-value signals in healthcare.

Bristol-Myers Squibb (BMY) – Validea Guru: Partha Mohanram Growth Model at 88%

October 15, 2025, 5:32 PM EDT. Validea's guru report for Bristol-Myers Squibb (BMY) shows the stock ranks highest under the P/B Growth Investor model, based on Partha Mohanram's growth framework. The model searches for low book-to-market stocks with momentum indicators of sustained growth. BMY earns an 88% score, where a rating of 80%+ signals interest and 90%+ signals strong interest. On the tested criteria, the stock passes key measures such as Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, CFO to Assets vs ROA, and CAPEX to Assets; it is also favorable on R&D to Assets. The analysis positions BMY as a large-cap growth candidate within Biotechnology & Drugs, though investors should weigh sector dynamics and valuation against the score signals.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Solid Fundamentals

October 15, 2025, 5:30 PM EDT. Bristol-Myers Squibb (BMY) earns the top signal from Validea's P/B Growth Investor model, a Partha Mohanram-based framework that seeks low book-to-market stocks with signs of sustained growth. The stock is rated 88%, suggesting notable interest, with scores above 90% indicating strong interest and 80%+ indicating some interest. In this analysis, BMY passes key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS, RETURN ON ASSETS VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, and CAPITAL EXPENDITURES TO ASSETS; the only noted weakness is RESEARCH AND DEVELOPMENT TO ASSETS, marked FAIL. This frames BMY as a growth stock within the Biotechnology & Drugs space under this guru-driven lens, reflecting fundamentals and valuation.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Signals Strong Interest

October 15, 2025, 5:28 PM EDT. Bristol-Myers Squibb (BMY) scores highest among Validea's 22 guru strategies using the Partha Mohanram P/B Growth Investor model. The model targets low book-to-market stocks with growth traits, and BMY's fundamentals earn an 88% rating, signaling strong interest (80%+; 90%+ would indicate very strong interest). Key takeaway: the stock passes most tests-Book/Market ratio, Return on Assets, Cash Flow from Operations to Assets, CFO-to-Assets vs ROA, ROA variance, Sales variance, Advertising to Assets, Capital expenditures to assets-with the notable exception of R&D to Assets, which fails. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs industry.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model

October 15, 2025, 5:26 PM EDT. Validea's guru fundamental report flags BRISTOL-MYERS SQUIBB CO (BMY) as a standout under Partha Mohanram's P/B Growth Investor model. The framework targets low book-to-market names with traits tied to sustained future growth. BMY earns an 88% rating, indicating strong interest from this strategy. It is a large-cap growth stock in the Biotechnology & Drugs sector. The accompanying table shows numerous PASS results across criteria like BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, among others, underscoring a favorable growth profile. The analysis reflects Mohanram's focus on winners among low book-to-market stocks, where scores near or above the 90% threshold imply very strong interest. Investors may view BMY as a growth-oriented holding within this factor-based framework.

BMY Tops Partha Mohanram P/B Growth Model: Validea Guru Analysis

October 15, 2025, 5:24 PM EDT. Bristol-Myers Squibb (BMY) ranks highest under the P/B Growth Investor model from Partha Mohanram, reflecting a low book-to-market with growth traits. The stock is described as a large-cap growth name in the Biotechnology & Drugs space, earning an 88% rating-above the 80% threshold that signals interest and well above 90% for strong interest. Key tests show BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, and others like R&D to Assets: PASS, CAPITAL EXPENDITURES TO ASSETS: PASS. While not all criteria are independent or equally weighted, the overall analysis depicts a constructive signal for BMY within Validea's guru framework.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Interest

October 15, 2025, 5:22 PM EDT. Bristol-Myers Squibb Co. (BMY) earns top marks among Validea's 22 guru strategies under the P/B Growth Investor model based on Partha Mohanram. The growth model screens for low BOOK/MARKET RATIO stocks with signs of sustained future growth. BMY is rated 88%, indicating the strategy has some interest (scores above 90% imply stronger interest). The overview notes the stock passes the core tests-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS (and related comparisons)-with only minor caveats. In short, BMY aligns with growth criteria under this factor-based approach, supporting its appeal within Validea's framework.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals for Bristol-Myers Squibb

October 15, 2025, 5:18 PM EDT. Validea's guru fundamental report rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model developed by Partha Mohanram, yielding an 88% score. This growth framework looks for low book-to-market stocks with characteristics linked to sustained future growth. BMY is described as a large-cap stock in Biotechnology & Drugs, with most tests in the table showing PASS across criteria like BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS. The analysis notes that a score of 80%+ indicates at least some interest, while 90%+ signals strong interest. Investors should view this factor-based signal in the context of Validea's broader guru framework and other strategies before trading.

Bristol-Myers Squibb (BMY) Tops Partha Mohanram Growth Signal | Validea Analysis

October 15, 2025, 5:16 PM EDT. Validea's guru fundamental report rates Bristol-Myers Squibb (BMY) highly under the P/B Growth Investor model of Partha Mohanram, ranking BMY at 88% and placing it among the strongest signals among 22 guru strategies. The model favors low book-to-market stocks with signs of sustained future growth and notes BMY as a large-cap growth stock in the Biotechnology & Drugs space. The score indicates notable interest, with a typical benchmark of 80%+ and 90%+ for rising enthusiasm. In the table, crucial tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS all pass, while others are tilted in favor of growth characteristics. As always, factors should be weighed with other fundamentals and market conditions.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 15, 2025, 5:14 PM EDT. Bristol-Myers Squibb Co. (BMY) scores highest on Validea's P/B Growth Investor model championed by Partha Mohanram, seeking low book-to-market stocks with durable growth. The model rates BMY at 88%, and Validea notes that a score of 80%+ signals interest, while 90%+ signals strong interest. Across the table, key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and CAPITAL EXPENDITURES TO ASSETS are PASS, with R&D TO ASSETS flagged as a weakness. The analysis emphasizes Mohanram's growth framework and Validea's coverage of guru strategies, offering a data-driven view of BMY's fundamentals and valuation within a growth-oriented factor portfolio.

BMY Tops Partha Mohanram P/B Growth Screen – 88% Validea Rating

October 15, 2025, 5:12 PM EDT. Validea's guru report for Bristol-Myers Squibb (BMY) shows the stock rates highest on the P/B Growth Investor model developed by Partha Mohanram. The 88% rating signals favorable fundamentals and valuation, with >80% indicating interest and >90% signaling strong interest. Across key tests, BMY passes on Book/Market, Return on Assets (ROA), Cash Flow from Operations to Assets, and related metrics, with detailed analysis highlighting solid asset efficiency, operating cash flow, and R&D to assets. The model favors low book-to-market stocks with growth traits, and BMY's profile as a large-cap Biotechnology & Drugs issuer aligns with the growth framework. Overall, the score suggests meaningful interest within this growth approach.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 15, 2025, 5:10 PM EDT. Validea's guru fundamental report rates BRISTOL-MYERS SQUIBB CO (BMY) highest under the P/B Growth Investor model, a renowned growth screen developed by Partha Mohanram. The stock is categorized as a large-cap growth issue in Biotechnology & Drugs, with a model rating of 88%, indicating meaningful interest from the strategy. The assessment shows strong pass marks across key metrics such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, with some tests highlighting margins and growth considerations. As a result, BMY presents as a notable candidate for growth-oriented portfolios following Mohanram's framework, though investors should weigh valuation alongside other guru models and market factors.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates Bristol-Myers Squibb at 88%

October 15, 2025, 5:08 PM EDT. Bristol-Myers Squibb Co (BMY) earns a high score under Validea's Partha Mohanram P/B Growth Investor model, a low book-to-market growth screen. With an 88% rating, the stock is flagged as a potential growth name in the Biotechnology & Drugs space. The model marks key tests as PASS (e.g., BOOK/MARKET RATIO, RETURN ON ASSETS) and notes favorable asset-driven metrics like CFO/Assets and ROA stability. A 80%+ score signals interest; 90%+ signals strong interest. The accompanying table outlines how BMY fares on tests including R&D to Assets, Capex to Assets, and related efficiency measures, emphasizing growth orientation, valuation, and fundamental quality for investors.

BMY Factor-Based Stock Analysis: Partha Mohanram P/B Growth Model Signals Interest

October 15, 2025, 5:06 PM EDT. Bristol-Myers Squibb Co (BMY) scores highly under Validea's Partha Mohanram P/B Growth Investor model, a growth-focused screen for low book-to-market stocks with durable earnings. The stock is a large-cap growth name in the Biotechnology & Drugs sector, with a model rating of 88%-above 80% signals interest and near 90% signals strong interest. Core tests are PASS for BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related measures, including CFO to assets and ROA variance. The table also shows SALES VARIANCE, ADVERTISING TO ASSETS, and CAPITAL EXPENDITURES TO ASSETS as PASS, while RESEARCH AND DEVELOPMENT TO ASSETS is labeled FAIL. Overall, BMY is portrayed as a growth-oriented name with solid fundamentals, albeit with a caveat on R&D-to-assets.

BMY Factor-Based Stock Analysis – Partha Mohanram Growth Model Signals Strength

October 15, 2025, 5:04 PM EDT. Validea rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model developed by Partha Mohanram, giving an 88% rating. The growth-focused, low book-to-market framework flags BMY as a large-cap growth stock in the Biotech & Drugs sector. The table shows PASS on most tests-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics-while RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. A score above 80% typically indicates some interest, above 90% strong interest. Overall, BMY appears favorable for growth-oriented investors following Mohanram's strategy, though the model notes a weakness in R&D TO ASSETS. This reflects guru-driven fundamental screening, not a standalone buy recommendation.

Bristol-Myers Squibb (BMY) Growth-Based Score Under Partha Mohanram P/B Growth Model

October 15, 2025, 5:02 PM EDT. Validea's guru-based analysis assigns BMY a strong signal under the P/B Growth Investor model built on Partha Mohanram's framework. The model seeks low book-to-market names with signs of sustained growth, and Bristol-Myers Squibb sits as a large-cap Biotechnology & Drugs stock rated at 88%-well above the threshold for investor interest and approaching strong-interest territory at 90%+. The screen shows broad compatibility: BOOK/MARKET RATIO PASS, RETURN ON ASSETS PASS, CASH FLOW FROM OPERATIONS TO ASSETS PASS, OPERATIONS TO ROAS PASS, with some caveats like R&D TO ASSETS: FAIL. Overall, the report indicates fundamental strength and valuation merit within this guru framework, suggesting it remains a stock to watch for growth investors seeking exposure to the biotech sector.

BMY Factor-Based Stock Analysis: Validea's Partha Mohanram Growth Model

October 15, 2025, 5:00 PM EDT. Validea's guru analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model, which targets low book-to-market stocks with signs of sustained future growth. BMY scores 88%, with 80%+ signaling some interest and 90%+ signaling strong interest. In this framework, key tests are generally PASS for metrics like BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and others; the stock is categorized as a large-cap growth name in the Biotechnology & Drugs space. The analysis reflects Mohanram's view that growth persistence can outperform over time, with the score indicating notable interest from this strategy while acknowledging some weaker points. Overall, BMY shows meaningful strength on this factor-based approach.

BMY Scores High on Partha Mohanram P/B Growth Model

October 15, 2025, 4:58 PM EDT. Bristol-Myers Squibb Co. (BMY) earns the top rating under Validea's Partha Mohanram P/B Growth Investor model, scoring 88% and signaling growth-oriented buy interest. The model targets low book-to-market stocks with indicators of sustained future growth, and BMY is listed as a large-cap Biotechnology & Drugs stock. A score of 80%+ typically implies shareholder interest, while 90%+ would indicate strong interest. The guru analysis highlights several pass signals, including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS among others. One noted weakness is R&D to Assets. Overall, the model presents favorable fundamentals relative to growth criteria, but investors should treat it as one data point within a broader, risk-aware evaluation.

Bristol-Myers Squibb (BMY) Factor-Based Stock Analysis – Partha Mohanram Growth Model (88%)

October 15, 2025, 4:56 PM EDT. The Validea guru report rates BRISTOL-MYERS SQUIBB CO (BMY) at 88% under the P/B Growth Investor model from Partha Mohanram, signaling growth characteristics for this large-cap in Biotechnology & Drugs. The model favors low book-to-market stocks with indicators of sustained growth. In BMY's profile, key tests show BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, and ADVERTISING TO ASSETS: PASS among others. A notable exception is R&D TO ASSETS: FAIL, which drags the overall score. The rating framework notes that scores above 80% indicate interest and above 90% indicate strong interest.

BMY Factor-Based Stock Analysis: Validea Mohanram Growth Model Highlights

October 15, 2025, 4:54 PM EDT. Validea's guru report ranks BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model, the published strategy of Partha Mohanram. The model targets low book-to-market stocks with traits linked to sustained future growth. BMY scores 88%, signaling substantial interest (scores above 80% indicate potential, above 90% strong interest). The overview notes Book/Market Ratio: PASS, Return on Assets: PASS, Cash Flow from Operations to Assets: PASS, R&D to Assets: FAIL, and other metrics like Sales Variance and CAPEX to Assets: PASS. The report also highlights Mohanram's research and the strategy's focus on growth persistence. Overall, BMY appears attractive within this factor framework, tempered by the weakness in R&D to Assets.

Bristol-Myers Squibb (BMY) Shines in Partha Mohanram's P/B Growth Model with 88% Score

October 15, 2025, 4:52 PM EDT. Validea's guru report flags Bristol-Myers Squibb Co. (BMY) as a top pick under the P/B Growth Investor approach devised by Partha Mohanram. The model targets low book-to-market stocks with signs of sustained growth. On this screen, BMY scores 88%, suggesting meaningful interest from this strategy. The table highlights strengths across several tests – Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, and more – with all key metrics passing or near-pass, including R&D to assets and CapEx to assets. The result supports a favorable view of BMY among growth-oriented investors, though it's important to weigh fundamentals against broader market conditions and biotech sector risks.

BMY Factor-Based Stock Analysis: High Rating Under Partha Mohanram's P/B Growth Model

October 15, 2025, 4:50 PM EDT. Validea's guru fundamental analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model. The stock earns an 88% rating, indicating strong interest from this growth framework based on a low book-to-market profile. The test table shows PASS on key measures such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, with one notable weakness: RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. An 80%+ score generally signals interest, and BMY breaking the 90% threshold would indicate very strong enthusiasm. In this framework, BMY is a large-cap growth stock in the Biotechnology & Drugs sector, highlighted by the favorable score despite the R&D-to-assets caveat.

BMY Tops Partha Mohanram P/B Growth Model in Validea Guru Analysis

October 15, 2025, 4:48 PM EDT. Validea's guru fundamental report assigns Bristol-Myers Squibb Co (BMY) the top spot among 22 guru strategies under Partha Mohanram's P/B Growth Investor model. The growth-focused framework seeks low book-to-market stocks with signs of sustained expansion, and BMY scores 88%-well above the 80% threshold that signals investor interest and near 90% for strong interest. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs industry. The model's tests show many positives (BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, etc.), with R&D to assets flagged as a noted weakness. Overall, the stock is highlighted as a potential growth contributor under this strategy.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates Bristol-Myers Squibb at 88%

October 15, 2025, 4:46 PM EDT. Validea's guru report for Bristol-Myers Squibb Co (BMY) ranks highest among 22 guru strategies under Partha Mohanram's P/B Growth Investor model. This growth framework seeks low book-to-market stocks with characteristics of sustained future growth. BMY is a large-cap growth stock in the Biotechnology & Drugs industry, earning an 88% rating based on fundamentals and valuation. A score of 80%+ signals some interest; above 90% signals strong interest. The accompanying table shows many tests as PASS, including BOOK/MARKET RATIO and RETURN ON ASSETS, while R&D TO ASSETS: FAIL is noted. Other metrics such as CASH FLOW FROM OPERATIONS TO ASSETS also PASS. Overall, the Mohanram framework suggests a favorable stance on BMY with a caveat on R&D intensity.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Score 88%

October 15, 2025, 4:44 PM EDT. Validea's guru fundamental analysis ranks BRISTOL-MYERS SQUIBB CO (BMY) highest among 22 guru strategies using the P/B Growth Investor model from Partha Mohanram. This growth model screens for low book-to-market stocks with traits tied to sustained growth. BMY's rating stands at 88%, with 80%+ signaling interest and >90% indicating strong interest. The criteria snapshot shows BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, and RESEARCH AND DEVELOPMENT TO ASSETS: FAIL among others. BMY is a large-cap growth stock in the Biotechnology & Drugs industry. The result underlines the model's focus on fundamentals and growth potential and notes Mohanram's approach has historically outperformed in growth stock selection.

BMY gets 88% on Partha Mohanram's P/B Growth Model (Validea Guru Analysis)

October 15, 2025, 4:42 PM EDT. Validea's guru fundamental report places BRISTOL-MYERS SQUIBB CO (BMY) at the top of its 22-strategy suite under Partha Mohanram's P/B Growth Investor model. The model seeks low book-to-market stocks with characteristics linked to sustained growth. BMY earns an 88% rating, signaling strong fundamental setup and investor interest per Validea's thresholds (80% indicates some interest; 90% signals strong interest). The analysis shows PASS for BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics; even areas like R&D to assets and CAPEX to assets are evaluated. The write-up also explains Mohanram's background and how his growth framework identifies winners among low B/M firms. Overall, BMY is framed as a high-conviction growth candidate within the biotechnology/drug space.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Interest

October 15, 2025, 4:40 PM EDT. Validea's Guru Analysis flags Bristol-Myers Squibb Co. (BMY) as a top pick under the P/B Growth Investor model of Partha Mohanram. The model targets low book-to-market stocks with signs of sustained growth. BMY earns an 88% rating on fundamentals and valuation, with 80%+ signaling interest and 90%+ signaling strong interest. In the summary table, key tests are BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW TO ASSETS: PASS, ADVERTISING TO ASSETS: PASS, RESEARCH AND DEVELOPMENT TO ASSETS: PASS. Overall, the stock is viewed favorably within this factor framework, reflecting its large-cap growth profile in the Biotechnology & Drugs sector. Note: this reflects Validea's guru-based methodology.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Interest

October 15, 2025, 4:38 PM EDT. Validea's guru-based assessment rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model from Partha Mohanram, topping 22 strategies for this name. The large-cap growth stock in the Biotechnology & Drugs group earns an 88% rating, indicating notable interest (80%+ is some interest; 90%+ is strong). The model targets low book-to-market firms with signs of sustained growth. BMY passes key criteria such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, among others, with several tests showing strength. This summary highlights how this growth-oriented framework views BMY as a potential candidate for investors seeking growth with solid fundamentals, per Validea's analysis of Partha Mohanram's approach.

BMY Tops Partha Mohanram Growth Model in Validea Guru Analysis

October 15, 2025, 4:36 PM EDT. Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) shows it rates highest on the P/B Growth Investor model using Partha Mohanram's framework. The growth model seeks low book-to-market stocks with signs of sustained future growth. BMY, a large-cap in Biotechnology & Drugs, earns an 88% rating based on fundamentals and valuation; a score of 80%+ signals interest, while 90%+ signals strong interest. The summary table shows many tests passing (e.g., BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS), with R&D TO ASSETS listed as failed. The report underscores Mohanram's research approach and Validea's application of guru strategies to identify growth potential in pharma.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Interest

October 15, 2025, 4:34 PM EDT. Validea's guru framework rates Bristol-Myers Squibb (BMY) highly under the P/B Growth Investor model developed by Partha Mohanram. The model seeks low book-to-market stocks with growth traits, and BMY logs an 88% score, indicating notable interest from this strategy. As a large-cap growth stock in the Biotechnology & Drugs sector, BMY passes several tests (e.g., BOOK/MARKET RATIO PASS, RETURN ON ASSETS PASS, CASH FLOW TO ASSETS PASS), with the table highlighting strong points and some weaker, less independent criteria. A score of 80%+ generally signals interest; 90%+ would imply strong enthusiasm. Overall, the stock's fundamentals align with this growth framework, though investors should weigh industry risk and portfolio diversification against the model's signals.

BMY Factor-Based Stock Analysis: Validea Signals 88% Mohanram Growth Model

October 15, 2025, 4:32 PM EDT. Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) rates the stock highly under the P/B Growth Investor model derived from Partha Mohanram's research, giving BMY an 88% score and signaling some interest (scores above 90% signal strong interest). The growth model seeks low book-to-market stocks with traits linked to sustained growth. In this analysis, most tests pass-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, ROA variance, etc.-with RESEARCH AND DEVELOPMENT TO ASSETS noted as a weakness. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs industry. The write-up also provides background on Mohanram and Validea's methodology, emphasizing that an 88% rating is favorable but not a guarantee of momentum.

BMY Tops Validea's Partha Mohanram Growth Model with an 88% Score

October 15, 2025, 4:30 PM EDT. Bristol-Myers Squibb Co. (BMY) earns a high rating under Validea's Partha Mohanram Growth Investor approach, scoring 88% based on fundamentals and valuation. The model targets low book-to-market stocks with growth traits, and BMY shows strengths across key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS. The dashboard notes a PASS on most criteria, with one noted weakness in RESEARCH AND DEVELOPMENT TO ASSETS, which is shown as FAILED. The analysis places BMY among large-cap growth names in the Biotechnology & Drugs space, suggesting growing interest when the score sits above 80% and strong interest above 90%.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model

October 15, 2025, 4:28 PM EDT. Validea's guru-based read on BRISTOL-MYERS SQUIBB CO (BMY) places it at the top of Partha Mohanram's P/B Growth Investor model. The strategy seeks low book-to-market stocks with signs of durable growth. BMY, a large-cap growth stock in Biotechnology & Drugs, earns 88% under this model, signaling notable interest (80%+ indicates some interest; 90%+ strong interest). The accompanying criteria table shows most tests pass: BOOK/MARKET RATIO: PASS; RETURN ON ASSETS: PASS; CASH FLOW FROM OPERATIONS TO ASSETS: PASS; CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS; RETURN ON ASSETS VARIANCE: PASS; SALES VARIANCE: PASS; ADVERTISING TO ASSETS: PASS; CAPITAL EXPENDITURES TO ASSETS: PASS; RESEARCH AND DEVELOPMENT TO ASSETS: FAILED. Overall, the growth-focus signals are favorable, with R&D-to-assets being the primary weakness under this model.

BMY Factor-Based Stock Analysis: Validea Growth Score 88% under Partha Mohanram Model

October 15, 2025, 4:26 PM EDT. Validea's guru framework rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model developed by Partha Mohanram, giving an 88% rating. The model targets low book-to-market stocks with growth traits. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs sector. An 80%+ score signals interest, with 90%+ indicating strong interest. In the test table, most criteria are PASS (Book/Market Ratio, ROA, CFO to assets, CFO/ROA, ROA variance, Sales variance, Advertising to assets, Capex to assets). The notable exception is R&D to assets which FAILED, highlighting a potential weakness in the growth thesis. Overall, the stock shows compelling fundamentals per this strategy but with some gaps to monitor.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 15, 2025, 4:24 PM EDT. Validea's guru fundamental report ranks Bristol-Myers Squibb (BMY) highest among 22 guru strategies under the P/B Growth Investor model developed by Partha Mohanram. The stock displays a strong growth profile with a current score of 88%, indicating notable interest from the strategy; scores above 90% signal strong interest. The analysis shows BMY as a large-cap Biotechnology & Drugs stock with multiple PASS signals across metrics such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS. Emphasizing a low book-to-market characteristic, the report frames BMY within factor-based stock portfolios and notes the potential for sustained growth within the model's framework.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 15, 2025, 4:22 PM EDT. Bristol-Myers Squibb (BMY) earns top marks under Validea's Partha Mohanram Growth Model (P/B Growth Investor). Among 22 guru strategies, BMY rates 88%, signaling notable interest. The model seeks low book-to-market stocks with sustained growth, and for BMY the evaluation shows strong results across many tests: BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, and other criteria. The stock is a large-cap growth name in the Biotechnology & Drugs industry. The rating is high: a score above 80% suggests interest and above 90% strong interest. Notably, the table shows a potential weakness: RESEARCH AND DEVELOPMENT TO ASSETS: FAILED. Overall, the model supports consideration of BMY within a growth-focused framework.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals High Interest

October 15, 2025, 4:20 PM EDT. Validea's guru fundamental report rates Bristol-Myers Squibb (BMY) at 88% under the P/B Growth Investor model – the growth-focused framework from Partha Mohanram. The stock is categorized as a large-cap growth name in the Biotechnology & Drugs space, with a score indicating notable investor interest. The model emphasizes low Book/Market with growth traits. BMY PASSes most tests across BOOK/MARKET, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics, though R&D TO ASSETS fails. Overall, the report places BMY within a tier of strategy-driven interest, with scores of 80%+ generally signaling attention and 90%+ signaling strong interest.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Scores Bristol-Myers Squibb at 88%

October 15, 2025, 4:18 PM EDT. Bristol-Myers Squibb Co. (BMY) tops Validea's Partha Mohanram P/B Growth model with an 88% rating, suggesting strong interest from this growth-focused screen. The model favors low book-to-market stocks showing sustained growth characteristics. BMY's score indicates solid fundamentals and favorable valuation within the Biotechnology & Drugs sector. The table of tests shows PASS for BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and other criteria, with overall emphasis on growth momentum, cash flow quality, and asset efficiency. While not all tests are equal, the aggregate result points to a stock that could benefit from growth orientation, solid ROA and CFO-to-Asset strength, and favorable investor sentiment under this strategy.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model

October 15, 2025, 4:16 PM EDT. Validea's guru report rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model by Partha Mohanram. The growth screen looks for low book-to-market stocks with signs of sustained future growth. BMY scores 88%, suggesting strong interest from this strategy. The overview shows many PASS signals across key tests, including BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and R&D TO ASSETS. As a large-cap player in Biotechnology & Drugs, BMY is positioned as a growth stock with favorable fundamentals per this model. While not the sole criterion, a score above 80% indicates meaningful alignment with the strategy's themes of growth, quality, and valuation.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals High Interest

October 15, 2025, 4:14 PM EDT. Validea ranks BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model, part of its guru-based coverage. The model seeks low book-to-market stocks with characteristics of sustained growth, and BMY scores 88% based on fundamentals and valuation, with 80%+ suggesting interest and 90%+ signaling strong interest. The analysis shows PASS on most tests-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW TO ASSETS, and more-though RESEARCH AND DEVELOPMENT TO ASSETS shows a failure, indicating some growth-investing caveats. The piece highlights Partha Mohanram's framework and notes BMY as a large-cap growth stock in the Biotechnology & Drugs space. Overall, this factor-based view flags potential upside but warns about R&D allocation intensity.

BMY Factor-Based Stock Analysis: Validea's Partha Mohanram Growth Model

October 15, 2025, 4:12 PM EDT. Bristol-Myers Squibb Co. (BMY) scores highly on Validea's Partha Mohanram P/B Growth Investor model, obtaining 88% based on fundamentals and valuation. The growth framework favors low book-to-market stocks with signs of sustained expansion. BMY passes key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and CFFO TO ROA, with favorable ROA variance and asset-related metrics. The stock is a large-cap growth name in Biotechnology & Drugs. Though 80%+ indicates interest and 90% signals strong interest, valuations and growth trends remain important considerations. Overall, BMY appears to be a noteworthy candidate under the Mohanram growth framework, combining solid fundamentals with growth-oriented characteristics and some sector-related risk.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals for Bristol-Myers Squibb

October 15, 2025, 4:10 PM EDT. Bristol-Myers Squibb Co (BMY) earns the highest score among Validea's guru models under Partha Mohanram's P/B Growth Investor strategy. The model targets low book-to-market stocks with indicators of sustained growth. BMY is classified as a large-cap biotechnology & drugs stock, rated 88% by this strategy, suggesting meaningful investor interest. The accompanying table shows many positive checks: BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, and others like R&D TO ASSETS: PASS, with only limited weaknesses. Overall, the analysis indicates the stock may meet growth criteria and warrants consideration for growth-focused portfolios that rely on fundamentals and valuation signals from Mohanram's framework.

BMY Factor-Based Stock Analysis: Partha Mohanram P/B Growth Score Reaches 88%

October 15, 2025, 4:08 PM EDT. Bristol-Myers Squibb Co. (BMY) earns a strong score under Validea's Partha Mohanram P/B Growth model, rating 88%, signaling notable interest from this guru strategy. The model targets low book-to-market stocks with growth traits, placing BMY in the large-cap Biotechnology & Drugs space. The overview shows BMY passes several criteria-BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS-with others offering favorable signals for growth. An 88% score suggests the stock aligns with the strategy's framework for potential sustained upside. Investors should weigh how BMY's fundamentals and valuation fit within a broader, factor-based approach to biotech equities and ongoing disease-treatments catalysts.

BMY Factor-Based Stock Analysis: 88% Mohanram P/B Growth Model

October 15, 2025, 4:06 PM EDT. Validea's guru-based analysis ranks BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model. BMY earns 88% on the model, reflecting a low book-to-market profile paired with growth characteristics that Mohanram's framework associates with sustained future growth. Among the 22 guru strategies Validea tracks, this approach places BMY in strong interest territory (typically 80%+; >90% signals strong interest). The table shows PASS results for BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS and related checks, with RESEARCH AND DEVELOPMENT TO ASSETS flagged as FAIL. Important caveat: R&D to assets is a weak point in this model. As a large-cap biotech/drug stock, BMY's fundamentals appear solid under this growth lens, though investors should consider R&D variability and industry dynamics.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Scores 88%

October 15, 2025, 4:04 PM EDT. Validea's guru-based analysis ranks BRISTOL-MYERS SQUIBB CO (BMY) highest under the P/B Growth Investor model from Partha Mohanram. The growth framework targets low book-to-market stocks with sustained growth characteristics, and BMY earns an 88% rating-above the 80% threshold that signals interest and below the 90% mark for strongest conviction. The report notes strong fundamentals across key checks (e.g., BOOK/MARKET RATIO, ROA, CFO/Assets, R&D to Assets), aligning with the model's criteria for a large-cap Biotechnology & Drugs name. Overall, BMY's passing signals on multiple tests suggest potential continued upside per this factor-based approach, though investors should consider how the model's growth tilt fits their risk profile.

BMY Factor-Based Stock Analysis (Partha Mohanram P/B Growth)

October 15, 2025, 4:02 PM EDT. Validea's guru-based analysis ranks BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model. The growth-focused approach favors low book-to-market stocks with strong future growth traits. BMY earns an 88% rating, signaling strong interest from this strategy. Key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS pass, while related metrics like ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, and RESEARCH AND DEVELOPMENT TO ASSETS align with the model. As a large-cap biotech stock in the Biotechnology & Drugs space, BMY appears to meet many growth criteria and may appeal to Mohanram followers. The score reflects strategy weighting, not a universal buy/sell signal.

BMY Factor-Based Stock Analysis: Partha Mohanram's P/B Growth Model Hits 88%

October 15, 2025, 4:00 PM EDT. Bristol-Myers Squibb Co (BMY) rates highly under Validea's Partha Mohanram P/B Growth model with an 88% score, indicating interest. The P/B Growth framework targets low book-to-market stocks with characteristics associated with sustained growth. In this analysis, most tests are PASS-including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS-with the sole notable exception being RESEARCH AND DEVELOPMENT TO ASSETS, which FAILS. A score of 80%+ signals some interest; 90%+ signals strong interest. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs space. The report also frames the guru approach, Partha Mohanram's background, and Validea's context for interpreting the signal.

BMY Factor-Based Stock Analysis: Validea's Partha Mohanram Growth Signal

October 15, 2025, 3:58 PM EDT. Validea's guru report on Bristol-Myers Squibb Co. (BMY) flags a strong signal under the P/B Growth Investor model from Partha Mohanram. Of 22 guru strategies, this growth-style score is 88%, indicating notable interest. Described as a large-cap growth stock in Biotechnology & Drugs, BMY emphasizes a low book-to-market profile aligned with growth persistence. The summary table shows many tests passing, including BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, and CASH FLOW FROM OPERATIONS TO ASSETS: PASS, with the RESEARCH AND DEVELOPMENT TO ASSETS: FAIL noted. Overall, the strategy suggests a favorable setup for BMY, albeit with a caution on one criterion that warrants deeper look.

BMY Tops Partha Mohanram P/B Growth Signal with 88% Guru Score

October 15, 2025, 3:56 PM EDT. Bristol-Myers Squibb Co (BMY) earns the top spot among 22 guru strategies from Validea's Partha Mohanram P/B Growth Investor model, scoring 88% based on growth-oriented fundamentals. This low book-to-market, high-growth framework flags BMY as a potential stock with sustained future expansion. BMY is a large-cap growth stock in the Biotechnology & Drugs industry. The score suggests interest (scores >=80%), with strong interest typically above 90%. In the detailed checks, the stock shows PASS in BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CFO/ROA, ROA VARIANCE, and SALES VARIANCE, as well as ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS. However, RESEARCH AND DEVELOPMENT TO ASSETS FAIL, indicating a weakness in how R&D spending is reflected in assets.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Highlights

October 15, 2025, 3:54 PM EDT. Bristol-Myers Squibb (BMY) scores highly under Validea's Partha Mohanram P/B Growth model, at 88%, signaling attractive fundamentals and growth potential. The model targets low book-to-market stocks with sustained growth, and BMY is a large-cap Biotechnology & Drugs stock. A score above 80% indicates interest; above 90% signals strong interest. The guru table shows PASS on key metrics like Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, and CFO/ROA, while R&D to Assets is a weakness. Overall, the analysis highlights favorable fundamentals under this factor-based framework and notes Partha Mohanram's growth criteria as a driver of Validea's assessment.

BMY Factor-Based Growth Analysis Under Partha Mohanram's P/B Growth Model

October 15, 2025, 3:52 PM EDT. Validea's guru fundamental report rates Bristol-Myers Squibb Co. (BMY) highest under the P/B Growth Investor model from Partha Mohanram. The growth model seeks low book-to-market stocks with signs of sustained future expansion. BMY is a large-cap growth name in the Biotechnology & Drugs industry. The strategy score is 88%, indicating meaningful interest (scores ≥80% signal potential interest; ≥90% signals strong interest). In the tests, several criteria show PASS (e.g., BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS), but RESEARCH AND DEVELOPMENT TO ASSETS is FAILED. Overall, this factor framework suggests a favorable tilt toward BMY on fundamentals and valuation, even as investors monitor R&D efficiency and pipeline risk inherent to biotech.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model at 88%

October 15, 2025, 3:50 PM EDT. Bristol-Myers Squibb Co (BMY) scores highly under Validea's P/B Growth Investor model, the published strategy of Partha Mohanram. The model seeks low book-to-market stocks with signs of sustained future growth, and BMY's fundamentals trigger an 88% rating, signaling strong interest. Among the tests, key metrics such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS pass, with some components like RESEARCH AND DEVELOPMENT TO ASSETS not meeting the criterion. Positioned as a large-cap growth stock in the Biotechnology & Drugs space, BMY presents as a name the strategy flags for potential continued expansion, though investors should review the one failing criterion in the context of the broader growth profile.

BMY Tops Partha Mohanram Growth Model (88%)

October 15, 2025, 3:48 PM EDT. Validea's guru report on BRISTOL-MYERS SQUIBB CO (BMY) shows it rates highest among 22 guru strategies under the P/B Growth Investor model by Partha Mohanram. The growth model targets low Book-to-Market stocks with signs of sustained growth. BMY scores 88%, with 80% typically signaling interest and 90% signaling strong interest. The assessment highlights strengths in Book/Market, Return on Assets, Cash Flow from Operations to Assets, and Cash Flow to ROA, while metrics like R&D to Assets and other criteria influence the overall rating. In short, BMY appears as a favorable growth stock within Biotechnology & Drugs based on Validea's fundamentals and valuation signals.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Highlights 88% Rating

October 15, 2025, 3:46 PM EDT. Validea's guru fundamental report rates Bristol-Myers Squibb Co. (BMY) highly under Partha Mohanram's P/B Growth Investor model. The stock earns an 88% score, indicating notable interest from this growth framework that emphasizes low book-to-market stocks with signs of sustained growth. Classified as a large-cap growth stock in Biotechnology & Drugs, BMY shows a majority of tests as PASS across criteria such as BOOK/MARKET, ROA, CFO/Assets, and R&D-to-Assets, among others. An 88% rating suggests the strategy has at least some interest (80%+) and, near 90%+, may indicate stronger conviction. The report frames BMY within Mohanram's research on separating winners from losers among growth stocks and notes Validea's methodology alongside historical insights.

Bristol-Myers Squibb Co (BMY) Scores 88% Under Partha Mohanram Growth Model, Validea Guru Analysis

October 15, 2025, 3:44 PM EDT. Validea's guru fundamental report flags Bristol-Myers Squibb Co (BMY) as a top pick under the published P/B Growth Investor model created by Partha Mohanram. This growth framework seeks low book-to-market stocks with traits linked to sustained future growth. For BMY, the model returns an 88% score, signaling strong interest (scores above 80% are noteworthy; above 90% indicate robust conviction). The results highlight strengths across key criteria, including BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, and related measures such as RESEARCH AND DEVELOPMENT TO ASSETS: PASS and CAPITAL EXPENDITURES TO ASSETS: PASS. Overall, BMY is portrayed as favorable within this growth-oriented factor, though weights vary by criterion.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Highlights 88%

October 15, 2025, 3:42 PM EDT. Bristol-Myers Squibb Co. (BMY) earns a strong score under Validea's Partha Mohanram P/B Growth Investor model, which screens for low book-to-market stocks with signs of sustained future growth. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs sector, with an 88% rating. A score above 80% signals notable interest, while above 90% suggests strong conviction. In this analysis, BMY passes the key tests for the model-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CFO to ROA, ROA variance, SALES VARIANCE, ADVERTISING TO ASSETS, CAPEX TO ASSETS-but fails on RESEARCH AND DEVELOPMENT TO ASSETS. The overview highlights the stock's fundamentals and valuation alignment with Mohanram's growth framework, and points to BMY as a candidate of interest under the growth paradigm.

Bristol-Myers Squibb (BMY) Factor-Based Growth Score: 88% under Mohanram's P/B Growth Model

October 15, 2025, 3:40 PM EDT. BMY stands out in Validea's guru framework, ranking highest under the P/B Growth Investor model from Partha Mohanram. This growth approach targets low book-to-market stocks with sustained growth traits, and BMY earns an 88% rating-well above the 80% threshold that flags interest and approaching the 90% mark for strong interest. The analysis notes passes across core criteria such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics, with some criteria weighted differently. As a large-cap Biotechnology & Drugs name, BMY combines solid fundamentals with growth upside, underscoring potential appeal for growth-oriented investors following Mohanram's framework.

Bristol-Myers Squibb (BMY) Factor-Based Stock Analysis – Mohanram Growth Model

October 15, 2025, 3:38 PM EDT. Validea's guru framework highlights Bristol-Myers Squibb Co. (BMY) under the Partha Mohanram P/B Growth model. The stock is a large-cap growth play in the Biotechnology & Drugs sector, with a current rating of 88%. The model seeks low book-to-market stocks with signs of sustained future growth. Key checks-BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, R&D TO ASSETS-and related criteria-mostly PASS, with weights varying. A score of 80%+ signals interest; 88% indicates notable interest, though not the top tier (90%+). Overall, BMY shows solid fundamentals and favorable valuation signals within its growth framework, making it a meaningful candidate for this factor-based approach.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates Bristol-Myers Squibb at 88%

October 15, 2025, 3:36 PM EDT. Validea's guru fundamental report flags BRISTOL-MYERS SQUIBB CO (BMY) as the top pick among 22 strategies under the Partha Mohanram P/B Growth Investor model. The model looks for low book-to-market stocks with signs of durable growth, and BMY scores 88%, signaling strong interest from this approach. The stock is described as a large-cap Biotechnology & Drugs name. The scorecard notes key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics mostly PASS, with R&D TO ASSETS and CAPEX TO ASSETS highlighted as favorable. Overall, the framework implies solid fundamentals and attractive valuation, with a high signal from the Mohanram growth criteria for investors tracking factor-based strategies.

Bristol-Myers Squibb (BMY) Rated 88% by Validea's Partha Mohanram P/B Growth Strategy

October 15, 2025, 3:34 PM EDT. Validea's guru analysis for Bristol-Myers Squibb (BMY) shows BMY scoring highest among 22 guru strategies under the P/B Growth Investor model designed by Partha Mohanram. The model looks for low book-to-market stocks with signs of sustained growth; BMY, a large-cap growth stock in the Biotechnology & Drugs sector, earns an 88% rating based on fundamentals and valuation. An 80%+ score signals interest, while 90%+ indicates strong interest. The summary table shows many tests PASS (e.g., BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, etc.), but notes a weakness for RESEARCH AND DEVELOPMENT TO ASSETS (FAILD). The report also provides background on Partha Mohanram and the concept of factor-based stock portfolios.

BMY Factor-Based Stock Analysis: Partha Mohanram's P/B Growth Model Rates Bristol-Myers Squibb at 88%

October 15, 2025, 3:32 PM EDT. Validea's guru-based assessment ranks Bristol-Myers Squibb (BMY) highly under the Partha Mohanram P/B Growth Investor model. Of 22 guru strategies, BMY scores 88%, signaling notable interest from this growth framework. The model targets low book-to-market stocks with indicators of sustained future growth, and BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs sector. The report notes frequent PASS outcomes on key tests (BOOK/MARKET RATIO, ROA, CFO to assets, R&D to assets, etc.) and shows a favorable overall fundamental picture. An emphasis is placed on Mohanram's research on distinguishing winners among low book-to-market stocks, his academic role at the University of Toronto and his chair at the John H. Watson Chair in Value Investing.

Bristol-Myers Squibb Co (BMY) Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strong Interest

October 15, 2025, 3:30 PM EDT. Validea's guru fundamental report for Bristol-Myers Squibb Co (BMY) uses the P/B Growth Investor model from Partha Mohanram. The model seeks low book-to-market stocks with sustained growth. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs sector, and the rating is 88%, implying the strategy has interest (80%) and strong interest above 90%. The accompanying table shows key tests: BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS all passing; R&D TO ASSETS is listed as FAIL. Overall, the framework flags favorable fundamentals and valuation for BMY, though the R&D-to-assets issue may merit closer scrutiny.

BMY Factor-Based Stock Analysis: Partha Mohanram's P/B Growth leads with 88%

October 15, 2025, 3:28 PM EDT. Validea's guru analysis places BRISTOL-MYERS SQUIBB CO (BMY) at the top of its P/B Growth Investor model, a Partha Mohanram framework that seeks low book-to-market names with growth signals. Among 22 guru strategies tracked, BMY earns an 88% score under this model, signaling strong interest from growth-oriented screens. The table notes that key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW TO ASSETS, and R&D TO ASSETS show favorable results, while some metrics carry less weight within the strategy. As a large-cap biotech and drugs firm, BMY's fundamentals and valuation align with growth potential per Mohanram's research, though caveats apply to factor-based stock portfolios.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Highlights

October 15, 2025, 3:26 PM EDT. Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) shows the stock rates highest on Partha Mohanram's P/B Growth Investor model. This growth model seeks low book-to-market stocks with signs of sustained future growth. BMY, a large-cap growth stock in the Biotechnology & Drugs industry, earns an 88% score, where 80%+ suggests interest and 90%+ signals strong interest. The accompanying table indicates several criteria pass (e.g., BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS), with this framework highlighting strengths in fundamentals and valuation. While not a guarantee, the model's strength suggests potential upside if growth and profitability trends persist, though investors should consider broader market and company risks.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals

October 15, 2025, 3:24 PM EDT. Validea's guru fundamental report places BRISTOL-MYERS SQUIBB CO (BMY) near the top among its 22 guru strategies via the P/B Growth Investor model derived from Partha Mohanram. This growth approach favors low book-to-market stocks that show traits tied to sustained expansion. BMY earns an 88% rating, indicating meaningful interest (scores ≥80% are noteworthy; ≥90% signals strong interest). The analysis shows pass rates across criteria like BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, with emphasis on CASH FLOW FROM OPERATIONS TO ASSETS vs. RETURN ON ASSETS and RESEARCH AND DEVELOPMENT TO ASSETS. Overall, the model emphasizes growth signals within financial statements, not just valuation, producing a favorable view of BMY for factor-based portfolios.

BMY Shines in Partha Mohanram's P/B Growth Model with 88% Validea Rating

October 15, 2025, 3:22 PM EDT. Validea's guru-based analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model pioneered by Partha Mohanram. The approach targets low book-to-market stocks with sustained future growth, and BMY posts an 88% rating based on fundamentals and valuation. Across the model's criteria, key metrics such as Book/Market Ratio, Return on Assets, and CFO to Assets pass, while R&D to Assets marks a concern (Fail). The result positions BMY as a potential growth name in the Biotechnology & Drugs space, reflecting a blend of quality signals and valuation that some investors may find attractive.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Highlights

October 15, 2025, 3:20 PM EDT. Validea's guru fundamental report for Bristol-Myers Squibb Co (BMY) finds BMY rates highly under Partha Mohanram's P/B Growth Investor model. The growth framework targets low book-to-market names with signs of sustained future expansion. BMY is categorized as a large-cap growth stock in the Biotechnology & Drugs sector. The model delivers an 88% rating, where a score of 80%+ signals investor interest and 90%+ signals strong interest. The positive read comes from multiple passes in the table-Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, and R&D to Assets, among others-though weights and independence vary. Overall, the analysis indicates interest from this strategy in BMY, with attention to model limitations and sector specifics.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals 88% Rating

October 15, 2025, 3:18 PM EDT. Bristol-Myers Squibb (BMY) scores highly under Validea's Partha Mohanram P/B Growth Investor model, reaching an 88% rating. The growth framework targets low book-to-market stocks with characteristics of sustained future growth. BMY is a large-cap growth stock in the Biotechnology & Drugs industry. Highlights include PASS results on BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics, plus favorable ROA stability and R&D-to-assets alignment. While not all criteria carry equal weight, the overview underscores strong points for a growth-oriented portfolio and suggests potential for continued earnings expansion. Investors should compare this Guru strategy signal with other fundamentals and valuations.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates Bristol-Myers Squibb at 88%

October 15, 2025, 3:16 PM EDT. BRISTOL-MYERS SQUIBB CO (BMY) is identified as a large-cap growth stock in the Biotechnology & Drugs sector. Under Validea's guru-based evaluation, BMY ranks highest on the P/B Growth Investor model crafted from Partha Mohanram's framework. The stock earns an 88% score, signaling substantial interest (scores ≥80% indicate some interest; >90% signal strong interest). In the table of tests, key metrics like BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS show PASS; several items remain favorable, such as R&D TO ASSETS and CAPEX TO ASSETS. The analysis highlights the model's emphasis on low book-to-market with growth traits, and provides context on Mohanram's contribution to factor-based investing.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strength

October 15, 2025, 3:14 PM EDT. Validea's guru analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model, scoring 88% based on Partha Mohanram's growth framework. The model seeks low book-to-market stocks with indicators of sustained future growth. BMY is categorized as a large-cap Biotechnology & Drugs name, and the 88% reading suggests substantial interest (80% threshold signals interest; 90% signals strong interest). The summary table shows most tests pass, including Book/Market Ratio, Return on Assets, CFO/Assets, CFO/Assets vs ROA, Operating Cash Flow to Assets, and Advertising to Assets. Notably, R&D to Assets is flagged as failed. Overall, this factor-based view highlights BMY as a potential growth candidate within pharma, though investors should weigh the R&D asset treatment and broader biotech cycle.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model

October 15, 2025, 3:12 PM EDT. Bristol-Myers Squibb Co (BMY) lands the highest score in Validea's Partha Mohanram P/B Growth Investor model, a framework that seeks low book-to-market stocks with sustained growth. As a large-cap biotechnology stock, BMY earns an 88% rating based on fundamentals and valuation, signaling notable investor interest (80%+) and potential strong interest (>90%). The table shows mixed results: PASS for BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CFO to assets vs ROA, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS, and R&D TO ASSETS (PASS); however R&D TO ASSETS is listed as FAILED. The analysis reflects Mohanram's approach to distinguish growth winners from losers, with BMY aligned to growth criteria despite R&D-related weak point.

BMY Tops Partha Mohanram P/B Growth Signals in Validea Guru Report

October 15, 2025, 3:10 PM EDT. Bristol-Myers Squibb Co (BMY) shows the strongest signal among Validea's 22 guru strategies under Partha Mohanram's P/B Growth Investor model. The growth framework targets low book-to-market stocks with growth traits. BMY scores 88% under this strategy, with thresholds of 80% indicating interest and above 90% signaling strong interest. The stock is classified as a large-cap growth name in Biotechnology & Drugs. The criteria largely pass (Book/Market, ROA, CFO ratios, operating metrics), with one exception: Research and Development to assets FAILED. Overall, the report presents BMY as a compelling growth candidate within the guru framework, though not a slam-dunk.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Finds 88% Rating

October 15, 2025, 3:08 PM EDT. Bristol-Myers Squibb Co. (BMY) scores highly under Validea's guru-based framework, led by Partha Mohanram's P/B Growth Investor model. The low book-to-market, sustained-growth criteria yield an 88% rating, with a typical threshold of 80% for interest and 90% for strong interest. The report shows the stock passes key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and related metrics like R&D TO ASSETS and CAPEX TO ASSETS. While not all criteria are equal, the overview highlights BMY as a large-cap growth play in Biotechnology & Drugs with favorable fundamentals and valuation signals per Mohanram's framework. Overall, the analysis suggests notable interest from this factor-based lens, consistent with BMY's growth-oriented profile.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Signals Strength

October 15, 2025, 3:06 PM EDT. Validea's guru-based analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model from Partha Mohanram. The model seeks low book-to-market stocks with characteristics of sustained future growth. BMY is a large-cap Biotechnology & Drugs stock, rated 88% by this strategy, indicating meaningful interest from growth-focused screens. In Validea's framework, a score of 80% or higher implies some merit, while above 90% signals strong interest. The accompanying table shows numerous PASS flags across criteria such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, with notes on their relationships (e.g., ROA vs CFO, R&D to assets). Overall, the analysis suggests a favorable growth profile for BMY within this factor-based approach, despite varying weightings.

BMY Receives High Score Under Partha Mohanram's P/B Growth Model

October 15, 2025, 3:04 PM EDT. BMY is rated highly by Validea's Guru framework using Partha Mohanram's P/B Growth Investor model. Among 22 guru strategies, Bristol-Myers Squibb earns an 88% score, reflecting a stock with low book-to-market traits and characteristics linked to sustained future growth. The Biotechnology & Drugs large-cap showcases favorable fundamentals and valuation under this growth model. In the accompanying test table, key checks such as BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW measures pass; some metrics like R&D to assets are flagged as not meeting the criterion. The 88% rating suggests at least some interest in BMY from this specific model, with scores above 90% typically signaling strong interest. Partha Mohanram's research, which informs these screens, aims to separate growth winners from losers among low book-to-market stocks.

BMY Factor-Based Stock Analysis: Mohanram Growth Model Signals Strength at 88%

October 15, 2025, 3:02 PM EDT. Validea's guru report rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model. BMY is a large-cap growth stock in the Biotechnology & Drugs industry. The model assigns an 88% score, where 80%+ indicates interest and 90%+ signals strong interest. The summary table shows most tests passing: Book/Market, Return on Assets, Cash Flow from Operations to Assets, Cash Flow from Ops to Assets vs ROA, ROA variance, Sales variance, Advertising to Assets, Capital Expenditures to Assets; however, R&D to Assets is the sole failing criterion. Overall, the strategy implies meaningful growth potential for BMY based on the Mohanram framework. The write-up also notes Mohanram's research on separating winners from losers among low book-to-market stocks.

Bristol-Myers Squibb (BMY) Strong in Mohanram P/B Growth Model – 88% Rating

October 15, 2025, 3:00 PM EDT. Validea's guru-based analysis of Bristol-Myers Squibb (BMY) shows a strong signal from the P/B Growth Investor model based on Partha Mohanram's framework for low book-to-market stocks with growth. The stock earns an 88% rating, indicating notable interest from this growth strategy. The detailed table reports a mix of PASS results across key metrics, including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS, with RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. Other factors such as ADVERTISING TO ASSETS and CAPITAL EXPENDITURES TO ASSETS are PASS, suggesting a generally favorable asset-side growth profile within the biotech space. Overall, the report positions BMY as a high-conviction pick among factor-based growth strategies.

BMY Factor-Based Growth Analysis: 88% Mohanram P/B Growth Rating

October 15, 2025, 2:58 PM EDT. Validea's guru fundamental report rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model. This growth framework searches for low book-to-market stocks with signs of sustained future growth. BMY scores 88% under this strategy, with 80%+ signaling some interest and 90%+ signaling strong interest. The stock is treated as a large-cap growth name in the Biotechnology & Drugs industry. The overview notes PASS results on key tests such as BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, and more, while the line for RESEARCH AND DEVELOPMENT TO ASSETS shows: FAIL. The analysis reflects Mohanram's research and Validea's model portfolios, indicating meaningful however not universal alignment with growth characteristics.

BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Highlights

October 15, 2025, 2:56 PM EDT. Bristol-Myers Squibb Co (BMY) rates highly under Validea's Partha Mohanram P/B Growth Investor model, scoring 88% for growth fundamentals. The model searches for low book-to-market stocks with signs of sustained future growth, placing BMY in the large-cap Biotech/Drugs space as a potential growth candidate. An 88% rating signals noteworthy interest; thresholds cite 80%+ as some interest and 90%+ as strong interest. The scorecard shows passes on key criteria, including BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS (as well as CFO to ROA). Other assets-related checks (CAPITAL EXPENDITURES TO ASSETS, ADVERTISING TO ASSETS) pass, while RESEARCH AND DEVELOPMENT TO ASSETS failed. Overall, BMY appears as a plausible growth pick under this guru framework with a caveat on R&D capitalization.

BMY Factor-Based Growth Analysis: Partha Mohanram P/B Growth Model

October 15, 2025, 2:54 PM EDT. Validea's guru fundamental report covers BRISTOL-MYERS SQUIBB CO (BMY). Among 22 guru strategies, BMY rates highest using the P/B Growth Investor model based on Partha Mohanram. This growth framework seeks low book-to-market stocks with characteristics of sustained growth. BMY earns an 88% rating, signaling notable interest. The stock is described as a large-cap growth name in the Biotechnology & Drugs industry. The table notes several tests as PASS (e.g., BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS), though RESEARCH AND DEVELOPMENT TO ASSETS is listed as FAILED. Partha Mohanram's background and his growth-tilted research are summarized. Overall, a score above 80% suggests interest, with BMY at the high end at 88%.

BMY Factor-Based Stock Analysis: 88% Mohanram Growth Model Rating

October 15, 2025, 2:52 PM EDT. Validea's guru fundamental report rates Bristol-Myers Squibb Co (BMY) highly under the Partha Mohanram P/B Growth Investor model. The growth model seeks low book-to-market stocks with signs of sustained growth. BMY scores 88%, indicating strong interest under this strategy (scores ≥80% are of interest; ≥90% strong). The stock passes key tests-Book/Market, Return on Assets, and Cash Flow from Operations to Assets-and shows favorable metrics for CFO/Assets, R&D to Assets, and other growth-oriented criteria. The report positions BMY as a large-cap growth pick in the Biotechnology & Drugs industry, highlighting undervaluation relative to growth signals. For investors tracking factor-based portfolios, BMY offers exposure to a classic growth factor in healthcare per Partha Mohanram's framework.

BX Factor-Based Stock Analysis: Mixed Signals from Pim van Vliet Strategy

October 15, 2025, 2:51 PM EDT. Validea's Pim van Vliet-based assessment ranks BLACKSTONE INC (BX) highest among the 22 guru strategies in their Multi-Factor Investor model, which targets low-volatility stocks with solid momentum and favorable net payout yields. BX is a large-cap growth name in the Investment Services space. The strategy rating for BX is 56%, reflecting what Validea deems favorable fundamentals and valuation, though below the threshold typically signaling strong interest (80%+). In the accompanying test table, BX shows Market Cap: PASS, Standard Deviation: PASS, Twelve Minus One Momentum: NEUTRAL, Net Payout Yield: NEUTRAL, and Final Rank: FAILED. Overall, the model suggests some potential but not a clear buy signal, illustrating the conservative volatility preference of Pim van Vliet.

REGN Factor-Based Stock Analysis: Benjamin Graham Value Signals on Regeneron (REGN)

October 15, 2025, 2:50 PM EDT. Validea's guru fundamental report rates REGN (REGENERON PHARMACEUTICALS INC) highly under a Benjamin Graham-based Value Investor model. The stock earns 71% on this strategy, with the analysis highlighting low valuation signals (P/E, P/B) alongside solid long-term earnings growth and reasonable debt metrics. In the strategy's table, REGN passes on Sector, Sales, Current Ratio, Long-Term Debt relative to Net Current Assets, and Long-Term EPS Growth, but fails on P/E and Price/Book ratios. The piece explains Benjamin Graham as the Father of Value Investing and notes Validea's broader research library and portfolio work. As with all research, the views are those of the author and may not reflect Nasdaq, Inc.

D.R. Horton (DHI) Scores 91% in Peter Lynch PEG-Based Guru Analysis

October 15, 2025, 2:49 PM EDT. Validea's guru model based on Peter Lynch flags DHI as a standout among large-cap builders. The stock is evaluated under the P/E/Growth framework, seeking a reasonable price relative to earnings growth with a solid balance sheet. DHI shows a high overall rating (91%), suggesting strong interest from this strategy, versus thresholds of 80% and 90% for varying levels of enthusiasm. The detailed screen notes the stock passes on INVENTORY TO SALES, the P/E TO GROWTH test, and EARNINGS PER SHARE, with TOTAL DEBT/EQUITY and FREE CASH FLOW in neutral territory and NET CASH POSITION also neutral. Assigned to the Construction Services space, DHI benefits from a robust fundamental profile within this Lynch-inspired approach. Bottom line: the strategy indicates a constructive view on DHI based on valuation relative to growth and balance-sheet strength.

CVS Health Corp: Acquirer's Multiple Deep-Value View at 78%

October 15, 2025, 2:48 PM EDT. CVS Health Corp (CVS) earns a 78% rating from Validea's Tobias Carlisle's Acquirer's Multiple framework, indicating some interest based on fundamentals and valuation. The model centers on deep-value investing and potential takeover targets. CVS is described as a large-cap growth stock in the Retail (Drugs) space. The score sits below the top tier (a score above 90% signals strong interest; around 80% signals some interest), so while the overall view is positive, not all tests align. The accompanying table shows Sector: PASS, Quality: PASS, but Acquirer's Multiple: FAIL. The report reflects Tobias Carlisle's emphasis on deep value and takeover potential; investors should balance the takeover narrative with the failing Acquirer's Multiple signal.

RCL Factor-Based Stock Analysis: Validea Momentum Model Rates Royal Caribbean at 100%

October 15, 2025, 2:47 PM EDT. Validea's guru-based analysis rates ROYAL CARIBBEAN CRUISES LTD (RCL) highest among its 22 strategies using the Quantitative Momentum model credited to Wesley Gray. The approach seeks stocks with strong, intermediate-term relative performance and currently gives RCL a 100% score, signaling strong interest from the momentum screen. RCL is categorized as a large-cap growth stock in the Water Transportation industry. While the model emphasizes momentum and historical performance, the rating underscores how the stock meets the strategy's tests and suggests potential upside from persistent trends. Investors should consider how momentum signals align with fundamentals and sector dynamics.

Fed Beige Book: U.S. Economic Activity Little Changed

October 15, 2025, 2:46 PM EDT. The latest Beige Book from the Federal Reserve shows U.S. economic activity little changed since early September. In the twelve districts, three reported slight to modest growth, five reported no change, and four noted a slight softening. Overall consumer spending has edged down, though auto sales rose in some districts due to strong demand for electric vehicles ahead of the tax-credit expiration. On the inflation front, prices rose again, with several districts pointing to faster input costs from higher import bills and rising services costs. Employment was largely stable, but labor demand remained muted; some districts cited job cuts through layoffs and attrition, linked to weaker demand, uncertainty, and, in some cases, higher AI investments. Looking ahead, outlooks vary by district and sector, with sentiment improving in some areas and uncertainty weighing on others.

ZRE:CA Stock Analysis & AI Signals – October 15, 2025 Update

October 15, 2025, 2:45 PM EDT. An updated market note for ZRE:CA, the BMO Equal Weight REITs Index ETF, presents actionable trading plans and AI-generated signals. The long-term plan proposes buying near 21.25 with a target of 22.71 and a stop at 21.14. A complementary short setup targets 22.71 with a 21.25 objective and a stop at 22.82. The report flags Updated AI-Generated Signals for ZRE:CA and includes a timestamp of Oct 15, 2025 02:16 PM ET. Ratings on Oct 15 list Near: Neutral, Mid: Weak, Long: Neutral. Chart access is referenced alongside the AI signals. Traders should monitor price action around the 21.25-22.71 range and consider the AI signals as a guide to confirm momentum and risk controls.

Notable Wednesday Options Activity: PNC, AXON, GNRC Highlight Heavy Volume

October 15, 2025, 2:44 PM EDT. Today's notable S&P 500 option activity centers on PNC and AXON and GNRC. PNC saw 13,017 contracts traded (~1.3M underlying shares), about 78.2% of its 1-month average daily volume, with notable interest in the $185 strike call expiring Oct 17, 2025. AXON options traded 3,249 contracts (~324,900 shares), about 54.8% of its average daily volume, led by the $600 strike put expiring Jan 16, 2026. GNRC logged 5,670 contracts (~567,000 shares), about 53.3% of its average daily volume, with elevated activity in the $200 strike call expiring Oct 17, 2025. For more expirations, visit StockOptionsChannel.com.

ZDM:CA Stock Analysis – Buy near 31.27 with 31.11 stop; AI signals for BMO MSCI EAFE Hedged to CAD ETF

October 15, 2025, 2:43 PM EDT. ZDM:CA stock analysis for the BMO MSCI EAFE Hedged to CAD Index ETF shows a near-term buy near 31.27 with a stop at 31.11. No short position is offered at this time. The update highlights AI-generated signals for ZDM:CA and a ratings table across Near, Mid, and Long horizons, with categories Strong, Weak, and Neutral. The timestamp is October 15, 2025, 02:28 PM ET, guiding traders to monitor the evolving AI-driven outlook for ZDM:CA and the referenced price levels.

Trump's Trade War Upends Soybean Market With No Aid In Sight

October 15, 2025, 2:12 PM EDT. Trump's tariff fight has rattled the U.S. soybean market, sending futures volatile as buyers weigh demand amid a looming policy stalemate. Without new government aid on the horizon, farmers face lower prices and greater uncertainty, pressuring planting decisions and cash flows. Traders gauge the duration of the dispute, the risk of Chinese retaliation, and how much of the crop will reach buyers in a slower global market. The shock extends beyond soybeans, reshaping related commodities, shipping routes, and hedging strategies as producers and processors scramble to lock in profits amid a liquidity squeeze. With policy clarity still missing, the market braces for continued volatility until a deal or new aid program emerges.

Two Dividend Stocks I'm Thankful I Owned This Year: Meta Platforms and Johnson & Johnson

October 15, 2025, 2:10 PM EDT. Two dividend payers stood out this year: Meta Platforms and Johnson & Johnson. Meta's AI push helped it deliver strong 2025 results, with Q2 revenue of $47.5B (up 22%) and net income up 36%, and its open-source AI strategy could attract developers and lift ad ROI. Despite a modest forward yield of 0.3%, the stock's growth runway may pay off long term. Johnson & Johnson remains a steady dividend anchor even amid talc-related lawsuits and regulatory headwinds, illustrating resilience and diversification benefits. The combination shows how a growth-oriented tech name and a diversified healthcare stalwart can coexist in a well-rounded income portfolio. Investors benefited this year from owning both, with potential for continued income and upside as AI and healthcare evolve.

Bunge shares jump 11% on Trump's China cooking oil embargo threat

October 15, 2025, 2:01 PM EDT. Shares of Bunge jumped more than 11% after President Trump floated a possible termination of U.S. purchases of Chinese cooking oil in retaliation over Beijing's soy dealings. As a major soybean processor and cooking oil producer, Bunge also issued a full-year outlook of $7.30-$7.60 per share, little above the FactSet consensus of about $7.39. The rise follows news of a broader U.S.-China tariff and export-control backdrop, including the merger with Viterra. The stock is up roughly 18% year-to-date. ADM also edged higher, up about 1.5%, as investors weigh the potential impact of a China oil embargo on the sector.

Wall Street surges as earnings season kicks off; UBS sees 'bull market intact'

October 15, 2025, 1:57 PM EDT. Stocks edged higher on Wednesday as banks and tech giants report solid profits, lifting market sentiment into earnings season. The S&P 500 rose about 0.8%, the Dow added roughly 254 points, and the Nasdaq gained around 1.1%. UBS Global Wealth Management said early results suggest a favorable start to earnings season, noting 80% beat sales and 70% beat EPS, though the average surprise was modest. Tech names helped push higher, with ASML rising in Europe and Broadcom and Nvidia lifting the U.S. indices. Big banks climbed-Bank of America up 5% and Morgan Stanley up 6%-while PNC Financial fell after guiding lower profits and Abbott Laboratories slipped on revenue misses. Sustained earnings growth and policy expectations are seen as key to a bull market intact.

PFW Advisors Exits $6M Stake in Vanguard Total Bond Market ETF (BND)

October 15, 2025, 1:43 PM EDT. PFW Advisors LLC disclosed in an October 14, 2025 SEC filing that it fully exited its position in the Vanguard Total Bond Market Index Fund (BND) during Q3 2025, selling 81,510 shares for an estimated $6 million. The firm now holds 0 shares in BND, which previously represented about 1.8% of its AUM. Post-trade portfolio shifts show top holdings including VMC, IWF, KO, IWD and IWR, each disclosed as millions of dollars and percentages of AUM. As of October 15, 2025, BND traded around $74.70, up ~3.7% YTD, and still lagged the S&P 500 by roughly 9.7 percentage points. The move signals a potential tilt away from broad fixed-income exposure toward equity ETFs and blue-chip stocks, though BND remains a core, low-cost fixed-income option for many portfolios.

Constellation Energy Rises on Bullish Price Target, Nuclear Strength and Data Center Growth

October 15, 2025, 1:42 PM EDT. Shares of Constellation Energy (CEG) are extending a rally after an analyst from KeyBanc bumped up the price target to $417 from $357, citing the rising value of data and Constellation's role in supporting data-center infrastructure. With an outperform rating, Sophie Karp and her team see about a 7% upside from around $389.56. The company operates the largest nuclear fleet in the U.S. and has tied its plans to restart Three Mile Island to support Microsoft's data-center operations, appealing to investors seeking lower-risk nuclear exposure. Still, the timeframe remains unclear, and some may prefer other picks despite Constellation's steady profits.

European Stocks Rise as LVMH Rally Lifts French Markets

October 15, 2025, 1:41 PM EDT. European stocks moved higher on Wednesday as a rally in France lifted sentiment, with the pan-European Stoxx 600 up 0.6% to 567.77. The CAC 40 rose 2.0% as LVMH jumped 12.2% on solid Q3 sales helped by improving Chinese demand, with peers L'Oréal, Hermès and Richemont also higher. The DAX dipped 0.2% and the FTSE 100 fell 0.3%. ASML added 3.1% after Q3 orders beat estimates, while Asetek, PageGroup and British Land posted gains on upbeat results and deals. Conversely, Aurubis dropped 6.5% after Salzgitter sold €500m of bonds convertible to stock. On data, French CPI rose 1.2% YoY in September-the highest in eight months-while Eurozone industrial output fell 1.2% MoM in August, underscoring demand headwinds.

Affirm Valuation Under Scrutiny After Volatile Stock Swings

October 15, 2025, 1:40 PM EDT. Affirm Holdings has traded in a wide range as investors weigh its growth against risk. The stock is down about 5% last week and more than 12% in the month, even as a 12-month return sits around +52% and a three-year gain tops +270%. Valuation checks currently rate the stock poorly, with Affirm scoring just 1/6 on the model's metrics. The Excess Returns framework shows the per-share intrinsic value of $23.95, well below the current price, implying the shares are overvalued by roughly 200% according to this method. Core inputs: book value $9.44, EPS $1.62 (six-analyst consensus), cost of equity $1.11, excess return $0.51, ROE forecast ~11.77%, and BVPS $13.76. A more holistic view also weighs the lofty sentiment versus fundamentals, suggesting investors should tread carefully.

Paragon Capital Sells 7,653 Coinbase Shares, Keeps Coinbase as Third-Largest 13F Holding

October 15, 2025, 1:32 PM EDT. Paragon Capital Management disclosed in an SEC 13F filing for the period ended Sept. 30, 2025 that it sold 7,653 Coinbase Global shares, an estimated $2.6 million trade based on the quarterly average price. The move trims Coinbase to about 9.4% of Paragon's 13F AUM, down from 9.9%. Coinbase remains Paragon's third-largest holding, with roughly $50.1 million of AUM. Top holdings after the filing include Vanguard Dividend Appreciation ETF and Invesco S&P 500 Quality ETF. As of Oct. 14, 2025, COIN traded near $341.55, up about 73.9% year over year and outperforming the S&P 500 by roughly 79.4 percentage points. Paragon's disclosure reflects 13F holdings; there is no intraperiod disclosure requirement.

Karooooo Earnings: Cartrack Delivers Growth; Shares Slip on Valuation

October 15, 2025, 1:31 PM EDT. Karooooo (KARO) posted better-than-expected Q2 results as revenue rose 21% year over year, led by a 20% rise in Cartrack subscription revenue, which now accounts for about 90% of sales. Cartrack subscribers climbed 2.46 million, up 15% YoY, with 70,740 net adds in Q2. Outside Cartrack, Karooooo Logistics delivered 38% growth to ZAR139 million. Gross margin edged down to 68%, while operating margin remained solid at 26% (Cartrack at 29%). Adjusted EPS rose 13% to ZAR8.28, though marketing spend surged 34% to acquire customers. Management kept the fiscal 2026 outlook intact, guiding Cartrack subscription revenue up 16-21% and adjusted EPS of ZAR32.50-ZAR35.50. Shares fell ~12% after hours as investors weighed valuation, despite a robust growth backdrop and a stable margin trajectory.

Omeros Stock Soars 149% on $2.1B Novo Nordisk Deal for MASP-3 Inhibitor OMS906

October 15, 2025, 1:30 PM EDT. Omeros Corporation (OMER) jumped about 149% to $10.19 after announcing a $2.1 billion licensing and asset purchase deal with Novo Nordisk for its MASP-3 inhibitor candidate zaltenibart (OMS906). The pact grants Novo Nordisk exclusive global rights to develop and commercialize zaltenibart for rare blood and kidney disorders, with an upfront $340 million payment and near-term milestones, plus additional milestone-based payouts. In morning trading, the stock opened at $11.53, touched a high of $12.77 and a low of $4.33; volume ran to 77.9 million shares vs. a 1.2 million average. OMER has traded in a 52-week range of $0.92-$12.87. The deal underscores a major valuation shift for Omeros as it leverages its pipeline.

Nscale Expands NVIDIA GB300 GPU Deployment With Microsoft Across Europe and the U.S.

October 15, 2025, 1:29 PM EDT. Nscale inks an expanded deal with Microsoft to deploy about 200,000 NVIDIA GB300 GPUs of hyperscale AI infrastructure across Europe and the U.S., in collaboration with Dell. The plan includes ~104,000 GPUs for a ~240MW hyperscale campus in Texas and ~12,600 GPUs at the Start Campus in Sines, Portugal, beginning in Q1 2026. Nscale pitches itself as a partner of choice for major tech leaders, delivering sovereign AI solutions inside the EU. The news comes as Microsoft trades near $514.12 on the Nasdaq.

U.S. Mortgage Applications Fall for Third Week, MBA Reports Decline in Purchase and Refinance

October 15, 2025, 1:28 PM EDT. Mortgage activity in the U.S. declined for the third straight week, with the MBA's weekly survey showing a 1.8% drop in the market composite index for house-purchase applications. The refinance index fell 1%, while the purchase index slipped 3%. The share of refinances rose to 53.6% of total applications, and ARM activity eased to 9.3%. The 30-year fixed rate ticked down to 6.42%. MBA economist Joel Kan noted that conventional and VA applications fell, but FHA apps rose, with FHA refinances up about 12% as FHA rates remained more than 10 bps lower than conventional rates. Purchase activity remained about 20% above year-ago levels, supported by pockets of improving inventory.

AI trading floods Wall Street with 1.2 trillion order messages per day, NYSE president says

October 15, 2025, 1:27 PM EDT. AI-driven trading is accelerating activity on Wall Street, with the NYSE processing about 1.2 trillion order messages per day – triple the level from four years ago. NYSE President Lynn Martin says AI and high-speed algorithms are central to monitoring flows, since human surveillance can't keep up with velocity, and the exchange uses AI in its regulatory function to detect manipulation and cyber threats. The NYSE also operates a private, offline data center with no internet to shield core trading from cyber risk. Despite the surge, Martin notes the IPO market is reviving, with more listings in 2025 as companies tap public capital.

Truist Cuts TDG Target to $1,647, Keeps Buy; TDG Shares Slump as Analysts Weigh In

October 15, 2025, 1:26 PM EDT. Truist Financial trimmed its Transdigm Group price target from $1,730 to $1,647 while keeping a buy rating, signaling a potential upside of about 30.9% from the prior close. The note comes as other analysts reiterate or adjust targets: Citigroup lifted to $1,795 with a buy, Goldman Sachs up to $1,709 with a buy, Jefferies modestly cut to $1,490 but still buy, and BMO initiated with an outperform at $1,420. Market reaction showed TDG down about 4.1% to $1,258.03 on the session. TDG trades around its 50- and 200-day averages ($1,333.20 / $1,406.36). The company posted Q2 results: EPS of $9.60 vs $9.75 consensus; revenue $2.24B. FY2025 guidance: $36.33-$37.15 EPS; 12-month target consensus near $1,564.56.

NYSE president calls for more 'sanity' in online betting markets as Polymarket investment weighs on debate

October 15, 2025, 1:25 PM EDT. NYSE President Lynn Martin argues online betting markets are the next evolution driving market dynamics, following a $2 billion investment from NYSE's parent in Polymarket, a leading online predictions site focused on geopolitical outcomes that can swing stock prices. She urged more sanity to curb retail excesses seen during the SPAC and meme-stock booms, tying the issue to regulation and leveraging the regulatory framework to guide behavior. When asked if betting markets should be regulated more like stock markets, she said she couldn't say. The remarks highlight a debate over balancing innovation in financial markets with safeguards to limit speculative volatility.

NYSE Group President: Staying Private Longer Is a Good Thing for Markets

October 15, 2025, 1:09 PM EDT. NYSE Group President Lynn Martin argues that companies staying private longer is a good thing for markets. She says it lets firms refine strategy, build their business, and decide what they want to be in the next chapter. While rivals like Nasdaq pursue pre-IPO offerings, NYSE has largely stayed out. CEOs weigh two aims: reward employees and reward shareholders. Signs of a revived IPO appetite emerge as private firms gear up for public markets amid investor demand to back innovation and LPs' capital-return pressures. Martin stresses the situation can be volatile-an open, shut, open, shut pattern-with the government shutdown as a minor speed bump.

NYSE Chief Says Staying Private Longer Is a Good Thing for Markets

October 15, 2025, 1:08 PM EDT. NYSE Group President Lynn Martin frames the trend of firms staying private longer as a net positive for markets. Delaying IPOs gives companies time to refine strategy, build their business, and decide what they want to be for their next chapter. While Nasdaq experiments with pre-IPO access for regular investors, NYSE has largely stayed out. The motive is twofold: to reward employees and to reward shareholders. There are signs the IPO drought may be easing as CEOs and investors show renewed appetite from public-market participants and as LPs push for faster capital returns. Martin calls the cycle an open, shut, open, shut situation, with a government shutdown a minor speed bump rather than a decisive obstacle.

IMF Finds Tariffs Modestly Drag US Growth; Progressive Drops; Fed Split on Policy Path

October 15, 2025, 1:03 PM EDT. Markets are digesting an IMF update that shows tariffs have weighed on US growth only modestly, with GDP seen at about 2.0% in 2025 and 2.1% in 2026 as deals and front-loading purchases blunt the hit. Inflation is expected to ease and joblessness to rise gently. Separately, Progressive (PGR) sank early after weak Q3 results, dragging the S&P 500 and underscoring earnings risk. In Washington, Fed officials remain divided on the path for rates, with factions trading a move now versus waits for inflation data, leaving near-term policy bets uncertain for markets.

CME launches options on Solana and XRP futures, signaling broader crypto derivatives expansion

October 15, 2025, 1:02 PM EDT. CME has begun facilitating options on Solana and XRP futures, expanding crypto derivatives beyond BTC and ETH. The exchange shows five contracts outstanding for each asset so far. First XRP option trades linked Wintermute and Superstate, while Solana options paired Galaxy Digital with Cumberland DRW. CME notes broad client support as it looks to help market participants manage exposure and explore new strategies across crypto futures. In Q3, Solana futures averaged about 4,300 contracts traded daily, with XRP averaging 2,100, suggesting Solana is more active. Notional open interest reached a record $39 billion in mid-September. CME's move reinforces crypto as commodities under the CFTC framework, and market participants see this as a sign of a maturing crypto options market.

First Horizon (FHN) crosses below its 200-day moving average

October 15, 2025, 1:00 PM EDT. On Wednesday, shares of First Horizon Corp (FHN) slipped below their 200-day moving average of $23.48, trading as low as $20.70. The stock was down about 12.7% on the session. The chart overlays a 1-year performance versus the 200-day average, with a 52-week range of $20.48 to $24.92; the latest trade was $21.69. The cross underscores near-term volatility as investors weigh whether the breach signals further weakness or a new support level for the stock.

Nasdaq 100 Movers: Constellation Energy Leads; Roper Technologies Dips

October 15, 2025, 12:59 PM EDT. Constellation Energy (CEG) led the Nasdaq 100 in early trading, climbing about 5.3% as it posted a sharp year-to-date gain of 83.3%. The day's weakest component was Roper Technologies (ROP), down roughly 1.2%, with YTD performance dipping about 2.4%. Also in motion were AstraZeneca, off around 1.2%, and Lam Research, up about 3.3%. The moves reflect a mixed session for the Nasdaq 100, with energy and tech hardware showing notable swings. Investors may be watching for how these components influence the index as the session progresses. Video: Nasdaq 100 Movers: ROP, CEG.

SPLG Leads ETF Inflows; TDAQ Surges 39.6% in Units

October 15, 2025, 12:58 PM EDT. ETF Channel data show SPLG led weekly inflows, adding 32.6 million units (+2.9%). Among SPLG's components, Nvidia is up ~1.4% and Microsoft ~0.5% in early trading. On a percentage basis, TDAQ posted the largest inflows, adding 190,000 units for a 39.6% rise in outstanding shares. The moves underscore demand for broad-market exposure, with SPLG benefiting large-cap tech exposure and TDAQ signaling appetite for its underlying mix. Video: SPLG, TDAQ: Big ETF Inflows.

XVOL and CONY: Big ETF Outflows Highlight Shift; YieldMax COIN Strategy Leads in Units Destroyed

October 15, 2025, 12:57 PM EDT. ETF Channel data show pronounced outflows across the ETF universe. The largest week-over-week unit loss occurred in the YieldMax COIN Option Income Strategy ETF, with 16,925,000 units removed, a drop of 8.7%. On a percentage basis, XVOL experienced the steepest outflow, shedding about 50,000 units for a 40.0% tumble in outstanding shares versus the prior week. The movements underscore shifting risk appetites and liquidity dynamics in recently popular or complex structures. Investors might be reassessing niche strategies like option-income plays amid changing volatility regimes. As always, traders should consider liquidity and tracking error implications when evaluating outsized outflows in these specialized ETFs.

Bharti Airtel and IBM Team Up to Expand Airtel Cloud With AI-Powered Power Systems Across India

October 15, 2025, 12:55 PM EDT. Bharti Airtel and IBM announced a strategic alliance to bolster Airtel Cloud by weaving IBM's cloud, AI, and hybrid computing capabilities into Airtel's telco-grade infrastructure. The collaboration will deliver IBM Power systems as a Service, including AI-ready Power11 servers, to Airtel Cloud customers and support mission-critical workloads in government, healthcare, and banking. With multizone expansions planned in Chennai and Mumbai, Airtel's Indian availability zones will rise from four to ten. The partners say the deal will help regulated sectors modernize, harness AI in hybrid settings, and accelerate secure digital transformation. IBM stock was trading around $284.38, up about 3% on the NYSE at the time of the announcement.

TAL Education Group (TAL) Crosses Above 200-DMA

October 15, 2025, 12:54 PM EDT. Shares of TAL Education Group (Symbol: TAL) crossed above its 200-day moving average of $11.13 on Wednesday, trading as high as $11.14. The stock was up about 6.6% on the day, with a last trade near $11.23. The stock's 52-week range spans $8.50 to $15.30. A move above the 200-DMA can be viewed as a bullish signal, though investors should consider the broader market context.

CubeSmart Breaks Above 200-Day Moving Average (CUBE)

October 15, 2025, 12:53 PM EDT. CubeSmart (Symbol: CUBE) shares climbed on Friday after crossing above their 200-day moving average of $41.78, trading as high as $41.98. The stock was about 1.5% higher on the day, with the last trade around $41.95. The chart tracks its one-year performance against the 200-day moving average. CubeSmart's 52-week range runs from a low of $33.175 to a high of $47.81. A break above the 200-day moving average can signal renewed momentum for traders, highlighting a potential bullish cue. The piece also notes a link to find out which other dividend stocks recently crossed above their 200-day moving average.

Synopsys (SNPS) Valuation Under Scrutiny After Recent Share-Price Volatility

October 15, 2025, 12:52 PM EDT. Synopsys (SNPS) has shown steady revenue and profit growth, but its stock has been choppy: a 7.1% one-week dip and a 22.3% slide over three months, with a -14.3% one-year TSR. Long-term holders have still doubled returns over five years. The stock trades well below analysts' averages, and a primary question is whether there is untapped upside or if the market has priced in future gains. The bear-case: the shares at roughly $443.76 vs a popular narrative fair value of $556.40 suggests upside, aided by the shift toward SaaS, cloud-based EDA, and subscription and service models that could boost revenue visibility. Risks include export restrictions and headwinds in the Design IP segment that could temper growth and valuation. Valuation is centered on a price/earnings multiple near 70.7x versus software peers around 34-47x.

XLRE Breaks Above 200-Day Moving Average, Eyes Higher After Bullish Cross

October 15, 2025, 12:51 PM EDT. XLRE cleared its 200-day moving average near $41.50, trading as high as $42.02 and up about 1.6% on the session. The Real Estate Select Sector SPDR Fund's one-year chart compares performance to the MA, with a 52-week range of $35.76 to $45.48 and a latest print near $41.90. The bullish cross may invite follow-through buyers, though the ETF remains within a broad trading range as it approaches resistance nearer the year's high. The piece also hints at a list of other ETFs that recently crossed above their 200-day moving average.

Dow Movers: Nike Leads Gains as Travelers Dip; Verizon and Amazon Move

October 15, 2025, 12:50 PM EDT. In early trading, Nike is among the Dow's best performers, up about 7.2% as a standout component. Year-to-date, Nike has fallen roughly 17.4%. By contrast, Travelers Companies is the day's laggard, down about 2.2%, though it remains up about 9.5% for the year. Other notable moves include Verizon Communications (down ~2.2%) and Amazon.com (up ~7.0%). These shifts shape a mixed start for the Dow Jones Industrial Average, with gains led by consumer names and diversified insurers alongside the tech/communications complex. VIDEO: Dow Movers: TRV, NKE. The views expressed here are those of the author and do not necessarily reflect Nasdaq, Inc.

S&P 500 Movers: BG Leads as PGR Dips in Early Trading

October 15, 2025, 12:49 PM EDT. During the first hours of trading, BG (Bunge Limited) jumped about 11.0%, helping the S&P 500 components climb, with year-to-date up about 17.7%. The worst performer so far is PGR (Progressive), down around 7.8% on the day and roughly 7.5% lower year-to-date. Other movers include Abbott Laboratories down about 3.0% and Morgan Stanley up about 6.5%. A video titled 'S&P 500 Movers: PGR, BG' accompanies the report.

Validea's Martin Zweig Growth Investor Picks IT Stocks: KAROOOOO LTD (KARO) Rated 77%

October 15, 2025, 12:48 PM EDT. Validea's Growth Investor model, reflecting Martin Zweig's approach, rates KARO (KAROOOOO LTD) as a top Information Technology pick with a 77% score. KARO is a Singapore-based provider of real-time mobility data analytics via its SaaS platform, spanning Cartrack, Carzuka, and Karooooo Logistics. The company delivers on revenue growth and earnings momentum while maintaining a reasonable valuation and moderate debt. The score suggests notable interest but not the strongest level (below the typical >90% threshold). The analysis highlights solid fundamentals, a growth-oriented business in IoT-enabled mobility, and exposure to last-mile delivery and vehicle marketplaces. Investors should consider valuation, earnings persistence, and market risk within the Information Technology space.

Validea's Top Information Technology Stocks Based On Warren Buffett Strategy

October 15, 2025, 12:47 PM EDT. Validea's Patient Investor model applies Warren Buffett's principles to identify top IT stocks. The framework seeks long-term, predictable profitability, low debt, and reasonable valuations. Check Point Software Technologies Ltd (CHKP) emerges as a leading name in cybersecurity, offering AI-powered, cloud-delivered security via the Check Point Infinity Architecture. The stock carries a 79% Buffett-style score, indicating interest but not a first-tier signal (scores above 90% show strong interest). The model's tests show EARNINGS PREDICTABILITY, DEBT SERVICE, RETURN ON EQUITY, RETURN ON TOTAL CAPITAL, and FREE CASH FLOW as PASS, with USE OF RETAINED EARNINGS and SHARE REPURCHASE showing mixed results. Overall, CHKP highlights the growing need for secure IT infrastructure in enterprises and governments, aligning with Buffett's emphasis on durable franchises at sensible valuations.

Validea's Top IT Stocks Based On Peter Lynch P/E/Growth Model

October 15, 2025, 12:46 PM EDT. Validea identifies leading Information Technology stocks using the Peter Lynch-inspired P/E/Growth Investor model. The list spotlights FIRST SOLAR INC (FSLR), a large-cap growth stock in Semiconductors, rated 93% based on fundamentals and valuation; a score above 90% signals strong interest. First Solar is a photovoltaic company focused on CdTe modules, including the Series 6 Plus and Series 7 lines. The analysis covers metrics like P/E/GROWTH RATIO, SALES AND P/E RATIO, EPS GROWTH RATE, TOTAL DEBT/EQUITY RATIO, and FREE CASH FLOW with many tests passing and cash metrics shown as neutral. Another top pick is FORTINET INC (FTNT), rated 91%, a cybersecurity firm delivering integrated security platforms, Secure Access Service Edge (SASE), and AI-driven ops. The piece highlights Validea's framework for ranking IT names.

Validea's Top IT Stocks Based On Joel Greenblatt Earnings Yield Investor

October 15, 2025, 12:45 PM EDT. Validea's Earnings Yield Investor model, based on Joel Greenblatt, flags Ituran Location and Control Ltd (ITRN) and Dell Technologies Inc (DELL) among the top Information Technology stocks. Ituran is a small-cap value stock in the Communications Services space; its EARNINGS YIELD is NEUTRAL, RETURN ON TANGIBLE CAPITAL is NEUTRAL, with a FINAL RANKING: PASS, indicating favorable fundamentals and valuation per the strategy. Dell Technologies (DELL) is a large-cap growth stock in Computer Hardware, rated at about 70% by the model, signaling some interest but not the top tier. The analysis emphasizes how earnings yield and return on tangible capital drive IT stock selection, balancing value signals with growth characteristics across names like ITRN and DELL.

ICICI Bank (IBN) Crosses Above 200-Day Moving Average

October 15, 2025, 12:44 PM EDT. On Friday, ICICI Bank Ltd (IBN) traded above its 200-day moving average of $29.09, hitting as high as $29.29. The stock was up about 1% on the session. The chart shows IBN's one-year performance relative to the moving average. The stock's 52-week low sits at $25.125 and the 52-week high at $32.14, with the latest trade around $29.18. If the move sustains, it could attract momentum traders as the price sits near the midpoint of its annual range. Investors may monitor whether the breakout holds as the stock continues to test resistance near the moving average.

Crown Castle (CCI) crosses above its 200-day moving average; shares rise 2.2%

October 15, 2025, 12:43 PM EDT. CCI crossed above its 200-day moving average of $102.94, trading as high as $103.81 on Wednesday. The stock was about 2.2% higher on the session. In the past year, CCI traded within a 52-week range of $84.72 to $119.50, with a last trade near $103.53. The DMA signal comes from TechnicalAnalysisChannel.com. A chart comparison shows one-year performance versus the moving average, highlighting the recent bullish cross amid a group of dividend stocks crossing above their own 200-day moving averages.

US stocks rally as bank earnings beat forecasts; Dow up 351 as Fed rate-cut bets lift sentiment

October 15, 2025, 12:42 PM EDT. US stock indexes surged as strong bank earnings and renewed expectations for Federal Reserve rate cuts overshadowed trade jitters. The Dow rose 351 points, the S&P 500 climbed 1%, and the Nasdaq Composite gained about 1.2%, led by tech and financials. Bank earnings were a standout: Bank of America up 23%, Morgan Stanley 45%, with Goldman Sachs and Wells Fargo also beating forecasts. Nvidia, Intel and AMD posted gains, and Apple rose on a new M5 chip and upgraded devices. Gold hit a fresh high near $4,215/oz, while the 10-year yield slipped to 4.01%. Fed Chair Powell signaling rising downside risks to employment reinforced bets on a December cut, though U.S.-China tensions remain a key watch point.

JMST ETF Inflow Alert: $185.9M Week-Over-Week Increase in Units

October 15, 2025, 12:41 PM EDT. This week's standout is the JMST ETF, posting a $185.9 million inflow and a 3.9% rise in units outstanding (from 92.55M to 96.20M). The chart shows JMST's price relative to its 200-day moving average, with a last trade near $50.96 and a 52-week range of $50.42-$51.08. As new units are created, underlying holdings must be purchased, a dynamic to watch as inflows persist. The move highlights potential near-term price action around the 200-day moving average and the impact of changing units outstanding on the ETF's flow. Readers may also explore which other ETFs saw notable inflows this week.

TLT ETF Inflow Alert: ~$1.7B Inflow and 3.0% WoW Rise in 20+ Year Treasury Bond ETF

October 15, 2025, 12:40 PM EDT. An ETF Channel scan shows a notable inflow into the TLT (iShares 20+ Year Treasury Bond ETF). Week-over-week, estimated inflows reach approximately $1.7 billion, lifting shares outstanding by about 3.0% (from 624,500,000 to 643,400,000). The chart tracks TLT against the 200-day moving average, with a 52-week range of $82.42 – $101.64 and a last price of $92.33. Creation of new units occurs to meet demand, while destruction can affect the underlying holdings. Investors should monitor weekly data as inflows can signal demand shifts for long-duration Treasuries. Click here to see which nine other ETFs had notable inflows.

EMLC ETF Sees $245.9M Inflow, 6.5% WoW Increase in Shares Outstanding

October 15, 2025, 12:39 PM EDT. ETF Channel flags a notable flow into the VanEck J.P. Morgan EM Local Currency Bond ETF (EMLC). The fund recorded an approximate $245.9 million inflow, about 6.5% week-over-week growth in outstanding units (rising from 148,822,682 to 158,522,682). A one-year chart tracks EMLC vs. its 200-day moving average. The 52-week range runs from a low of $22.9425 to a high of $25.795, with the latest trade around $25.43. Inflows can necessitate buying the underlying holdings, while outflows do the opposite. The ETF space continues to watch for notable inflows/outflows as a gauge of demand.

XLSR ETF Suffers $143.9M Outflow; XLP/XLC/MCK Movers

October 15, 2025, 12:38 PM EDT. An ETF Channel analysis shows the SPDR SSGA US Sector Rotation ETF (XLSR) posting a roughly $143.9 million outflow, about 14.6% week over week as outstanding shares drop from 16.6M to 14.18M. Among XLSR's top components, XLP rose about 0.6%, XLC gained roughly 1.1%, and MCK was higher by around 1% today. The report notes that large flows can affect underlying holdings as units are created or destroyed. The chart compares to the 200-day moving average, with XLSR last at $60.17 and a 52-week range of $43.22-$60.525. For full holdings and more on the outflows, see the XLSR holdings page and the linked ETF Channel report.

AIQ ETF Inflow Surges as BABA, TSLA, PLTR Lead Gains

October 15, 2025, 12:37 PM EDT. AIQ ETF logged a notable week-over-week inflow of about $242.6 million, a 3.9% rise in outstanding units (from 123,940,002 to 128,810,002). Among its top holdings, Alibaba (BABA) rose ~2.6%, Tesla (TSLA) ~1.8%, and Palantir (PLTR) ~2.1% today. The chart compares AIQ's 1-year performance with its 200-day moving average. AIQ's 52-week range runs from a low of $30.60 to a high of $51.58, with the last trade near $50.87. ETF unit creation/destruction can affect underlying demand, as inflows often require buying the ETF's holdings. For more detail, see the AIQ Holdings page and other ETFs with notable inflows.

Stock market today climbs on strong bank earnings and rate-cut hopes amid US-China jitters

October 15, 2025, 12:36 PM EDT. U.S. stocks rose as earnings season kicked off with solid bank results – Bank of America and Morgan Stanley posting strong quarters – lifting the Dow about 0.4%, the S&P 500 roughly 0.7%, and the Nasdaq around 1%. A solid start to earnings helped ease US-China jitters and a looming government shutdown. Fed Chair Jerome Powell signaled rising downside risks to employment, fueling bets on rate cuts later this month and in December (probabilities near 96%). Apple helped lead tech gains after unveiling the M5 chip and refreshed devices. Gold traded at fresh records near $4,211 an ounce and silver around $51 as investors sought safety in hard assets.

BBEU ETF Inflows Reach $678.7M; 16.4% WoW Rise in Outstanding Units

October 15, 2025, 12:34 PM EDT. BBEU ETF (Symbol: BBEU) posted a notable inflow of about $678.7 million, a 16.4% week-over-week increase in outstanding units (from 59,149,596 to 68,849,596). The move comes with BBEU trading near $70.17, within its 52-week range of $54.58-$71.07. The chart highlights the price relative to its 200-day moving average as a reference for momentum. ETFs create or destroy units to meet investor demand, so weekly inflows can reflect changing appetite for their underlying holdings and potentially impact liquidity. Monitoring week-over-week changes in shares outstanding helps identify notable inflows or outflows that may presage shifts in holdings. Additional context on other inflows is available.

Ex-Dividend Reminder: MGRC, AYI and NVT Trade Ex-Dividend on 10/17/25

October 15, 2025, 12:33 PM EDT. On 10/17/25, MGRC, AYI and NVT go ex-dividend. McGrath RentCorp will pay a quarterly dividend of $0.485, Acuity Inc $0.17, and nVent Electric PLC $0.20. Using MGRC's recent price of $116.70, the ex-dividend move implies about 0.42% lower opens for MGRC, with AYI near 0.05% and NVT around 0.20% lower, all else equal. Current annualized yields shown are approximately 1.66% for MGRC, 0.19% for AYI, and 0.80% for NVT. Dividends are not guaranteed; review historical dividend stability to gauge ongoing yield. In intraday trade, MGRC + 1.1%, AYI + 0.8%, NVT + 0.1%.

EOG Resources Ex-Dividend: $0.91 Quarterly Payout, 2.82% Yield

October 15, 2025, 12:32 PM EDT. EOG Resources, Inc. (EOG) is scheduled to trade ex-dividend on 7/17/24, with a quarterly dividend of $0.91 payable on 7/31/24. Based on a recent price near $128.95, the payout is about 0.71% for the ex-date, and the current annualized yield is ~2.82%. The stock has traded within a 52-week range of $108.94-$139.67, with a last trade around $129.94. In Monday trading, EOG was up roughly 0.6%. As always, dividend history and price action can help gauge whether the current yield is sustainable going forward.

SM Energy Ex-Dividend $0.20 on 4/17/25; Yield Near 3.64%

October 15, 2025, 12:31 PM EDT. SM Energy Co. (SM) is set to go ex-dividend on 4/17/25, with a quarterly dividend of $0.20 payable on 5/5/25. At a recent price around $21.96, the yield is about 0.91% on the ex-date and an annualized yield near 3.64%. The shares last traded around $21.85, within a 52-week range of $19.67-$51.94. The chart compares SM's performance to its 200-day moving average, with Tuesday trading showing the stock up roughly 1%. Expect modest price pressure on the ex-date, all else equal, as investors assess income against near-term setup.

Ex-Dividend Reminder: CL, WSM and CBRL Trade Ex-Dividend on 10/17/25

October 15, 2025, 12:30 PM EDT. On 10/17/25, three names in our Dividend Channel coverage-Colgate-Palmolive (CL), Williams-Sonoma (WSM) and Cracker Barrel Old Country Store (CBRL)-go ex-dividend. CL will pay a quarterly dividend of $0.52 on 11/14/25, WSM $0.66 on 11/21/25, and CBRL $0.25 on 11/12/25. At current prices, CL's payout implies about a 0.66% decline, WSM about 0.35%, and CBRL around 0.60%, all else equal. The implied annualized yields are roughly 2.65% for CL, 1.38% for WSM, and 2.42% for CBRL. Viewers can review dividend histories to gauge sustainability and potential consistency of future payments.

Reaves Utility Income Fund (UTG) Ex-Dividend on 11/15/24; $0.19 Monthly Dividend

October 15, 2025, 12:29 PM EDT. Reaves Utility Income Fund (UTG) is set to trade ex-dividend on 11/15/24 with a monthly dividend of $0.19, payable 11/29/24. At a recent price around $33.67, this payout equates to about 0.56%. The current estimated yield is 6.77% annually. The stock's 52-week range spans $25.26 to $33.72, with the last trade near $33.68. UTG was up roughly 0.5% on the day, reflecting ongoing demand for monthly dividend stocks. History suggests the dividend is worth watching to gauge whether the latest payout is likely to continue.

Quaker Houghton (KWR) Ex-Dividend Reminder and Yield Update

October 15, 2025, 12:28 PM EDT. Quaker Houghton (KWR) goes ex-dividend on 10/17/25 with a quarterly payout of $0.508 per share, payable 10/31/25. At a recent price around $131.49, the dividend equates to about 0.39% of the share price, or roughly a 1.55% annual yield when annualized. While dividends can vary, the historical context helps gauge the likelihood of continued payments. The stock trades near its 52-week range low of $95.91 and high of $180.965, with last trade around $131.88. In today's session, KWR is up about 1.5%. For investors, consider how the ex-dividend date and yield fit your income strategy and risk tolerance.

Ex-Dividend Reminder: Revvity, Dime Community Bancshares and TD SYNNEX

October 15, 2025, 12:27 PM EDT. On 10/17/25, Revvity (RVTY), Dime Community Bancshares (DCOM) and TD SYNNEX (SNX) go ex-dividend. Revvity pays $0.07 quarterly on 11/7/25 (~0.08% of a $91.04 price). Dime Community Bancshares pays $0.25 on 10/24/25 (~0.82%). TD SYNNEX pays $0.44 on 10/31/25 (~0.28%). Expect slight price dips at open for each stock reflecting the ex-dividend drop; annualized yields are ~0.31% for Revvity, 3.30% for Dime Community, and 1.14% for TD SYNNEX. Wednesday trading shows modest gains in RVTY (~0.1%), DCOM (~3.6%), SNX (~0.5%).

U.S. Stocks Rally on Strong Earnings; Banks Lift Indices as Tech, Gold, and Semiconductors Rally

October 15, 2025, 12:26 PM EDT. U.S. stocks jumped midweek after upbeat earnings from Morgan Stanley and Bank of America helped lift the major indices. The Nasdaq climbed about 1.3%, the S&P 500 added around 1.0%, and the Dow rose roughly 0.6%, with each index pulling back from session highs. Gains were broad, supported by solid results from financials and strength in ASML on expectations of higher 2026 sales. Abbott tacked lower on softer revenues. Traders watched for comments from President Trump on U.S.-China trade and digested the New York Fed's October manufacturing activity revival, which turned positive after a September slump. Sub-indices showed notable leadership from gold stocks and semiconductors, while overseas markets traded mixed amid a global risk appetite.

Insider Buy: Concentrix CEO Purchases 1,000 CNXC Shares at $45.35

October 15, 2025, 12:25 PM EDT. In a notable insider move, Concentrix CEO Christopher A. Caldwell bought 1,000 shares of CNXC on Friday at $45.35 per share, for a total of $45,350. The stake is modestly profitable year-to-date, with the position up about 1.2% from the cost as the stock trades near the day's high of $45.89. The stock was up about 2.2% on Wednesday. Caldwell previously purchased CNXC on two occasions in the past 12 months, totaling $93,435 at an average of $46.72 per share. Investors should weigh insider activity with broader fundamentals and price action; one purchase does not guarantee future gains, but it signals confidence from management.

CHDN December 2026 Options: YieldBoost Highlights $85 Put and $95 Call

October 15, 2025, 12:24 PM EDT. CHDN options for the December 2026 expiration are now available. The $85 put currently bids around $8.00, which, if sold to open, implies a cost basis near $77 and about a 4% discount to the current price. The odds of the put expiring worthless are about 66%, with a YieldBoost potential of roughly 9.41% on cash and 8.01% annualized. On the call side, the $95 call bids around $9.50; if you own CHDN at about $88.09 and sell to open, that covered call could yield about 18.63% if called away at expiration. Stock Options Channel tracks these odds and includes trailing-12-month charts to aid evaluation of fundamentals and risk.

Notable DIA ETF Outflow Detected; SHW, TRV, MMM in Focus

October 15, 2025, 12:23 PM EDT. Weekly look at ETF share activity highlights a notable outflow from the DIA ETF, with an estimated $254.5 million decline, about 0.6% WoW (86,742,867 to 86,192,867 shares). Among DIA's top holdings, SHW is up ~0.2%, TRV down ~1.9%, and MMM up ~1.7%. The chart shows a 52-week range of $366.32-$470.38, with a last price of $466.44. The 200-day moving average is a referenced technical level mentioned. The article notes that ETF flows can reflect unit creation/destruction and impact underlying holdings. For more detail, readers can view the full DIA holdings.

SPTI Sees Large Inflows as Outstanding Units Rise 2.4% WoW

October 15, 2025, 12:22 PM EDT. SPDR Portfolio Intermediate Term Treasury ETF (SPTI) posted large inflows this week, with an estimated $139.1 million into its shares, a 2.4% week-over-week rise in outstanding units (from 208.3 million to 213.2 million). The data, drawn from ETF Channel, highlights how new units are created to meet investor demand, potentially impacting the ETF's underlying holdings. As for price action, SPTI traded around $28.39 latest, within its 52-week range of $27.0107 to $28.72. The chart comparison to the 200-day moving average suggests the last trade sits near that benchmark. The inflow signal adds to the narrative of steady demand for intermediate-term Treasuries via this ETF.

IYR ETF Sees $142.8M Outflow; WELL, PLD, EQIX Move

October 15, 2025, 12:21 PM EDT. ETF Channel flags a notable week-over-week outflow in the iShares U.S. Real Estate ETF (IYR): about $142.8 million, a 3.8% drop in shares outstanding (from 39.45M to 37.95M). Among IYR's largest components, WELL is up ~1.3%, PLD ~4.5%, and EQIX ~0.5% today. IYR's 52-week range runs from $81.53 to $103.46, with a last trade near $96.52. Traders may also monitor the ETF's relationship to its 200-day moving average as a quick technical check.

USO Sees Large Inflows: $172.8M Week-Over-Week Rise in Outstanding Units

October 15, 2025, 12:20 PM EDT. USO, the United States Oil Fund ETF, posted notable inflows this week, with an estimated $172.8 million rise in outstanding units-a 16.4% WoW increase from 12,823,603 to 14,923,603. The move underscores renewed demand for the oil proxy and may require additional underlying purchases as new units are created. The current quote trades near $80.99, inside a 52-week range of $60.67-$84.58, and traders often evaluate price against the 200-day moving average for momentum. The report also references other ETFs with inflows, illustrating broader ETF-portfolio flows to start the period.

Notable ETF Outflow Detected in HYG (iBoxx $ High Yield)

October 15, 2025, 12:19 PM EDT. Week-over-week, the iShares iBoxx $ High Yield Corporate Bond ETF (HYG) shows a notable outflow: roughly $298.5 million, about a 2.0% drop in shares outstanding (196.4M to 192.4M). The chart compares HYG's price with its 200-day moving average, with a 52-week range of $70.40 to $77.34 and a last trade near $74.74. As with ETFs, units can be created or destroyed, and large flows can affect the underlying holdings. For context, see which 9 other ETFs experienced notable outflows.

Notable ETF Outflow in AVLV; UNP, VZ, GM in Focus

October 15, 2025, 12:18 PM EDT. AVLV saw a notable week-over-week outflow of about $193.5 million, a 2.3% drop from 118.3 million to 115.6 million outstanding units. Among AVLV's top holdings, UNP is up about 0.1%, VZ down about 0.2%, and GM higher by about 1.3%. The ETF's price context shows a 52-week range of $55.67 to $73.01, with a last trade near $72.29, and emphasis on the 200-day moving average as a comparative benchmark. The piece explains ETF unit creation/destruction mechanics: outflows can require selling underlying holdings. A holdings list link is provided, and readers are directed to other ETFs with notable outflows.

SRLN ETF Outflow Alert: $801.5M Exit Drives 11.8% WoW Decline

October 15, 2025, 12:17 PM EDT. Evidence shows SRLN saw an approximate $801.5 million outflow this week, a 11.8% week-over-week drop from 164,250,000 to 144,900,000 shares. The SPDR Blackstone Senior Loan ETF remains trading near its 52-week low/high of $40.71 / $42.15 with a last price of $41.50. The chart highlights the stock's relationship to the 200-day moving average, a common tool for assessing trend. ETF flows track creation/destruction of units, so sizable outflows can reflect shifting demand and may influence the fund's underlying holdings. Additional context on other outflows and market commentary may be found in related notes.

XLP ETF Outflow: $300.6M Weekly Decline, WMT Higher, PG/MO Mixed

October 15, 2025, 12:16 PM EDT. ETF Channel flags a notable outflow from the Consumer Staples Select Sector SPDR Fund (XLP) of about $300.6 million, a 1.9% week-over-week decline (shares outstanding: 202,721,809 to 198,921,809). Among XLP's top components, Walmart (WMT) is up about 2.1%, Procter & Gamble (PG) down about 0.3%, and Altria (MO) up about 0.2%. The fund's 52-week range runs roughly $75.61-$84.35 with the latest trade near $79.56. A look at the 200-day moving average provides a rough technical context. See full holdings and other outflow notes linked in the report.

FDN Leads ETF Inflows as CSCO, RBLX, SNOW Drive Notable Component Moves

October 15, 2025, 12:15 PM EDT. ETF Channel data show a standout week for FDN: an approximate $167.2 million inflow and a 2.2% rise in outstanding units to 27,600,002 from 27,000,002. Among FDN's top holdings, CSCO is up about 2.2%, RBLX up about 5%, and SNOW higher by roughly 0.7% today. A full list of holdings is linked in the report. The chart contrasts FDN's price with its 200-day moving average, noting a 52-week range of $191.37 to $287.81 and a last trade near $282.17. Traders often compare the price to the 200-day moving average as a technical signal. See the full inflow roundup for nine other ETFs with notable flows.

JPMorgan Active Bond ETF JBND Sees $206.9M Inflow, 6% WoW Increase

October 15, 2025, 12:14 PM EDT. JBND, JPMorgan's Active Bond ETF, posted a $206.9 million inflow, a 6.0% week-over-week rise in outstanding units (from 63,550,000 to 67,350,000). The latest price trades near $54.50, within the 52-week range: $51.645-$54.605. The chart highlights the ETF's relation to its 200-day moving average, a common technical gauge. Increased unit creation reflects investor demand, which can influence underlying holdings as managers adjust exposure. This inflow sits within ETF Channel's broader flow notes, with additional inflows noted for other ETFs in the space.

Citigroup Stock Forecast 2025-2030: Analyst Targets, Technical Outlook and Market Trends

October 15, 2025, 12:13 PM EDT. Citigroup shares drifted near session lows as banking-sector weakness persisted ahead of Q3 results. Trading volumes stayed elevated amid expectations that investment banking activity could support fees after a summer M&A rebound. A firmer U.S. dollar and Fed signals for rate cuts frame the backdrop, with the central bank having cut to 4.0%-4.25% in September. Analyst targets vary: Evercore ISI at $87, UBS at $100, Wells Fargo at $125, and Morgan Stanley at $129, with consensus around $100-$125 for the next 12 months. Elevated optimism hinges on restructuring progress, though investors remain mindful of execution risks. Citigroup traded about $93.68 on Oct 13, 2025, showing a neutral-to-bearish technical setup: trading below key SMAs but above longer-term supports; momentum remained moderate.

Experts' Top 4 Predictions for 2026 Stock Market and What They Mean for Investors

October 15, 2025, 12:12 PM EDT. Experts foresee a mixed 2026 for stocks: volatility persists as tariffs keep inflation pressure high, while the Fed signals two more rate cuts could spur activity. Unemployment trends and inflation remain the key drivers; lower rates could lift equities but are not a guarantee, and a sharp correction remains plausible if growth falters or inflation expectations unanchor. Inflation and tariff policies threaten consumer spending, especially in consumer-driven sectors. AI and tech remain a focus, with continued investment in data centers and energy infrastructure potentially supporting long-term growth, even as some analysts warn of a AI bubble and stretched valuations. Investors should balance opportunities with elevated risk and watch policy moves, unemployment, and inflation data into 2026.

Bessent: Stock drop won't trigger US-China talks; rare earth policy spurs coordinated response

October 15, 2025, 12:11 PM EDT. US Treasury Secretary Scott Bessent said the stock market's decline won't force the administration into concessions with Beijing amid US-China tensions. He framed negotiations as driven by national economic interests, not market moves. Bessent also forecast a coordinated global response to China's restrictions on rare earth minerals exports, promising cooperation with the US's allies-Europe, Australia, Canada, India and other democracies. He noted foreign firms would still need approval for exports containing trace rare earths. The remarks came at a CNBC-hosted forum in Washington ahead of IMF/World Bank meetings.

Stock Futures Rise as Banks Beat, Beige Book in Focus Amid Shutdown

October 15, 2025, 12:09 PM EDT. Stock futures edged higher as investors digest earnings from banks and watch trade tensions with China. Nasdaq futures +1%, S&P 500 +0.8%, Dow +0.5% in early trading, while gold hits a fresh record above $4,210 an ounce and Bitcoin trades near $112k. The 10-year yield sits around 4.02%. Bank of America and Morgan Stanley topped expectations on revenue and EPS, extending a run of solid bank data even as executives flag macro risks amid tariffs and asset prices. ASML Holding gains after a stronger-than-expected quarterly print, and Stellantis plans a $13 billion push into U.S. production. All eyes turn to the Fed Beige Book at 2 p.m. ET as CPI data is delayed by the ongoing government shutdown; traders await guidance ahead of the next policy meeting.

Nscale Lands Up To $14B Microsoft Deal, Accelerating IPO Push

October 15, 2025, 12:08 PM EDT. UK AI infrastructure upstart Nscale has landed a deal with Microsoft valued at up to $14 billion, signaling rapid scale in the AI data-centre race and fueling an IPO push by late 2026. The pact covers about 104,000 Nvidia GB300 GPUs in a Texas data centre over 12-18 months, plus 12,600 GPUs for its Start Campus in Portugal, building on a $6.2 billion contract in Norway. Fresh funding of around $1.1 billion, led by Aker, values the company near $3 billion. Backers include Nvidia, Dell, Nokia, and Fidelity. In the UK, £2-£2.5 billion of data-centre investment is planned, including a greenfield site in Loughton, Essex with 50 MW (expandable to 90 MW), live in Q4 2026. Execution and power-supply risks loom for the IPO plan.

US stocks rally as earnings season kicks off; Powell signals rate cuts on horizon

October 15, 2025, 12:07 PM EDT. US equities advanced on Wednesday after a solid start to earnings season, with the Dow up about 0.4%, the S&P 500 up ~0.7%, and the Nasdaq higher by ~1%. Bank of America posted a 23% jump in profit, while Morgan Stanley surged 45%, with PNC Financial and Abbott Laboratories on the morning docket. Positive surprises from ASML and LVMH supported sentiment, aided by Fed Chair Jerome Powell's remarks hinting at lower rates as downside employment risks rise. Traders priced in high odds of a rate cut later this month and again in December, ahead of the Beige Book data. US-China trade tensions and the looming government shutdown add uncertainty, while gold and silver climb to fresh highs.

State Street Stock Forecast 2025-2030: Analysts See Custody Growth Amid Margin Pressure

October 15, 2025, 12:04 PM EDT. State Street has posted a mixed performance as earnings season unfolds for major banks. The Mizuho offshore custody acquisition adds about $580bn in assets under custody and supports a case for custody-related growth, though fee income growth remains challenged by competitive pressures and costs. With the Q3 2025 earnings looming (Oct 17), analyst targets span a wide range: BoA remains sell, RBC is hold near $125, Goldman raises to $130 with a buy, KBW to $132 with an outperform, and Morgan Stanley to $162 with an overweight. Overall, forecasts sit in roughly $125-$162, reflecting growth from custody/assets and higher rates, but tempered by margin pressure and rate sensitivity. Long-term calls are uncertain and hinge on policy paths.

NVIDIA Stock (NVDA) Wins Street-High $320 Price Target as Top HSBC Analyst Sees 'Big AI Upside'

October 15, 2025, 12:01 PM EDT. HSBC's top analyst Frank Lee upgraded NVIDIA (NVDA) to Buy and lifted its price target to $320, the street's high, about 78% above the close of $180. He points to a faster-growing AI data-center business, broader GPU demand, and rising output, with FY27 revenue pegged at $351 billion (up 36% vs consensus) and EPS of $8.75. Lee says the AI GPU market is expanding beyond cloud giants to large-scale projects, potentially delivering hundreds of billions in sales in coming years, and sees TSMC GPU production near 700,000 wafers in FY2027 (up 140%). China risk persists, but a 2026 rebound could lift sales. TipRanks shows a Strong Buy with roughly $225 average target, about a 25% upside.

Pixelworks to Sell Shanghai Subsidiary to VeriSilicon for RMB 950 Million; PXLW Shares Fall Over 32%

October 15, 2025, 11:58 AM EDT. Pixelworks announced a definitive agreement to sell its controlling interest in Pixelworks Semiconductor Technology (Shanghai) Co., Ltd. to a VeriSilicon-led SPV for RMB 950 million. The deal includes a release of certain repurchase rights, with Pixelworks expected to receive about $50-$60 million in cash on closing, which the company expects by the end of 2025. CEO Todd DeBonis framed the sale as an optimal path to unlock value for Pixelworks and its Shanghai shareholders. In trading, PXLW fell sharply, down about 32% to roughly $10.12 on the Nasdaq at the time of reporting.

UNP Factor-Based Stock Analysis: Buffett-Inspired Validea Review

October 15, 2025, 11:57 AM EDT. UNP is ranked highest by Validea's Warren Buffett-oriented Patient Investor model among 22 guru strategies. The rating is 75%, with higher scores typically indicating greater interest (80%+ and 90%+ signal stronger interest). The detailed analysis shows: EARNINGS PREDICTABILITY: PASS, DEBT SERVICE: PASS, RETURN ON EQUITY: PASS, RETURN ON TOTAL CAPITAL: PASS, FREE CASH FLOW: PASS, USE OF RETAINED EARNINGS: FAIL, SHARE REPURCHASE: PASS, INITIAL RATE OF RETURN: PASS, EXPECTED RETURN: PASS. As a large-cap growth stock in the Railroads industry, UNP's Buffett-based metrics emphasize long-term profitability and reasonable debt levels. Overall, the model suggests some interest, with a note that a higher score would indicate stronger conviction.

PG: Procter & Gamble Tops Partha Mohanram's P/B Growth Model (88% Score)

October 15, 2025, 11:56 AM EDT. Procter & Gamble (PG) earns a high signal under Partha Mohanram's P/B Growth Investor model, a growth screen focused on low book-to-market stocks with durable earnings. Validea reports PG scoring 88% on this approach, suggesting the stock merits investor attention. The model flags a mix of strengths and weaknesses: BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, ROA VARIANCE: PASS, SALES VARIANCE: PASS, ADVERTISING TO ASSETS: PASS, CAPITAL EXPENDITURES TO ASSETS: PASS, but RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. The result points to solid fundamentals and favorable valuation, though growth drivers may be tempered by R&D intensity. In short, PG shows notable alignment with the model's growth criteria, potentially placing it on the radar of growth-focused portfolios.

BKNG Factor-Based Stock Analysis: Pim van Vliet's Low-Volatility Momentum Signal for Booking Holdings

October 15, 2025, 11:55 AM EDT. Validea's guru analysis for Booking Holdings Inc. (BKNG) follows Pim van Vliet's conservative, multi-factor approach, prioritizing low volatility with momentum and favorable payout signals. The summary table shows: MARKET CAP: PASS, STANDARD DEVIATION: PASS, TWELVE MINUS ONE MOMENTUM: NEUTRAL, NET PAYOUT YIELD: NEUTRAL, FINAL RANK: PASS. BKNG is a large-cap growth stock in the Personal Services industry, and the analysis assigns a 100% score based on fundamentals; 80%+ typically signals interest and 90%+ signals strong interest. In short, the model emphasizes stability, momentum, and payout signals, though momentum and payout remain neutral in this instance.

PDD Holdings: Motley Fool Small-Cap Growth Strategy Rates PDD at 68%

October 15, 2025, 11:54 AM EDT. Validea's Guru Analysis for PDD HOLDINGS INC – ADR (PDD) shows a 68% rating from the Motley Fool's Small-Cap Growth Investor model, suggesting solid fundamentals and price momentum but several headwinds. Key takes: Profit Margin and Cash Flow from Operations are PASS, as are Profit Margin Consistency, Cash and Cash Equivalents, Inventory to Sales, Accounts Receivable to Sales, and the Long-Term Debt/Equity Ratio. Detractors include The Fool Ratio (P/E to Growth), Sales, Insider Holdings, Daily Dollar Volume, and Income Tax Percentage. R&D as a % of Sales is Neutral; Average Shares Outstanding is PASS. Overall, the score signals mixed signals with moderate interest from this strategy.

APLD Factor-Based Stock Analysis: Validea's Quant Momentum Signals 77% Rating

October 15, 2025, 11:53 AM EDT. Validea's guru-based review spots APLD (Applied Digital Corp) as a top pick under Wesley Gray's Quantitative Momentum framework. Among 22 guru strategies, APLD rates highest on this model, driven by its intermediate-term relative strength and consistent performance. The stock is categorized as a mid-cap growth name in the Computer Services industry. The model assigns a 77% rating based on fundamentals and valuation; historically, a score of 80% signals some interest and above 90% signals strong interest. The included universe and momentum checks weigh factors like return consistency and seasonality, though not all criteria carry equal weight. The analysis is anchored by Gray's approach from Alpha Architect, which emphasizes momentum signals and disciplined stock selection. Note: Validea's team also provides context on Wesley Gray's background and the broader guru framework.

RBLX Factor-Based Stock Analysis: Partha Mohanram Growth Model

October 15, 2025, 11:52 AM EDT. Validea's Partha Mohanram P/B Growth Investor model flags Roblox Corp (RBLX) as a growth-oriented idea with a 55% rating, signaling some interest but not a strong conviction. The model seeks low book-to-market stocks with signs of sustained future growth. Key tests show: BOOK/MARKET RATIO pass; RETURN ON ASSETS fail; CASH FLOW FROM OPERATIONS TO ASSETS fail; ROA variance pass; SALES VARIANCE fail; ADVERTISING TO ASSETS fail; CAPITAL EXPENDITURES TO ASSETS pass; RESEARCH AND DEVELOPMENT TO ASSETS pass. Overall is mixed: stronger signals in asset deployment and growth inputs (R&D, capex) but weaker profitability and operating cash flow metrics. The analysis reflects Mohanram's framework for separating potential winners from losers among low book-to-market stocks.

AST SPACEMOBILE (ASTS) Factor-Based Stock Analysis – Motley Fool Growth Signals in Validea Model

October 15, 2025, 11:51 AM EDT. AST SPACEMOBILE Inc (ASTS) is flagged by Validea's small-cap growth model using Motley Fool's published strategy. The stock shows a 59% rating under the Small-Cap Growth Investor framework, suggesting modest interest based on fundamentals and valuation; a score above 80% usually signals interest, and above 90% signals strong interest. The guru table reveals mixed results: Profit Margin: Fail, Relative Strength: Pass, Insider Holdings: Pass, Cash Flow From Ops: Fail, Profit Margin Consistency: Pass, R&D % of Sales: Neutral, Cash & Equivalents: Pass, Long-Term Debt/Equity: Fail, The Fool Ratio (P/E to Growth): Fail, Sales: Pass, Daily Dollar Volume: Fail, Price: Pass, Income Tax %: Fail. ASTS is categorized as a mid-cap growth stock in Communications Services. Overall, the model indicates cautious interest with several red flags amid a mixed fundamentals picture.

WBD Momentum-Based Stock Analysis Signals High Gray Framework Interest

October 15, 2025, 11:50 AM EDT. Warner Bros Discovery (WBD) earns a strong Quantitative Momentum rating from Validea's Wesley Gray framework, scoring 94% and signaling notable interest from the model. As a large-cap growth stock in the Motion Pictures group, WBD shows solid intermediate-term relative performance and a favorable momentum signal. The assessment highlights strengths in momentum, return consistency, and other Gray criteria, while noting universe screening and seasonality considerations. An above-90% score suggests notable interest from this strategy, but investors should still weigh valuation, sector dynamics, and the inherent risks of momentum-based approaches.

Shopify (SHOP) Zweig Growth Investor Score 77%: P/E Limitation, Earnings Momentum Intact

October 15, 2025, 11:49 AM EDT. Validea's Growth Investor model (based on Martin Zweig) rates Shopify Inc (SHOP) as a large-cap growth stock in Business Services, with a 77% score. The framework seeks persistent accelerating earnings and sales growth, with reasonable valuation and modest debt. Key readouts: P/E ratio = FAIL; revenue growth in relation to EPS growth = PASS; sales growth rate = PASS; current quarter earnings = PASS; quarterly earnings one year ago = PASS; positive earnings growth rate for current quarter = PASS; earnings growth rate for the past several quarters = PASS; EPS growth for current quarter > prior 3 quarters = PASS; EPS growth vs historical growth rate = PASS; earnings persistence = FAIL; total debt/equity ratio = PASS; insider transactions = PASS. Overall, solid fundamentals with momentum, but watch the valuation and earnings persistence.

ACN Factor-Based Stock Analysis: Buffett-Inspired Validea Rating for Accenture PLC

October 15, 2025, 11:48 AM EDT. Validea's guru fundamental report rates ACCENTURE PLC (ACN) highest among 22 guru strategies under the Patient Investor framework. ACN earns 85% based on fundamentals and valuation, with a threshold of 80% signaling interest and 90% signaling strong interest. Key positives across tests include EARNINGS PREDICTABILITY, DEBT SERVICE, RETURN ON EQUITY, RETURN ON TOTAL CAPITAL, FREE CASH FLOW, and INITIAL RATE OF RETURN all passing. Use of RETAINED EARNINGS and EXPECTED RETURN also pass; SHARE REPURCHASE is Neutral. ACN is positioned as a large-cap growth stock in the Computer Services industry, characterized by long-term profitability and moderate debt. Investors should note that this summary reflects the guru model's framework and is not a standalone recommendation.

Pfizer (PFE) Tops Validea's Greenblatt Earnings Yield Strategy

October 15, 2025, 11:47 AM EDT. Validea's guru fundamental report for Pfizer (PFE) shows the stock scoring highest across 22 guru strategies under the Earnings Yield Investor model inspired by Joel Greenblatt. The approach seeks high return on capital and earnings yield to identify value plays. Pfizer is categorized as a large-cap value stock in the Biotechnology & Drugs industry, with a 100% rating under this strategy and a typical signal that scores above 90% indicate strong interest. The summary notes a neutral reading on Earnings Yield and Return on Tangible Capital, with a Pass final ranking. Validea's analysis links to the classic Greenblatt Magic Formula framework, emphasizing fundamental valuation over market timing.

SNPS Factor-Based Growth Review: Mixed Zweig Signals, 46% Rating

October 15, 2025, 11:46 AM EDT. SYNOPSYS INC (SNPS) is evaluated by Validea's Growth Investor model based on Martin Zweig's strategy. The stock shows mixed signals: earnings and sales have some growth momentum, but key momentum checks fail. The rating is 46%, below the typical high-interest threshold, signaling only modest interest from the Zweig framework. Positive points include: earnings persistence, long-term EPS growth, total debt/equity ratio, and insider transactions. Negatives include: P/E ratio failure, revenue growth relative to EPS growth, EPS growth consistency across quarters, and the need for current-quarter EPS to exceed prior quarters. Overall, SNPS appears as a large-cap growth stock with selective strengths and several growth-readiness caveats under the Zweig model.

ABBVIE Inc. Scores 77% Under Partha Mohanram P/B Growth Investor Model

October 15, 2025, 11:45 AM EDT. ABBVIE INC (ABBV) scores 77% under Validea's Partha Mohanram P/B Growth Investor model, signaling some interest but not a high-conviction buy. The model targets low book-to-market stocks with traits linked to sustained growth. Highlights: BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, ROA VARIANCE: PASS, SALES VARIANCE: PASS, ADVERTISING TO ASSETS: PASS. Notably, CAPITAL EXPENDITURES TO ASSETS: FAIL and RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. ABBVIE is a large-cap growth stock in the Biotechnology & Drugs industry. A score above 90% would indicate strong interest; at 77%, the model shows moderate interest with some caveats about asset-intensive investments. This snapshot illustrates how Mohanram's framework differentiates growth signals from the amount of investment.

PNC Financial Services Group Q3 2025 Earnings Conference Call at 11:00 AM ET

October 15, 2025, 11:44 AM EDT. PNC Financial Services Group Inc. will host a Q3 2025 earnings conference call at 11:00 AM ET on October 15, 2025, to discuss quarterly results and outlook. Management will review key drivers and provide forward-looking guidance, with a Q&A session for analysts. Access the live webcast via the investor relations page at https://investor.pnc.com/news-events/events-presentations. Note: the views expressed are those of the author and do not necessarily reflect those of Nasdaq, Inc.

Apple Unveils M5 AI-Accelerated Chips for MacBook Pro, iPad Pro, and Vision Pro

October 15, 2025, 11:43 AM EDT. Apple unveils the M5, its AI-optimized system on a chip, boosting performance for the 14-inch MacBook Pro, iPad Pro, and Vision Pro. The M5 features a next-generation 10-core GPU with a Neural Accelerator in each core, delivering up to 4x peak GPU compute vs M4 and up to 45% higher graphics thanks to third-generation ray tracing. It also includes a up to 10-core CPU (six efficiency cores, four performance cores), a larger 16-core Neural Engine, a robust media engine, and about a 30% jump in memory bandwidth to 153GB/s. New devices arrive with starting prices: MacBook Pro from $1,599, iPad Pro with M5, and Vision Pro with M5 starting at $3,499; pre-orders open now, stores begin Oct 22. The shift signals Apple's push in AI workflows and premium hardware ecosystems.

INTU Factor-Based Stock Analysis: Partha Mohanram Growth Model Rates INTUIT INC at 77%

October 15, 2025, 11:42 AM EDT. INTUIT INC. (INTU) earns a 77% rating from Validea's Partha Mohanram Growth Investor model, the top score among its 22 guru systems. The model seeks low book-to-market stocks with sustained growth potential and classifies INTU as a large-cap growth name in the Software & Programming space. Key test results: BOOK/MARKET RATIO: PASS, RETURN ON ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS: PASS, CASH FLOW FROM OPERATIONS TO ASSETS VS. ROA: PASS, ROA VARIANCE: PASS, SALES VARIANCE: PASS, ADVERTISING TO ASSETS: PASS, but CAPITAL EXPENDITURES TO ASSETS: FAIL and RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. A 77% rating indicates some interest but not strong conviction-scores above 90% would imply strong conviction. The note outlines how INTU aligns with or deviates from Mohanram's growth criteria.

Snowflake SNOW: Mixed Signals in Motley Fool Small-Cap Growth Model (Validea)

October 15, 2025, 11:41 AM EDT. Validea's SNOWFLAKE INC (SNOW) guru analysis shows a mixed read from the Motley Fool's Small-Cap Growth Investor model. SNOW posts a 48% score, well below the 80% threshold for interest despite the stock's large-cap growth profile. The table highlights several FAILs (Profit Margin, Relative Strength, Insider Holdings, R&D as % of Sales, Income Tax Percentage, Sales) alongside PASS signals (Compare Sales and EPS Growth YoY, Profit Margin Consistency, Cash Flow from Operations, Cash & Equivalents, Accounts Receivable to Sales, Long-Term Debt/EQUITY, Average Shares Outstanding, Price). The result suggests limited appeal within this Fool-based framework, with some positives like solid cash positioning and price strength, but multiple fundamentals holding back a stronger endorsement.

PEP Factor-Based Growth Analysis: Partha Mohanram Model Rates PepsiCo at 88%

October 15, 2025, 11:40 AM EDT. PepsiCo, Inc. (PEP) is highlighted by Validea's Partha Mohanram growth-factor model, which favors low book-to-market stocks with signs of sustained growth. The stock earns an 88% rating under this strategy, indicating notable interest from the model's criteria. Core strengths include: Book/Market ratio PASS, Return on Assets PASS, Cash Flow from Operations to Assets PASS, CFO/ROA PASS, Sales Variance PASS, Advertising to Assets FAIL, Capital Expenditures to Assets PASS, R&D to Assets PASS. The overall takeaway is that PEP shows solid fundamentals and favorable valuation per the Partha Mohanram framework, though some efficiency metrics warrant monitoring (advertising intensity). As a large-cap growth stock in the Beverages (Non-Alcoholic) group, PEP remains a potential candidate for growth-oriented portfolios with appetite for quality earnings.

CVX Factor-Based Stock Analysis: Peter Lynch P/E/Growth Signals for Chevron

October 15, 2025, 11:39 AM EDT. Validea's guru fundamental analysis for Chevron Corp (CVX) places it at the top of its Peter Lynch P/E/Growth model, rating CVX 93% based on fundamentals and valuation. The strategy seeks a stock priced right against earnings growth with a strong balance sheet. CVX is a large-cap value stock in the Oil & Gas Operations group. The table shows all key checks passing on this strategy: P/E/Growth Ratio PASS, Sales and P/E Ratio PASS, Inventory to Sales PASS, EPS Growth Rate PASS, and Total Debt/Equity PASS. A score of 80%+ signals interest, while 90%+ indicates strong interest. In short, the analysis suggests strong fit for this Peter Lynch approach, though investors should consider broader market context and other guru signals before trading.

RDDT Factor-Based Stock Analysis: Partha Mohanram P/B Growth Model Signals Mixed View

October 15, 2025, 11:38 AM EDT. Validea applies Partha Mohanram's P/B Growth model to REDDIT INC (RDDT), rating the stock 77%-indicating interest but not strong conviction. The model seeks low book-to-market names with growth signals. RDDT is described as a large-cap growth stock in Business Services. Key test highlights: Book/Market Ratio PASS; Return on Assets FAIL; Cash Flow from Operations to Assets PASS; CFO to assets vs ROA PASS; Sales Variance FAIL; Advertising to Assets FAIL; Capital Expenditures to Assets PASS; R&D to Assets PASS. A 77% score suggests the strategy sees potential but requires confirmation; scores above 80% imply some interest; above 90% strong interest. The report outlines both strengths and weaknesses under this growth framework.

CSCO Factor-Based Stock Analysis: High Rating on Pim van Vliet's Multi-Factor Model

October 15, 2025, 11:37 AM EDT. Cisco Systems Inc. (CSCO) earns a strong signal from Validea's Pim van Vliet-based multi-factor model. The strategy targets low volatility, momentum, and favorable net payout yield dynamics. CSCO scores 93%, indicating strong interest per the model's thresholds. In the strategy's tests, CSCO shows Market Cap: Pass, Standard Deviation: Pass, Momentum: Neutral, and Net Payout Yield: Neutral, with a Final Rank: Pass. As a large-cap growth stock in the Communications Equipment sector, CSCO's mix of stability and momentum is highlighted as a potential fit for conservative factor investing. The rating reflects solid fundamentals and valuation alignment under this specific framework, though individual weights and other criteria should be reviewed before any decision.

GE Factor-Based Stock Analysis: Pim van Vliet Multi-Factor Review

October 15, 2025, 11:36 AM EDT. GENERAL ELECTRIC CO (GE) appears favorably within Validea's Pim van Vliet factor model, earning an 81% score under the multi-factor approach that targets low volatility, momentum, and high net payout yield. GE is positioned as a large-cap value stock in the Aerospace & Defense sector. The test table shows: Market Cap: Pass, Standard Deviation: Pass, Twelve Minus One Momentum: Neutral, Net Payout Yield: Neutral, with a Final Rank: Fail. While the model flags solid fundamentals and valuation, the mixed momentum and payout signals keep the overall rating from crossing into strong interest. The discussion reflects van Vliet's emphasis on risk-aware investing and conservatism, and situates GE within Validea's broader guru framework for stock selection.

GS Factor-Based Stock Analysis: Goldman Sachs (GS) and the Shareholder Yield Model

October 15, 2025, 11:35 AM EDT. Validea's guru fundamental report places GOLDMAN SACHS GROUP INC (GS) at the top of its Shareholder Yield Investor model (Meb Faber). GS scores 85% on the strategy, with a score above 90% indicating strong interest. Breakdown: UNIVERSE PASS, NET PAYOUT YIELD PASS, QUALITY AND DEBT FAIL, VALUATION PASS, RELATIVE STRENGTH PASS, SHAREHOLDER YIELD PASS. The model seeks companies that return cash to shareholders via dividends, buybacks and debt paydown. As a large-cap growth stock in the Investment Services industry, GS shows solid cash-return characteristics but a notable debt/quality concern kept the overall rating below the strongest tier. Investors should weigh how the cash-return emphasis aligns with their strategy.

HD Factor-Based Stock Analysis: Pim van Vliet Multi-Factor View on Home Depot (HD)

October 15, 2025, 11:34 AM EDT. Validea's guru analysis for HOME DEPOT INC (HD) applies Pim van Vliet's low-volatility, multi-factor framework. The model targets stocks with low volatility, strong momentum, and favorable net payout yields. HD scores 81% under this strategy, indicating some interest. The table summary shows: MARKET CAP: PASS, STANDARD DEVIATION: PASS, TWELVE MINUS ONE MOMENTUM: NEUTRAL, NET PAYOUT YIELD: NEUTRAL, FINAL RANK: FAIL. HD is a large-cap growth name in the Retail (Home Improvement) sector. Although the overall score is solid, the final rank flags that this stock may not fully satisfy the strategy's criteria yet. The report emphasizes a conservative factor tilt and the balance of risk, momentum, and payout signals.

ADBE Factor-Based Stock Analysis: Pim van Vliet Low-Volatility Momentum Signals

October 15, 2025, 11:33 AM EDT. Validea's Pim van Vliet multi-factor framework spots ADBE as a leading candidate among the 22 guru strategies, combining low volatility characteristics with momentum and a cautious stance on net payout yield. The model assigns 81% to Adobe based on fundamentals and valuation, with a typical threshold of 80% for interest and 90% for strong conviction. Market-cap and standard deviation pass, while 12-month momentum is neutral and net payout yield is neutral. Despite the favorable rating, the overall final rank is failed, signaling residual concerns even as the stock shows defensive appeal within the software/growth space led by Adobe.

Snuggle expands investment in Kornit Digital's Atlas MAX PLUS and DTG platform; Kornit stock climbs pre-market

October 15, 2025, 11:32 AM EDT. Snuggle has increased its investment in Kornit Digital Ltd.'s Atlas MAX PLUS, Atlas MAX POLY, and Titan Smart Textile Dryer to scale its direct-to-garment production. Using the Atlas MAX platforms, Snuggle can now produce over 24,000 pieces daily at its Peterborough facility, as it more than tripled its production space since 2017. Akil Thathia, Director and Founder, says the partnership with Kornit is strategic to ongoing growth. In markets, Kornit stock was up more than 2% in pre-market trading after closing at $14.27 on Tuesday, up 1.35%. The investment highlights continued demand for Kornit's print-on-demand technology for online retailers and decorators.

Xero to Acquire Melio Limited for $2.5B, Targeting Accelerated US Growth

October 15, 2025, 11:31 AM EDT. Xero Limited (XRO.AX) announced the acquisition of Melio Limited, a US SMB bill-pay platform, for an upfront payment of $2.5 billion funded by cash, debt, and new Xero shares. The deal aims to consolidate cash-flow management and operations on a single platform, expanding Xero's footprint in the US and accelerating revenue growth. Xero now expects the combined business to more than double its fiscal year 2025 group revenue by fiscal year 2028. Transaction costs of NZ$52 million will be recognised in operating expenses in H1 FY2026. Xero's share price closed at AUD 157.07, up 1.66% on the ASX.

Insider Buying Surges in Vanguard Health Care ETF (VHT) Holdings; UNH Leads With Director Purchases, ILMN Also Active

October 15, 2025, 11:30 AM EDT. Inside the Vanguard Health Care ETF (VHT), about 21.3% of holdings on a weighted basis show insider buying over the past six months. The largest component, UnitedHealth Group (UNH), accounts for about 5.26% of VHT and has seen five directors and officers purchase shares in recent Form 4 filings. Notable buys include CEO Stephen Hemsley and President & CFO John Rex, among others, with aggregate insider activity topping several million dollars. UNH trades around $360 per share, and the holdings total roughly $910.7 million. The ETF's second highlight is Illumina (ILMN), a smaller position (~0.26% of assets) where two executives filed purchases totaling about $1.0 million. The data reflects ongoing insider activity across the healthcare cohort.

Surge Components Q3 Revenue Drops 71% to $2.30M; Profit $0.47M, EPS $0.08

October 15, 2025, 11:29 AM EDT. Surge Components, Inc. reported third-quarter profit of $0.47 million, or $0.08 per share, roughly flat versus last year's $0.08. Revenue fell 71.1% year over year to $2.30 million from $7.97 million. The GAAP results show earnings of $0.47 million vs $0.44 million a year ago, while EPS remained at $0.08. The large revenue decline highlights softer demand for the company's components portfolio amid a tougher market. Investors will be watching for any signs of cost containment or a rebound in top-line growth in the next quarter.

24X National Exchange Opens for 23/5 Trading, SEC-Approved Milestone in U.S. Equity Markets

October 15, 2025, 11:28 AM EDT. 24X National Exchange today announced the launch of 24X, the first SEC-approved national exchange to offer 23-hour trading of U.S. equities, from 4:00 a.m. to 8:00 p.m. ET on weekdays. The platform aims to expand access for global investors, including institutions and retail traders, by extending U.S. market hours and enabling more responsive trading around global news and economic events. Built on MEMX Technologies, the exchange emphasizes regulatory oversight, market integrity, and cost efficiency, with a UTP feed code 'G'. CEO Dmitri Galinov says the move marks a milestone toward around-the-clock access, with a planned 23/5 rollout in the second half of 2026 that would include a nightly maintenance pause. Pending approvals, the launch is described as transformational for worldwide traders seeking enhanced liquidity and flexible timing.

Argus Raises BlackRock Price Target to $1,330 with Buy Rating

October 15, 2025, 11:25 AM EDT. Argus boosted BlackRock's price target to $1,330 from $1,165 and reiterated a Buy rating, signaling about 10.15% upside from the prior close. The note follows a flurry of positive calls from peers, with Keefe, Bruyette & Woods raising to $1,300 (outperform), Deutsche Bank at $1,320 (buy) and Evercore ISI at $1,230 (outperform). JPMorgan and UBS offered more mixed views (JPM: $1,242 neutral; UBS: $980 neutral). MarketBeat shows a Moderate Buy consensus with a $1,294.19 target. In recent results, BlackRock posted $11.55 EPS on revenue of $6.51B, with a 29.68% net margin and 15.53% ROE; revenue rose 25.2% year over year. Insider Fabrizio Freda sold 4,434 shares at about $1,122.81.

Wall Street rises as banks and tech giants lead the charge

October 15, 2025, 11:24 AM EDT. Stocks rose on Wednesday after strong profit reports from major banks and technology companies. The S&P 500 climbed about 0.7%, the Dow Jones Industrial Average gained roughly 226 points (about 0.5%), and the Nasdaq composite added around 0.9%. The session followed a roller-coaster day that swung from losses to gains as investors digested quarterly results from heavyweight lenders and chipmakers. Traders anchored on earnings visibility in financials and software/AI-linked names, helping lift risk sentiment and the broader market. Despite some lingering macro questions, gains were led by the banks and tech sectors, offsetting weakness elsewhere.

Brookfield to Acquire Remaining Oaktree Stake for $3B; Close Expected in Q1 2026

October 15, 2025, 11:23 AM EDT. Brookfield Asset Management Ltd. and Brookfield Corporation announced a proposed transaction to acquire the remaining 26% stake in Oaktree for about $3 billion, enabling full integration to strengthen the firm's credit platform and expand its U.S. market presence. The deal is slated to close in Q1 2026, subject to regulatory approvals. The stock's latest rating on TSE:BAM is Hold with a C$62.00 price target. Spark's AI analyst view is Neutral; while Brookfield shows a solid financial base and strategic growth, technical indicators point to a bearish trend and a high P/E valuation. Still, the group benefits from strong liquidity and diversified exposure to infrastructure, renewables, private equity, real estate, and credit. Trading volume averages ~1.46 million; market cap is about C$124.4B; analysts see potential but expect volatility.

Community Trust Bancorp Q3 Profit Climbs, But Misses Estimates

October 15, 2025, 11:22 AM EDT. Community Trust Bancorp Inc. (CTBI) reported Q3 earnings that climbed from a year ago but missed Wall Street estimates. Net income totaled $23.91 million, or $1.32 per share, up from $22.14 million, or $1.23 per share, a year earlier. Analysts expected about $1.38 per share. Revenue rose 17.7% to $55.55 million from $47.2 million. The results show year-over-year growth in both EPS and revenue even as the company fell short of the consensus on EPS.

Novo Nordisk to acquire zaltenibart asset from Omeros in definitive deal; phase 3 plan and milestone structure

October 15, 2025, 11:21 AM EDT. In a definitive asset purchase and license agreement, Novo Nordisk (NVO) gains exclusive global rights to develop and commercialise zaltenibart for all indications, while Omeros retains certain MASP-3 preclinical programs. Omeros will receive $340 million upfront and near-term milestones and could earn up to $2.1 billion in development and commercial milestones, plus tiered royalties on net sales. Novo Nordisk plans a global Phase 3 program in paroxysmal nocturnal hemoglobinuria after closing, targeted for Q4 2025. The deal is scheduled to close in Q4 2025. In pre-market trading, NVO was around $56.25, down about 0.7%. The agreement creates a potential catalyst for Novo Nordisk while preserving MASP-3 research flexibility for Omeros.

Liberty Energy (LBRT) Valuation Review: 5% Dip, Volatility, and Potential Upside

October 15, 2025, 11:20 AM EDT. Liberty Energy (LBRT) has slipped about 5% week-to-week, revisiting its valuation debate, even as it climbs ~15% this month. After a volatile year, the stock is ~41% lower YTD, with a negative one-year total return despite recent momentum. The shares sit well below analyst targets, fueling questions about a genuine buying opportunity versus a market already pricing in a rebound. A popular narrative still argues the stock is undervalued, with a stated fair value near $14.61. The thesis hinges on steady demand for oil and gas, strategic tech advantages, and improvement in margins, but faces risks from weak oil prices and shifting sentiment. Investors should balance valuation against momentum while assessing their risk tolerance.

Globant (NYSE:GLOB) A Fresh Valuation Look After Red Sea Global Tech Partnership

October 15, 2025, 11:19 AM EDT. Globant (NYSE:GLOB) kicked off the week with a major tech win: leading the implementation of Red Sea Global's Connected Visitor Experience on Adobe platforms, signaling strength in AI-driven, tailored enterprise solutions. Yet the stock's momentum contrasts with a challenging 12-month track record: 30-day return of 6.4% but total shareholder return down 72% over the year. A popular narrative argues the stock is undervalued-about a fair value of $100.79 versus a recent close near $59.69-driven by recurring revenue, AI platforms, and high-profile partnerships (OpenAI, AWS) that could lift revenue growth and margins. Investors face a tradeoff: near-term demand softness and project timing vs. longer-term upside if the Red Sea win catalyzes durable growth and profitability.

Morgan Stanley lifts General Dynamics price target to $360, signaling ~7% upside

October 15, 2025, 11:18 AM EDT. Morgan Stanley raised its price objective on General Dynamics (NYSE: GD) from $328 to $360, while leaving an equal-weight rating and signaling an upside of ~7.3% from current levels. The note follows a string of analyst moves: TD Cowen to $300 (Buy), UBS to $333 (Neutral), Wall Street Zen to Buy, Wolfe Research to $400 (Outperform), and Susquehanna to $365 (Positive). MarketBeat shows a Consensus Hold with an average target of $327.44. GD traded around $335.52 at the open. Key metrics include a debt-to-equity of 0.32, a current ratio of 1.36, a P/E of 22.5, and a PEG of 2.06. Q2 earnings were $3.74 on $13.04B revenue; FY2025 EPS guidance is ~15.05-15.15.

Rakuten Considers US IPO for Credit Card Business as SoftBank's PayPay IPO Looms

October 15, 2025, 11:17 AM EDT. Rakuten is weighing a US IPO for its credit card unit, per Reuters, with a decision sparked by SoftBank's plan to list PayPay in the U.S. Investors have penciled in a PayPay valuation above $20 billion. Credit cards remain a core pillar of Rakuten's ecosystem, spanning online shopping, banking, and loyalty points. The group has been pushing AI across its platform to streamline applications and expand merchant capabilities. Separately, PYMNTS notes mobile wallets are reshaping card use: users still rely on cards, but prefer tap or scan for speed and security. The IPO timing will hinge on broader fintech sentiment and Rakuten's ability to monetize its AI and payments push.

Cambodia defends Prince Holding Group as U.S. and U.K. sanction Chen Zhi in global scam case

October 15, 2025, 11:16 AM EDT. Cambodia said it hopes the U.S. and U.K. have enough evidence as they sanction the Prince Holding Group and its chairman Chen Zhi in a global scam case, stressing it treats all major investors equally. Interior Ministry spokesman Touch Sokhak said the group complied with Cambodian law and that Chen's Cambodian citizenship was legal. The sanctions accuse Chen of operating a transnational fraud network, trafficking workers, bribery, and laundering profits through online gambling and crypto mining. The U.S. seized over $14B in bitcoin and charged Chen with wire fraud and money laundering; the U.K. froze Chen's assets in Britain, including a mansion and office building. Analysts warn that dismantling the online infrastructure is essential to curb rebranding, while Chen remains at large and could face up to 40 years if convicted.

CRWD: Validea Partha Mohanram P/B Growth Model Signals Strong Growth Fit

October 15, 2025, 11:15 AM EDT. CRWD's stock is rated highly by Validea's guru framework using Partha Mohanram's P/B Growth Investor model. The model favors low book-to-market stocks with signs of sustained future growth, and CRWD is a large-cap growth name in Software & Programming with an 88% rating-well above the 80% threshold signaling interest and near the 90% level indicating strong interest. The detailed tests show strengths in several metrics: BOOK/MARKET RATIO PASS, RETURN ON ASSETS PASS, CASH FLOW FROM OPERATIONS TO ASSETS PASS, RETURN ON ASSETS VARIANCE PASS, SALES VARIANCE PASS, CAPITAL EXPENDITURES TO ASSETS PASS, and RESEARCH AND DEVELOPMENT TO ASSETS PASS. A notable caveat is ADVERTISING TO ASSETS FAIL, a potential weakness to monitor alongside the stock's growth orientation.

Walmart (WMT) Pim van Vliet Multi-Factor stock analysis signals Moderate Interest

October 15, 2025, 11:14 AM EDT. Validea's Pim van Vliet multi-factor assessment flags Walmart (WMT) as a high-score large- cap growth pick in Retail (Grocery). The model prioritizes low volatility stocks alongside momentum and net payout yield considerations. WMT posts an overall score of 87%, with the following tests: MARKET CAP: PASS; STANDARD DEVIATION: PASS; TWELVE MINUS ONE MOMENTUM: NEUTRAL; NET PAYOUT YIELD: NEUTRAL; FINAL RANK: PASS. A score of 80%+ indicates some interest, while above 90% signals strong interest. At 87%, Walmart shows notable interest but not the strongest endorsement among the lineup. Investors should factor in this conservative factor signal with fundamentals and other factors before trading.

Mastercard MA Stock: Buffett-Style Patient Investor Analysis (Validea)

October 15, 2025, 11:13 AM EDT. Validea's guru fundamental report rates Mastercard (MA) highly under the Warren Buffett-based Patient Investor model. Among 22 guru strategies, MA scores 100%, signaling strong interest from this approach that values long-term, predictable profits and conservative balance sheets. Mastercard is described as a large-cap growth stock in the Consumer Financial Services group. The Buffett-based tests show EARNINGS PREDICTABILITY, RETURN ON EQUITY, RETURN ON ASSETS, FREE CASH FLOW, USE OF RETAINED EARNINGS, SHARE REPURCHASE, INITIAL RATE OF RETURN, and EXPECTED RETURN all PASS. The summary notes a focus on long-run profitability, manageable debt, and reasonable valuation. Overall, the analysis positions MA as a potential long-hold idea for investors seeking quality, durable profitability and supportive capital allocation signals, per Validea's Buffett portfolio framework.

BA Factor-Based Stock Analysis: Pim van Vliet Framework Signals Mixed for Boeing (BA)

October 15, 2025, 11:12 AM EDT. Validea's guru-factor view for Boeing Co (BA) centers on Pim van Vliet's factor framework, which combines low volatility, momentum, and net payout yield within a conservative approach. BA is categorized as a large-cap growth stock in Aerospace & Defense. The overall rating is 75% (fundamentals and valuation), meaning modest interest rather than strong conviction (80%+ signals notable interest; 90%+ signals strong interest). In the criterion table: market cap: PASS, standard deviation: PASS, twelve-minus-one momentum: NEUTRAL, net payout yield: NEUTRAL, and the FINAL RANK: FAILED. The result suggests solid fundamentals but mixed momentum/payout signals temper enthusiasm under this model.

MP Materials Corp (MP): Momentum Signal Under Wesley Gray Quantitative Momentum Model

October 15, 2025, 11:11 AM EDT. Validea's guru fundamental report rates MP MATERIALS CORP (MP) highly on the Wesley Gray Quantitative Momentum model. Among 22 guru strategies, MP shows the strongest signal under this momentum approach, driven by the stock's intermediate-term relative performance. The model assigns a 72% rating, indicating meaningful investor interest though not at the highest level. MP is described as a large-cap growth stock in the Metal Mining industry. The report notes that 80%+ typically signals some interest and 90%+ signals strong interest. While not all tests weigh the same, the overall momentum signal supports a favorable view for investors using quantitative momentum strategies.

Caterpillar CAT Factor-Based Stock Analysis: Pim van Vliet Strategy Signals Strong Interest

October 15, 2025, 11:10 AM EDT. Validea's guru-based review flags Caterpillar (CAT) as a top pick under the Pim van Vliet-inspired Multi-Factor Investor model. The approach targets low-volatility stocks with solid momentum and favorable net payout yield. CAT scores 93% under this framework, with a final rank of PASS and strong fundamentals/valuation. The stock clears key screens for Market Cap and Standard Deviation, while Momentum and Net Payout Yield are Neutral. This places CAT in the range where 80%+ is considered of interest, and 90%+ signals strong interest. The report notes CAT as a large-cap growth stock in Construction & Agricultural Machinery and highlights the model's conservative, low-risk factor emphasis.

ROCKET LAB (RKLB) Factor-Based Stock Analysis: Partha Mohanram Growth Model

October 15, 2025, 11:09 AM EDT. ROCKET LAB USA INC (RKLB) is evaluated by Validea using the Partha Mohanram P/B Growth Investor model, which favors low book-to-market stocks with sustained growth. RKLB is a mid-cap growth stock in the Aerospace & Defense sector. The model assigns a 55% rating, indicating some interest rather than strong conviction (80%+ or 90%+ would indicate higher interest). In the detailed criteria, RKLB shows mixed signals: BOOK/MARKET RATIO: PASS; RETURN ON ASSETS: FAIL; CASH FLOW FROM OPERATIONS TO ASSETS: FAIL; CASH FLOW FROM OPERATIONS TO ASSETS VS. ROA: PASS; ROA VARIANCE: PASS; SALES VARIANCE: FAIL; ADVERTISING TO ASSETS: FAIL; CAPITAL EXPENDITURES TO ASSETS: PASS; R&D TO ASSETS: PASS. Overall, several positives (R&D/Capex alignment) exist but notable profitability and cash-flow weaknesses temper enthusiasm.

Lam Research (LRCX): Buffett-driven Validea Score of 86%

October 15, 2025, 11:08 AM EDT. Lam Research Corporation (LRCX) earns a Buffett-driven endorsement from Validea's guru model, scoring 86% across 22 strategies under the Patient Investor framework. The approach targets firms with long-term profitability, low debt, and reasonable valuations, signaling notable interest in LRCX as a large-cap semiconductors growth stock. Key takeaways include earnings predictability, debt service strength, return on equity being a PASS, free cash flow strength, and active use of retained earnings plus share repurchases. It also shows a favorable initial/expected return profile. The sole weakness is return on total capital failing to meet the criterion, tempering the overall thesis. For investors, LRCX offers Buffett-style reliability amid semiconductor cycles, with caveats around capital-efficiency metrics.

UBER Scores 66% in Validea's Wesley Gray Quantitative Momentum Analysis

October 15, 2025, 11:07 AM EDT. Validea's guru-based review of UBER TECHNOLOGIES INC (UBER) shows the stock ranking highest on the firm's Quantitative Momentum model, a strategy developed from Wesley Gray's work. The momentum approach searches for stocks with strong, consistent intermediate-term relative performance. UBER is categorized as a large-cap growth stock in the Business Services industry. The current rating from this strategy is 66%, signaling some degree of interest but not the strong conviction seen at 80%+ (and well below the 90%+ range that would suggest strong interest). The report notes that not all criteria carry equal weight and provides a snapshot of the stock's strong and weak points under this approach. Overall, UBER's 66% score suggests modest momentum exposure rather than a high-conviction signal.

HIMS earns 77% on Partha Mohanram P/B Growth Investor model

October 15, 2025, 11:06 AM EDT. HIMS & HERS HEALTH INC (HIMS) rates highest under Validea's Partha Mohanram P/B Growth Investor model among 22 guru strategies. The stock shows a 77% score, indicating some interest but below the 90% threshold for strong conviction. Core tests: BOOK/MARKET RATIO: PASS; RETURN ON ASSETS: PASS; CASH FLOW FROM OPERATIONS TO ASSETS: PASS; CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS: PASS; ROA VARIANCE: PASS; SALES VARIANCE: FAIL; ADVERTISING TO ASSETS: PASS; CAPITAL EXPENDITURES TO ASSETS: PASS; RESEARCH AND DEVELOPMENT TO ASSETS: FAIL. The model targets low book-to-market stocks with signs of sustained future growth. HIMS is a mid-cap growth stock in the Biotechnology & Drugs space, with strengths and weaknesses described within the growth framework.

PANW Factor-Based Growth Analysis: Validea Mohanram Model Rates PANW at 88%

October 15, 2025, 11:05 AM EDT. Validea's guru framework ranks PALO ALTO NETWORKS INC (PANW) highest among 22 guru strategies in the P/B Growth Investor model (Partha Mohanram). The stock earns an 88% score, where scores above 80% indicate interest and above 90% signal strong interest. The analysis shows multiple pass results across key tests-Book/Market, Return on Assets, CFO to assets, CFO vs ROA variance, Sales variance, Advertising to assets, Capex to assets, and R&D to assets-with one caveat: R&D to assets is a FAIL. PANW is a large-cap growth name in the Software & Programming industry. Overall, the model flags solid fundamentals and meaningful upside potential, tempered by the noted weakness in R&D capitalization within this strategy.

JNJ Factor-Based Stock Analysis: Partha Mohanram Growth Model

October 15, 2025, 11:04 AM EDT. Validea's guru fundamental report ranks JOHNSON & JOHNSON (JNJ) highly among 22 guru strategies using Partha Mohanram's P/B Growth Investor model. The growth framework seeks low book-to-market stocks with signs of sustained future growth, and JNJ posts an 88% rating-where 80%+ indicates interest and 90%+ indicates strong interest. The accompanying table shows JNJ passing key tests across several metrics, including Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, and related items, while R&D to Assets is flagged as failed. Labeled as a large-cap growth stock in the Biotechnology & Drugs industry, the analysis emphasizes strong fundamentals and favorable valuation within the Mohanram framework, with noted weakness in R&D intensity relative to assets.

BAC Factor-Based Stock Analysis: Pim van Vliet Model Yields 81% but Final Rank Fails

October 15, 2025, 11:01 AM EDT. Validea's Pim van Vliet factor model rates BANK OF AMERICA (BAC) at 81%, signaling some interest but not a buy signal. The strategy targets low volatility stocks with momentum and net payout yield considerations. In BAC's case, the stock is a large-cap value name in the Money Center Banks sector. The table shows MARKET CAP: PASS and STANDARD DEVIATION: PASS, with TWELVE MINUS ONE MOMENTUM: NEUTRAL and NET PAYOUT YIELD: NEUTRAL, final rank is FAILED. Despite the favorable fundamentals, the model's overall verdict is cautious for BAC at this time.

XOM Factor-Based Stock Analysis: Peter Lynch Strategy Yields 93% Rating

October 15, 2025, 11:00 AM EDT. Exxon Mobil (XOM) earns the top mark under Validea's Peter Lynch-based P/E/Growth strategy. The model rates the stock 93%, indicating strong interest. Criteria outlook shows strong results on P/E/Growth tests, with P/E, Sales, Inventory to Sales, and EPS Growth Rate passing, and Total Debt/Equity also passing. Free Cash Flow is flagged as neutral, and Net Cash Position is neutral rather than cash-rich. XOM is a large-cap value stock in the Oil & Gas Operations group. A score of 80% or more signals interest, while above 90% signals strong interest. Peter Lynch's approach emphasizes finding stocks at reasonable prices relative to growth with solid balance sheets.

SMCI Factor-Based Peter Lynch P/E/Growth Analysis (74% Rating)

October 15, 2025, 10:59 AM EDT. Validea rates SUPER MICRO COMPUTER INC (SMCI) 74% under its Peter Lynch P/E/Growth Investor model, indicating moderate interest. The screen favors a stock trading at a reasonable price relative to growth with a solid balance sheet, but key gaps temper enthusiasm. Highlights include P/E/GROWTH RATIO PASS, SALES AND P/E RATIO PASS, INVENTORY TO SALES PASS, TOTAL DEBT/EQUITY RATIO PASS. Weak spot: EPS GROWTH RATE FAIL. Other notes show FREE CASH FLOW NEUTRAL and NET CASH POSITION NEUTRAL. SMCI is a large-cap growth stock in Computer Hardware; with a 74% score, the model suggests some interest but not a strong endorsement. Investors may watch for improving earnings growth and cash flow signals to lift the thesis above the threshold.

Domino's Delivers Q3 Beat, Sparks Rebound Path for DPZ Stock

October 15, 2025, 10:58 AM EDT. DPZ delivered a Q3 beat that reinforced a path for a rebound in the stock. The setup envisions potentially +20% this year and well above +100% over the long term, fueled by aggressive capital returns via a dividend and sizable share buybacks (down ~2.6% last year). The stock trades ~24x forward earnings vs. market-average multiples, with some analysts suggesting a higher growth runway and a value play (MarketBeat notes a much lower 10x on a 2035 basis). In Q3, revenue rose 6.3% to a record quarter; drivers included supply chain, U.S. royalties, ad revenue, and higher market-basket pricing; U.S. comps +5.2%, international +1.7%. Margins expanded despite non-cash headwinds from China; FCF up 31%, net cash up 23%. 12-month target around $492.54 implies ~16% upside.

NYSE Pre-Market Update: Markets Edge Higher as Earnings Roll In; Embraer Celebrates 25th Listing Anniversary

October 15, 2025, 10:57 AM EDT. Stocks move higher in the NYSE pre-market as investors weigh the latest quarterly results and ongoing US-China trade developments. Early earnings from Bank of America and Morgan Stanley help set the tone, while Washington-sparked policy chatter and reports that China may boycott U.S. soybeans keep sentiment mixed. The update also highlights a health-tech surge after Oura revealed a Series E of more than $900 million, valuing the company around $11 billion. In corporate news, HPE outlined a long-term strategy to boost shareholder value and Planet Labs hosted its 2025 investor day. The day also commemorates Embraer's 25th listing anniversary on the NYSE, underscoring durable market interest in listings as traders await further macro cues.

Jim Cramer's Top 10 Stocks to Watch on Wednesday: Banks, AI, and Data Centers

October 15, 2025, 10:56 AM EDT. Jim Cramer's Wednesday watchlist blends strong bank earnings with questions about earnings growth versus net interest income, spotlighting Bank of America and Morgan Stanley as lenders rally after solid prints. He flags potential AI-driven upside and the integration of Salesforce's Agentforce, while Abbott Labs wrestles with tariff-driven guidance and a >3% drop. M&A chatter surrounds Papa John's (Apollo bid) and data-center demand via deals led by BlackRock and Nvidia to buy Aligned Data Centers. The week also notes ASML's robust quarter and China's softer sales, a cautious take on GE Vernova after a downgrade, and upside on Johnson & Johnson (spin-off) and Nike with a fresh $100 target. In sum, earnings momentum, AI tooling, and data-center activity are the main drivers.

JPMorgan Cuts HON Target to $212 as Banks Adjust Honeywell Outlook

October 15, 2025, 10:55 AM EDT. JPMorgan Chase & Co. lowered its price target on Honeywell International (HON) from $222 to $212, while maintaining a Neutral rating. The move follows mixed views across peers, with TD Cowen trimming to $250, Barclays lifting to $265 (Overweight), Morgan Stanley up to $245, and Wells Fargo easing to $220 (Equal Weight). Weiss Ratings remains Buy (B-). MarketBeat shows a Moderate Buy consensus and a $251.67 target. HON opened around $208.61, with a 12-month range of $179.36-$242.77. Core metrics cited include a P/E of 23.73, a PEG of 2.27, and a $132.45B market cap. Insider note: CEO Lucian Boldea sold 42,149 shares for about $9.34M.

Wall Street Gains as Earnings Focus Replaces U.S.-China Tensions

October 15, 2025, 10:54 AM EDT. Stocks edged higher as investors shift focus from souring U.S.-China relations to corporate earnings. The S&P 500 and Nasdaq rose modestly, buoyed by solid quarterly results and upbeat guidance from heavyweight names, while the Dow logged gains in a cautious mood. Traders weighed inflation risks against expectations that earnings season will validate growth and justify valuations. Treasury yields held steady, supporting a risk-on tone. Leadership came from technology, consumer discretionary, and communication services, with financials and energy mixed. Market participants priced in resilience in earnings and demand trends, awaiting forward guidance on margins and policy signals from central banks.